oxytocin profile

Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	439302
CHEMBL ID	395429
CHEBI ID	7872
SCHEMBL ID	29048
MeSH ID	M0015703

Synonym
[3h]ot (human, mouse, rat)
otx ,
gtpl2176
[3h]oxytocin
(2s)-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2s)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-n-[(2s)-1-[(2-amino-2-oxoethyl)amino]-4
gtpl2174
syntocinon
ti-001
pitocin
oxytocin (jp17/usp/inn)
syntocinon (tn)
D00089
oxytocin (tn)
pitocin (tn)
uteracon
syntocinone
partocon
nobitocin s
syntocin
oxitocina [inn-spanish]
oxytocin 20 usp units in dextrose 5%
orasthin
endopituitrina
di-sipidin
oxystin
atonin o
synthetic oxytocin
utedrin
vasopressin, 3-l-isoleucine-8-l-leucine-
oxetakain [czech]
oxytocine [inn-french]
oxytocin 10 usp units in dextrose 5%
oxytocin 5 usp units in dextrose 5%
(1-hemicystine)oxytocin
piton s
l-cysteinyl-l-tyrosyl-l-isoleucyl-l-glutaminyl-l-asparaginyl-l-cysteinyl-l-prolyl-l-leucylglycinamide cyclic (1-6)-disulfide
ossitocina [dcit]
brn 3586108
oxytocinum [inn-latin]
synpitan
ocytocinum
alpha-hypophamine
presoxin
3-isoleucine-8-leucine vasopressin
hsdb 2182
einecs 200-048-4
BCBCMAP01_000094
1-({(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-(4-hydroxybenzyl)-13-[(1s)-1-methylpropyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-l-prolyl-l-leucylglycinamide
CHEBI:7872 ,
oxytocine
oxytocinum
oxitocina
l-cysteinyl-l-tyrosyl-l-isoleucyl-l-glutaminyl-l-asparaginyl-l-cysteinyl-l-prolyl-l-leucylglycinamide cyclic(1-6)-disulfide
ot
ocytocin
C00746
50-56-6
OXT ,
oxytocin
oxytocin, lyophilized powder, ~15 iu/mg solid (prepared from synthetic oxytocin)
NCGC00167132-01
cys-tyr-ile-gln-asn-cys-pro-leu-gly-nh2, cyclic 1-6 disulfide
tnx1900
CHEMBL395429 ,
tnx-1900
intertocine s
tta-121
(2s)-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2s)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-n-[(2s)-1-[(2-amino-2-oxoethyl)amino]-
bdbm50205990
1-[19-amino-7-(2-amino-2-oxo-ethyl)-10-(3-amino-3-oxo-propyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-13-sec-butyl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-n-[1-[(2-amino-1-methyl-2-oxo-ethyl)carbamoyl]-3-methyl-butyl]pyrrolidine
A828179
AKOS015994657
c43h66n12o12s2
unii-1jqs135eyn
ossitocina
1jqs135eyn ,
oxoject
oxytocin [usp:inn:ban:jan]
oxetakain
XNOPRXBHLZRZKH-DSZYJQQASA-N
SCHEMBL29048
HS-2021
DTXSID8048361 ,
W-105951
AC-28730
mfcd00076731
sr-01000945111
SR-01000945111-1
oxytocin, united states pharmacopeia (usp) reference standard
oxytocin, european pharmacopoeia (ep) reference standard
oxytocin (syntocinon)
glycinamide, l-cysteinyl-l-tyrosyl-l-isoleucyl-l-glutaminyl-l-asparaginyl-l-cysteinyl-l-prolyl-l-leucyl-, cyclic (1->6)-disulfide
oxytocin-(leucine-5,5,5-d3, glycine-2,2-d2) trifluoroacetate salt
oxytocin,(s)
Q169960
AMY25364
l-cysteinyl-l-tyrosyl-l-isoleucyl-l-glutaminyl-l-asparaginyl-l-cysteinyl-l-prolyl-l-leucylglycinamide cyclic (1-->6)-disulfide
a-hypophamine
HB2929
cyiqncplg
(gly-9 = c-terminal amide, disulfide bridge between 1 - 6)
oxytocin (usp-rs)
oxytocin (usp impurity)
(1-hemicystine)-oxytocin
piton-s
oxytocin (label under distributors)
pvl oxytocin injectable
oxytocin (high potency powder)
oxytocin, for bioassay
dtxcid4028335
oxytocin (usp:inn:ban:jan)
oxitocina (inn-spanish)
oxytocin (mart.)
glycinamide, l-cysteinyl-l-tyrosyl-l-isoleucyl-l-glutaminyl-l-asparaginyl-l-cysteinyl-l-propyl-l-leucyl-, cyclic (1-6)-di-
oxytocin (usp monograph)
h01bb02
oxytocin injectable
1-(((4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-(4-hydroxybenzyl)-13-((1s)-1-methylpropyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl)carbonyl)-l-prolyl-l-leucylglycinamide
oxytocinum (inn-latin)
oxytocine (inn-french)

Research Excerpts

Overview

Excerpt	Reference
"Oxytocin (OT) is a peptide hormone agonist of the OT receptor (OTR) that plays an important role in social behaviors such as pair bonding, maternal bonding and trust. "	( Bai, G; Duplantier, A; Fonseca, KR; Goetz, GH; Gray, DL; Kablaoui, NM; Rogers, BN; Sciabola, S; Vanase-Frawley, MA, 2016)
"Oxytocin (OT) is a neuropeptide involved in a wide variety of physiological actions, both peripherally and centrally. "	( Adachi, Y; Asami, T; Nakayama, M; Sakimura, K; Shimizu, Y; Terao, Y; Yano, T, 2017)
"Oxytocin (OT) is a peptide hormone agonist of the oxytocin receptor (OTR) that has been proposed as a therapeutic to treat a number of social and emotional disorders in addition to its current clinical use to induce labor and treat postpartum bleeding. "	( Kablaoui, N; Sciabola, S; Vanase-Frawley, M, 2018)
"Oxytocin (OT) is an exciting potential therapeutic agent, but it is highly sensitive to modification and suffers extensive degradation at elevated temperature and in vivo. "	( Beard, R; Gee, AD; Grundschober, C; Py, G; Schmitt, M; Stucki, A; Tate, EW, 2018)
"Oxytocin is a neuropeptide that binds copper ions in nature. "	( Alshanski, I; Hurevich, M; Shalev, DE; Yitzchaik, S, 2021)
"Oxytocin is a hormone produced by the hypothalamus and released by the posterior pituitary."	( Choudhary, M; Craciunas, L; Kollmann, M; Raine-Fenning, N; Tsampras, N, 2021)
"Oxytocin (OXT) is a nine amino acid neuropeptide hormone that has become one of the most intensively studied molecules in the past few decades. "	( Chen, K; Liu, D; Yang, LN; Yin, XP; Zhu, LQ, 2022)
"Oxytocin is a hypothalamic neuropeptide involved in the inhibition of nociception transmission at spinal dorsal horn (SDH) level (the first station where the incoming peripheral signals is modulated). "	( Cifuentes-Diaz, C; Condés-Lara, M; González-Hernández, A; Martínez-Lorenzana, G; Palma-Tirado, L, 2021)
"Oxytocin (OT) is a neuropeptide widely implicated in reducing physical pain and negative emotions; however, whether OT has an effect on reducing intense social pain (e.g., romantic rejection) remains unknown."	( Leppänen, PHT; Li, H; Li, P; Otieno, SCSA; Zhang, X, 2021)
"Oxytocin is a naturally occurring hormone that has gained attention for its potential analgesic properties."	( Campbell, TS; Cooper, L; Flusk, D; MacInnes, A; Mekhael, AA; Nasr-Esfahani, M; Poulin, PA; Rash, JA; Robert, M; Yi, Y, 2021)
"Oxytocin is a neuropituitary hormone that is involved in a wide range of psychosocial behaviors. "	( Kwon, HB; Lee, D, 2022)
"Oxytocin is a neuromodulator and hormone that is typically associated with social cognition and behavior. "	( Andreassen, OA; Bettella, F; de Lange, AG; Haram, M; Quintana, DS; Steen, NE; Westlye, LT; Winterton, A, 2021)
"Oxytocin (OT) is a neuropeptide hormone that has anxiolytic and antidepressant effects, and positive effects on social affiliation and behaviour, particularly in parenting and attachment relationships. "	( Fearon, P; Feldman, R; Fonagy, P; Lindley Baron-Cohen, K, 2022)
"Oxytocin is a molecule that emerges as a potent analgesic in preclinical and clinical studies. "	( Condés-Lara, M; González-Gallardo, A; González-Hernández, A; Martínez-Lorenzana, G; Salinas-Abarca, AB; Vázquez-Cuevas, FG, 2022)
"Oxytocin (OT) is a key modulator of human social cognition, popular in behavioral neuroscience. "	( Antunes, M; da Cruz, J; Figueiredo, P; Kosilo, M; Mehta, MA; Prata, D; Zelenina, M, 2022)
"Oxytocin is a peptide hormone that mainly functions to control the contractility of smooth muscles and sex-related steroidogenesis in male reproductive tracts. "	( Pakdeesanaeha, T; Techarungchaikul, S; Tharasanit, T; Thongsima, T; Tiptanavattana, N, 2022)
"Oxytocin is a potent uterotonic agent administered to nearly all patients during childbirth in the United States. "	( England, SK; Fang, Y; Frolova, AI; Imoukhuede, PI; Malik, M; Prifti, K; Roh, M; Wakle-Prabagaran, M, 2022)
"Oxytocin is a nonapeptide hormone involved in numerous physiological functions. "	( Douglass, AD; Jarosova, R; Johnson, MA, 2022)
"Oxytocin (OT) is a nonapeptide mainly produced in the supraoptic and paraventricular nuclei. "	( Han, L; Liu, N; Ma, M; Yang, H, 2022)
"Oxytocin (OXT) is a neuropeptide that can facilitate prosocial behavior and decrease social stress and anxiety but can also increase aggression in some contexts. "	( Guoynes, CD; Marler, CA, 2022)
"Oxytocin is a neuropeptide hormone that plays an important role in social bonding and behavior. "	( Allam, M; El-Ganainy, SO; Elbahnasi, AI; Ghazy, AA; Gowayed, MA; Mansour, AM; Soliman, OA, 2022)
"Oxytocin is a neuropeptide that can produce anxiolytic effects and promote social approach. "	( Black, AM; Gegenhuber, B; Luo, PX; Minie, VA; Rios, RA; Tollkuhn, J; Torres, LY; Trainor, BC; Tran, AM; Xu, CK; Zakharenkov, HC, 2022)
"Oxytocin (OXT) is a neuropeptide and hormone involved in emotional functioning and also seems to play a role in moderating the stress response. "	( Aigner, M; Bernegger, A; Carlberg, L; Fischer-Hansal, D; Fuxjäger, M; Haslacher, H; Huber, J; Inaner, M; Kapusta, ND; Kasper, S; Kienesberger, K; Koller, R; Ludwig, B; Meisner, L; Schmelzle, N; Schoenthaler, S; Schosser, A; Senft, B; Swoboda, MMM; Swoboda, P; Weinhaeusel, A; Zotter, M, 2022)
"Oxytocin is a neuropeptide synthesized in the hypothalamus. "	( Hidema, S; Maejima, Y; Nishimori, K; Nollet, KE; Ono, T; Shimomura, K; Tomita, H; Yaginuma, H; Yamachi, M; Yokota, S; Yu, Z, 2022)
"Oxytocin is a well-established regulator of social behaviour. "	( Gonzalez, A; Hammock, EAD, 2022)
"Oxytocin (OX) is a posterior pituitary hormone secreted into the blood from axon terminals projecting from the posterior pituitary. "	( Kumagai, T; Shiba, H; Shindo, S; Takeda, K, 2022)
"Oxytocin is a nonapeptide synthesized in the paraventricular and supraoptic nuclei of the hypothalamus. "	( Carbone, MG; Carter, S; Diep, PT; Marazziti, D, 2022)
"Oxytocin (OXT) is a hypothalamic neuropeptide that is released from the posterior pituitary gland and at specific targets in the central nervous system (CNS). "	( Alizadeh, H; Cumming, P; Fathabadipour, S; Goharbakhsh, N; Michel, TM; Mohammadi, Z; Palizgar, F; Roshani, F; Vafaee, MS, 2022)
"Oxytocin is a hormone secreted from definite neuroendocrine neurons located in specific nuclei in the hypothalamus (mainly from paraventricular and supraoptic nuclei), and its main known function is the contraction of uterine and/or mammary gland cells responsible for parturition and breastfeeding. "	( Tsingotjidou, AS, 2022)
"Oxytocin is a first-line pharmaceutical for preventing and treating postpartum hemorrhage, which acts through oxytocin receptors on uterine myocytes."	( Connelly, JJ; Erickson, EN; Krol, KM; Myatt, L; Perkeybile, AM, 2022)
"Oxytocin (OXT) is a peptide hormone produced in the hypothalamus that plays a neuromodulatory role in emotion, stress, and anxiety. "	( Lopes, S; Osório, FL, 2023)
"Oxytocin is a neurohormone that is routinely administered to patients during dilation and evacuation procedures (D&E) to control bleeding despite minimal evidence in support of this common practice. "	( Anderson, CM; Fontanilla, T; Kaneshiro, B; Soon, R; Tschann, M; Whitehouse, K, 2022)
"Oxytocin is a pleiotropic molecule which, in addition to its facilitating action during parturition and milk ejection, is involved in social and prosocial behaviors such as attachment. "	( Freund-Mercier, MJ, 2022)
"Oxytocin (OT) is a neurohormone that regulates the so-called "social brain" and is mainly studied in adulthood. "	( Muscatelli, F, 2022)
"Oxytocin (OT) is a prominent regulator of many aspects of mammalian social behavior and stored in large dense-cored vesicles (LDCVs) in hypothalamic neurons. "	( Bracher, F; Callebert, J; Cancela, JM; Dakouane-Giudicelli, M; de la Porte, S; Desvignes, N; Fossier, P; Galione, A; Gilmaire, FO; Granon, S; Grimm, C; Kawakami, N; Launay, JM; Martucci, LL; Morris, J; Paulcan, S; Sakamoto, H; Sicard, C; Spix, B; Têtu, M; Vaillend, C, 2023)
"Oxytocin is a neuropeptide hormone that impacts fear, and social recognition."	( Abd-ElGawad, M; Ahmed, SK; Alsawareah, A; Alsharabasy, MA; Manirambona, E; Mohamed, MR; Shalma, NM; Taha, AM; Taha, NA, 2023)
"Oxytocin is a peptide-hormone extensively studied for its multifaceted biological functions and has recently gained attention for its role in eating behavior, through its action as an anorexigenic neuropeptide. "	( Clarke, G; Cuesta-Marti, C; Hyland, N; Muguerza, B; Schellekens, H; Uhlig, F, 2023)
"Oxytocin is a peptide neurophysin hormone made up of nine amino acids and is used in induction of one in four births worldwide (more than 13 percent in the United States). "	( Argun, AA; Heffernan, MJ; Rana, M; Vega, SP; Ward, NE; Yildirim, N, 2023)
"Oxytocin is a hormone with functions in: reproduction, maternal bonding, milk ejection, and feeding/social behavior, and is reported to be present in a variety of tissues. "	( Byron, M; Card, C; Diel de Amorim, M; Dong, L; Foster, RA; Klein, C; Saleh, M; Saleh, T, 2023)
"Oxytocin (OT) is a neuropeptide that is synthesized in hypothalamic regions, secreted from the posterior lobe of the pituitary gland, and is involved in the control of appetite, body weight, and metabolism."	( Arakaki, R; Iwasa, T; Kamada, S; Kawakita, T; Kinouchi, R; Kon, M; Mineda, A; Noguchi, H; Shinohara, N; Takeda, A; Uchishiba, M; Yamamoto, S; Yamamoto, Y; Yoshida, K, 2023)
"Oxytocin is a neuropeptide hormone that plays a key role in social behavior, stress regulation, and mental health. "	( Abreu do Valle, H; Dinstein, I; Hanley, GE; Hutchison, S; Iarocci, G; Ip, A; Karim, JL; Lanphear, B; Lanphear, N; Meiri, G; Menashe, I; Nitschke, AS; Oberlander, TF; Solomon, S; Zusman, EZ, 2023)
"As oxytocin is a major regulator of sociability, the impact of perinatal morphine exposure on oxytocin peptide expression was also examined."	( Harder, HJ; Murphy, AZ; Searles, CT; Vogt, ME, 2023)
"Oxytocin acts as a neuroprotective agent by preventing neuro-apoptosis, neuro-inflammation, and neuronal oxidative stress, and by restoring mitochondrial function."	( Allahverdikhani, M; Emanuele, E; Gholami, M; Hayes, AW; Kamrani-Sharif, R; Motaghinejad, M; Salehirad, M, 2023)
"Oxytocin is a critical social regulator and anti-inflammatory hormone that modulates stress-related functions and social behaviors and alleviates diseases."	( Jin, Y; Qing, H; Quan, Z; Song, D; Yan, Y, 2023)
"Oxytocin (OXT) is a neurohypophyseal hormone that plays a pivotal role in the regulation of mammalian behavior, and is involved in health and well-being processes."	( Abruzzo, PM; Canaider, S; Facchin, F; Marini, S; Pampanella, L; Petrocelli, G; Tassinari, R; Ventura, C; Zamagni, E, 2023)
"Oxytocin (OXT) is a neuropeptide that regulates memory, emotion, stress response, and behavior in the brain. "	( Kasuya, E; Kuwahara, M; Momita, K; Sutoh, M; Yayou, KI; Yoshida, M, 2023)
"The oxytocin gene (OXT) is a promising candidate for reproductive traits in mammals."	( Al-Shuhaib, MBS; Al-Thuwaini, TM; Alghetaa, HF; Alkhammas, AH; Khazaal, NM, 2023)
"Oxytocin is a neuropeptide that is important for maternal physiology and childcare, including parturition and milk ejection during nursing"	( Bair-Marshall, CJ; Froemke, RC; Issa, HA; Jung, K; Kwon, HB; Martin, KA; Valtcheva, S; Zhang, Y, 2023)
"Oxytocin (OT) is a neurohypophyseal peptide hormone containing a disulphide-bridged pseudocyclic conformation. "	( Chorev, M; Gruber, CW; Jewgiński, M; Larregola, M; Latajka, R; Lequin, O; Macchia, L; Nuti, F; Papini, AM; Retzl, B; Rovero, P; Staśkiewicz, A; Street, ME; Tomašević, N, 2023)
"Oxytocin (OXT) is a neurohypophyseal hormone that influences a wide range of affiliative behaviors, such as pair-bonding and infant care, across mammals. "	( Cerrito, P; Spear, JK, 2023)
"Oxytocin (OXT) is a hypothalamic peptide that plays a number of roles in the body, being involved in labor and lactation, as well as cognitive-emotional processes and social behavior. "	( Jowik, K; Malewska-Kasprzak, M; Tyszkiewicz-Nwafor, M, 2023)
"Oxytocin (OXT) is a neuropeptide hormone termed "love hormone" produced and released during childbirth and lactation. "	( Fukuda, J; Kageyama, T; Seo, J; Yan, L, 2023)
"Oxytocin (OXT) is a key regulator of social decision-making processes such as information gathering, as it contextually modulates social salience and can induce long-term structural plasticity, including neurogenesis."	( Bymers, J; Herro, ZJ; Marler, CA; Monari, PK, 2023)
"Oxytocin is a neuropeptide synthesized in the hypothalamus."	( Chen, J; Chen, Q; Chen, X; Liu, R; Lu, B; Meng, B; Mo, L; Sheng, L; Sun, D; Wang, Q; Xing, X; Yuan, H; Zheng, J, 2024)
"Oxytocin is a neuropeptide implicated in a variety of central processes, such as social and reproductive behaviors."	( Koulousakis, P; Prickaerts, J; Rombaut, B; Schepers, M; van den Hove, D; Vanmierlo, T; Willems, E, 2023)
"Oxytocin is a key hormone in childbirth, and synthetic oxytocin is widely administered to induce or speed labour. "	( Berg, M; Buckley, S; Dencker, A; Downe, S; Ekström-Bergström, A; Hadjigeorgiou, E; Kielbratowska, B; Kotłowska, A; Lengler, L; Leon-Larios, F; Lindström, B; Magistretti, CM; Pajalic, Z; Uvnäs-Moberg, K, 2019)
"Oxytocin is an effective drug for induction of labour, but is associated with serious adverse effects of which uterine tachysystole, fetal distress and the need of immediate delivery are the most common. "	( Bakker, JJH; Boie, S; Bor, P; Glavind, J; Steer, PJ; Uldbjerg, N; van der Post, JAM, 2019)
"Oxytocin is a nonapeptide consisting of a cyclic six amino-acid structure and a tail of three amino acids. "	( Handlin, L; Kendall-Tackett, K; Petersson, M; Uvnäs Moberg, K, 2019)
"Oxytocin is a key modulator of social interaction, but we possess little knowledge of its underlying effects on neuropsychological processes. "	( Heinrichs, M; Koenig, T; Schiller, B, 2019)
"Oxytocin is a hormone of interest in reproduction, but also in the field of psychology and behavior, being considered as a biomarker of positive emotions. "	( Cerón, JJ; Escribano, D; López-Arjona, M; Manteca, X; Martínez-Subiela, S; Mateo, SV, 2020)
"Oxytocin (OT) is a neuropeptide associated with trauma, sociality, and depression. "	( Connemann, BJ; Gahr, M; Kammer, T; Kiefer, M; Montag, C; Richter, K; Sanwald, S; Schönfeldt-Lecuona, C; Widenhorn-Müller, K, 2020)
"Oxytocin is a peptide hormone with high affinity to both Zn"	( Alshanski, I; Buchwald, J; Cuniberti, G; Dianat, A; Gutierrez, R; Hurevich, M; Mervinetsky, E; Tadi, KK; Yitzchaik, S, 2020)
"Oxytocin is a novel candidate substance to relieve neuropathic pain, as demonstrated in various animal models with nerve injury."	( Fujita, S; Kobayashi, M; Mayahara, K; Motoyoshi, M; Noma, D; Zama, M, 2020)
"Oxytocin is a central nervous system peptide which regulates socioemotional functioning and may mediate physiologic processes in a range of psychiatric disorders, particularly those characterized by interpersonal dysfunction."	( Beatty, C; Fang, A; Germine, L; Jacoby, RJ; Lawson, EA; Plessow, F; Wilhelm, S, 2020)
"Oxytocin (OT) is a neuroactive peptide that influences the processing of fearful stimuli in the amygdala. "	( Crane, JW; Delaney, AJ; Fam, J; Holmes, NM; Westbrook, RF, 2020)
"Oxytocin does not seem to be an essential drug for all ambulance units."	( Harve-Rytsälä, H; Klemettilä, E; Lääperi, M; Nuutila, M; Rahkonen, L, 2020)
"Oxytocin is a stress-buffering hormone in the brain that modulates the physiological effects of stress."	( Cai, W; Guo, Q; He, Z; Hou, W; Tai, F; Wang, L; Yang, Y; Yuan, W; Zhang, J; Zhang, X, 2020)
"Oxytocin is a hormone naturally produced in the human body that can make the womb (uterus) contract during labor. "	( Botchway, A; Campbell, P; Diaz-Sylvester, PL; Diebold, T; Groesch, K; Hedden, L; Kurian, JR; Loret de Mola, JR; Scherbel, JR; Soltys, SM; Wilson, T, 2020)
"Oxytocin is a central neuromodulator required for facilitating mate preferences for familiar individuals in a monogamous rodent (prairie vole), irrespective of sex. "	( Ansai, S; Inoue, S; Iwasaki, S; Kamei, Y; Kinoshita, M; Mito, M; Nakagawa, S; Naruse, K; Okuyama, T; Takeuchi, H; Yokoi, S; Young, LJ, 2020)
"Oxytocin is a key mediator of emotional and social behavior that seems to be of relevance for the development and maintenance of addictive behaviors. "	( Bach, P; Bühler, S; Bumb, JM; Kiefer, F; Koopmann, A; Reinhard, I; Rietschel, M; Vollstädt-Klein, S; Witt, SH; Zimmermann, S, 2021)
"Oxytocin (OXT) is a small peptide with 9 amino acids that is neuroprotective to many neurological disorders."	( Almansob, YAM; Almansoub, HAMM; Hu, F; Liu, D; Lu, Y; Mahaman, YAR; Salissou, MTM; Tang, H; Wang, DQ; Wu, Y; Zhou, LT, 2020)
"Oxytocin is a peptide involved in the modulation of social cognition, emotional skills and the reward system, all deficient in PTSD, and thus it has been suggested as a promising pharmacological target."	( Brondino, N; Damiani, S; de Cagna, F; Fusar-Poli, L; Giovanna, G; Mori, A; Politi, P; Rocchetti, M, 2020)
"Oxytocin is a hypothalamic hormone that is directly secreted into the brain and reaches the blood circulation through the neurohypophysis."	( Cifani, C; Friuli, M; Gaetani, S; Romano, A, 2020)
"Oxytocin is a neuropeptide known to affect social behaviour and cognition. "	( Auer, MK; Brandi, ML; Gebert, D; Kopczak, A; Schilbach, L, 2020)
"Oxytocin is an important modulator of human affiliative behaviors, including social skills, human pair bonding, and friendship. "	( Chew, SH; Chiao, B; Ebstein, RP; Lei, Z; Tolomeo, S, 2020)
"Oxytocin is a commonly used drug in the labor and delivery unit. "	( Barrett, J; Bas Lnado, M; Lipworth, H; Melamed, N; Page, A; Vitner, D; Weiner, E, 2020)
"Oxytocin (OXT) is a nonapeptide that exerts anxiolytic effects in the brain. "	( Boyle, CA; Hu, B; Lei, S, 2020)
"Oxytocin is a neurohormone involved in domestic dogs' socio-cognitive abilities which appears to be key in the display of gazing behavior as a communicative signal. "	( Barrera, G; Bentosela, M; Cavalli, CM; Dzik, MV, 2020)
"Oxytocin (OT) is a neurohypophysial hormone and neuropeptide produced by the hypothalamus and released by the pituitary gland. "	( Dome, P; Gonda, X; Sharma, SR; Tarazi, FI, 2020)
"Oxytocin is a neuropeptide highly involved in the perception of facets of social relationship such as their quality feelings of belongingness, and mutual trust."	( Ahmadpanah, M; Brand, S; Ghiasi, F; Haghighi, M; Jahangard, L; Sadeghi Bahmani, D; Salehi, I; Shayganfard, M, 2020)
"Oxytocin (OT) is a critical molecule for social recognition and memory that mediates social and emotional behaviours. "	( Brenner, C; Cherepanov, SM; Furuhara, K; Gerasimenko, M; Higashida, H; Ishihara, K; Lopatina, O; Salmina, AB; Shabalova, AA; Tsuji, C; Yokoyama, S, 2020)
"Oxytocin is an important neuromodulator involved in cognition and socio-emotional processing that exerts its central activities via oxytocin receptors. "	( Jeon, S; Kang, JI; Kim, HW; Kim, SJ; Park, CI, 2020)
"Oxytocin is a hormone that is increasingly being used for welfare evaluation in animals. "	( Cerón, JJ; Escribano, D; López-Arjona, M; Martínez-Subiela, S; Mateo, SV; Tecles, F, 2021)
"Oxytocin (Oxt) is a nine amino acid peptide important in energy regulation and is essential to stress-related disorders. "	( Camerino, C, 2020)
"Oxytocin (OT) is a great facilitator of social life but, although its effects on socially relevant brain regions have been extensively studied, OT neuron activity during actual social interactions remains unexplored. "	( Althammer, F; Baudon, A; Benusiglio, D; Bludau, A; Charlet, A; Conzelmann, KK; Darbon, P; Eliava, M; Grinevich, V; Hagiwara, D; Hilfiger, L; Kirchner, MK; Lefevre, A; Leng, G; Neumann, ID; Oberhuber, M; Roy, RK; Schimmer, J; Schwarz, M; Stern, JE; Tang, Y; Wagner, S; Wang, S, 2020)
"Oxytocin is a key hormone in breastfeeding. "	( Buckley, S; Dencker, A; Ekström-Bergström, A; Grylka-Baeschlin, S; Hadjigeorgiu, E; Kotlowska, A; Leahy-Warren, P; Lengler, L; Luegmair, K; Massarotti, C; Olza, I; Pajalic, Z; Uvnäs Moberg, K; Villarmea, S, 2020)
"Oxytocin is a hormone whose role in understanding intergenerational risk from pregnancy to child emotional disorders is dependent on relational context."	( Galbally, M; IJzendoorn, MV; Keelan, J; Lewis, AJ; MacMillan, KK; Power, J; Watson, SJ, 2020)
"Oxytocin is a pleiotropic, peptide hormone with broad implications for general health, adaptation, development, reproduction, and social behavior. "	( Carter, CS; Connelly, JJ; Davis, JM; Ferris, CF; Kenkel, WM; Kingsbury, MA; MacLean, EL; Nazarloo, HP; Perkeybile, AM; Porges, SW; Wilson, SR; Yee, JR, 2020)
"Oxytocin is a peptide of nine amino acids and a well-known anti-inflammatory, anti-oxidant, and immune-modulator, which is protective against ALI/ARDS, nephrotoxicity, sepsis, and ischemia- reperfusion medical condition."	( Shrivastava, R; Shrivastava, VK; Thakur, P, 2021)
"Oxytocin (OT) is a neuropeptide whose central receptor-mediated actions include reducing food intake. "	( Chandra, A; Grill, HJ; Hayes, MR; Kalluri, A; Ong, ZY; Wald, HS, 2020)
"Oxytocin (OXT) is a newly emerged treatment for disorders like autism and schizophrenia and recently is using to alleviate depression and anxiety."	( Khodagholi, F; Maleki, A; Moslemi, M; Motamedi, F; Mousavi, MA; Rafiei, S, 2022)
"Oxytocin (OT) is a neuropeptide hormone that modulates several social behaviors and can affect the anxiety and stress response. "	( Damián, JP; de Soto, L; Espindola, D; Gil, J; van Lier, E, 2021)
"Oxytocin (OXT) is a nonapeptide that serves as a neuromodulator in the brain and a hormone participating in parturition and lactation in the periphery. "	( Boyle, CA; Hu, B; Lei, S, 2021)
"Oxytocin is a neuroendocrine hormone and benefits childbirth and breastfeeding."	( Chen, Y; Wang, H, 2020)
"Oxytocin (OT) is a neurohypophysial hormone that plays a role in lactation and parturition and exerts diverse biological actions via the OT receptor. "	( Kato, Y; Yokose, S, 2021)
"Oxytocin (OT) is a neuropeptide hormone secreted by the posterior pituitary gland. "	( Carsons, SE; DeLeon, J; Glass, DS; Gomolin, IH; Karten, A; Kasselman, LJ; Pinkhasov, A; Reiss, AB; Renna, HA; Vernice, NA, 2021)
"Oxytocin (OXT) is an important peptide that is mainly used as a therapeutic drug to induce labor or strengthen uterine contractions, or to control bleeding after childbirth. "	( Choteau, T; Daireaux, A; Josephs, RD; Li, H; Li, M; Martos, G; Westwood, S; Wielgosz, RI, 2021)
"Oxytocin (OT) is a neuropeptide hormone. "	( Boitsova, EB; Cherepanov, SM; Furuhara, K; Gerasimenko, M; Harashima, A; Higashida, H; Liang, M; Munesue, SI; Yamamoto, Y; Yuhi, T; Zhong, J, 2021)
"Oxytocin is a neuropeptide released by the central nervous system. "	( Behtaji, S; Ghafouri-Fard, S; Rederstorff, M; Sattari, A; Sayad, A; Taheri, M, 2021)
"Oxytocin is a cyclic nonapeptide used to induce labor and prevent bleeding after childbirth. "	( Ghasemisarabbadieh, M; Gizurarson, S; Sveinbjörnsson, BR, 2021)
"Oxytocin (OT) is a nanopeptide released into systemic circulation via the posterior pituitary (peripheral) and into the central nervous system via widespread OTergic pathways (central). "	( Blue, SW; Erikson, DW; Kaucher, AV; Shnitko, TA, 2021)
"Oxytocin (OT) is a key factor for maternal behavior. "	( Brown, CH; Cui, D; Hou, C; Hou, D; Jia, SW; Li, D; Li, T; Liu, X; Liu, Y; Wang, X; Wang, YF, 2021)
"Oxytocin (OT) is a neuropeptide produced by hypothalamic neurons and is known to modulate social behavior among other functions. "	( Benusiglio, D; Charlet, A; Grinevich, V; Krabichler, Q; Lefevre, A; Tang, Y, 2021)
"Oxytocin is a nonapeptide hormone used in labor to initiate uterine contractions and to prevent and treat postpartum hemorrhage. "	( Gomaa, Y; Kolluru, C; Lee, D; Milewski, M; Prausnitz, MR; Saklatvala, R; Zhang, J, 2021)
"The oxytocin (Oxt) system is a known neuromodulator of social behaviors, but also appears to contribute to the development of sex-specific neural circuitry. "	( Aulino, EA; Caldwell, HK, 2021)
"Oxytocin (OT) is a nonapeptide hormone that can improve cardiomyocyte proliferation, suggesting a potential heart regeneration function. "	( Alizadeh, AM; Ghandian Zanjan, M; Gharghi, M; Keshavarz, P; Khalighfard, S; Khodayari, H; Khodayari, S; Khori, V; Mohammad Zadeh, F; Tavakoli-Far, B, 2021)
"Oxytocin is a well-known neurohypophysial hormone that plays an important role in behavioral anxiety and nociception. "	( Chen, QY; Chen, T; Fan, K; Li, XH; Liu, RH; Lu, JS; Matsuura, T; Miao, Z; Shi, W; Wei, F; Wei, S; Xue, M; Yang, J; Zhou, Z; Zhuo, M, 2021)
"Oxytocin is a hormone that mediates interpersonal relationships through enhancing social recognition, social memory, and reducing stress. "	( Jaeggi, AV; John, S, 2021)
"Oxytocin (OT), which is a hypothalamic hormone, plays an important antinociceptive role."	( Chen, L; Pan, Q; Qin, G; Tian, R; Wang, Y; Wen, Q; Zhang, D; Zhang, Y; Zhou, J, 2021)
"Oxytocin (OXT) is a neuropeptide involved in a plethora of behavioral and physiological processes. "	( Jurek, B; Neumann, ID; Pandamooz, S; Salehi, MS, 2021)
"Oxytocin is a neuropeptide traditionally recognised for involvement in labour, delivery and lactation."	( Campbell, TS; Jarrell, JF; Nasr-Esfahani, M; Rash, JA; Robert, M; Toivonen, K, 2017)
"Oxytocin is a potent anorexigen and is believed to have a role in satiety signaling. "	( Hume, C; Menzies, J; Sabatier, N, 2017)
"Oxytocin (OXT) is a neuropeptide that plays a pivotal role among species peripherally and centrally. "	( Long, C; Misrani, A; Tabassum, S, 2017)
"Oxytocin (OT) is a hypothalamic neuropeptide that modulates fear and anxiety-like behaviors. "	( Dabrowska, J; Moaddab, M, 2017)
"Oxytocin is a potent uterotonic agent that is widely used for induction and augmentation of labor. "	( Ashley-Koch, AE; Garrett, ME; Grotegut, CA; Miranda, ML; Ngan, E; Swamy, GK, 2017)
"Oxytocin (OXT) is an evolutionarily ancient neuropeptide with strong links to affiliative and prosocial behaviors, and the management of stress. "	( Davis, C; Kennedy, JL; Patte, K; Zai, C, 2017)
"Oxytocin (OXT) is a neuropeptide that activates the oxytocin receptor (OXTR), a rhodopsin family G-protein coupled receptor. "	( Bird, IM; Chiu, MA; Halbach, P; Pattnaik, BR; Pillers, DM; York, N, 2017)
"Oxytocin is a neuropeptide hormone used clinically for more than 50 years due to its ability to induce uterine contractions and milk ejection. "	( Al-Saqi, SH; Jonasson, AF; Nielsen, EI; Uvnäs-Moberg, K, 2017)
"Oxytocin (OXT) is a peptide hormone that plays a central role in the regulation of parturition and lactation. "	( An, BS; Kang, SS; Kim, SC; Kim, SS; Lee, JE; Yang, HS, 2017)
"Oxytocin (OT) is a critical molecule for social recognition that mediates social and emotional behaviors. "	( Akther, S; Amina, S; Higashida, H; Liang, M; Liu, HX; Lopatina, O; Nishimura, T; Yuhi, T; Zhong, J, 2018)
"Oxytocin is a neuropeptide produced in the hypothalamus that controls energy homeostasis and has an inhibitory role on food intake."	( Garnica-Siqueira, MC; Martins, AB; Uchôa, ET; Zaia, CTBV; Zaia, DAM, 2018)
"Oxytocin (OT) is a neuropeptide that exerts multiple actions throughout the brain and periphery. "	( Iremonger, KJ; Jamieson, BB; Nair, BB, 2017)
"Oxytocin is a neuropeptide known to influence how humans share material resources. "	( Blokpoel, M; de Boer, M; Kokal, I; Liu, R; Roelofs, K; Stolk, A; Toni, I; van Rooij, I, 2017)
"Oxytocin (OT) is a human peptide hormone that is traditionally used as a medication to facilitate childbirth."	( Liu, F; Liu, S; Pan, S; Tan, J; Zhao, W, 2017)
"Oxytocin is a hormone with various actions. "	( Brauchi, S; Cabezas-Bratesco, D; Cao, C; Chelluboina, B; Cohen, AM; Dawson, T; Demirkhanyan, L; Domene, C; Kusuda, R; Nersesyan, Y; Oakes, V; Sun, X; Veeravalli, KK; Zakharian, E; Zimmermann, K, 2017)
"Oxytocin (Oxt) is a neuropeptide with many functions, including modulation of social behavior(s) and anxiety. "	( Bales, KL; Downing, GM; Guoynes, CD; Jacob, S; Simmons, TC; Solomon, M, 2018)
"Oxytocin is a social and reproductive hormone that also plays critical roles in a range of homeostatic processes, including thermoregulation. "	( Alberts, JR; Harshaw, C; Leffel, JK, 2018)
"Oxytocin (OT) is a social hormone that may help researchers understand how nurse-guided interventions during initial infant hospitalization, such as supporting human milk expression, promoting comforting touch, and reducing exposure to stressors, affect preterm brain development."	( Harrison, TM; Shoben, A; Sinnott, L; Steward, D; Weber, A, 2018)
"Oxytocin (OXT) is a cyclic nonapeptide, two amino acids of which are cysteine, forming an intramolecular disulfide bond. "	( Arai, M; Furubayashi, T; Inoue, D; Katsumi, H; Kimura, S; Kiriyama, A; Kusamori, K; Sakane, T; Tanaka, A; Yamamoto, A; Yutani, R, 2018)
"Oxytocin is a neuropeptide that plays a key role in social processing and there are several studies suggesting that intranasally administered oxytocin may enhance social cognitive abilities and visual attention in healthy and clinical groups. "	( Grainger, SA; Henry, JD; Labuschagne, I; Rendell, PG; Steinvik, HR; Vanman, EJ, 2018)
"Oxytocin (OT) is a hypothalamic nonapeptide that mediates a host of physiological and behavioral processes including reproductive physiology and social attachments. "	( French, JA; Mustoe, A; Taylor, JH, 2018)
"Oxytocin (OT) is an endogenous neuropeptide that, while originally thought to promote trust, has more recently been found to be context-dependent. "	( Dickerson, BC; Ide, JS; La Camera, G; Lawson, EA; Mujica-Parodi, LR; Nedic, S; Strey, SL; Wald, LL; Wong, KF, 2018)
"Oxytocin (OT) is a well-known neuropeptides which together with vasopressin, melatonin, insulin and other hormones can alter both behavior and physiological or neuronal functions. "	( Ababei, D; Antioch, I; Balmus, IM; Ciobica, A; Dobrin, R; Lefter, R, 2018)
"Oxytocin (OXT) is a neuropeptide that has several biological functions, including regulation of stress pathways."	( Aston-Jones, G; Kohtz, AS; Lin, B; Smith, ME, 2018)
"Oxytocin is a neuropeptide associated with maternal behavior. "	( Carter, CS; Feeley, N; Gold, I; Hayton, B; MacKinnon, AL; Santhakumaran, S; Zelkowitz, P, 2018)
"Oxytocin (OT) is a 9-amine neuropeptide that plays an essential role in mammalian labor, lactation, maternal bonding, and social affiliation. "	( Eto, M; Fujii, H; Fujii, Y; Hirayama, S; Ishibashi, N; Manabe, S; Meguro, Y; Miyano, K; Narita, M; Nonaka, M; Ogino, T; Sata, N; Ueta, Y; Uezono, Y; Yada, T; Yoshida, Y, 2018)
"Oxytocin (OXT) is a neuropeptide which has a critical role in human social behaviour and cognition. "	( Grace, SA; Heinrichs, M; Kordsachia, C; Labuschagne, I; Rossell, SL, 2018)
"Oxytocin (OT) is a neuropeptide which influences the expression of social behavior and regulates its distribution according to the social context - OT is associated with increased pro-social effects in the absence of social threat and defensive aggression when threats are present. "	( Crane, J; Delaney, A; Fam, J; Holmes, N; Westbrook, RF, 2018)
"Oxytocin is a promising candidate for the treatment of social-deficit disorders such as Autism Spectrum Disorder, but oxytocin cannot readily pass the blood-brain barrier. "	( Braz Gomes, K; D'Souza, C; D'Souza, MJ; Mulla, NS; Murnane, KS; Zaman, RU, 2018)
"Oxytocin is a hypothalamic neuropeptide that has demonstrated promise in modulating neurobiological and behavioral correlates of PTSD."	( Brady, KT; Flanagan, JC; Hand, A; Jarnecke, AM; Joseph, JE; Moran-Santa Maria, MM, 2018)
"Oxytocin (OT) is a neurohormone that has gained interest recently due to its emerging role in cognition and social/emotional behaviors, including possibly depression and autism. "	( Franke, AA; Lai, JF; Lee, MR; Li, X; Menden, A, 2019)
"Oxytocin is a hormone impacting the social cognition and interpersonal trust."	( Li, L; Liu, X; Meng, S; Wang, Y; Zhao, S; Zheng, Y, 2018)
"Oxytocin is an effective drug for this purpose, but associated with serious adverse effects of which uterine tachysystole, fetal distress and the need for immediate delivery are the most common."	( Bakker, JJ; Boie, S; Bor, P; de Graaf, I; Glavind, J; Mol, BWJ; Thornton, JG; Uldbjerg, N; Velu, AV, 2018)
"Oxytocin is an important neuromodulator in the mammalian brain that increases information salience and circuit plasticity, but its signaling mechanisms and circuit effect are not fully understood. "	( Carcea, I; Chao, MV; Eyring, KW; Froemke, RC; Mitre, M; Tirko, NN; Tsien, RW, 2018)
"Oxytocin is a neuropeptide involved in a range of social processes, and prior research has shown that intranasal oxytocin (iOT) may enhance trusting behaviors. "	( Grainger, SA; Henry, JD; Steinvik, HR; Vanman, EJ, 2019)
"Oxytocin (OT) is a nonapeptide hormone mainly synthesized in the magnocellular neurons of the paraventricular and supraoptic nucleus of the hypothalamus. "	( Gruson, D, 2018)
"Oxytocin is an uterotonic drug with profound cardiovascular effects, which in compromised patients could lead to serious events. "	( Hjorth, U; Olofsson, P; Rabow, S; Schönbeck, S, 2018)
"Oxytocin is a neuropeptide synthesized in the anterior hypothalamus which plays an important role in controlling social and emotional behaviour, body weight and metabolism."	( Bhargava, R; Daughters, KL; Rees, A, 2019)
"Oxytocin (OXT) is a neuropeptide that regulates sexual reproduction and social interaction and has recently earned specific attention due to its role in adjusting neurobiological and behavioral correlates of PTSD; however, the mechanism by which this is achieved remains unclear."	( Chen, CC; Lin, CC; Liu, YP; Tzeng, NS; Wang, SC, 2018)
"The oxytocinergic system is a primary biological system involved in regulating a child's needs for bonding and for protection from threats. "	( Baião, R; Baptista, J; Belsky, J; Carneiro, A; Fearon, P; Mesquita, AR; Nogueira, M; Oliveira, C; Pinto, R; Soares, I, 2019)
"Oxytocin is a large-molecule neuropeptide with pro-social behavioral effects and therapeutic promise for social-deficit disorders."	( D'Souza, MJ; Murnane, KS; Oppong-Damoah, A; Zaman, RU, 2019)
"Oxytocin is a hypothalamus derived, posterior pituitary stored nonapeptide which has gained recent interest as an important neuropsychiatric and metabolic hormone beyond its classic role in lactation and parturition. "	( Barengolts, E; Casagrande, A; Dugas, LR; Eisenberg, Y; Layden, BT; McArthur, M; Murad, S, 2019)
"Oxytocin (OT) is a well-characterized neurotransmitter that participates in a wide range of physiological processes including the inhibition of food intake. "	( Cline, MA; Denbow, DM; Gilbert, ER; Koskinen, A; McConn, BR; Siegel, PB, 2019)
"Oxytocin is a neuropeptide involved in animal and human reproductive and social behavior. "	( Alnæs, D; Andreassen, OA; Córdova-Palomera, A; Dieset, I; Kaufmann, T; Quintana, DS; Rokicki, J; van der Meer, D; Westlye, LT, 2019)
"Oxytocin (OT) is a neuropeptide hormone that has many beneficial biological effects, including protection against age-related disorders. "	( Cho, SY; Choi, DH; Kim, AY; Kim, J; Shin, DW; Son, ED, 2019)
"Oxytocin (OXT) is an established endogenous polypeptide produced in the supraoptic nucleus (SON) and paraventricular nucleus (PVN) of the hypothalamus."	( Kawasaki, M; Maruyama, T; Matsuura, T; Motojima, Y; Nishimura, H; Nishimura, K; Ohnishi, H; Onaka, T; Saito, R; Sakai, A; Sonoda, S; Suzuki, H; Ueno, H; Ueta, Y; Yamanaka, Y; Yoshimura, M, 2019)
"Oxytocin is a neuropeptide involved in bodily processes (eg, breast feeding) and in the onset of social behaviours (eg, bonding)."	( Crucianelli, L; Fotopoulou, A; Jenkinson, P; Paloyelis, Y; Ricciardi, L; Robinson, P; Serpell, L, 2019)
"Oxytocin is a powerful hormone that regulates social interaction, sexual reproduction, maternal–infant bonding, milk release, empathy, and anxiety."	( Ateş, M; Gümüş, H; Güvendi, G; Kandiş, S; Karakılıç, A; Kızıldağ, S; Koç, B; Uysal, N; Yüce, Z; Yüksel, O, 2019)
"Oxytocin is a nonapeptide mammalian hormone, best known for its role in childbirth, parturition and lactation. "	( Cavuto, M; de Bartolomeis, A; De Berardis, D; Di Giannantonio, M; Fornaro, M; Iasevoli, F; Marini, S; Martinotti, G; Mazza, M; Sepede, G; Srinivasan, V; Tomasetti, C; Valchera, A, 2013)
"Oxytocin (OXT) is a nine-amino-acid peptide hormone that is mainly released at the times of uterine contractions during parturition and milk ejection during lactation, whereas a similar peptide hormone, arginine vasopressin, primarily exerts direct antidiuretic action on the kidney and causes vasoconstriction of the peripheral vessels. "	( Kitano, T; Yamashita, K, 2013)
"Oxytocin (OXY) is a well-known nonapeptide that functions in reproduction. "	( Arbak, S; Aydin, U; Bakir, I; Ercan, F; Erkanli Senturk, G; Erkanli, K; Isiksacan, N; Tuncdemir, M, 2013)
"Oxytocin is a hypothalamic neuropeptide that has been shown to moderate behavioral responding to stress as well as play a role in the neuroadaptations that occur as a consequence of long-term drug use."	( Baker, NL; Brady, KT; Maria, MM; McRae-Clark, AL, 2013)
"The oxytocin receptor is a typical class I G protein-coupled receptor that is primarily linked to phospholipase C-β via Gq proteins but can also be coupled to other G proteins, leading to different functional effects."	( Brito, MN; Brito, NA; Chaves, VE; Tilelli, CQ, 2013)
"Oxytocin (OXT) is a hormone that has been implicated in human social behavior, and that has also been associated with regulation of inflammation."	( Fernandes, JM; Roberts, DL; Service, H; Velligan, D; Walss-Bass, C, 2013)
"Oxytocin (OT) is a mammalian neuropeptide that modulates activation of fear extinction-based neural circuits and fear responses."	( Acheson, D; de Wilde, S; Feifel, D; Lohr, J; McKinney, R; Risbrough, V, 2013)
"Oxytocin (OT) is a cyclic nonapeptide containing one internal disulfide bond between its Cys(1) and Cys(6) residues. "	( Finnman, J; Flipo, M; Galyean, R; Schteingart, CD; Wiśniewski, K, 2013)
"Oxytocin (OT) is a neuropeptide shown to attenuate inflammatory responses in both humans and animals, but the specific mechanism underlying these actions has not yet been identified. "	( McDonald-Jones, G; Miller, GE; Ross, KM, 2013)
"Oxytocin (OXT) is a neurohypophysial hormone which is synthesized in the paraventricular and supraoptic nuclei of the hypothalamus. "	( Kontoangelos, K; Papadimitriou, GN; Papageorgiou, CC; Rabavilas, AD; Raptis, AE, 2013)
"Oxytocin (OT) is a neuropeptide whose emerging sphere of influence on mammalian behaviour and demonstrated impact on psychiatric illness suggest it may have potential in AN."	( Maguire, S; O'Dell, A; Russell, J; Touyz, L, 2013)
"Oxytocin is a major neuropeptide that modulates the brain functions involved in social behaviour and interaction. "	( Butterfield, DA; Cai, J; Dowling, A; Hill, J; Makani, V; Orjiako, D; Park, J; Pierce, W; Sie, KS; Sultana, R; Tatangelo, M, 2013)
"Oxytocin is an evolutionarily highly preserved neuropeptide that contributes to the regulation of social interactions including the processing of facial stimuli. "	( Born, J; Fischer, S; Hallschmid, M; Heinrichs, M; Ott, V; Thienel, M, 2014)
"Oxytocin (OT) is an endogenous and therapeutic hormone necessary for maternal health. "	( Creamer, JS; Krauss, ST; Lunte, SM, 2014)
"Oxytocin is a hormone involved in social behavior and stress; thus, we focus on the impact that social buffering has on the stress response and the governing effects of oxytocin."	( Smith, AS; Wang, Z, 2014)
"Oxytocin (OT) is a well known reproductive hormone in mammals, but the physiological roles of MT in chickens have not been clarified well."	( Cline, MA; Khan, MS; Masunari, K; Tachibana, T, 2013)
"Oxytocin is a potent neuromodulator which can improve social cognitive functions including empathy, trust, cooperation and social learning."	( Eckstein, M; Hurlemann, R, 2013)
"Oxytocin was found to be a viable alternative to hCG for triggering ovulation in infertile patients."	( Gupta, HP; Mehrotra, S; Saxena, P; Singh, U; Tandon, I, 2014)
"Oxytocin is a neuromodulatory hormone involved in social emotional processing associated with attentional processes."	( Kim, CH; Kim, YR; Park, JH; Pyo, J; Treasure, J, 2014)
"Oxytocin is a potent regulator of these processes."	( Bakker, FC; Biesheuvel, TH; Denys, D; Frijling, JL; Goslings, JC; Honig, A; Koch, SB; Luitse, JS; Nawijn, L; Olff, M; van Zuiden, M; Veltman, DJ, 2014)
"Oxytocin is a valuable, time-tested drug and one of the most commonly used medications during labour and delivery.It acts on the smooth muscle of the uterus to stimulate contractions. "	( , 2014)
"Oxytocin (OT) is a neuropeptide previously related to reward, learning, memory, and stress, events associated with cocaine addiction. "	( Hernández-Burgos, MM; Maldonado-Vlaar, CS; Martínez-Rivera, A; Montalvo, J; Morales-Rivera, A; Pérez-Colón, J; Rivera, R; Rodríguez-Borrero, E, 2014)
"Oxytocin is a nonapeptide hormone that has a central role in the regulation of parturition and lactation. "	( Arrowsmith, S; Wray, S, 2014)
"Oxytocin (OT) is a nonapeptide with an impressive variety of physiological functions. "	( de Jong, TR; Korte, SM; Olivier, B; Veening, JG; Waldinger, MD, 2015)
"Oxytocin is a well known drug most commonly used in obstetrics for induction or augmentation of labor."	( Arámbula-Almanza, J; Camarena-Pulido, EE; López-Ramírez, CE, 2014)
"Oxytocin (OT) is a neuropeptide involved in mammalian social behavior. "	( Bales, KL; Crawley, JN; Jacob, S; Larke, RH; Mendoza, SP; Pride, MC; Puhger, KR; Sahagun, E; Silverman, JL; Solomon, M, 2014)
"Oxytocin is a nonapeptide involved in a wide range of physiologic and behavioral functions. "	( Bortolini, MC; Comas, D; Lucion, AB; Paixão-Côrtes, VR; Paré, P; Pissinatti, A; Rigo, MM; Salzano, FM; Sinigaglia, M; Tovo-Rodrigues, L; Vargas-Pinilla, P; Vieira, CM; Vieira, GF; Xavier, A, 2015)
"Oxytocin is a hormone known for a long time, mainly used in the field of gynecology. "	( Altirriba, J; Golay, A; Pataky, Z; Rohner-Jeanrenaud, F, 2015)
"Oxytocin (OXT) is an important neurohypophyseal hormone that influences wide spectrum of reproductive and social processes. "	( French, JA; Harrison, EB; Lu, G; Moriyama, H; Mustoe, AC; Ren, D, 2015)
"Oxytocin (OXT) is a well-known neurohypophysial hormone that is synthesised in the paraventricular (PVN) and supraoptic nuclei (SON) of the hypothalamus. "	( Hashimoto, H; Ishikura, T; Kawasaki, M; Maruyama, T; Matsuura, T; Mori, T; Motojima, Y; Ohkubo, JI; Ohnishi, H; Sabanai, K; Sakai, A; Ueta, Y; Yoshimura, M, 2015)
"Oxytocin (OT) is a neuropeptide, which can be seen to be one of the molecules of the decade due to its profound prosocial effects in nonvertebrate and vertebrate species, including humans. "	( Busnelli, M; Chini, B; Eliava, M; Grinevich, V; Knobloch-Bollmann, HS, 2016)
"Oxytocin is a key regulator of social bonding and is positively linked to affiliation and prosocial behavior in several mammal species. "	( Burkart, JM; Finkenwirth, C; van Schaik, C; Ziegler, TE, 2015)
"Oxytocin is a nonapeptide that also serves as a neuromodulator in the human central nervous system. "	( Abu-Akel, A; Shamay-Tsoory, SG, 2016)
"Oxytocin is a potential therapeutic for the core symptoms of autism spectrum disorder (ASD), which is currently untreatable with pharmacotherapy. "	( Yamasue, H, 2016)
"Oxytocin (OT) is a nonapeptide that, in addition to its role as a hormone regulating peripheral reproductive-relevant functions, acts as a neurotransmitter in the brain."	( Feifel, D; MacDonald, K; Shilling, PD, 2016)
"Oxytocin is an anorexigenic neuropeptide similar to vasopressin that is associated with social cognition and obsessive-compulsive behavior."	( Butler, MG; Driscoll, DJ; Johnson, L; Manzardo, AM; Miller, JL, 2016)
"Oxytocin (OT) is a deeply conserved nonapeptide that acts both peripherally and centrally to modulate reproductive physiology and sociosexual behavior across divergent taxa, including humans. "	( Inoue, K; Jamal, YA; Johnson, ZV; Keebaugh, AC; Walum, H; Xiao, Y; Young, LJ, 2016)
"Oxytocin is a neuropeptide regulating social-affiliative and reproductive behaviour in mammals. "	( Fotopoulou, A; Howard, MA; Krahé, C; Maltezos, S; Paloyelis, Y; Williams, SC, 2016)
"Oxytocin is assumed to be a potential therapeutic agent for schizophrenia, with a special link to social cognitive functions."	( Bukovskaya, O; Shmukler, A, 2016)
"Oxytocin (OT) is a neuropeptide that mediates a variety of complex social behaviors in animals and humans. "	( Allen, PC; Bales, KL; Freeman, SM; Hwa, GG; Roberts, JA; Samineni, S; Stockinger, D, 2016)
"Oxytocin, which is a well-known hormone secreting during pregnancy, has antioxidant and antiinflammatory effect."	( Altintoprak, N; Atalay Erdoğan, B; Aydin, S; Bekmez Bilmez, ZE; Demir, MG; Kösemihal, E; Şanli, A, 2016)
"As oxytocin is a putative treatment for schizophrenia, the effect of repeated dosing of OT on OT levels, clinical symptoms and the relationship between the two is of interest."	( Buchanan, RW; Kelly, DL; Lee, MR; Linthicum, J; Liu, F; McMahon, RP; Rubin, LH; Strauss, GP; Verbalis, JG; Wehring, HJ, 2016)
"Oxytocin (OT) is a nonapeptide that regulates peripheral reproductive-relevant functions, and also acts as a neurotransmitter in the brain."	( Feifel, D; Shilling, PD, 2016)
"Oxytocin (OT) is a neuropeptide elaborated by the hypothalamic paraventricular (PVN) and supraoptic (SON) nuclei. "	( Althammer, F; Busnelli, M; Chao, MV; Charlet, A; Chavant, V; Chini, B; Ciobanu, AC; da Silva Gouveia, M; Eliava, M; Froemke, RC; Giese, G; Goumon, Y; Grinevich, V; Gruber, T; Knobloch-Bollmann, HS; Kuner, R; Melchior, M; Mitre, M; Petit-Demoulière, N; Poisbeau, P; Roth, LC; Seeburg, PH; Sprengel, R; Stoop, R; Tan, LL; Tang, Y; Triana Del Rio, R; Wahis, J, 2016)
"Oxytocin (Oxt) is a key neuropeptide that regulates maternal behaviors as well as social behaviors in mammals. "	( Kaitsuka, T; Matsunaga, N; Matsunaga, T; Tomizawa, K; Watanabe, S; Wei, FY, 2016)
"Oxytocin is a neuroendocrine hormone associated with social behavior."	( Bonan, CD; Gaspary, KV; Siebel, AM; Zimmermann, FF, 2016)
"Oxytocin is a neuropeptide involved in social-approach behaviors in humans and others mammals."	( Cochran, RN; Denison, L; Filkowski, MM; Haas, BW; Ishak, A; Nishitani, S; Smith, AK, 2016)
"Oxytocin (OT) is a neuromodulator that facilitates pair-bonding, maternal care and social approach. "	( Atabaki, K; Donhoffner, ME; Goings, SP; Wood, RI, 2016)
"Oxytocin is a hormone that may not only influence reproductive mechanisms in mammals but also their social behavior, including pair bonding. "	( Bruckmaier, RM; Burger, D; Käser, R; Sieme, H; Thomas, S; Wedekind, C, 2016)
"Oxytocin is a neuropeptide widely recognized for its role in regulating social and reproductive behavior. "	( Heffernan, J; Heisel, C; Hsu, DT; Love, TM; Mickey, BJ; Peciña, M; Zubieta, JK, 2016)
"Oxytocin is a hypothalamic neuropeptide that has gained attention for the effects on social behavior. "	( Froemke, RC; Marlin, BJ, 2017)
"Oxytocin (OXT), which is a well-known neurohypophysial hormone that is synthesized in the paraventricular (PVN) and supraoptic nuclei (SON) of the hypothalamus, is secreted from the posterior pituitary (PP) into the systemic circulation, where it plays an essential role in reproduction, especially during and after childbirth. "	( Kawasaki, M; Matsuura, T; Motojima, Y; Ohnishi, H; Sakai, A; Ueta, Y, 2016)
"Oxytocin is a hormone therapeutically used mainly for its peripheral effects during pregnancy in the uterus and breasts. "	( Hess, L; Kurzová, A; Málek, J; Slíva, J; Votava, M, 2016)
"Oxytocin (OXT) is a neuropeptide hormone synthesized and secreted by hypothalamic neurons and has been reported to play a significant role in pain modulation. "	( Asaka, J; Iwata, K; Katagiri, A; Kubo, A; Shinoda, M; Suzuki, T; Takeda, M; Yeomans, DC, 2017)
"Oxytocin is a hypothalamic peptide that contributes to maternal infant bonding and has diverse pro-social effects in adults."	( Elliott, T; Hamer, RM; Jarskog, LF; Johnson, JL; Pedersen, CA; Penn, DL; Rau, SW, 2017)
"Oxytocin (OT) is a neurohypophysial hormone which has been found to play a central role in the regulation of human parturition. "	( Bennett, PR; Kim, SH; Terzidou, V, 2017)
"Oxytocin is a hypothalamic neuropeptide that promotes prosocial behaviors and plays a role in drug-related neuroadaptations; as such, oxytocin may enhance the effect of MET on cannabis outcomes."	( Baker, NL; McRae-Clark, AL; Sherman, BJ, 2017)
"Oxytocin (OXT) is a pleiotropic regulator of physiology and behavior. "	( Greenwood, MA; Hammock, EA, 2017)
"Oxytocin (OT) is a well-known neurohypophysical hormone that is synthesized in the paraventricular (PVN) and supraoptic nuclei (SON) of the hypothalamus."	( Chen, H; Li, X; Wu, T; Wu, Y; Xu, B; Xu, X, 2017)
"Oxytocin (OT) is a potential treatment for multiple neuropsychiatric disorders. "	( Akhlaghi, F; Averbeck, BB; Cummins, A; Diao, XX; Huestis, MA; Lee, MR; Leggio, L; Scheidweiler, KB, 2018)
"Oxytocin is a commonly used uterotonic that can cause significant and even fatal hypotension, particularly when given as a bolus. "	( Archer, TL; Carter, B; Knape, K; Liles, D; Wheeler, AS, 2008)
"Oxytocin is a mammalian hormone that is released mainly after distension of the uterine cervix. "	( Kwon, J; Lee, ES; Lee, YM; Park, SH; Soo, KH; Uhm, KO, 2008)
"Oxytocin is a short peptide with multiple functions in human biology and has been implicated in autism. "	( Daly, A; Tyler-Smith, C; Wu, L; Xu, Y; Xue, Y, 2008)
"Oxytocin is a hormone and neurotransmitter found to have anti-inflammatory functions in rodents. "	( Clodi, M; Geyeregger, R; Luger, A; Luger, TA; Riedl, M; Struck, J; Stulnig, TM; Vila, G, 2008)
"Oxytocin (OXT) is a nine-amino-acid peptide that is synthesized in the paraventricular and supraoptic nucleus of the hypothalamus and released into the bloodstream by axon terminals in the posterior pituitary where it plays an important role in facilitating uterine contractions during parturition and in milk let-down."	( Bartz, JA; Hollander, E, 2008)
"Oxytocin is a neuropeptide recently associated with social behavior in animals and humans, but the study of its function in populations with social deficits such as autism, schizophrenia, and social anxiety disorder has only recently begun. "	( Hoge, EA; Kaufman, RE; Pollack, MH; Simon, NM; Zak, PJ, 2008)
"Oxytocin is a hypothalamic neuropeptide that plays a key role in mammalian female reproductive function. "	( Amico, JA; Cai, HM; Cyranowski, JM; Frank, E; Hofkens, TL; Seltman, H, 2008)
"Oxytocin is a neuropeptide with widespread influence on many physiological and social functions including: labor and birth, lactation, sexual behavior, nurturing maternal behaviors, and stress reduction. "	( Bell, A; Carter, CS; Pournajafi-Nazarloo, H; Schwertz, D; Watanabe, K; White-Traut, R, 2009)
"Oxytocin (Oxt) is a nonapeptide hormone best known for its role in lactation and parturition. "	( Lee, HJ; Macbeth, AH; Pagani, JH; Young, WS, 2009)
"Oxytocin is a neuropeptide that can reduce neophobia and improve social affiliation. "	( Magara, F; Stoop, R; Terrettaz, T; Viviani, D, 2010)
"Oxytocin is a nine amino acid peptide involved in a wide spectrum of physiological functions; predominantly those concerning reproduction and differentiation are of interest. "	( Anastasiadou, V; Antsaklis, A; Beretsos, P; Bletsa, R; Dinopoulou, V; Elenis, E; Fotinos, A; Kiapekou, E; Koussoulakos, S; Lekka, K; Loutradis, D; Stefanidis, K, 2009)
"Oxytocin is a nonapeptide of the neurohypophyseal protein family that binds specifically to the oxytocin receptor to produce a multitude of central and peripheral physiological responses. "	( Assinder, SJ; Tom, N, 2010)
"Oxytocin is a cyclic nonapeptide whose best known effects are stimulation of uterine smooth muscle cells during labor and of milk ejection during lactation. "	( Casti, A; Cossu, M; DE Lisa, A; Isola, M; Isola, R; Lantini, MS; Massa, D; Solinas, P, 2010)
"Oxytocin is a high-alert drug for which safety precautions are crucial. "	( Grant, K; Kauffman, T; Mandel, D; Pirko, C; Schneider, J; Williams, L, 2009)
"Oxytocin is a neurohypophyseal hormone hypothesized to coordinate both the causes and effects of positive social interactions, and may be involved in positive physiological adaptations such as buffering the deleterious effects of stress and promoting resilience."	( Adler, GK; Appleton, A; Block, J; Kubzansky, LD; Mendes, WB, 2009)
"Oxytocin (OT) is a peptide increasingly studied in relation to human social interactions, affiliation, and clinical disorders. "	( Davenport, RE; Grewen, KM; Light, KC, 2010)
"Oxytocin is a neuropeptide that is associated with increased trust. "	( Blair, RJ; Marsh, AA; Pine, DS; Yu, HH, 2010)
"Oxytocin (OT) is a peptide involved in several physiological functions in the central nervous system including central cardiovascular regulation. "	( Covenas, R; Diaz-Cabiale, Z; Narvaez, JA; Narvaez, M; Parrado, C; Vela, C, 2010)
"Oxytocin receptor is a seven transmembrane receptor widely expressed in the CNS that triggers G(i) or G(q) protein-mediated signaling cascades leading to the regulation of a variety of neuroendocrine and cognitive functions. "	( Bulgheroni, E; Busnelli, M; Chini, B; Gravati, M; Parenti, M; Reversi, A; Spaiardi, P; Toselli, M, 2010)
"Oxytocin is a nonapeptide (i.e., it has nine amino acids)."	( Green, JJ; Hollander, E, 2010)
"Oxytocin is a neurohypophyseal protein that regulates a number of central and peripheral responses such as uterine contractions and milk ejection."	( Amrani, Y; Baidouri, H; Brightling, CE; Cooper, PR; Griswold, D; Huang, C; Jain, D; Keslacy, S; Li, K; Li, L; Liu, V; Panettieri, RA; Siddiqui, S; Sims, MW; Syed, F; Zhao, H, 2010)
"Oxytocin (OT) is a nonapeptide essential for maternal care. "	( Brooks, LR; Chung, WC; Tsai, PS, 2010)
"Oxytocin is a potent inducer of penile erection when injected into the central nervous system. "	( Argiolas, A; Melis, MR, 2011)
"Oxytocin (OT) is a versatile neuropeptide that is involved in a variety of mammalian behaviors, and its role in reproductive function and behavior has been well established. "	( Bhatt, R; Gil, M; Hull, EM; Picotte, KB, 2011)
"Oxytocin (OT) is a neuropeptide with an extremely low endogenous level (low pg/ml) in human plasma. "	( Fast, DM; Lin, Z; Steenwyk, R; Zhang, G; Zhang, Y, 2011)
"Oxytocin (OT) is a biomarker that may be associated with a calm, relaxed state, and positive emotion."	( Kikusui, T; Mitsui, S; Mogi, K; Nagasawa, M; Ohta, M; Ohtani, N; Yamamoto, M, 2011)
"Oxytocin (OT) is a female hormone with the main function of facilitating uterine contraction and milk ejection. "	( Teng, RB; Zhang, XH, 2011)
"Oxytocin (OT) is a primitive neurohypophyseal hormone that plays a primary and indispensible role in mammalian lactation. "	( Colaianni, G; Colucci, S; Cuscito, C; Dell'Endice, S; Di Benedetto, A; Grano, M; Greco, G; Iqbal, J; Li, J; Peng, Y; Sun, L; Tamma, R; Yuen, T; Zaidi, M; Zallone, A; Zhu, G; Zhu, LL, 2011)
"Oxytocin is a peptide hormone involved in appetite and energy homeostasis."	( Blum, JI; Donoho, DA; Herzog, DB; Klibanski, A; Lawson, EA; Meenaghan, EM; Miller, KK; Misra, M; Sluss, PM, 2011)
"Oxytocin is a peptide hormone produced in the hypothalamus and it is best known for its role in labour and lactation. "	( Edwall, L; Jonasson, AF; Uvnäs-Moberg, K, 2011)
"Oxytocin (OT) is a neuropeptide acting both as a peripheral hormone and in the brain as neurotransmitter and neuromodulator. "	( Chottova-Dvorakova, M; Hynie, S; Klenerova, V; Mistrova, E; Sida, P; Skopek, P; Slavikova, J, 2011)
"Oxytocin is a neuropeptide associated with social affiliation and maternal caregiving. "	( Fonagy, P; Iyengar, U; Kim, S; Strathearn, L, 2012)
"Oxytocin (OT) is a neuropeptide that is attracting growing attention from researchers interested in human emotional and social behavior. "	( de Timary, P; Gross, JJ; Lane, A; Luminet, O; Mikolajczak, M; Rimé, B, 2013)
"Oxytocin is a neuropeptide produced primarily in the hypothalamus and is best known for its roles in parturition and lactation. "	( Denda, M; Denda, S; Goto, M; Kumamoto, J; Takei, K; Tsutsumi, M, 2012)
"Oxytocin is a neuropeptide that is associated with increases in social affiliative behaviors, particularly toward infants. "	( Blair, RJ; Goldman, D; Gorodetsky, EK; Marsh, AA; Pine, DS; Yu, HH, 2012)
"Oxytocin (OXT) is a peptide hormone that binds the OXT receptor on myometrial cells, initiating an intracellular signaling cascade, resulting in accumulation of intracellular calcium and smooth muscle contraction. "	( López Bernal, A; McArdle, CA; Pont, JN, 2012)
"Oxytocin (OT) is a neurohypophyseal peptide traditionally associated with female reproductive functioning, and more recently with prosocial behavior. "	( Gonzales, JA; Herderick, EE; McCabe, PM; Mendez, AJ; Noller, CM; Rossetti, MA; Schneiderman, N; Szeto, A, 2013)
"Oxytocin is a hormone, which is released into the circulation in response to acute or chronic stress stimuli. "	( Barancik, M; Bartekova, M; Jezova, D; Ondrejcakova, M; Ravingerova, T, 2012)
"Oxytocin (OT) is a hormone shown to be involved in social bonding in animal models. "	( Bales, KL; Conley, OG; Downing, GM; Guoynes, CD; Jacob, S; Lee, MH; Mendoza, SP; Perkeybile, AM; Solomon, M; Yun, CR, 2013)
"Oxytocin is a neuromodulator with antidepressant-like effects. "	( Chai, SY; De Bundel, D; Demaegdt, H; Gard, P; Loyens, E; Michotte, Y; Smolders, I; Vanderheyden, P, 2013)
"Oxytocin is a peptide hormone that has shown relatively widespread effects on prosocial behaviors in other species."	( Holmes, MM; Mooney, SJ, 2013)
"Oxytocin is a peptide drug used to induce labor and prevent bleeding after childbirth. "	( Avanti, C; Frijlink, HW; Hinrichs, WL; Mulder, FA; Oktaviani, NA, 2013)
"Oxytocin (OT) is a neurohypophysial hormone with unclear physiological functions in the male. "	( Bencini, E; Brocchi, S; Crescioli, C; Filippi, S; Forti, G; Granchi, S; Ledda, F; Luconi, M; Maggi, M; Mancina, R; Natali, A; Noci, I; Vannelli, GB; Vignozzi, L, 2002)
"Oxytocin is an important modulator of female reproductive functions including parturition, lactation and maternal behavior, while vasopressin regulates water balance and acts as a neurotransmitter. "	( Dellovade, TL; Merchenthaler, I; Shughrue, PJ, 2002)
"Oxytocin is an essential hormone for mammalian labor and lactation. "	( Iga, N; Itano, T; Li, ST; Lu, YF; Matsui, H; Matsushita, M; Miyamoto, O; Moriwaki, A; Tomizawa, K, 2003)
"Oxytocin (OT) is a neurohypophysial hormone with overall unclear physiological functions in the male. "	( Filippi, S; Forti, G; Ledda, F; Maggi, M; Vannelli, GB; Vignozzi, L, 2003)
"Oxytocin is a treatment of choice for augmentation and induction of labor; however, no consensus exists regarding optimal dosing. "	( Johnston, AK; Lodolce, AE; Patka, JH, 2005)
"Oxytocin (OT) acts as a neuromodulator/neurotransmitter within the central nervous system (CNS) and regulates a diverse range of CNS functions. "	( Boikess, S; Luo, B; Malberg, JE; Ping, J; Potestio, L; Rahman, Z; Ring, RH; Rizzo, S; Rosenzweig-Lipson, S; Schechter, LE, 2006)
"Oxytocin (OXY) is a very abundant neuropeptide exerting a wide spectrum of central and peripheral effects as neurohormone, neurotransmitter, or neuromodulator. "	( Kiss, A; Mikkelsen, JD, 2005)
"Oxytocin is a small peptide hormone with multiple sites of action in human body. "	( Blanks, A; Gullam, J; Shmygol, A; Thornton, S, 2006)
"Oxytocin is a key hormone involved in milk ejection. "	( Mondal, M; Prakash, BS; Rajkhowa, C, 2006)
"Oxytocin (OT) is a neuropeptide synthesized in the paraventricular (PVN) and supraoptic nuclei (SON) in the hypothalamus. "	( Cruz, T; Emiliano, AB; Fudge, JL; Pannoni, V, 2007)
"Oxytocin (OT) is a neuropeptide that is produced primarily in the hypothalamus and is best known for its role in mammalian birth and lactation. "	( Bello, D; Carter, CS; Kramer, KM; Pournajafi-Nazarloo, H; Schwertz, D; White-Traut, R; Ziegler, TE, 2007)
"Oxytocin (OT) is a neurosecretory nonapeptide synthesized in hypothalamic cells that project to the neurohypophysis as well as to widely distributed sites in the central nervous system. "	( Antunes-Rodrigues, J; Garcia-Cairasco, N; Gati, CD; Marroni, SS; Nakano, FN; Oliveira, JA, 2007)
"Oxytocin is a peptide hormone produced by the neurohypophysis. "	( Nicholson, HD; Whittington, K, 2007)
"Oxytocin (OT) is a neurohypophysial hormone synthesized in the paraventricular and supraoptic nuclei of the hypothalamus. "	( Catena Dell'osso, M; Marazziti, D, 2008)
"Oxytocin is a highly successful and safe agent for inducing labor and has a fairly large therapeutic index. "	( Petrie, RH; Shyken, JM, 1995)
"Oxytocin (OT) is a neurohypophysial hormone with potent stimulating activity of the pregnant uterus, but its physiological role in parturition is still unclear. "	( Higuchi, T; Liu, CX; Matsukawa, S; Negoro, H; Saito, H, 1995)
"Oxytocin (OT) is a neurosecretory nonapeptide synthesized in hypothalamic cells, which project to widely distributed sites in the CNS as well as the neurohypophysis. "	( Anderson, GM; Barr, LC; Chappell, PB; Goodman, WK; Leckman, JF; McDougle, CJ; North, WG; Pauls, DL; Price, LH; Riddle, MA, 1994)
"Oxytocin is a nonapeptide hormone that participates in the regulation of parturition and lactation. "	( Amico, J; Ginns, EI; Hennighausen, L; LaMarca, ME; McKinney, C; Shepard, E; Wagner, KU; Young, WS, 1996)
"Oxytocin is a cheap atoxic drug and should be given routinely after vaginal delivery."	( Fogelstam, K; Fridman, G; Larsson, A; Nordström, L; Rydhstroem, H, 1997)
"Oxytocin is a negative chronotropic and positive inotropic agent in hearts from pregnant and nonpregnant rats. "	( Cefalo, RC; Coulson, CC; Mayer, DC; Thorp, JM, 1997)
"Oxytocin is an acute stimulus of prostaglandin (PG) F2alpha secretion from the ovine uterine endometrium. "	( Burns, PD; Graf, GA; Hayes, SH; Silvia, WJ; Tsai, SJ; Wiltbank, MC, 1997)
"Oxytocin is a neurohypophyseal hormone that has long been associated with uterine contraction during parturition and milk ejection during nursing. "	( Insel, TR; Wang, Z; Young, L, 1997)
"Oxytocin is a nonapeptide hormone that participates in the regulation of parturition and lactation. "	( Amico, J; DeVries, AC; Ginns, EI; Hennighausen, L; LaMarca, ME; Nelson, RJ; Shepard, E; Wagner, KU; Young, WS; Zimmer, A, 1998)
"Oxytocin is a nonapeptide hormone (CYIQNCPLG-NH2, OT), controlling labor and lactation in mammalian females, via interactions with specific cellular membrane receptors (OTRs). "	( Ciarkowski, J; Czaplewski, C; Politowska, E, 1999)
"Oxytocin is a classic reproductive neuropeptide in the female mammal, but its functions in the brain of the male have been less well studied. "	( Holsboer, F; Landgraf, R; Neumann, ID; Torner, L; Wigger, A, 2000)
"Oxytocin (OT) is a hypothalamic nonapeptide that is synthesized as part of a larger precursor protein that also contains an approximately 10-kDa protein called neurophysin at its C-terminus. "	( Gainer, H; Iacangelo, A; Kusano, K; Young, WS; Zerfas, P; Zhang, BJ, 2002)
"Oxytocin is a neurohypophyseal peptide hormone that induces labor and lactation in mammals. "	( Blomberg, D; Brickmann, K; Ekholm, K; Johansson, B; Kihlberg, J; Nilsson, A; Sethson, I; Yuan, Z, 2002)
"Oxytocin (OT) is a nine amino acid peptide synthesized in hypothalamic cells which project either to the neurohypophysis or to sites within the central nervous system. "	( Insel, TR, 1992)
"Oxytocin is a hypothalamic neuropeptide with both centrally and peripherally directed pathways. "	( Brandt, HA; Demitrack, MA; Gold, PW; Jimerson, DC; Lesem, MD; Listwak, SJ, 1990)
"Oxytocin is a major peptide product of the ruminant corpus luteum, and the release of oxytocin from serum-free cultures of bovine granulosa cells is stimulated by insulin and insulin-like growth factor-I (IGF-I). "	( Furuya, K; Holtorf, AP; Ivell, R; McArdle, CA, 1989)
"1. Oxytocin is a nonapeptide hormone first isolated in the central nervous system in the supraoptic and paraventricular nuclei of the hypothalamus. "	( Demitrack, MA; Gold, PW, 1988)
"Oxytocin (OXY) is a nonapeptide of hypothalamic origin which has defined roles in the female reproductive functions of lactation and labor. "	( Kasting, NW, 1986)
"Oxytocin is a potent uterine stimulant that is used for the induction and augmentation of labor, antenatal fetal assessment, and control of postpartum hemorrhage. "	( Kruse, J, 1986)

Effects

Excerpt	Reference
"Oxytocin (OT) has a well-established role in reproductive behaviours; however, it recently emerged as an important regulator of energy homeostasis. "	( Asker, M; Bhat, YR; Börchers, S; Borner, T; De Jonghe, BC; Doebley, S; Doyle, RP; Furst, CD; Hayes, MR; Krieger, JP; Liles, A; Longo, F; Maric, I; Skibicka, KP; Tinsley, IC, 2023)
"Oxytocin has a narrow therapeutic index and the optimal dosing for any individual woman varies widely."	( Ashley-Koch, AE; Garrett, ME; Grotegut, CA; Miranda, ML; Ngan, E; Swamy, GK, 2017)
"Oxytocin (OT) has an anti-inflammatory and antioxidant effect in the different inflammatory models. "	( Aziz, NM; Ragy, MM, 2017)
"Oxytocin has a conserved role in regulating animal social behaviour including parental-offspring interactions. "	( Calahorro, F; de Freitas, R; Dillon, J; Feist, E; Holden-Dye, L; Hudson, A; O'Connor, V; Schoofs, L; Scott, E; Wand, M, 2017)
"Oxytocin has an important function in breastfeeding via its role in the milk ejection reflex and in attachment and bonding processes. "	( Colodro-Conde, L; Lind, PA; Martin, NG; Medland, SE; Ordoñana, JR; Sánchez-Romera, JF; Zhu, G, 2018)
"Oxytocin (OT) has a postconditioning effect against the ischemia-reperfusion (I/R) injury. "	( Alizadeh, AM; Farnoosh, G; Ghayour-Mobarhan, M; Jamialahmadi, K; Jand, Y; Khori, V; Polshekan, M; Rajaei, M; Saeidi, M, 2019)
"Oxytocin has a protective effect against I/R injury in skeletal muscle and may reduce the incidence of compartment syndrome."	( Arbak, S; Aydin, U; Bakir, I; Ercan, F; Erkanli Senturk, G; Erkanli, K; Isiksacan, N; Tuncdemir, M, 2013)
"Oxytocin (OXT) has a plethora of effects on brain function. "	( Kovács, GL; Sarnyai, Z, 2014)
"Oxytocin has a significant role in neurogenesis, and this may have implications in regeneration of adult neurons."	( Jafarzadeh, N; Javeri, A; Khaleghi, M; Taha, MF, 2014)
"Oxytocin has a wide range of effects over neural activity in response to social and emotional processing, which is further modulated by sex and task specificity. "	( Allen, P; Averbeck, B; Fusar-Poli, P; McGuire, P; Meyer-Lindenberg, A; Radua, J; Shergill, SS; Wigton, R, 2015)
"Oxytocin has a modulatory role in natural and drug reward processes. "	( Ghee, SM; Reichel, CM; See, RE; Zhou, L, 2015)
"Oxytocin has a crucial role in social behaviour, although its effects on social cognition are not fully understood. "	( Carson, DS; Cox, RE; Dadds, MR; Guastella, AJ; Mitchell, PB, 2009)
"Oxytocin has a substantial role in social attachment, affiliation and sexual behavior."	( Baskerville, TA; Douglas, AJ, 2010)
"Oxytocin has a combination of pharmacologic effects that result in a "sense of safety" for the patient, which is a prerequisite to successful treatment of PTSD."	( Denys, D; Langeland, W; Olff, M; Witteveen, A, 2010)
"Oxytocin (OT) has an organizational effect within the central nervous system and can have long-lasting effects on the expression of social behavior. "	( Cushing, BS; Eaton, JL; Nguyen, KN; Papademetriou, E; Raghanti, MA; Roache, L; Troyer, E, 2012)
"Oxytocin has an important role in the management of labour. "	( Buchanan, SL; Ford, JB; Morris, JM; Patterson, JA; Roberts, CL, 2012)
"Oxytocin has a fundamental role in social behavior. "	( Andari, E; Mottolese, R; Schneider, FC; Sirigu, A; Vindras, P, 2014)
"Oxytocin (OT) has an important role in bond formation and social reciprocity, and animal studies indicate that OT functioning is transferred from parent to child through patterns of parental care. "	( Ebstein, RP; Feldman, R; Gordon, I; Gutbir, T; Influs, M, 2013)
"Oxytocin (OT) has a wide range of effects throughout the body. "	( Grahn, N; Monstein, HJ; Ohlsson, B; Truedsson, M, 2004)
"Oxytocin has an antidiuretic effect and increases the urinary excretion of AQP2 in humans whose urinary concentration mechanism is preserved. "	( Ahn, C; Han, JS; Jeon, US; Joo, KW; Kim, GH; Kim, S; Kim, SY; Kim, YS; Lee, JS; Oh, YK; Park, J, 2004)
"Oxytocin (OT) has a dual action in the uterus: a uterotonic action on myometrial cells and a prostaglandin (PG)-releasing action on endometrial/decidual cells. "	( Chan, WY; Chen, DL; Manning, M, 1993)
"oxytocin has a selective permissive effect on the excitation of oxytocin neurones from the ventral tegmentum, and this supports previous in vitro studies suggesting that centrally released oxytocin may act as a modulator of afferent transmission to the magnocellular nuclei."	( Cosgrave, AS; Richardson, CM; Wakerley, JB, 2000)
"Oxytocin has been administered in clinical practice to many children with autism spectrum disorder."	( Alderman, C; Bhapkar, M; Chandrasekhar, T; Crosson, H; Dean, R; Giamberardino, SN; Gregory, SG; Hong, N; Johnson, JL; Kim, SJ; King, BH; Kolevzon, A; Luo, S; Marler, S; McDougle, CJ; Minjarez, M; Montgomery, A; Mullett, JE; Nowinski, LA; Palumbo, ML; Rockhill, CM; Sanders, KB; Scheer, A; She, L; Shuffrey, LC; Siecinski, SK; Sikich, L; Siper, P; Spanos, M; Trelles, MDP; Veenstra-VanderWeele, J; Weissman, J; Witters Cundiff, A; Zappone, B, 2021)
"The oxytocin (OXT) system has garnered considerable interest due to its influence on diverse behaviours. "	( Bowen, MT; Hoyos, CM; Raymond, JS; Rehn, S, 2021)
"Oxytocin (OXT) has attracted research interest for its potential involvement in many of the behavioural problems observed in childhood. "	( Martins, D; Monteiro, L; Santos, AJ; Torres, N; Vaughn, BE; Veríssimo, M, 2022)
"Oxytocin has been revealed to work for anxiety suppression and anti-stress as well as for psychosocial behavior and reproductive functions. "	( Onaka, T; Takayanagi, Y, 2021)
"Oxytocin has been used to treat neurodevelopmental conditions in adolescent patients but possible effects on reproductive development have not been well investigated. "	( Bales, KL; Berger, T; Conley, AJ; Cotterman, RF; Del Razo, RA; Dufek, ME; Goetze, LR; Jacob, S; Mendoza, SP; Sahagún, E; Weinstein, TAR, 2022)
"Oxytocin has historically been linked to processes involved with maternal behavior. "	( Grieb, ZA; Taylor, JH, 2022)
"Oxytocin (OT) has been proposed as a potential biomarker in the treatment of depression given its involvement in depression-related psychological and physiological functions and the formation of close relationships."	( Atzil-Slonim, D; Bar-Kalifa, E; Feldman, R; Gilboa-Schechtman, E; Paz, A; Rotter, I; Stolowicz-Melman, D; Wolff, M; Zagoory, O, 2022)
"Oxytocin has become a popular analyte in behavioral endocrinology in recent years, due in part to its roles in social behavior, stress physiology, and cognition. "	( Carter, CS; Gnanadesikan, GE; Hammock, EAD; Hart, R; Lewis, RJ; MacLean, EL; Tecot, SR, 2022)
"Oxytocin (OT) has been shown to have antistress and antidepressant-like effects in male rodents."	( Enjoji, M; Harada, H; Mori, M; Murata, Y; Ohe, K; Shizunaga, H; Tajiri, Y; Terada, K, 2022)
"Oxytocin levels have been correlated over time with mental illness, with numerous studies focusing on oxytocin and the pathophysiology of the main psychiatric disorders, such as autism, schizophrenia, personality disorders, mood, and eating disorders."	( Bîrsan, M; Chiriță, R; Cristofor, AC; Dobrin, I; Dobrin, RP; Florea, T; Pădurariu, M; Palimariciuc, M, 2022)
"Oxytocinegic system has been shown to be implicated in the pathophysiology of schizophrenia."	( Akbari, M; Akhavan-Bahabadi, M; Badrlou, E; Eghtedarian, R; Eslami, S; Ghafouri-Fard, S; Mahmud Hussen, B; Neishabouri, SM; Taheri, M, 2022)
"Oxytocin has been detected in the mammalian retina; however, the expression and possible function of oxytocin receptors (OxtR) in the retina remain unknown."	( Dai, M; Han, X; Hu, S; Ma, Y; Wang, Y; Weng, S; Xiao, L; Zhang, Y, 2022)
"Oxytocin has attracted research attention due to its role in promoting social bonding. "	( Brooks, J; Kano, F; Morimura, N; Yamamoto, S; Yeow, H, 2022)
"Oxytocin has recently gained significant attention because of its role in the pathophysiology and management of dominant neuropsychiatric disorders. "	( Alawy, AY; Elbahnasi, AI; Ghazy, AA; Gowayed, MA; Mansour, AM; Soliman, OA, 2023)
"Oxytocin (OT) has shown promise as a potential pharmacotherapy for PSUD."	( Bacon, AK; Bailey, LG; Chen, AY; Hersey, M; Lee, MR; Leggio, L; Tanda, G, 2023)
"Oxytocin (OT) has a well-established role in reproductive behaviours; however, it recently emerged as an important regulator of energy homeostasis. "	( Asker, M; Bhat, YR; Börchers, S; Borner, T; De Jonghe, BC; Doebley, S; Doyle, RP; Furst, CD; Hayes, MR; Krieger, JP; Liles, A; Longo, F; Maric, I; Skibicka, KP; Tinsley, IC, 2023)
"Oxytocin has the potential to improve treatment outcome among inpatients. "	( Bloch, Y; Grossman-Giron, A; Kivity, Y; Maoz, H; Mendlovic, S; Nitzan, U; Tzur Bitan, D; Zilcha-Mano, S, 2023)
"The oxytocin receptor has long been considered critical for social bonding and parenting in prairie voles. "	( Harony-Nicolas, H; Rajamani, KT, 2023)
"Oxytocin (OT) has been studied as a therapeutic neuropeptide in various diseases, but its effect on the ovary and uterus is not fully known. "	( Abdulova, A; Isildar, B; Sahin, H; Senturk, GE; Sezer, Z, 2023)
"Oxytocin has been shown to alleviate emotional disorders by modulating the hypothalamic-pituitary-adrenal (HPA) axis and the central immune system."	( Chen, Z; Gong, Y; Jiang, J; Tian, M; Xiao, L; Yang, M, 2023)
"Oxytocin has traditionally been known for its physiological effects on muscle contraction associated with birth and lactation, but in the last years is widely used as a biomarker of "positive experiences" in psychology and behavior. "	( Botía, M; Cerón, JJ; López-Arjona, M; Martínez-Subiela, S, 2023)
"Oxytocin (OT) has been detected in various body fluids, including blood, urine, saliva, breastmilk, and spinal fluid. "	( Feldman, R; Levine, A; Zagoory-Sharon, O, 2023)
"Oxytocin (OXT) has been reported to act as a growth regulator in various tumor cells. "	( Choi, J; Chung, CH; Eom, YW; Jo, YS; Kwon, HJ; Kwon, JY; Lee, EJ; Lee, ES; Lim, JS, 2019)
"Oxytocin has been proposed to have clearer beneficial effects when added to social learning paradigms."	( Alaerts, K; Bakermans-Kranenburg, MJ; Bosmans, G; Casteels, K; Ceulemans, E; de Winter, S; Salemink, E; Santens, T; van IJzendoorn, MH; Verhaeghe, J; Verhees, MWFT, 2020)
"Oxytocin (OT) has been reported to have a protective effect in lipopolysaccharide-induced experimental acute lung injury (ALI). "	( Chang, CP; Chen, TH; Lin, CH; Tsai, CC; Yang, HH, 2019)
"Oxytocin has previously been demonstrated to exert pro-social effects and modulate eye gaze during face exploration."	( Bell, V; Coutrot, A; D'Oliveira, T; Mareschal, I; Porffy, LA; Shergill, SS; Wigton, R, 2020)
"Oxytocin (OT) has modulatory effects in both human behavior and in the brain, which is not limited in the specific brain area but also with the potential effect on connectivity with other brain regions. "	( Feng, C; Liu, Q; Liu, X; Lu, X; Wu, H, 2020)
"Oxytocin (OT) has been shown to promote prosocial behavior; however, it remains unclear whether OT affects responsibility attribution and hypothetical resource allocation."	( Li, P; Xu, Q; Yang, S, 2020)
"Oxytocin (OT) has been widely linked to positive social interactions, and there is great interest in OT as a therapy for a variety of neuropsychiatric conditions. "	( De Oliveira Sergio, T; De Oliveira, DC; Frias, AT; Vilela-Costa, HH; Zangrossi, H; Zuardi, AW, 2020)
"Oxytocin has poor penetration of the blood-brain barrier, therefore we tested a nanoparticle drug, TRIOZAN™ (Ovensa Inc.), which permits greater blood-brain-barrier penetration."	( Casanueva-Reimon, L; Duarte-Guterman, P; Galea, LAM; Go, KA; Lieblich, SE; Qiu, W; Splinter, JEJ, 2020)
"Oxytocin (OT) has gained considerable interest in recent years as a potential treatment for alcoholism and other substance use disorders. "	( Krause, EG; Peris, J; Steck, MR, 2020)
"Oxytocin (OT) has been implicated in various aspects of social behaviors. "	( Abu-Akel, A; Peled-Avron, L; Shamay-Tsoory, S, 2020)
"Oxytocin has garnered considerable interest for its role in social behavior, as well as for the potential of intranasal administration to treat social difficulties. "	( Guastella, AJ; Quintana, DS, 2020)
"Oxytocin (OT) has shown a cardioprotective effect on myocardial ischemia/reperfusion injury (MIRI). "	( Chen, H; Qian, J; Qu, Y; Song, N; Wang, Z; Xiong, W; Yang, Y; Yao, M; Zhou, R, 2020)
"Oxytocin (OT) has been suggested as a biological mechanism by which bonds are formed and strengthened across species."	( Dolev-Amit, T; Feldman, R; Shamay-Tsoory, S; Zagoory-Sharon, O; Zilcha-Mano, S, 2020)
"Oxytocin has been suggested as a potential therapeutic agent in autism and other neuropsychiatric conditions. "	( Bacova, Z; Bakos, J; Bukatova, S; Frimmel, K; Kokavcova, M; Meliskova, V; Ostatnikova, D; Reichova, A, 2020)
"Oxytocin has largely been associated with both stress regulation and social cognition in psychiatric patients and in non-clinical populations in previous studies."	( Buenache, E; Carrasco, JL; De la Vega, I; Díaz-Marsá, M; Leza, JC; López-Villatoro, JM; MacDowell, KS; Moreno, B, 2020)
"Oxytocin has been shown to be important for social behavior and emotional attachments in early life and may also mediate effects of early experiences on social motivation in adulthood. "	( Boccia, ML; Cook, C; Marson, L; Pedersen, C, 2021)
"Oxytocin has been a hormone of interest in understanding both depression and parenting. "	( Galbally, M; IJzendoorn, MV; Keelan, J; Lewis, AJ; MacMillan, KK; Power, J; Watson, SJ, 2020)
"Oxytocin has been found to play an important role in human social cognition and social interaction. "	( Huang, L; Liao, Z; Luo, S, 2021)
"Oxytocin (OT) has broad effects in the brain and plays an important role in cognitive, social, and neuroendocrine function. "	( D'Souza, MJ; Escayg, A; Heaton, EC; Murnane, KS; Shapiro, L; Thelin, JT; Wong, JC; Zaman, RU, 2021)
"Oxytocin (OT) has been shown to modulate fear learning, yet effects on fear generalization remain unknown."	( Becker, B; Dou, H; Lei, Y; Zou, L, 2021)
"The oxytocinergic system has been assumed to contribute to food intake, possibly via interactions with dopamine. "	( Brown, EC; Lange, F; Liu, L; Madipakkam, AR; Melkonyan, A; Meyer, W; Münte, TF; Park, SQ; Ringelmann, L; Schmid, SM, 2020)
"Oxytocin has drawn significant research attention for its role in modulating mammalian social behavior. "	( Brooks, J; Kano, F; Kikusui, T; Morimura, N; Nagasawa, M; Sato, Y; Yamamoto, S; Yeow, H, 2021)
"Oxytocin has recently received remarkable attention for its role as a modulator of human behaviour. "	( Dipasquale, O; Martins, D; Paloyelis, Y, 2021)
"Oxytocin (OT) has been linked with maternal bonding and caregiving, but less is known about the role of OT in human fatherhood and paternal caregiving."	( Grumi, S; Provenzi, L; Saracino, A; Volling, BL, 2021)
"Oxytocin has been highlighted as a potential paracrine mediator of BPH."	( Ellem, SJ; Exintaris, B; Frydenberg, M; Hammar, J; Kraska, J; Lawrentschuk, N; Lee, SN; Middendorff, R; Niranjan, B; Papargiris, M; Risbridger, GP; Ryan, A; Teng, L; Whittaker, M, 2021)
"Oxytocin (OXT) has been shown to increase orientation to the eye region."	( Gao, S; Hu, Z; Jia, H; Shi, Y; Zheng, Y, 2021)
"Oxytocin has been associated with anxiolytic and stress reducing effects in a number of studies. "	( Bertsch, K; Ditzen, B; Herpertz, SC; Müller, LE; Schneider, E, 2021)
"The oxytocin (OXT) system has been strongly implicated in the regulation of social behaviour and anxiety, potentially contributing to the aetiology of a wide range of neuropathologies. "	( Casey, S; Cryan, JF; Dinan, TG; Golubeva, AV; Moloney, GM; Morais, LH; Ramos Costa, AP; Scott, KA, 2021)
"Oxytocin deficiency has been suggested in patients with hypopituitarism; however, diagnostic testing for oxytocin deficiency has not been developed."	( Chifu, I; Christ-Crain, M; Eckert, A; Fassnacht, M; Fenske, W; Lawson, EA; Refardt, J; Sailer, CO; Schnyder, I; Urwyler, SA; Varghese, N; Verbalis, JG; Winzeler, B, 2021)
"Oxytocin has been reported to have an antipsychotic-like effect; moreover, COX-2 inhibitors lead to a reduction in positive symptoms of psychosis, specifically in the first episode of illness."	( Bellomo, A; Borraccino, L; Cuoco, F; De Berardis, D; Delle Monache, S; Fornaro, M; Gianfelice, G; Magnifico, G; Piccininni, C; Ricci, F; Rinaldi, A; Ventriglio, A, 2021)
"Oxytocin has therefore been considered a promising candidate for the treatment of social difficulties in ASD."	( Alter, P; Haberhausen, M; Kamp-Becker, I; Krach, S; Mayer, AV; Paulus, FM; Stehr, T; Stroth, S; Wermter, AK, 2021)
"Oxytocin has garnered much interest due to its role in affective states, social behaviors, and diverse physiological functions. "	( Carter, CS; Gnanadesikan, GE; Hammock, EAD; MacLean, EL; Tecot, SR, 2021)
"Oxytocin has a narrow therapeutic index and the optimal dosing for any individual woman varies widely."	( Ashley-Koch, AE; Garrett, ME; Grotegut, CA; Miranda, ML; Ngan, E; Swamy, GK, 2017)
"The oxytocin system has recently received increasing attention due to its effect on complex human behaviours. "	( Ciobica, A; Kis, A; Topál, J, 2017)
"Oxytocin (OT) has the potential to be a marker of neurobiological processes that offer infant neuroprotection."	( Harrison, TM; Shoben, A; Sinnott, L; Steward, D; Weber, A, 2017)
"Oxytocin (OT) has emerged as a mediator of endogenous analgesia in behavioral and electrophysiological experiments. "	( Arámburo, C; Carranza, M; Condés-Lara, M; González-Hernández, A; Manzano-García, A; Martínez-Lorenzana, G; Tello-García, IA, 2017)
"Oxytocin (OT) has an anti-inflammatory and antioxidant effect in the different inflammatory models. "	( Aziz, NM; Ragy, MM, 2017)
"Oxytocin has a conserved role in regulating animal social behaviour including parental-offspring interactions. "	( Calahorro, F; de Freitas, R; Dillon, J; Feist, E; Holden-Dye, L; Hudson, A; O'Connor, V; Schoofs, L; Scott, E; Wand, M, 2017)
"The oxytocin system has been linked to the regulation of repetitive behavior in both animal models and humans, but many of its downstream targets have still to be found."	( Alachkar, A; Civelli, O; Garau, C; Nishimori, K; Sanathara, NM; Wang, L; Wang, Z; Xu, X, 2018)
"Oxytocin has central actions that modulate synaptic plasticity and the occurrence of social behavior in rodents. "	( Becker, RO; Giovenardi, M; Rasia-Filho, AA, 2017)
"Oxytocin (OXT) has been considered as a neuroregulator mediating social behaviors and stress-related disorders. "	( Li, H; Li, X; Liu, B; Shi, C; Wang, H; Wang, T; Wang, Y; Wu, Y; Xu, ZD; Yang, Y; Zhang, P, 2018)
"Oxytocin (OT) has been reported to increase social contact, however some studies have related OT to reduced social contact, particularly with unfamiliar individuals. "	( Cai, Z; Dong, N; Du, P; Hao, X; He, Z; Hou, W; Jia, R; Tai, F; Yang, J; Yuan, W, 2017)
"Oxytocin has gained a reputation in popular culture as a simple "love drug" or "cuddle hormone", yet emerging biological evidence indicates that the effects of oxytocin are complex, mediating a suite of behavioral traits that range from ultrasocial to antisocial. "	( Blumstein, DT; Cristofari, H; Jerome, EL; Petelle, MB; Smith, JE, 2017)
"Oxytocin (OXT) has previously been implicated in a range of prosocial behaviors such as trust and emotion recognition. "	( Daughters, K; Hubble, K; Manstead, ASR; Rees, A; Thapar, A; van Goozen, SHM, 2017)
"Oxytocin neurons have been shown to be activated by stressful stimuli and to have prosocial and anxiolytic actions."	( Inutsuka, A; Nasanbuyan, N; Nishimori, K; Onaka, T; Takayanagi, Y; Yamanaka, A; Yoshida, M, 2018)
"Oxytocin has traditionally been used to prevent postpartum hemorrhage."	( Caceda, SI; Ramos, RR; Saborido, CM, 2018)
"Oxytocin has high affinity for the vasopressin V1A receptor (V1AR) which has been implicated in numerous oxytocin-dependent social behaviours."	( Baracz, SJ; Cornish, JL; Everett, NA; McGregor, IS, 2018)
"Oxytocin has an important function in breastfeeding via its role in the milk ejection reflex and in attachment and bonding processes. "	( Colodro-Conde, L; Lind, PA; Martin, NG; Medland, SE; Ordoñana, JR; Sánchez-Romera, JF; Zhu, G, 2018)
"Oxytocin has shown to play a role in appetite control in humans and is considered an anorexigenic peptide."	( Chen, S; Chester, C; Kelly, DL; Liu, F; McMahon, RP; Warren, KR; Wehring, HJ, 2018)
"Oxytocin (OT) has a postconditioning effect against the ischemia-reperfusion (I/R) injury. "	( Alizadeh, AM; Farnoosh, G; Ghayour-Mobarhan, M; Jamialahmadi, K; Jand, Y; Khori, V; Polshekan, M; Rajaei, M; Saeidi, M, 2019)
"Oxytocin (OT) has drawn the attention of researchers since 1930. "	( Jurek, B; Winter, J, 2019)
"Oxytocin has known antinociceptive effects and is upregulated perinatally. "	( Ende, HB; Nandi, M; Schreiber, KL; Soens, MA; Strichartz, GR, 2019)
"Oxytocin (OT) has gained attention not only as anxiolytic drug and as potential treatment option for autistic children; it also acts as a growth and differentiation factor in neuronal cells. "	( Berger, I; Jurek, B; Meyer, M; Winter, J, 2018)
"Oxytocin (OT) has the suppressive effects on breast tumor formation and development. "	( Alizadeh, AM; Heidarian, Y; Khalighfard, S; Khodayari, H; Khori, V, 2018)
"Oxytocin (OT) has been demonstrated to be involved in various social behaviors in mammals. "	( Dhungel, S; Kondo, Y; Nishimori, K; Orikasa, C; Rai, D; Sakuma, Y; Terada, M, 2019)
"Oxytocin signalling has been implicated in multiple disorders involving centrally regulated pathways, including obesity, autism, schizophrenia and depression."	( Chruścicka, B; Cryan, JF; Dinan, TG; Druelle, C; Nally, K; Schellekens, H; Stamou, P; Wallace Fitzsimons, SE, 2019)
"The oxytocinergic system has been proposed as a pathophysiological candidate for AN."	( Crucianelli, L; Fotopoulou, A; Jenkinson, P; Paloyelis, Y; Ricciardi, L; Robinson, P; Serpell, L, 2019)
"Oxytocin has traditionally been regarded as a prosocial hormone, but studies on social cognition in mammalian models suggest it may play a more nuanced role in modulating social discrimination based on social salience and stimulus valence."	( Cummings, ME; Fry, D; Ramsey, ME, 2019)
"Oxytocin also has anti-inflammatory properties that have not been examined in cancer."	( Ahmed, R; Bender, D; Cole, SW; Cuneo, MG; Goodheart, M; Kinner, EM; Lutgendorf, SK; McCabe, PM; Mendez, AJ; Schachner, BI; Schrepf, A; Sood, AK; Szeto, A; Thaker, PH, 2019)
"Oxytocin has shown promise in animal models of atherosclerosis and in some human studies as well."	( De Leon, J; Glass, AD; Glass, DS; Kasselman, LJ; Lam, E; Reiss, AB, 2019)
"Oxytocin has been shown to stimulate social approach behaviors, although effects may depend on contextual and individual difference factors. "	( Bekker, MHJ; Karreman, A; Kir, M; Kunst, LE; Riem, MME; Sluijtman, A; Steenbakkers, FDF, 2019)
"Oxytocin has been shown to promote a host of social behaviors in humans but the exact mechanisms by which it exerts its effects are unspecified. "	( Penton-Voak, IS; Rowe, AC; Theodoridou, A, 2013)
"Oxytocin (OT) has been a candidate for the treatment of autism spectrum disorders (ASD), and the impact of intranasally delivered OT on ASD has been investigated. "	( Kagitani-Shimono, K; Kimura, T; Mohri, I; Nakamura, A; Oishi, M; Onaka, T; Ozono, K; Sanefuji, W; Tachibana, M; Taniike, M; Yamamoto, T, 2013)
"Oxytocin (OT) has been linked to social behavior in rodents, non-human primates, and adult humans, but almost nothing is known about brain OT activity in human newborns or its impact on social development. "	( Abramova, M; Clark, CL; Feldman, H; Hornbeak, K; Hyde, SA; Parker, KJ; Pasca, AM; Penn, AA; St John, N, 2013)
"Oxytocin has a protective effect against I/R injury in skeletal muscle and may reduce the incidence of compartment syndrome."	( Arbak, S; Aydin, U; Bakir, I; Ercan, F; Erkanli Senturk, G; Erkanli, K; Isiksacan, N; Tuncdemir, M, 2013)
"Oxytocin has been shown to affect human social information processing including recognition memory for faces. "	( Bird, CW; Curran, T; Freeman, M; Herzmann, G, 2013)
"Oxytocin has long been advocated as a treatment for slow progress in labour but it is unclear to what extent it improves the outcomes for that labour and whether it actually reduces the caesarean section rate or maternal and fetal morbidity."	( Bugg, GJ; Siddiqui, F; Thornton, JG, 2013)
"Oxytocin has been reported for a wide range of adverse effects in different species of lactating animals. "	( Anwar, H; Awais, MM; Iqbal, Z; Khaliq, T; Muhammad, F; Rahman, ZU; Sadaf, S, 2013)
"The oxytocin system has bidirectional interactions with the stress-axis, autonomic nervous system, neurotransmitter systems (e.g."	( Buisman-Pijlman, FT; Carter, CS; Gordon, JJ; Hull, PR; Sumracki, NM; Tops, M, 2014)
"Oxytocin (OXT) has a plethora of effects on brain function. "	( Kovács, GL; Sarnyai, Z, 2014)
"Oxytocin (OT) has been shown to play a crucial role in the biology of social interaction. "	( Chen, KC; Chen, PS; Chi, MH; Lee, IH; Lee, LT; Tsai, HC; Tseng, HC; Yang, YK, 2014)
"Oxytocin has been reported to reduce the severity of pain, anxiety, and depression, and improve the quality of sleep, suggesting that it may be useful to treat fibromyalgia."	( Agabio, R; Carboni, M; Carta, MG; Mameli, S; Marchi, A; Melis, MR; Minerba, L; Pili, A; Pisanu, GM; Sardo, S; Trincas, G, 2014)
"Oxytocin has a significant role in neurogenesis, and this may have implications in regeneration of adult neurons."	( Jafarzadeh, N; Javeri, A; Khaleghi, M; Taha, MF, 2014)
"Oxytocin has been implicated in the modulation of energy metabolism in animals. "	( Ackerman, KE; Clarke, H; Lawson, EA; Marengi, DA; Misra, M; Slattery, M, 2014)
"Oxytocin disruption has been hypothesized to account for features of ASD, including impaired communication and social behavior, based on animal studies."	( Ceroni, F; Cook, EH; Francis, SM; Gawthrope, AJ; Jacob, S; Maestrini, E; Monaco, AP; Newbury, DF; Pagnamenta, AT; Pinto, D; Sagar, A; Simpson, NH; Tessman, DC, 2014)
"Oxytocin has repeatedly been shown to influence human behavior in social contexts; also, a relationship between oxytocin and the pathophysiology of autism spectrum disorder (ASD) has been suggested. "	( Anckarsäter, H; Hovey, D; Jonsson, L; Lichtenstein, P; Melke, J; Westberg, L; Zettergren, A, 2014)
"Oxytocin (OXT) has been implicated in the regulation of social behaviors, including intermale offensive aggression. "	( Althaus, M; Calcagnoli, F; de Boer, SF; Koolhaas, JM; Meyer, N, 2014)
"Oxytocin, especially, has been linked to prosocial behaviors such as trust and social bonds."	( Abu, Z; Beitchman, JH; Berall, L; Chen, S; Din, F; Malik, AI; Nowrouzi, B; Zai, CC, 2014)
"Oxytocin has been implicated in parent-infant attachment and social recognition. "	( Bakermans-Kranenburg, MJ; Bhandari, R; Kringelbach, ML; Parsons, CE; Stein, A; van der Veen, R; van IJzendoorn, MH; Voorthuis, A; Young, KS, 2014)
"Oxytocin also has opposing associations with hormonal contraceptives and adiposity in women with and without T1DM."	( Carter, CS; Danielson, KK; Elliott, ME; Kujath, AS; LeCaire, TJ; Quinn, L; Varady, KA, 2015)
"Oxytocin has been previously associated with social attachment behaviors in various species, however, most studies focused on partner preference in the socially-monogamous prairie vole. "	( Athanassiou, M; Madularu, D; Mumby, DG; Yee, JR, 2014)
"Oxytocin has been suggested as a novel therapeutic against obesity, because it induces weight loss and improves glucose tolerance in diet-induced obese rodents. "	( Altirriba, J; Arsenijevic, D; Caillon, A; Dulloo, A; Lyautey, J; Poher, AL; Rohner-Jeanrenaud, F; Veyrat-Durebex, C, 2014)
"Oxytocin (OT) has been proposed to play a crucial role in the social deficits of mental disorders and has been found to be dysregulated after social exclusion (ostracism) in patients with borderline personality disorder."	( Bauriedl-Schmidt, C; Buchheim, A; Falkai, P; Jobst, A; Mauer, MC; Padberg, F; Palagyi, A; Renneberg, B; Sabass, L; Sarubin, N; Zill, P, 2015)
"Oxytocin has a wide range of effects over neural activity in response to social and emotional processing, which is further modulated by sex and task specificity. "	( Allen, P; Averbeck, B; Fusar-Poli, P; McGuire, P; Meyer-Lindenberg, A; Radua, J; Shergill, SS; Wigton, R, 2015)
"Oxytocin has a modulatory role in natural and drug reward processes. "	( Ghee, SM; Reichel, CM; See, RE; Zhou, L, 2015)
"Oxytocin has been shown to improve social perception in patients with schizophrenia; however, the effect of oxytocin on the neural activity underlying facial emotion recognition has not been investigated."	( Han, HJ; Jang, JH; Jung, WH; Kang, DH; Kim, SN; Kim, SY; Kwon, JS; Park, HY; Park, JW; Shin, NY; Yun, JY, 2015)
"Oxytocin has been widely reported to affect social-communicative function and its neural underpinnings."	( Auyeung, B; Baron-Cohen, S; Bethlehem, RA; Chakrabarti, B; Deakin, JB; Dickens, L; Heinrichs, M; Lombardo, MV; Mooney, N; Sipple, JA; Sule, A; Thiemann, P, 2015)
"Oxytocin has the potential to modulate the pain experience due to its ubiquitous involvement in central and peripheral psychological and physiological processes, and thus offers promise as a therapeutic agent."	( Georgiou-Karistianis, N; Gibson, SJ; Giummarra, MJ; Tracy, LM, 2015)
"Oxytocin has been shown to play a role in regulating social behaviours in humans including fear and aggression."	( Hernádi, A; Kanizsár, O; Kis, A; Miklósi, B; Topál, J; Tóth, K, 2015)
"Oxytocin also has important actions in the brain: released from dendrites of neurones that innervate the posterior pituitary, oxytocin auto-excites the neurones to fire action potentials in co-ordinated bursts, causing secretion of pulses of oxytocin."	( Leng, G; Russell, JA, 2016)
"Oxytocin has been shown to decrease cocaine taking and seeking in male rats, suggesting potential treatment efficacy for drug addiction. "	( Ghee, SM; Leong, KC; Reichel, CM; See, RE; Zhou, L, 2016)
"Oxytocin has been suggested as a promising new treatment for neurodevelopmental disorders. "	( Bu, B; Chua, SE; Lam, S; Li, Q; McAlonan, GM; Sham, PC; Wang, W; Zhang, M; Zhang, X, 2015)
"The oxytocin (OXT) system has been identified as one candidate for mediating social buffering due to its role in the facilitation of social bonding and the expression of prosocial behavior."	( Carp, SB; Cavanaugh, J; French, JA; Rock, CM, 2016)
"Oxytocin (OT) has been implicated in a variety of mammalian reproductive and social behaviors, and the use of intranasal OT for clinical purposes is on the rise. "	( Kosaki, Y; Watanabe, S, 2016)
"Oxytocin (OT) has been shown to be involved in various aspects of social behavior related to reproduction, but little is known about its effects on nonreproductive social interaction between adults or the neuroanatomical location where OT exerts its action."	( Tai, FD; Yu, CJ; Zhang, SW, 2016)
"Oxytocin has antianxiety properties in humans and rodents. "	( Agostini, A; Ayers, L; Rosen, JB; Schulkin, J, 2016)
"Oxytocin has population selective antianxiety effects on non-cued unpredictable threat, but only in rats with low pre-fear baseline startle responses. "	( Agostini, A; Ayers, L; Rosen, JB; Schulkin, J, 2016)
"Oxytocin (OT) has been investigated in a number of psychiatric disorders owing to its effects on social interactions."	( Demirci, E; Kilic, E; Ozmen, S; Oztop, DB, 2016)
"Oxytocin has shown promising results as antipsychotic adjuvant in patients with schizophrenia."	( Afonso, AC; Andrade, VM; Damiani, AP; Daumann, F; Leffa, DD; Pedro, TH; Santos, MA; Souza, RP, 2017)
"Oxytocin (OXT) has anxiolytic effects and promotes prosocial behaviors in both rodents and humans, and evidence suggests that it plays a role in memory consolidation."	( Contreras, M; Fellous, JM; French, ED; Janezic, EM; Nagl, S; Uppalapati, S, 2016)
"Oxytocin (OT) has become a focus in investigations of autism spectrum disorder (ASD). "	( Feldman, R; Gordon, I; Jack, A; Leckman, JF; Pelphrey, KA; Pretzsch, CM; Vander Wyk, B, 2016)
"Oxytocin (OT) has been implicated in the formation and maintenance of various social relationships, including human romantic relationships. "	( Emery Thompson, M; Gangestad, SW; Grebe, NM; Grøntvedt, TV; Kennair, LEO; Kristoffersen, AA, 2017)
"Oxytocin has potent central effects on feeding behaviour, as well as on social and sexual behaviours, and one likely substrate for its anorectic effect is the ventromedial nucleus of the hypothalamus. "	( Caquineau, C; Leng, G; Onaka, T; Sabatier, N; Takayanagi, Y; Tobin, VA, 2008)
"Oxytocin has a crucial role in social behaviour, although its effects on social cognition are not fully understood. "	( Carson, DS; Cox, RE; Dadds, MR; Guastella, AJ; Mitchell, PB, 2009)
"Oxytocin (OT) has been shown to play an important role in social bonding in animals. "	( Kikusui, T; Nagasawa, M; Ohta, M; Onaka, T, 2009)
"The oxytocin receptor has been implicated in the regulation of reproductive physiology as well as social and emotional behaviors. "	( Inoue, K; Kimura, T; Nishimori, K; Onaka, T; Takayanagi, Y; Yoshida, M; Young, LJ, 2009)
"Oxytocin (OXY) has been shown to attenuate some of the physiological and behavioral alterations appearing in stressed rats. "	( Hlinak, Z; Hynie, S; Klenerova, V; Krejci, I; Sida, P, 2009)
"The oxytocinergic system has recently been placed amongst the most promising targets for various psychiatric treatments due to its role in prosocial behavior and anxiety reduction. "	( Fischer-Shofty, M; Harari, H; Levkovitz, Y; Shamay-Tsoory, SG, 2010)
"Oxytocin (OT) has been shown to reduce food intake."	( Antunes-Rodrigues, J; de Castro, M; Elias, LL; Mendes da Silva, LE; Uchoa, ET, 2009)
"Oxytocin has a substantial role in social attachment, affiliation and sexual behavior."	( Baskerville, TA; Douglas, AJ, 2010)
"Oxytocin (OT) has long been implicated in maternal bonding, sexual behavior and social affiliation behaviors. "	( Fakhry, H; Ishak, WW; Kahloon, M, 2011)
"Oxytocin has a combination of pharmacologic effects that result in a "sense of safety" for the patient, which is a prerequisite to successful treatment of PTSD."	( Denys, D; Langeland, W; Olff, M; Witteveen, A, 2010)
"Oxytocin (OT) has been suggested as a treatment to improve social behavior in autistic patients. "	( Braida, D; Bulgheroni, E; Busnelli, M; Capurro, V; Chini, B; Donzelli, A; Finardi, A; Lentini, D; Nishimori, K; Parenti, M; Parolaro, D; Pattini, L; Rubino, T; Sala, M, 2011)
"Oxytocin has important cardiovascular side-effects (hypotension, tachycardia and myocardial ischaemia)."	( Butwick, AJ; Carvalho, B; Dyer, RA, 2011)
"Oxytocin has known stress-reducing and attachment-enhancing effects. "	( Bartz, J; Braun, A; Crystal, S; Hamilton, H; Hollander, E; Ketay, S; Simeon, D, 2011)
"Oxytocin (OT) has an organizational effect within the central nervous system and can have long-lasting effects on the expression of social behavior. "	( Cushing, BS; Eaton, JL; Nguyen, KN; Papademetriou, E; Raghanti, MA; Roache, L; Troyer, E, 2012)
"Oxytocin has been reported to modulate human behavior in many social interactions of which attachment between mother and child is the child's first social relationship. "	( Karlsson, H; Kortesluoma, S, 2011)
"Oxytocin has been linked to social behavior, including social recognition, pair bonding and parenting, but its potential role in promoting neuronal growth has not been investigated. "	( Caponiti, JM; Gould, E; Leuner, B, 2012)
"Oxytocin has long been advocated as a treatment for slow progress in labour but it is unclear to what extent it improves the outcomes for that labour and whether it actually reduces the caesarean section rate or maternal and fetal morbidity."	( Bugg, GJ; Siddiqui, F; Thornton, JG, 2011)
"Oxytocin has numerous prosocial and antipsychotic-like effects in animals. "	( Casey, RL; Gibson, CM; Jarskog, LF; Leserman, J; Pedersen, CA; Penn, DL; Rau, SW; Salimi, K; Smedley, KL, 2011)
"Oxytocin (OT) has been reported to have a potential protective effect on stress-induced functional gastrointestinal disorders. "	( Cao, CY; Chang, XW; Li, YX; Qin, Y; Wang, HH; Xie, DP; Yang, X; Zhang, JP, 2011)
"Oxytocin (OXT) has been implicated in reproduction and social interactions and in the control of digestion and blood pressure. "	( Browning, KN; Jordan, D; Kellett, DO; Llewellyn-Smith, IJ; Travagli, RA, 2012)
"Oxytocin therefore has fascinating potential to reverse the corrosive effects of long-term drugs abuse on social behavior and to perhaps inoculate against future vulnerability to addictive disorders."	( Bowen, MT; McGregor, IS, 2012)
"Oxytocin has an important role in the management of labour. "	( Buchanan, SL; Ford, JB; Morris, JM; Patterson, JA; Roberts, CL, 2012)
"Oxytocin (OXT) has been proposed as a potential therapeutic agent for post-traumatic stress disorder (PTSD)."	( Neumann, ID; Slattery, DA; Toth, I, 2012)
"Oxytocin - though it has shown promise as a novel antipsychotic in multiple clinical trials - has as-yet poorly characterized effects on cognition, with some evidence indicating an amnestic profile."	( Cobb, P; Feifel, D; Macdonald, K; Minassian, A, 2012)
"Oxytocin has been shown to be associated with mental illness."	( Defrancesco, M; Deisenhammer, EA; Hinterhuber, H; Hofer, S; Kemmler, G; Schwitzer, O; Wildt, L, 2012)
"Oxytocin has been reported to play important roles in multiple social behaviors dependent on social recognition, and has been expected as one of the effective treatments of social impairments of patients with ASDs."	( Asano, M; Ishitobi, M; Kosaka, H; Munesue, T; Omori, M; Sato, M; Tomoda, A; Wada, Y, 2012)
"Oxytocin has a fundamental role in social behavior. "	( Andari, E; Mottolese, R; Schneider, FC; Sirigu, A; Vindras, P, 2014)
"Oxytocin (OT) has an important role in bond formation and social reciprocity, and animal studies indicate that OT functioning is transferred from parent to child through patterns of parental care. "	( Ebstein, RP; Feldman, R; Gordon, I; Gutbir, T; Influs, M, 2013)
"Oxytocin (OT) has been implicated in the cardiovascular responses to exercise, stress, and baroreflex adjustments. "	( Amico, J; Marcelo, MC; Michelini, LC; Morris, M, 2003)
"oxytocin have been estimated."	( RYDEN, G; SJOHOLM, I, 1962)
"oxytocin has no detectable effect on seminal parameters in men with severe oligozoospermia."	( Byrne, MM; Cooper, TG; Depenbusch, M; Nieschlag, E; Rolf, C, 2003)
"Oxytocin (OT) has a wide range of effects throughout the body. "	( Grahn, N; Monstein, HJ; Ohlsson, B; Truedsson, M, 2004)
"Oxytocin has an antidiuretic effect and increases the urinary excretion of AQP2 in humans whose urinary concentration mechanism is preserved. "	( Ahn, C; Han, JS; Jeon, US; Joo, KW; Kim, GH; Kim, S; Kim, SY; Kim, YS; Lee, JS; Oh, YK; Park, J, 2004)
"Oxytocin has been used to dilate the cervix as a means of accessing the uterus during conventional cervical insemination, but its effect on fertility is not well documented."	( Dingwall, WS; Gebbie, FE; King, ME; Matthews, KP; McKelvey, WA; Mylne, MJ; Robinson, JJ; Stewart, E, 2004)
"Oxytocin has been implicated in the regulation of prostate growth. "	( Assinder, S; Gould, M; Nicholson, H; Whittington, K, 2004)
"Oxytocin has been implicated in the regulation of prostate growth in eutherian mammals, and the initial aim of this study was to identify and localize the marsupial equivalent, mesotocin, and its receptor in the prostate of the brushtail possum."	( Assinder, SJ; Fink, JW; McLeod, BJ; Nicholson, HD; Parry, LJ, 2005)
"Oxytocin has many physiological roles, but its only irreplaceable role is to mediate milk let-down: oxytocin-deficient mice cannot feed their young; the pups suckle but no milk is let down, and they will die unless cross-fostered."	( Caquineau, C; Leng, G; Sabatier, N, 2005)
"Oxytocin (OT) has long been used as an uterotonic during labor management in women, and yet responses to OT infusion remain variable and unpredictable among patients. "	( Ayad, VJ; Kelly, E; López Bernal, A; McArdle, CA; Mundell, SJ; Smith, MP, 2006)
"Oxytocin has been used to assist breast feeding and milk expression, but few data are available to support this intervention in the neonatal unit setting."	( Blake, A; Fewtrell, MS; Hawdon, J; Loh, KL; Ridout, DA, 2006)
"Oxytocin properties have been studied in different experimental models in order to obtain evidence for its analgesic properties. "	( Condés-Lara, M; Freund-Mercier, MJ; López Hidalgo, M; Martínez-Lorenzana, G; Rodríguez-Jiménez, J; Rojas-Piloni, G, 2006)
"Oxytocin has been implicated in the modulation of somatosensory transmission such as nociception and pain. "	( Chugh, C; Jain, H; Mediratta, PK; Rathi, N; Reeta, Kh; Sharma, KK, 2006)
"Oxytocin has also been reported to exert a positive role in social attachment."	( Boutet, C; Buffin, A; Legros, JJ; Schelstraete, C; Vercueil, L, 2006)
"Oxytocin (OT) has been implicated in the expression of social behavior, stress responses, and may provide a mechanism by which social experience influences atherogenesis in WHHL rabbits."	( Gonzales, JA; Levine, JE; Llabre, MM; McCabe, PM; Mendez, AJ; Paredes, J; Schneiderman, N; Szeto, A; Zaias, J, 2006)
"Oxytocin (OT) has been implicated in reproductive functions, induction of maternal behavior as well as endocrine and neuroendocrine regulation of the cardiovascular system. "	( Azizi, F; Carter, CS; Cushing, BS; Papademeteriou, E; Partoo, L; Perry, A; Pournajafi-Nazarloo, H, 2007)
"Oxytocin has been demonstrated to be involved in pain modulation. "	( Chen, JM; Lin, BC; Liu, WY; Wang, CH; Yang, J; Yang, Y, 2007)
"Oxytocin has been shown to modulate contractility of prostate tissue and also to regulate local concentrations of the biologically active androgens."	( Nicholson, HD; Whittington, K, 2007)
"Thus oxytocin has the capacity to both stimulate and inhibit cell proliferation of osteosarcoma cells."	( Petersson, M, 2008)
"Oxytocin has been suggested to have behavioral effects opposite to those of vasopressin, and exogenous vasopressin is known to induce ACTH release in man. "	( Chiodera, P; Demey-Ponsart, E; Legros, JJ, 1982)
"Oxytocin has both insulin-like and insulin antagonistic actions in fat cells in vitro. "	( Rogol, AD; Stephenson, FA, 1984)
"Oxytocin has insulin-like activity in that it stimulates lipogenesis and increases pyruvate dehydrogenase activity. "	( Goren, HJ; Hanif, K; Hollenberg, MD; Lederis, K, 1982)
"The oxytocin-like hormone has been characterized as mesotocin by amino acid composition."	( Acher, R; Chauvet, J; Chauvet, MT; Hurpet, D, 1982)
"Oxytocin has been measured in peripheral plasma from chronically catheterized sheep both during estrus and the early luteal phase of the estrous cycle and also during pregnancy at 122-124 days gestation, 141-145 days gestation and during spontaneous labor at term. "	( Brennecke, SP; Kraemer, DL; Mitchell, MD; Webb, R, 1982)
"Oxytocin has been measured in fetal and maternal plasma samples obtained serially from 6 sheep during late pregnancy, spontaneous labor and labor induced by intrafetal infusion of Synacthen (ACTH1-24). "	( Anderson, AB; Brennecke, SP; Mitchell, MD; Turnbull, AC; Webb, R, 1982)
"Oxytocin (OT) has been detected in mammalian granulosa-luteal cells during the early stages. "	( Furuya, K; Imaizumi, E; Ishikawa, N; Katayama, E; Makimura, N; Mitsui, C; Mizumoto, Y; Murakami, M; Seki, K; Tokuoka, S, 1995)
"Oxytocin (OXT) has been implicated in the control of a variety of social and reproductive behaviors in several species. "	( Albers, HE; Whitman, DC, 1995)
"Oxytocin has been implicated in mother-infant bond formation."	( Carter, CS; Harbaugh, CR; Insel, TR; Williams, JR, 1994)
"An oxytocin-like hormone has been isolated from acetone-desiccated pituitary glands by using successively molecular sieving and high-pressure liquid chromatography."	( Acher, R; Bern, H; Chauvet, J; Chauvet, MT; Clarke, C; Michel, G, 1993)
"Oxytocin (OT) has a dual action in the uterus: a uterotonic action on myometrial cells and a prostaglandin (PG)-releasing action on endometrial/decidual cells. "	( Chan, WY; Chen, DL; Manning, M, 1993)
"Oxytocin has proved to be so safe, that there is only one contra-indication to its use and that is a grossly contracted pelvis."	( Allahbadia, G; Ambiye, V; Vaidya, P, 1993)
"Oxytocin has been identified in both non-human primate and human corpora lutea of the menstrual cycle by RIA, immunocytochemistry and HPLC. "	( Anwer, K; Dawood, MY; Khan-Dawood, FS; Yang, J, 1995)
"Oxytocin (OT) has been implicated in reproductive events. "	( Amico, JA; Crowley, RS; Insel, TR; O'Keefe, JA; Thomas, A, 1995)
"Oxytocin has been previously shown to augment GnRH-stimulated LH release. "	( Evans, JJ; Hurd, SJ; Mason, DR, 1996)
"Oxytocin (OT) has been shown to be the dominant peptide of the neurohypophysial family expressed by thymic epithelial and nurse cells (TEC/TNC) in various species. "	( Charlet, C; De Groote, D; Geenen, V; Godard, A; Heymann, D; Malgrange, B; Martens, H; Moonen, G; Robert, F; Soulillou, JP, 1996)
"Oxytocin has also been detected in the epididymis of the ram where active uptake of the peptide from luminal fluid has been demonstrated."	( Frayne, J; Harris, GC; Nicholson, HD, 1996)
"Oxytocin (OT) has been reported to mediate aggressive and affiliative behaviours in several species. "	( DeVries, AC; Nelson, RJ; Young, WS, 1997)
"Oxytocin (OT) has been implicated in neuroadaptive processes such as learning, memory, and social-affiliative behavior as well as in the regulation of physiological responses leading to adaptation to the changing external and internal environment. "	( Sarnyai, Z, 1998)
"Oxytocin has been thought of as an affiliation hormone because research on nonhuman mammals has demonstrated that it plays a key role in the initiation of maternal behavior and the formation of adult pair bonds."	( Altemus, M; Cooper, B; Enos, T; McGuinness, T; Turner, RA, 1999)
"oxytocin has a selective permissive effect on the excitation of oxytocin neurones from the ventral tegmentum, and this supports previous in vitro studies suggesting that centrally released oxytocin may act as a modulator of afferent transmission to the magnocellular nuclei."	( Cosgrave, AS; Richardson, CM; Wakerley, JB, 2000)
"Oxytocin has been used for several decades in close proximity to newborns, yet no published information is available regarding complications associated with its accidental administration to a newborn. "	( Hoff, DS; Maynard, RC, 2002)
"Oxytocin has been the most widely used and it is claimed by some to be free from side effects."	( Jeffcott, LB; Rossdale, PD, 1977)
"The oxytocinase levels have been tested prior to, during and after oxytocin challenge tests in 42 pregnant women. "	( Fährmann, M; Schumann, K, 1978)
"Oxytocin content has been measured by radioimmunoassay in microdissected hypothalamic nuclei. "	( George, JM; Marks, BM; Staples, S, 1976)
"Oxytocin has been shown to influence insulin, glucagon and blood glucose levels in various experimental situations. "	( Björkstrand, E; Eriksson, M; Uvnäs-Moberg, K, 1992)
"Oxytocin has been shown to advance gonadotropin secretion in pro-estrus rats. "	( Evans, JJ; Robinson, G, 1991)
"Oxytocin (OT) has been detected in ruminant preovulatory follicles. "	( Fortune, JE; Voss, AK, 1991)
"Oxytocin has been suggested to have glucoregulatory functions in rats, man and other mammals. "	( Lee, G; Shah, PR; Widmaier, EP, 1991)
"Oxytocin and its mRNA have been detected in bovine granulosa cells, but the function of follicular oxytocin is not well understood. "	( Fortune, JE; Voss, AK, 1991)
"Oxytocin (OT) has been shown to play a role in the control of physiological PRL release and has been demonstrated to have a direct effect on the pituitary to stimulate PRL secretion. "	( Mogg, RJ; Samson, WK, 1990)
"Oxytocin has the same type of effect presumably by acting at the V1-receptor."	( Fosset, M; Galizzi, JP; Lazdunski, M; Qar, J; Van Renterghem, C, 1987)
"(5) Oxytocin has little or no direct effect on luteal progesterone production."	( Fuchs, AR, 1988)

Actions

Excerpt	Reference
"The oxytocin receptor plays a significant role in peripheral regulation of parturition and lactation. "	( Mikusek, J; Nashar, PE; Reekie, TA; Whitfield, AA, 2022)
"Oxytocin did not produce sedation."	( Knackstedt, LA; Logan, CN; Peris, J; Polo Escorcia, AK; Reichel, CM; Rojas, G; Wilkinson, CS, 2022)
"Oxytocin (OT) plays a pivotal role in a variety of complex social behaviors by modulating approach-avoidance motivational tendencies, but recently, its social specificity has been challenged. "	( Alaerts, K; Daniels, N; Prinsen, J; Soriano, JR; Taillieu, A, 2021)
"The oxytocin (OXT) system plays a key role in promoting sensitive parenting and empathy."	( Boks, MPM; Bos, PA; Branje, S; Kraaijenvanger, EJ; Montoya, ER; Overbeek, G; Parianen Lesemann, FH; Spencer, H, 2022)
"The oxytocin (OXT) system plays a central role in social behavior across species and has a potential role in ASD."	( Ago, Y; Baba, M; Hashimoto, H; Hashimoto, R; Hayata-Takano, A; Kasai, A; Kitagawa, K; Mori, D; Nagayasu, K; Nakazawa, T; Ozaki, N; Seiriki, K; Takemoto, T; Takuma, K; Yokoyama, K, 2022)
"Oxytocin plays a vital role in social behavior and homeostatic processes, with animal models indicating that oxytocin receptor (OXTR) expression patterns in the brain influence behavior and physiology. "	( Andreassen, OA; Bahrami, S; de Lange, AG; Haukvik, UK; Kaufmann, T; Nærland, T; Quintana, DS; Rokicki, J; Sartorius, AM; Schwarz, E; Steen, NE; Stein, DJ; van der Meer, D; Westlye, LT, 2022)
"Oxytocin promotes maternal nurturing and bonding, enhances social reward, and increases the salience of social stimuli."	( de Vries, GJ; Petrulis, A; Rigney, N; Young, LJ, 2022)
"Oxytocin also plays a central role in almost every aspect of physical and mental health, including the coordination of sociality and loving relationships with physiological reactions to challenges across the lifespan."	( Carter, CS, 2022)
"Oxytocin (OXT) plays a significant role during pregnancy, especially toward the end of pregnancy. "	( An, BS; An, SM; Jeong, JS; Kim, DS; Kim, MJ; Kim, SC; Kim, SY, 2023)
"Oxytocin (OT) plays a pivotal role in early parent-child relationship formation and bonding that is critical for the social, cognitive, and emotional development of the child. "	( Asurlekar, AR; Chua, JS; Lim, LHK; Shorey, S, 2023)
"oxytocin promotes quiet wakefulness-a state of restful environmental awareness compatible with both oxytocin's anxiolytic effects and its enhancement of processing complex stimuli."	( Bowen, MT; Everett, NA; Gururajan, A; Raymond, JS, 2023)
"Oxytocin did not enhance CBM effects or independently exert effects."	( Alaerts, K; Bakermans-Kranenburg, MJ; Bosmans, G; Casteels, K; Ceulemans, E; de Winter, S; Salemink, E; Santens, T; van IJzendoorn, MH; Verhaeghe, J; Verhees, MWFT, 2020)
"Oxytocin plays important roles in the social and emotional behaviors of mammals. "	( Sakamoto, T; Sugimoto, S; Uekita, T, 2019)
"Oxytocin plays a pivotal role in the regulation of human parturition, however its role and modulation in the placenta is not fully understood. "	( Accialini, P; Etcheverry, T; Farina, M; Leguizamón, G; Malbrán, MN; Maté, S, 2020)
"Oxytocin induced an increase in the mRNA levels of Neuron-Specific Enolase (NSE) and a decrease in the mRNA levels of glial fibrillary acid protein (GFAP) - marker of astrocytes."	( Bacova, Z; Bakos, J; Bukatova, S; Filova, B; Reichova, A; Srancikova, A; Zatkova, M, 2020)
"Oxytocin concentration increase was significantly associated with greater subjective ratings of CT-targeted touch but not of non-CT-targeted touch, and with lower peak alpha frequency values indicating decreased cortical arousal."	( Portnova, GV; Proskurnina, EV; Skorokhodov, IV; Sokolova, SV; Varlamov, AA, 2020)
"Oxytocin may increase focus on others and has been shown to increase automatic imitation in healthy controls (HC)."	( Ahmadi, E; De Coster, L; Delucchi, K; Morrison, TE; O'Donovan, A; Stauffer, CS; Wen, J; Woolley, J, 2020)
"Oxytocin may enhance the salience of social proximity and may be a mechanism underlying previously reported social influences on cardiovascular and mental health. "	( Kop, WJ; Kunst, LE; Riem, MME, 2021)
"Oxytocin is known to increase attention to another's eyes in many mammalian species (e.g."	( Brooks, J; Kano, F; Kikusui, T; Morimura, N; Nagasawa, M; Sato, Y; Yamamoto, S; Yeow, H, 2021)
"Oxytocin use may increase this risk, which could be influenced by the process of induction or individual cervix condition."	( Gu, W; Liu, H; Luo, S; Zhang, H, 2021)
"Oxytocin plays an important role in human responses to threat processing. "	( Cai, H; Chen, J; Luo, YLL; Xie, Y; Yang, Z, 2021)
"Oxytocin plays an important role in social recognition in rodents, which is mediated predominantly by the olfactory system. "	( Du, H; Hang Pun, S; Lei, TC; Li, A; Li, BZ; Liu, P; Sun, C; Tang, K; Yin, Z, 2021)
"Oxytocin promotes social affiliation across various species, in part by altering social cognition to facilitate approach behaviour. "	( Brown, CA; Cardoso, C; Ellenbogen, MA; Orlando, MA; Wong, SF, 2021)
"Oxytocin (OT) promotes pro-sociality, bonding, and cooperation in a variety of species. "	( Deschner, T; Marshall-Pescini, S; Range, F; Schaebs, FS; Wirobski, G, 2021)
"The oxytocin system plays a role in stress responses and behavior modulation. "	( Chang, CY; Chou, MY; Chuang, HJ; Ho, HP, 2021)
"Oxytocin promotes osteoblasts differentiation and function, leading to an increased bone formation with no effect on bone resorption and an improvement of bone microarchitecture."	( Breuil, V; Ez-Zoubir, A; Trojani, MC, 2021)
"Oxytocin plays a role in regulation of feeding behaviors, social interactions, and emotional reactivity, which are all issues that significantly affect the quality of life for individuals with this syndrome."	( Butler, MG; Driscoll, DJ; Gold, JA; Kimonis, V; Miller, JL; Sulsona, C; Tamura, R, 2017)
"Oxytocin did not increase vigor during social encouragement in either group."	( Fulford, D; Treadway, M; Woolley, J, 2018)
"Oxytocin (OT) plays a salient role in contributing to the high levels of human sociality that characterize our species. "	( Chew, SH; Chong, A; Ebstein, RP; Gouin, JP; Lai, PS, 2019)
"Oxytocin plays an important hormonal role in the regulation of feeding and energy intake."	( Burrows, TL; Dayas, CV; Fenton, S; Garg, ML; Skinner, JA, 2018)
"Oxytocin (OT) plays an active role in adaptive stress-related responses and protects hippocampal synaptic plasticity and memory during stress."	( Koga, Y; Latt, HM; Matsui, H; Matsushita, H; Michiue, H; Morino, M; Nishiki, T; Tomizawa, K, 2018)
"Oxytocin plays an important role in supraspinal modulation of pain. "	( Taati, M; Tamaddonfard, E, 2018)
"Oxytocin plays an important role in social behavior. "	( Andreassen, OA; Djupesland, PG; Mahmoud, RA; Quintana, DS; Smerud, KT; Westlye, LT, 2018)
"Oxytocin plays a critical role in emotion processing and social behavior and has been shown to mediate the prosocial effects of MDMA in animals."	( Liechti, ME; Vizeli, P, 2018)
"Oxytocin (OT) plays a central role in learning and memory, but little is known of the impact of OT on METH-associated memory changes."	( Dong, YX; Fan, XY; Hou, Y; Liu, S; Wu, CF; Yang, JY, 2020)
"Oxytocin (OT) plays a crucial role in MB."	( Binder, EB; Buss, C; Entringer, S; Garg, E; Heim, CM; Kobor, MS; Lin, DTS; MacIsaac, JL; Meaney, MJ; O'Donnell, KJ; Provençal, N; Toepfer, P; Wadhwa, PD, 2019)
"Oxytocin also plays a role in interactive actions between stress and food intake and contributes to adaptive active coping behaviours."	( Onaka, T; Takayanagi, Y, 2019)
"Oxytocin (OT) plays a pivotal role in interpersonal bonding, affiliation, and trust, and its intranasal administration is increasingly considered as a potential treatment for autism spectrum disorder."	( Alaerts, K; Bernaerts, S; Daniels, N; Vanaudenaerde, B; Wenderoth, N, 2019)
"Oxytocin plays a vital role in the occurrence of preterm birth by interacting with oxytocin receptor (OTR), and thus OTR antagonists provide effective approaches for the treatment of early birth. "	( Li, Y; Luo, J; Xu, L; Yang, L; Yang, M; Zeng, Z, 2019)
"Oxytocin may increase the risk of a prolonged third stage compared to ergot alkaloids, although whether this translates into increased risk of manual placental removal is uncertain."	( Cuthbert, A; Leathersich, SJ; Salati, JA; Tolosa, JE; Williams, MJ, 2019)
"Oxytocin (OT) plays an important role in regulating gastric function. "	( Gao, S; Guo, F; Leng, H; Liu, X; Luan, X; Sun, X; Wang, Q; Xu, L; Zhang, X, 2019)
"Oxytocin (OT) promotes social and reproductive behaviors in mammals, and OT deficits may be linked to disordered social behaviors like autism and severe anxiety. "	( Bhatt, R; Gil, M; Hull, EM; Picotte, KB, 2013)
"Oxytocin is known to enhance recognition of emotional expressions and may increase attention to the eye region. "	( Chatzimanoli, M; Putman, P; Tollenaar, MS; van der Wee, NJ, 2013)
"Oxytocin can enhance trust in others, and may promote the extent to which a hypnotized person complies with the suggestion of a hypnotist."	( Bryant, RA; Hung, L, 2013)
"Oxytocin is given to increase contractions and high-dose regimens may potentially increase the number of spontaneous vaginal births, but as oxytocin can cause hyperstimulation of the uterus, there is a possibility of increased adverse events."	( Dowswell, T; Kenyon, S; Mori, R; Pledge, D; Tokumasu, H, 2013)
"The oxytocinergic system promotes social behavior and reduces anxiety. "	( Lahoud, N; Maroun, M, 2013)
"Oxytocin levels are lower in women with T1DM than matched controls. "	( Carter, CS; Danielson, KK; Elliott, ME; Kujath, AS; LeCaire, TJ; Quinn, L; Varady, KA, 2015)
"Oxytocin promotes social affiliation in humans. "	( Cardoso, C; Ellenbogen, MA; Joober, R; Linnen, AM, 2014)
"Oxytocin plays an analgesic role in modulation of nociception and pain. "	( Cui, S; Gong, L; Han, T; Huang, K; Kunze, W; Li, J; Liu, C; Liu, K; Ma, X; Xue, B; Zhang, M, 2015)
"Oxytocin (OXY) plays a crucial role in reproduction. "	( Arbak, S; Koroglu, P; Ozakpinar, OB; Senturk, GE; Uras, F; Yucel, D, 2015)
"Oxytocin (OXT) plays a prominent role in social cognition and may have clinical applications for disorders such as autism, schizophrenia and social anxiety. "	( Allen, P; Averbeck, B; Fusar-Poli, P; McGuire, P; Meyer-Lindenberg, A; Radua, J; Shergill, SS; Wigton, R, 2015)
"Oxytocin did not increase the levels of COX-2 (P = 0.38) but increased those of OTR (P = 0.001) and cPLA2 (P = 0.01) but not on the concentration of PGE2 in the media."	( Falchi, L; Scaramuzzi, RJ, 2015)
"Oxytocin (OT) plays an important role in pain modulation and antinociception in the central nervous system. "	( Cui, S; Gao, F; Gong, L; Kunze, W; Li, J; Liu, CY; Liu, K; Ma, X; Yu, X; Zhang, M; Zheng, W, 2015)
"Oxytocin (OT) plays a critical role in the formation of long lasting social attachments across a range of mammalian species. "	( Abu-Akel, A; Gillespie, SM; Mitchell, IJ, 2015)
"Oxytocin promotes prosocial behavior, especially in those individuals who are low in affiliation (e.g., avoidantly attached individuals), but can exacerbate interpersonal insecurities in those preoccupied with closeness (e.g., anxiously attached individuals). "	( Bartz, JA; Bolger, N; Hollander, E; Kolevzon, A; Ludwig, N; Lydon, JE; Zaki, J, 2015)
"Thus oxytocin promotes conformity to opinions of both in- and out-group members when social pressure is implicit, suggesting that it facilitates 'tend and befriend' behaviors by increasing the general level of social conformity."	( Huang, Y; Kendrick, KM; Yu, R; Zheng, H, 2015)
"Oxytocin (OT) plays a crucial role in parental-infant bonding and attachment. "	( Buchheim, A; Fritzsche, K; Gündel, H; Heinrichs, M; Kiefer, M; Rottler, E; Timm, L; Waller, C; Wittfoth, M; Wittfoth-Schardt, D, 2015)
"Oxytocin (OT) plays an important role in the onset of human labour by stimulating uterine contractions and promoting prostaglandin/inflammatory cytokine synthesis in amnion via oxytocin receptor (OTR) coupling. "	( Bennett, PR; Blanks, AM; Hanyaloglu, AC; Kim, SH; MacIntyre, DA; Terzidou, V; Thornton, S, 2016)
"Oxytocin promotes social skills and improves the quality of face processing in individuals with social dysfunctions such as autism spectrum disorder (ASD)."	( Andari, E; Leboyer, M; Richard, N; Sirigu, A, 2016)
"Oxytocin is known to cause fewer cardiovascular side effects when administered as a short-infusion compared to as an intravenous bolus."	( Bucher, HC; Dell-Kuster, S; Girard, T; Hoesli, I; Lapaire, O; Seeberger, E; Steiner, LA, 2016)
"Oxytocin promotes social interactions and recognition of conspecifics that rely on olfaction in most species. "	( Chao, MV; da Silva Gouveia, M; Froemke, RC; Grinevich, V; Kelsch, W; Meyer-Lindenberg, A; Mitre, M; Oettl, LL; Ravi, N; Scheller, MF; Schneider, M; Schneider, P; Shusterman, R; Young, WS, 2016)
"Oxytocin (OT) plays an important role in mediating alloparental behavior."	( Honda, Y; Kikusui, T; Koide, T; Kuroda, M; Maeda, S; Mogi, K; Nagasawa, M; Nishimori, K; Okabe, S; Ooyama, R; Takahashi, A; Tsuneoka, Y; Watarai, A, 2017)
"Oxytocin may cause adverse cardiovascular effects, including tachycardia and hypotension, whereas an inadequate dose can result in increased uterine bleeding."	( Barry, JJ; Bryant, M; Howat, PW; McCormack, DI; Sartain, JB, 2008)
"Oxytocin plays an important role in the progression, timing, and modulation of uterine contraction during labor and is widely used as an uterotonic agent. "	( Brighton, PJ; Challiss, RA; Konje, JC; Mistry, R; Morris, GE; Willets, JM, 2009)
"Oxytocin induction may increase the rate of interventions in labour.A suggestion that for women with prelabour rupture of membranes induction with vaginal prostaglandin may increase risk of infection for mother and baby warrants further study."	( Alfirevic, Z; Dowswell, T; Kelly, AJ, 2009)
"Oxytocin (OT) plays a determining role in social and pair bonding in many vertebrates and increasing evidence suggests it is a social hormone also in humans. "	( Bar-On, D; Bentin, S; Ebstein, RP; Israel, S; Perry, A; Shalev, I; Uzefovsky, F, 2010)
"Oxytocin plays an important role in monogamous pairbonded female voles, but not in polygamous voles. "	( Boe, CY; Cronin, KA; Kurian, AV; Pieper, BA; Snowdon, CT; Ziegler, TE, 2010)
"Oxytocin plays a key role in attachment bond formation and maintenance in animals and thus could be expected to affect attachment representations in humans."	( Bartz, JA; Bolger, N; Kolevzon, A; Ludwig, N; Lydon, JE; Ochsner, KN; Zaki, J, 2010)
"Oxytocin plays an important role in human attachment, trust, social perception, memory, and fear regulation. "	( Kéri, S; Kiss, I; Levy-Gigi, E, 2011)
"Oxytocin may activate the dopaminergic reward pathways in response to social cues."	( Strathearn, L, 2011)
"Oxytocin (OT) plays a key regulatory role in human social behaviour. "	( Griffiths, K; Guastella, AJ; Hickie, IB; Kemp, AH; Kuhnert, RL; Quintana, DS, 2012)
"Oxytocin may also cause cardiovascular effects by affecting other mediators, such as atrial natriuretic peptide (ANP), nitric oxide (NO) and alpha 2-adrenoreceptors."	( Petersson, M, 2002)
"Oxytocin (OT) plays an important role in social bonding, ultrasonic vocalizations and other sexual behaviors in mammalian species. "	( Kanwal, JS; Rao, PD, 2002)
"Oxytocin plays an important role in social-affiliative behaviors. "	( Gale, S; Lainhart, J; Ozonoff, S, 2003)
"Oxytocin seems to enhance the buffering effect of social support on stress responsiveness. "	( Baumgartner, T; Ehlert, U; Heinrichs, M; Kirschbaum, C, 2003)
"Oxytocin infusion can cause uterine contractions that decrease uterine perfusion. "	( Lee, CL; Soong, YK; Wang, CJ; Yen, CF; Yuen, LT, 2004)
"Oxytocin plays a major role in lactation mainly by its action on milk ejection via the contraction of myoepithelial cells. "	( Achard, C; Delpal, S; Lollivier, V; Marnet, PG; Ollivier-Bousquet, M; Rabot, A; Rainteau, D, 2006)
"Oxytocin (OT) plays a crucial role as a mediator of breast myoepithelial cell contraction, the process responsible for the ejection of milk during lactation, and is also involved in myoepithelial cell proliferation and postpartum mammary gland proliferation. "	( Cassoni, P; Chini, B; Reversi, A, 2005)
"Oxytocin may also cause "Ca2+-sensitization," a process whereby there is a greater contractile force generated from a given increase in cytosolic Ca2+, although the contribution of this process to myometrial contraction remains an area of debate."	( Arthur, P; Mitchell, BF; Taggart, MJ, 2007)
"The oxytocin-dependent increase in the tyrosine phosphorylation of MAP kinase displayed a transient time course and was dependent on the concentration of oxytocin applied to the cells."	( Hirota, K; Kanda, Y; Koike, K; Miyake, A; Nohara, A; Ohmichi, M; Sakamoto, Y; Zhang, ZX, 1995)
"Oxytocin provoked an increase in formation of inositol phosphates and intracellular calcium concentration, which was partly pertussis toxin resistant, providing evidence of G alpha q,11 activation."	( Asbóth, G; Barlow, DH; Bellinger, J; Europe-Finner, GN; López Bernal, A; Marshall, JM; Phaneuf, S, 1995)
"Oxytocin did not increase Ca2+ in cells stimulated with GnRH, whereas GnRH caused a spike Ca2+ increase even in the presence of oxytocin, implying that different mechanisms of desensitization (Ca2+ pool depletion and receptor uncoupling) are operating for two distinct PIC-coupled receptors in these cells."	( Evans, JJ; Forrest-Owen, W; McArdle, CA, 1997)
"Oxytocin plays a physiological stimulatory role on sexual behavior. "	( Arletti, R; Benelli, A; Bertolini, A; Calza, L; Cavazzuti, E; Giardino, L, 1997)
"Oxytocin levels increase in blood and CSF after various kinds of non-noxious sensory stimulation such as touch, light pressure and warm temperature in both female and male rats."	( Uvnäs-Moberg, K, 1997)
"Oxytocin inhibited the increase in leptin release due to dexamethasone without affecting leptin mRNA levels."	( Bahouth, SW; Fain, JN, 1998)
"Oxytocin plays an important role in the regulation of normal cognitive functions and behaviors, which are disturbed in schizophrenia. "	( Feifel, D; Reza, T, 1999)
"Oxytocin stimulates an increase in intracellular calcium in uterine myometrium by several mechanisms. "	( Dodge, K; Monga, M; Qian, A; Sanborn, BM; Wang, W; Yue, C, 1998)
"In oxytocin cells, the increase results from a mobilisation of Ca2+ from intracellular stores, whereas in vasopressin cells, it results mainly from an influx of Ca2+ through voltage-dependent channels."	( Dayanithi, G; Sabatier, N; Widmer, H, 2000)
"Oxytocin plays an important role at parturition due to its involvement in uterine contractions, foetal expulsion and the onset of maternal behaviour. "	( Calvert, SK; Chirnside, J; Deans, LA; Forsling, ML; Gilbert, CL; Goode, JA; Jarvis, S; Lawrence, AB; McLean, KA, 2000)
"Oxytocin probably plays a role as a neurotransmitter/neuromodulator in the hippocampus of the rat. "	( Raggenbass, M; Zaninetti, M, 2000)
"Oxytocin (OT) plays a key role in the process of labor."	( Chiao, JP; Friebe-Hoffmann, U; Rauk, PN, 2001)
"Oxytocin caused an increase and vasopressin a decrease in the self-stimulation rate."	( Betschen, K; Schulz, H; Schwarzberg, H; Unger, H, 1978)
"Oxytocin did not increase PGFM concentrations in BLK-OT heifers; however, a marked increase in PGFM was detected in the NOR-OT heifers in response to oxytocin."	( Beal, WE; Custer, EE; Del Vecchio, RP; Lewis, GS, 1992)
"Oxytocin did not enhance GnRH agonist-stimulated gonadotrophin release to the same extent as it increased basal secretion, but at low concentrations of GnRH agonist the effects were additive."	( Catt, KJ; Evans, JJ; Robinson, G, 1989)
"Oxytocin levels were lower in Group -P ewes with 'abnormal' CL on Day 5, than in 'normal' ewes in Groups -P (P less than 0.01) or +P (P less than 0.05)."	( Ayad, VJ; Gilbert, CL; Hunter, MG; Southee, JA; Wathes, DC, 1989)
"The oxytocin-induced increase in PGFM after 14 and 21 days of progesterone was significantly higher (P less than 0.001) 6 h after oestradiol injection than before the oestradiol injection."	( Goff, AK; Lafrance, M, 1988)
"Oxytocin induced an increase (P less than 0.01) in PGF secretion for endometrium from cyclic cows regardless of temperature."	( Gross, TS; Putney, DJ; Thatcher, WW, 1988)
"Oxytocin is known to increase plasma levels of insulin, glucagon and glucose in dogs. "	( Stock, S; Uvnäs-Moberg, K, 1987)
"Oxytocin-induced increase in spasm duration and microvascular dilatation was noted both in intact and pregnant animals."	( Fomina, IV; Orlov, VI; Ovsiannikov, VG, 1987)
"As oxytocin can cause an alteration in the timing of follicular maturation and ovulation processes study of communications between the adenohypophysis and areas containing oxytocin might be important for understanding physiological details of ovulation."	( Evans, JJ; Forster, ME; Robinson, G, 1985)

Treatment

Excerpt	Reference
"Oxytocin is the only treatment for dystocic labor."	( Wiberg-Itzel, E, 2022)
"Oxytocin treatment before electroejaculation resulted in an approximately twofold increase in sperm concentration and total sperm output/ejaculate, while this intervention did not significantly affect ejaculate volume, sperm quality or fertilizing ability."	( Pakdeesanaeha, T; Techarungchaikul, S; Tharasanit, T; Thongsima, T; Tiptanavattana, N, 2022)
"An oxytocin treatment*time interaction suggested a minor, transient suppression in weight gain after treatment ended."	( Bales, KL; Berger, T; Conley, AJ; Cotterman, RF; Del Razo, RA; Dufek, ME; Goetze, LR; Jacob, S; Mendoza, SP; Sahagún, E; Weinstein, TAR, 2022)
"Oxytocin treatment (1 mg/ml, i.p., 50 μl/pup) at postnatal days P2-P3 resulted in the reduction of Neuroligin 3 gene expression, and was accompanied by lower SHANK1 and SHANK3 mRNA levels in the hippocampus at P5 day."	( Bacova, Z; Bakos, J; Bukatova, S; Filova, B; Reichova, A; Srancikova, A; Zatkova, M, 2020)
"Oxytocin pre-treatment reduced myometrial contractility in AMA and control group women compared with their oxytocin-naïve counterparts, as a function of the desensitization phenomenon. "	( Balki, M; Carvalho, JCA; Luca, AM; Ramachandran, N, 2020)
"Oxytocin treatment robustly attenuated METH intake in both sexes, and SDV entirely prevented the suppressant effect of oxytocin (0.3 mg/kg) on METH intake, and partially prevented the effects of 1 mg/kg oxytocin in both sexes."	( Baracz, SJ; Cornish, JL; Costa, PA; Everett, NA; Turner, AJ, 2021)
"Oxytocin treatment attenuated stress response regardless of the stress duration verified by lower corticosterone level and favorable profile in EPM parameters measured."	( Alışık, M; Erel, Ö; Korkmaz, H; Önal, D; Pehlivanoğlu, B, 2020)
"Oxytocin treatment caused a prolongation of this period in aggressive males compared with control animals receiving saline solution (P <0.01)."	( Gulevich, RG; Konoshenko, MY; Kozhemyakina, RV; Shikhevich, SG, 2020)
"Oxytocin treatment compensated reduced levels of Synapsin I, PSD95 and Neuroligin 3 in siSHANK3 cells suggesting a marked potential of oxytocin to ameliorate defects present in conditions of SHANK3 deficiency."	( Bacova, Z; Bakos, J; Bukatova, S; Frimmel, K; Kokavcova, M; Meliskova, V; Ostatnikova, D; Reichova, A, 2020)
"Oxytocin treatment was well tolerated, and there were no serious adverse events."	( Damen, L; Delhanty, PJD; Donze, SH; Grootjen, LN; Hokken-Koelega, ACS; Huisman, TM; Juriaans, AF; Visser, JA, 2021)
"Oxytocin treatments not only cause an acute decrease in ethanol consumption, but can also change in efficacy over time."	( Caruso, MA; Fulenwider, HD; Robins, MT; Ryabinin, AE, 2021)
"Oxytocin treatment (1) ameliorated corticosterone-induced reduction of neurogenesis and number of parvalbumin-positive interneurons in the hippocampal CA1 region, (2) enhanced anxiolytic- and antidepressant-like effects of citalopram in the open field test, and (3) the SSRI/oxytocin synergy persisted in reversing the reduction of the Itgb3 gene expression and increased Itgb3/Chl1 ratio in the prefrontal cortices."	( Batinić, B; Gurwitz, D; Israel-Elgali, I; Jukić, M; Oved, K; Pešić, V; Puškaš, N; Shomron, N; Stanić, D, 2021)
"Oxytocin treatment did not affect any of the studied parameters independent of the involved pathogen."	( Bollwein, H; Bruckmaier, RM; Corti, S; Feldmann, M; Gross, JJ; Müller, ATM; Pfingstner, H; Stephan, R; Strasser, FJ; Wellnitz, O, 2021)
"Oxytocin treatment (1.0, 3.0, and 10.0mg/kg, i.p.) reduced alcohol consumption in male and female prairie voles in animals that had access to 15% ethanol vs water every other day for 12 alcohol drinking sessions."	( Bohidar, AE; Christian, SM; Freestone, DM; Ndem, JR; O'Kane, CM; Parian, MC; Romaine, CC; Stevenson, JR; Vogel, IR; Wenner, SM, 2017)
"Oxytocin treatment resulted in a decrease of oligodendrocyte marker mRNA - 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNPase) - in 21-day and 2-month old rats, while no change of CD68 mRNA, marker of microglia, was observed."	( Bačová, Z; Bakoš, J; Havránek, T; Lešťanová, Z; Mravec, B; Štrbák, V, 2017)
"Oxytocin treatment in DIO mice in vivo led to decreased body weight accompanied by an improvement in glucose tolerance, with no changes in plasma cytokine levels."	( Altirriba, J; Caillon, A; Deblon, N; Garrido-Urbani, S; Poher, AL; Rohner-Jeanrenaud, F; Ropraz, P, 2018)
"Oxytocin treatment decreases TNFα production both in vitro (in bone marrow-derived macrophages) and in vivo (in epididymal adipose tissue) in DIO mice. "	( Altirriba, J; Caillon, A; Deblon, N; Garrido-Urbani, S; Poher, AL; Rohner-Jeanrenaud, F; Ropraz, P, 2018)
"Oxytocin treatment rescued social activity deficits in GluN3A KO mice."	( Lee, JH; Wei, ZZ; Yu, SP; Zhang, JY, 2018)
"Oxytocin treatment is more effective in food intake regulation and fat mass decline for individuals with leptin resistance and higher BW, but is known to be less effective in individuals with normal BW."	( Maejima, Y; Nishimori, K; Shimomura, K; Yokota, S, 2018)
"Oxytocin treatment had positive metabolic effects in diabetic rabbits, which was based on the changes in glucose metabolism, insulin sensitivity, and lipid profiles. "	( Feng, X; Li, J; Lin, F; Lin, H; Mao, X; Rao, G; Zheng, M, 2018)
"Oxytocin treatment resulted in a significant increase in gene and protein expression of the scaffolding protein SHANK3."	( Alanazi, M; Bacova, Z; Bakos, J; Castejon, AM; Kiss, A; Lestanova, Z; Ostatnikova, D; Puerta, F; Reichova, A; Zatkova, M, 2018)
"Oxytocin pre-treatment restored a normal acute leptin response, decreasing food intake and body weight gain."	( Altirriba, J; Caillon, A; Chrétien, C; Labyb, M; Rohner-Jeanrenaud, F, 2018)
"Oxytocin treatment in rats with established social hierarchies abolished agonistic behaviors and reciprocal sniffing displays."	( Wesson, DW, 2013)
"Oxytocin treatment had no effect either on mRNA or protein level of TH and NET."	( Bozovic, N; Djordjevic, J; Dronjak, S; Jasnic, N; Jovanovic, P; Spasojevic, N; Stefanovic, B, 2014)
"Oxytocin treatment also upregulated the expression of oxytocin receptor mRNA."	( Jafarzadeh, N; Javeri, A; Khaleghi, M; Taha, MF, 2014)
"Oxytocin treatment had positive metabolic effects in diabetic rats. "	( Algendy, A; Elabd, SK; Mohasseb, M; Sabry, I, 2014)
"Oxytocin treatment prevented a decrease in the gene expression of only growth factors."	( Bacova, Z; Bakos, J; Havranek, T; Lestanova, Z; Strbak, V, 2014)
"Oxytocin-treated participants reported stronger positive attitudes toward themselves compared to placebo."	( Colonnello, V; Heinrichs, M, 2014)
"Oxytocin treatment significantly increased gene expression and protein levels of neurotrophins, MAP2, and synapsin I in the hippocampus."	( Bacova, Z; Bakos, J; Havranek, T; Hodosy, J; Lestanova, Z; Mravec, B; Strbak, V; Zatkova, M, 2015)
"Oxytocin pre-treatment of the dam decreased brain malondialdehyde, a marker of lipid peroxidation, as well as protein kinase C activity, both in anoxic pups and controls, suggesting oxytocin may reduce aspects of oxidative stress."	( Boksa, P; Nouel, D; Zhang, Y, 2015)
"Oxytocin treatment induced no changes in gene expression of MAP2; however, a decrease of protein levels was observed in all time intervals."	( Bacova, Z; Bakos, J; Havranek, T; Kiss, A; Lestanova, Z; Strbak, V, 2016)
"Oxytocin pretreatment results in attenuation of contractions induced by both oxytocin and carbetocin."	( Balki, M; Carvalho, JC; Cole, NM; Erik-Soussi, M; Ramachandran, N, 2016)
"Oxytocin treatment had no further effect either on catecholamine synthesis or content in socially stressed animals whereas a significant elevation of plasma norepinephrine and epinephrine were reduced."	( Dronjak, S; Jovanovic, P; Puskas, N; Spasojevic, N; Stefanovic, B, 2016)
"As oxytocin is a putative treatment for schizophrenia, the effect of repeated dosing of OT on OT levels, clinical symptoms and the relationship between the two is of interest."	( Buchanan, RW; Kelly, DL; Lee, MR; Linthicum, J; Liu, F; McMahon, RP; Rubin, LH; Strauss, GP; Verbalis, JG; Wehring, HJ, 2016)
"Oxytocin treatment had no effect on skin temperature."	( Aurich, C; Aurich, J; Ille, N; Nagel, C; Trenk, L; Wulf, M, 2017)
"Oxytocin treatment resulted in a transient or prolonged reduction of endotoxin-induced increases in plasma ACTH, cortisol, procalcitonin, TNF-alpha, IL-1 receptor antagonist, IL-4, IL-6, macrophage inflammatory protein-1alpha, macrophage inflammatory protein-1beta, monocyte chemoattractant protein-1 (MCP-1), interferon-inducible protein 10, and VEGF."	( Clodi, M; Geyeregger, R; Luger, A; Luger, TA; Riedl, M; Struck, J; Stulnig, TM; Vila, G, 2008)
"Oxytocin treatment (5 microg/kg and 30 microg/kg i.v.) resulted in significant increase in MAP in both control and running animals in a dose-dependent manner."	( Bakos, J; Bobryshev, P; Jezova, D; Kvetnanský, R; Tillinger, A, 2008)
"Oxytocin treatment decreased the exacerbated anxiety, MPO and MDA levels and inflammatory cell infiltration and submucosal edema while atosiban abolished all the protective effects of OT."	( Cetinel, S; Hancioğlu, S; Kiliç, M; Sener, E; Sener, G; Uner, C; Yeğen, BC, 2010)
"Oxytocin pretreatment significantly suppressed the mean amplitude of the myometrial contractions as compared to the controls when the strips were further subjected to oxytocin (1.02 vs 1.74 g; P < .0001), but not with further exposure to ergonovine (0.77 vs."	( Balki, M; Carvalho, JC; Cristian, AL; Kingdom, J, 2010)
"Oxytocin treatment seems to be superior to vaginal administration of PGE(2) to induce labor in term pregnancies complicated with PROM and unfavorable services."	( Gulerman, C; Gungor, AN; Gungor, T; Kanat-Pektas, M; Kunt, C; Kurt, RK; Mollamahmutoglu, L; Ozat, M, 2010)
"Oxytocin treatment had no effect on the incorporation of 5-bromo-2-deoxyuridine into DNA in the heart ventricle."	( Bakos, J; Garafova, A; Jezova, D; Kovacs, L; Kvetnansky, R; Ondrejcakova, M, 2010)
"Oxytocin-treated UCB-MSCs showed a decrease in tube formation but a drastic increase in transwell migration activity."	( Ahn, Y; Cho, JG; Hong, MH; Jeong, MH; Kang, JC; Kim, J; Kim, YS; Kwon, JS; Park, JC; Song, CH, 2010)
"The oxytocin-only treatment resulted in a significant (P < 0.01) dose-dependent increase in myometrial resting tension."	( Fowden, AL; Freestone, N; Mason, WT; Ousey, JC; Rossdale, PD, 2000)
"Oxytocin treatment decreased the diameter of adipocytes and increased the epididymal adipose tissue protein content without changing the adipose tissue mass. "	( Eckertova, M; Jezova, D; Krskova, K; Ondrejcakova, M; Zorad, S, 2011)
"Oxytocin treatment significantly reduced the NPY response to hypoglycemia."	( Cataldo, S; Chiodera, P; Coiro, V; Magotti, MG; Stella, A; Volpi, R; Volta, E, 2011)
"Oxytocin pretreatment blunted neurotoxin 6-OHDA reduction of cell viability in SH-SY5Y cells."	( Bacova, Z; Bakos, J; Ratulovska, N; Strbak, V, 2012)
"Oxytocin (OXT) pretreatment protects the heart during ischemia-reperfusion injury by activating ATP-dependent potassium (K(ATP)) channels. "	( Das, B; Sarkar, C, 2012)
"Oxytocin pretreatment of pregnant rat myometrium has been shown to reduce the contractions produced by further administration of oxytocin, as a function of the desensitization phenomenon. "	( Balki, M; Carvalho, JC; Erik-Soussi, M; Kanwal, N; Kingdom, J, 2012)
"Oxytocin treatment significantly reduced infarct size to 15.1 + 3.2% as compared to 32.4 + 3.5% in vehicle-treated rats (p < 0.01)."	( Barancik, M; Bartekova, M; Jezova, D; Ondrejcakova, M; Ravingerova, T, 2012)
"The oxytocin treatment i.c.v."	( Petersson, M, 2002)
"Oxytocin-treated sows had a significant decrease in farrowing time and expulsion intervals and also had a significantly higher number of stillborn piglets per litter, compared with control sows. "	( Alonso-Spilsbury, ML; López, A; Martínez-Burnes, J; Mota-Rojas, D; Ramírez-Necoechea, R; Trujillo-Ortega, ME, 2002)
"Oxytocin treatment decreased blood pressure independently of nutrition, whereas the increased plasma levels of corticosterone were lowered to normal levels in food-restricted offspring."	( Olausson, H; Sohlström, A; Uvnäs-Moberg, K, 2003)
"The oxytocin treatment decreased GR mRNA expression in CA1+2 and the dentate gyrus (P<0.05), tended to decrease GR mRNA expression in CA3 (P=0.07), and increased MR mRNA expression in the dentate gyrus (P<0.05)."	( Petersson, M; Uvnäs-Moberg, K, 2003)
"Oxytocin treatment increased the time to penile protrusion during electroejaculation in experiment 1 and during massage in experiment 2."	( Amundson, SD; Barth, AD; Brito, LF; Palmer, CW; Waldner, CL, 2004)
"Oxytocin is a treatment of choice for augmentation and induction of labor; however, no consensus exists regarding optimal dosing. "	( Johnston, AK; Lodolce, AE; Patka, JH, 2005)
"Oxytocin treatment in rats induces long-lasting antistress and growth promoting effects. "	( Petersson, M; Uvnäs-Moberg, K, 2004)
"Oxytocin treatment increased (P < 0.01) the number of pigs born alive with ruptured umbilical cords and those with different grades of meconium staining on their skin."	( Alonso-Spilsbury, M; López, A; Martínez-Burnes, J; Merino, A; Mota-Rojas, D; Orozco, H; Ramírez, R; Rosales, AM; Trujillo, ME, 2005)
"Oxytocin treatment reversed the burn-induced elevations in MDA and MPO levels and reduced the gastric damage scores (p<0.001, p<0.01), while TNF-alpha levels, which were increased significantly at 48thh after injury (p<0.001), were abolished with OT treatment (p<0.001)."	( Arbak, S; Erzik, C; Gedik, IE; Gedik, N; Işeri, SO; Uslu, B; Yeğen, BC, 2008)
"Oxytocin-treated subjects had a lower bias to judge not previously seen faces as being previously seen."	( Ehrhardt, R; Savaskan, E; Schächinger, H; Schulz, A; Walter, M, 2008)
"Oxytocin treatment significantly reversed the I/R-induced elevations in serum transaminase and TNF-alpha levels and in hepatic MPO and collagen levels, and reduced the hepatic damage scores."	( Düşünceli, F; Ercan, F; Gedik, N; Işeri, SO; Yeğen, BC; Yeğen, C, 2008)
"oxytocin (treatment 3) resulted in milking parameters very similar to those of treatment 2."	( Mayer, H; Prokopp, A; Schams, D; Worstorff, H, 1984)
"Oxytocin treatments given once daily on Days 5 and 6, or twice daily on Day 5 and 6 or 4, 5 and 6 resulted in shortened cycles and lower jugular progesterone concentrations in 1 of 5, 2 of 4 and 4 of 5 heifers, respectively."	( Hansel, W; Milvae, RA, 1980)
"Oxytocin treatment induced Fos expression in SON and brain stem neurons in both parturient rats and rats in which parturition was not induced."	( Antonijevic, IA; Bicknell, RJ; Douglas, AJ; Leng, G; Luckman, SM; Russell, JA, 1995)
"Oxytocin treatment of human myometrial smooth muscle cells resulted in a dose-dependent increase in intracellular free Ca2+ levels."	( Ambrus, G; Eta, E; Rao, CV, 1994)
"Oxytocin treatment did not produce lasting changes."	( Boer, GJ; de Vries, MC; Heinsbroek, RP; Quak, J, 1994)
"oxytocin-treated endometrium on Days 13, 16, and 19, respectively) with the greatest increase (p < 0.01) in responsiveness to oxytocin occurring between Days 16 and 19.(ABSTRACT TRUNCATED AT 250 WORDS)"	( Becker, WC; Mirando, MA; Whiteaker, SS, 1993)
"Oxytocin treatment increases 5 alpha-reductase activity in the prostate of healthy young rats but, unlike the testis, this rise in enzyme activity is only transient."	( Jenkin, L; Nicholson, HD, 1995)
"Oxytocin treatment caused a small increase in oxytocin receptor concentration in the luminal epithelium on days 8 and 10 (20 +/- 4 in Group P and 107 +/- 35 fmol mg protein-1 in Group OT, P < 0.01) but the rise on day 14 was not affected (267 +/- 82 in Group OT and 411 +/- 120 fmol mg protein-1 in Group OTW)."	( Lamming, GE; Mann, GE; Payne, JH; Riley, PR; Stevenson, KR; Wathes, DC, 1996)
"Oxytocin-treated male rats had increased circulating levels of cholecystokinin, a tendency to increased plasma levels of insulin (p = 0.066), and relatively more adipose tissue in the thigh and interscapular region, compared with controls."	( Alster, P; Björkstrand, E; Petersson, M; Sohlström, A; Uvnäs-Moberg, K, 1998)
"Oxytocin pretreatment for 2 h (n = 5) did not produce a significant effect."	( Emala, CW; Hirshman, CA; Kuhl, JS; Levitsky, HI; Lindeman, KS, 1998)
"If oxytocin treatment of OVX rats continued, a nadir of 12 mm Hg (118+/-1.7 mm Hg; p < 0.001) was reached after 8 days."	( Lundeberg, T; Petersson, M; Uvnäs-Moberg, K, 1999)
"The oxytocin treatment caused an elevation of plasma levels of oxytocin 1 day (p < 0.05) but not 3 and 10 days after treatment."	( Andersson, R; Hulting, A; Petersson, M; Uvnäs-Moberg, K, 1999)
"Oxytocin-treated food-restricted females had more body fat and lower plasma levels of IGF-I, IGFBP-1 and IGFBP-3 compared with saline-treated counterparts."	( Bang, P; Brismar, K; Carlsson-Skwirut, C; Sohlström, A; Uvnäs-Moberg, K, 1999)
"Oxytocin treatment decreases blood pressure and changes the pattern of spontaneous motor activity. "	( Lundeberg, T; Petersson, M; Uvnäs-Moberg, K, 1999)
"Oxytocin antagonist treatment further elevated the stress-induced (exposure to the elevated plus-maze or forced swimming) secretion of both corticotropin and corticosterone, but only in virgin and not in pregnant or lactating rats."	( Neumann, ID; Torner, L; Wigger, A, 2000)
"Oxytocin treatment may permanently alter endocrine axes resulting in anti-stress and anabolic effects. "	( Brismar, K; Olausson, H; Sohlström, A; Uvnäs-Moberg, K, 2002)
"Oxytocin pretreatment, which had no intrinsic effects, resulted in a robust selective attenuation of tolerance to ethanol-induced hypothermia, myorelaxation and akinesia."	( Jodogne, C; Klingbiel, P; Legros, JJ; Tirelli, E, 1991)
"Oxytocin treatment during infancy resulted in an elevation of novelty-induced grooming when compared to saline and untreated animals."	( Continella, G; Noonan, LR; Pedersen, CA, 1989)
"Oxytocin treatment did not, however, significantly affect the corticosterone response to the psychological stressor."	( Muir, JL; Pfister, HP, 1989)
"Oxytocin treatment during hourly milking also increased enzyme activity in milk from a nonresponding goat."	( Azzara, CD; Dimick, PS, 1989)
"With oxytocin treatment, after 4 d milk yield first increased and then significantly decreased, citrate concentration decreased significantly while there were no significant changes in lactoferrin or BSA concentration or in the yield of any other milk constituents."	( Fell, LR; Thomas, AS, 1985)
"In oxytocin-treated patients, however, both beta-EP and beta-LPH remained constant until parturition."	( Facchinetti, F; Galli, PA; Genazzani, AR; Petraglia, F; Volpe, A, 1985)
"Oxytocin treatment and, to a lesser extent, frequent milking without oxytocin, altered milk composition."	( Linzell, JL; Peaker, M, 1971)
"treatment with oxytocin ameliorates memory deficits in oxycodone-treated rats through inhibition of the ECS."	( Fan, XY; Jian, LY; Shi, G; Wan, YX, 2023)
"Treatment with oxytocin improved autistic like behaviours, normalized the number of neurons and the volume of the infralimbic region as well as the plasma BDNF level (p < 0.05)."	( Ardalan, M; Mansouri, M; Pouretemad, H; Roghani, M; Wegener, G, 2020)
"Treatment with oxytocin reversed this abnormality."	( Bacova, Z; Bakos, J; Bukatova, S; Muscatelli, F; Reichova, A; Schaller, F, 2021)
"Treatment with oxytocin and carbetocin reduced farrowing duration (P = 0.023) and sows treated with carbetocin had piglets with the least umbilical cord blood lactate (P = 0.008) and plasma protein (P = 0.005) concentrations."	( Kirkwood, RN; Plush, KL; Ward, SA, 2019)
"Pretreatment with oxytocin 10 and 10 M significantly reduced motility index (estimate [standard error]: -0.771 [0.270] square root units, P = 0.005 and -0.697 [0.293], P = 0.02, respectively) and area under the curve (-3.947 [1.909], P = 0.04 and -4.241 [2.189], P = 0.05, respectively) compared with control group, whereas pretreatment with oxytocin 10 M did not significantly attenuate contractions. "	( Balki, M; Carvalho, JC; Erik-Soussi, M; Kingdom, J, 2013)
"Pretreatment with oxytocin decreases oxytocin-induced myometrial contractions in a concentration and time-dependent manner, likely as a function of the oxytocin receptor desensitization phenomenon."	( Balki, M; Carvalho, JC; Erik-Soussi, M; Kingdom, J, 2013)
"The treatment with oxytocin after the exposure to MK-801 was able to reestablish the time spent in the segment closest to the conspecific school, as well as the time spent in the segment nearest to the mirror image."	( Bonan, CD; Gaspary, KV; Siebel, AM; Zimmermann, FF, 2016)
"Treatment with oxytocin resulted in a significant increase in specific phosphorylation (activation) of p38-MAPK and Akt kinase, an increase in phosphorylated Hsp27 and an elevation in atrial natriuretic peptide (ANP) levels in left ventricular heart tissue."	( Barancik, M; Bartekova, M; Jezova, D; Ondrejcakova, M; Ravingerova, T, 2012)
"Co-treatment with oxytocin and oxytocin receptor antagonist--atosiban--resulted in significant increase of MAP2 gene expression in SK-N-SH cells."	( Bacova, Z; Bakos, J; Krajnakova, L; Lestanova, Z; Paulikova, H; Strbak, V, 2013)
"Pretreatment with oxytocin resulted in a decrease in the percentage of cells that responded to subsequent oxytocin exposure. "	( Robinson, C; Schumann, R; Young, RC; Zhang, P, 2003)
"Pretreatment with oxytocin receptor antagonist centrally had no effect on ACTH responses to stress in either virgin or pregnant mice."	( Bosch, OJ; Brunton, PJ; Douglas, AJ; Neumann, ID; Russell, JA, 2003)
"When treated with oxytocin, Sca-1+ cells expressed genes of cardiac transcription factors and contractile proteins and showed sarcomeric structure and spontaneous beating."	( Akazawa, H; Kasanuki, H; Komuro, I; Matsuura, K; Nagai, T; Nakaya, H; Nishi, J; Nishigaki, N; Oyama, T; Sano, M; Sato, T; Toko, H; Wada, H, 2004)
"Treatment with oxytocin reduced the duration of the expulsion of the fetus, increased the number of IPS with ruptured umbilical cords and with severe meconium-stain degree and reduced the number of fetuses with inspiration attempts."	( Alonso-Spilsbury, M; Arch, E; López Mayagoitia, A; Martínez-Burnes, J; Mota-Rojas, D; Olmos, A; Ramírez-Necoechea, R; Trujillo, ME, 2004)
"Treatment with oxytocin antagonist resulted in a significant decrease in estrogen receptor alpha-immunoreactivity in the medial preoptic area in postnatal day 21 females."	( Carter, CS; Cushing, BS; Yamamoto, Y, 2006)
"Treatment with oxytocin may induce both nociceptive and anti-nociceptive effects."	( Agren, G; Lundeberg, T; Uvnäs-Moberg, K, 1997)
"Treatment with oxytocin resulted in higher body weight in males, 60 d after birth, and in females from d 60 and throughout the rest of the experiment, compared with controls."	( Alster, P; Björkstrand, E; Petersson, M; Sohlström, A; Uvnäs-Moberg, K, 1998)
"Treatment with oxytocin antagonist 10 min prior to behavioural testing on the elevated plus-maze significantly reduced the anxiety-related behaviour in both pregnant and lactating rats, without exerting similar effects in virgin female rats."	( Neumann, ID; Torner, L; Wigger, A, 2000)
"Treatment with oxytocin in vitro did not stimulate phosphoinositide hydrolysis significantly in vehicle- or oxytocin-injected pregnant gilts or pseudopregnant gilts."	( Carnahan, KG; Evans, MA; Ludwig, TE; Mirando, MA; Prince, BC; Uzumcu, M, 1999)
"Treatment with oxytocin antagonist had no immediate effect, but subsequently caused a significant reduction in both fluid output and the number of spermatozoa."	( Lapwood, KR; Nicholson, HD; Parkinson, TJ, 1999)
"Pre-treatment with oxytocin markedly improved avoidance learning in the Stock B high-emotional animals. "	( Ahlenius, S; Eklund, M; Hillegaart, V; Uvnäs-Moberg, K, 2000)
"Treatment with oxytocin alone resulted in the maintenance of corpora lutea, reduced follicular development and a low concentration of uterine oxytocin receptor."	( Sheldrick, EL, 1992)
"Treatment with oxytocin was associated with a shorter second stage (p = 0.01), a reduction in the number of non-rotational forceps deliveries (p = 0.03), and less perineal trauma (p = 0.03) but was not associated with any reduction in the number of rotational forceps deliveries performed for malposition of the occiput. "	( Edmonds, DK; Fraser, RB; Gilbert, L; Hall, JM; Jackson, A; Mutton, PM; Saunders, NJ; Spiby, H, 1989)
"Treatment of oxytocin-treated cells with relaxin (1.5 micrograms/ml), isoproterenol (10 microM) or (Bu)2 cAMP (1 mM) for 15 min resulted in a significant increase in cell length and area."	( Hsu, CJ; Sanborn, BM, 1986)

Pathways (2)

oxytocin is involved in 2 pathway(s), involving a total of 4 unique proteins and 14 unique compounds

Role	Description
oxytocic	A drug that stimulates contraction of the myometrium. Oxytocics are used to induce labour, obstetric at term, to prevent or control postpartum or postabortion haemorrhage, and to assess foetal status in high risk pregnancies. They may also be used alone or with other drugs to induce abortions (abortifacients).
vasodilator agent	A drug used to cause dilation of the blood vessels.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
peptide hormone	Any peptide with hormonal activity in animals, whether endocrine, neuroendocrine, or paracrine.
heterodetic cyclic peptide	A heterodetic cyclic peptide is a peptide consisting only of amino-acid residues, but in which the linkages forming the ring are not solely peptide bonds; one or more is an isopeptide, disulfide, ester, or other bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
CAMKK2 pathway	0	11
Oxytocin signaling	4	3

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	0.2818	0.0032	45.4673	12,589.2998	AID2517
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Sodium channel protein type 1 subunit alpha	Rattus norvegicus (Norway rat)	Ki	0.0610	0.0530	0.3770	1.9000	AID217709
Sodium channel protein type 2 subunit alpha	Rattus norvegicus (Norway rat)	Ki	0.0610	0.0530	0.3770	1.9000	AID217709
Sodium channel protein type 3 subunit alpha	Rattus norvegicus (Norway rat)	Ki	0.0610	0.0530	0.3770	1.9000	AID217709
Vasopressin V2 receptor	Homo sapiens (human)	Ki	3.6813	0.0004	0.4345	3.9811	AID1199942; AID1494504; AID217392
Oxytocin receptor	Homo sapiens (human)	IC50 (µMol)	0.0027	0.0027	0.2191	0.5190	AID294438
Oxytocin receptor	Homo sapiens (human)	Ki	0.0026	0.0001	0.0718	0.9780	AID1199939; AID1199951; AID1199952; AID1199953; AID1277198; AID1306778; AID1494505; AID151797; AID1593563; AID367068; AID549468
Vasopressin V1a receptor	Rattus norvegicus (Norway rat)	Ki	0.0610	0.0008	0.0300	0.1100	AID217709
Vasopressin V1a receptor	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0006	0.3835	2.0000	AID1178653
Vasopressin V1a receptor	Homo sapiens (human)	Ki	0.0737	0.0002	0.6235	7.0300	AID1199940; AID1494502; AID217086; AID367069
Vasopressin V1b receptor	Homo sapiens (human)	Ki	3.8910	0.0005	0.1897	1.7820	AID1199941; AID1494503
Vasopressin V1b receptor	Rattus norvegicus (Norway rat)	Ki	0.0610	0.0003	0.0158	0.0610	AID217709
Oxytocin receptor	Rattus norvegicus (Norway rat)	Ki	0.0013	0.0009	0.0489	0.2300	AID151927; AID151936
Vasopressin V2 receptor	Rattus norvegicus (Norway rat)	Ki	0.0700	0.0003	0.9791	9.7000	AID217708; AID217709
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	Ki	0.0610	0.0021	1.8407	10.0000	AID217709
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Vasopressin V2 receptor	Homo sapiens (human)	EC50 (µMol)	0.2641	0.0000	0.5506	6.7000	AID1178647; AID1386968; AID1386974; AID1494511
Oxytocin receptor	Homo sapiens (human)	EC50 (µMol)	0.0048	0.0000	0.0805	0.8810	AID1178646; AID1199949; AID1199950; AID1277199; AID1306776; AID1370595; AID1386960; AID1386975; AID1450439; AID1450445; AID1494508; AID1528624; AID1528626; AID1591639; AID1593562; AID1636591; AID549467; AID593577
Oxytocin receptor	Homo sapiens (human)	Kd	0.0067	0.0067	0.0067	0.0067	AID151793
Vasopressin V1a receptor	Homo sapiens (human)	EC50 (µMol)	0.0394	0.0000	0.1971	3.2000	AID1178648; AID1370597; AID1386964; AID1450440; AID1450441; AID1450446; AID1494509; AID1591640; AID1593564
Vasopressin V1b receptor	Homo sapiens (human)	EC50 (µMol)	0.0523	0.0000	0.0360	0.2400	AID1178649; AID1386966; AID1386978; AID1494510; AID1591641; AID1593565; AID593575
Oxytocin receptor	Mus musculus (house mouse)	EC50 (µMol)	0.0020	0.0020	0.0427	0.0780	AID1386962
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
positive regulation of systemic arterial blood pressure	Vasopressin V2 receptor	Homo sapiens (human)
renal water retention	Vasopressin V2 receptor	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Vasopressin V2 receptor	Homo sapiens (human)
activation of adenylate cyclase activity	Vasopressin V2 receptor	Homo sapiens (human)
hemostasis	Vasopressin V2 receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Vasopressin V2 receptor	Homo sapiens (human)
negative regulation of cell population proliferation	Vasopressin V2 receptor	Homo sapiens (human)
positive regulation of gene expression	Vasopressin V2 receptor	Homo sapiens (human)
telencephalon development	Vasopressin V2 receptor	Homo sapiens (human)
response to cytokine	Vasopressin V2 receptor	Homo sapiens (human)
positive regulation of intracellular signal transduction	Vasopressin V2 receptor	Homo sapiens (human)
cellular response to hormone stimulus	Vasopressin V2 receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Vasopressin V2 receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Vasopressin V2 receptor	Homo sapiens (human)
regulation of systemic arterial blood pressure by vasopressin	Vasopressin V2 receptor	Homo sapiens (human)
suckling behavior	Oxytocin receptor	Homo sapiens (human)
response to amphetamine	Oxytocin receptor	Homo sapiens (human)
muscle contraction	Oxytocin receptor	Homo sapiens (human)
cell surface receptor signaling pathway	Oxytocin receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Oxytocin receptor	Homo sapiens (human)
heart development	Oxytocin receptor	Homo sapiens (human)
lactation	Oxytocin receptor	Homo sapiens (human)
memory	Oxytocin receptor	Homo sapiens (human)
response to xenobiotic stimulus	Oxytocin receptor	Homo sapiens (human)
positive regulation of norepinephrine secretion	Oxytocin receptor	Homo sapiens (human)
telencephalon development	Oxytocin receptor	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Oxytocin receptor	Homo sapiens (human)
response to estradiol	Oxytocin receptor	Homo sapiens (human)
response to progesterone	Oxytocin receptor	Homo sapiens (human)
response to anoxia	Oxytocin receptor	Homo sapiens (human)
response to cytokine	Oxytocin receptor	Homo sapiens (human)
social behavior	Oxytocin receptor	Homo sapiens (human)
response to cocaine	Oxytocin receptor	Homo sapiens (human)
maternal behavior	Oxytocin receptor	Homo sapiens (human)
sperm ejaculation	Oxytocin receptor	Homo sapiens (human)
eating behavior	Oxytocin receptor	Homo sapiens (human)
response to peptide hormone	Oxytocin receptor	Homo sapiens (human)
estrous cycle	Oxytocin receptor	Homo sapiens (human)
positive regulation of blood pressure	Oxytocin receptor	Homo sapiens (human)
digestive tract development	Oxytocin receptor	Homo sapiens (human)
positive regulation of synapse assembly	Oxytocin receptor	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	Oxytocin receptor	Homo sapiens (human)
positive regulation of penile erection	Oxytocin receptor	Homo sapiens (human)
ERK1 and ERK2 cascade	Oxytocin receptor	Homo sapiens (human)
positive regulation of uterine smooth muscle contraction	Oxytocin receptor	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Oxytocin receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Oxytocin receptor	Homo sapiens (human)
female pregnancy	Oxytocin receptor	Homo sapiens (human)
regulation of systemic arterial blood pressure by vasopressin	Oxytocin receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Oxytocin receptor	Homo sapiens (human)
maternal process involved in parturition	Oxytocin receptor	Homo sapiens (human)
cellular response to hormone stimulus	Oxytocin receptor	Homo sapiens (human)
maternal aggressive behavior	Vasopressin V1a receptor	Homo sapiens (human)
positive regulation of systemic arterial blood pressure	Vasopressin V1a receptor	Homo sapiens (human)
generation of precursor metabolites and energy	Vasopressin V1a receptor	Homo sapiens (human)
activation of phospholipase C activity	Vasopressin V1a receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Vasopressin V1a receptor	Homo sapiens (human)
negative regulation of female receptivity	Vasopressin V1a receptor	Homo sapiens (human)
grooming behavior	Vasopressin V1a receptor	Homo sapiens (human)
blood circulation	Vasopressin V1a receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Vasopressin V1a receptor	Homo sapiens (human)
positive regulation of heart rate	Vasopressin V1a receptor	Homo sapiens (human)
positive regulation of glutamate secretion	Vasopressin V1a receptor	Homo sapiens (human)
myotube differentiation	Vasopressin V1a receptor	Homo sapiens (human)
calcium-mediated signaling	Vasopressin V1a receptor	Homo sapiens (human)
telencephalon development	Vasopressin V1a receptor	Homo sapiens (human)
positive regulation of cell growth	Vasopressin V1a receptor	Homo sapiens (human)
positive regulation of prostaglandin biosynthetic process	Vasopressin V1a receptor	Homo sapiens (human)
positive regulation of cellular pH reduction	Vasopressin V1a receptor	Homo sapiens (human)
social behavior	Vasopressin V1a receptor	Homo sapiens (human)
cellular response to water deprivation	Vasopressin V1a receptor	Homo sapiens (human)
maternal behavior	Vasopressin V1a receptor	Homo sapiens (human)
sperm ejaculation	Vasopressin V1a receptor	Homo sapiens (human)
response to corticosterone	Vasopressin V1a receptor	Homo sapiens (human)
negative regulation of transmission of nerve impulse	Vasopressin V1a receptor	Homo sapiens (human)
transport across blood-brain barrier	Vasopressin V1a receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Vasopressin V1a receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Vasopressin V1a receptor	Homo sapiens (human)
cellular response to hormone stimulus	Vasopressin V1a receptor	Homo sapiens (human)
regulation of systemic arterial blood pressure by vasopressin	Vasopressin V1a receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Vasopressin V1b receptor	Homo sapiens (human)
activation of phospholipase C activity	Vasopressin V1b receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Vasopressin V1b receptor	Homo sapiens (human)
positive regulation of phospholipase A2 activity	Vasopressin V1b receptor	Homo sapiens (human)
regulation of cell population proliferation	Vasopressin V1b receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Vasopressin V1b receptor	Homo sapiens (human)
symbiont entry into host cell	Vasopressin V1b receptor	Homo sapiens (human)
positive regulation of inositol phosphate biosynthetic process	Vasopressin V1b receptor	Homo sapiens (human)
positive regulation of arachidonic acid secretion	Vasopressin V1b receptor	Homo sapiens (human)
transport across blood-brain barrier	Vasopressin V1b receptor	Homo sapiens (human)
cellular response to hormone stimulus	Vasopressin V1b receptor	Homo sapiens (human)
regulation of systemic arterial blood pressure by vasopressin	Vasopressin V1b receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Vasopressin V1b receptor	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by hormone	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion homeostasis	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cardiac muscle contraction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cellular response to xenobiotic stimulus	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane depolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion import across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
vasopressin receptor activity	Vasopressin V2 receptor	Homo sapiens (human)
protein binding	Vasopressin V2 receptor	Homo sapiens (human)
peptide binding	Vasopressin V2 receptor	Homo sapiens (human)
peptide hormone binding	Oxytocin receptor	Homo sapiens (human)
peptide binding	Oxytocin receptor	Homo sapiens (human)
vasopressin receptor activity	Oxytocin receptor	Homo sapiens (human)
oxytocin receptor activity	Oxytocin receptor	Homo sapiens (human)
vasopressin receptor activity	Vasopressin V1a receptor	Homo sapiens (human)
protein kinase C binding	Vasopressin V1a receptor	Homo sapiens (human)
protein binding	Vasopressin V1a receptor	Homo sapiens (human)
peptide hormone binding	Vasopressin V1a receptor	Homo sapiens (human)
V1A vasopressin receptor binding	Vasopressin V1a receptor	Homo sapiens (human)
peptide binding	Vasopressin V1a receptor	Homo sapiens (human)
vasopressin receptor activity	Vasopressin V1b receptor	Homo sapiens (human)
protein kinase C binding	Vasopressin V1b receptor	Homo sapiens (human)
peptide binding	Vasopressin V1b receptor	Homo sapiens (human)
transcription cis-regulatory region binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ubiquitin protein ligase binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
identical protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein homodimerization activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
C3HC4-type RING finger domain binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
scaffold protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
endosome	Vasopressin V2 receptor	Homo sapiens (human)
endoplasmic reticulum	Vasopressin V2 receptor	Homo sapiens (human)
Golgi apparatus	Vasopressin V2 receptor	Homo sapiens (human)
plasma membrane	Vasopressin V2 receptor	Homo sapiens (human)
membrane	Vasopressin V2 receptor	Homo sapiens (human)
endocytic vesicle	Vasopressin V2 receptor	Homo sapiens (human)
clathrin-coated endocytic vesicle membrane	Vasopressin V2 receptor	Homo sapiens (human)
perinuclear region of cytoplasm	Vasopressin V2 receptor	Homo sapiens (human)
plasma membrane	Vasopressin V2 receptor	Homo sapiens (human)
plasma membrane	Oxytocin receptor	Homo sapiens (human)
microvillus	Oxytocin receptor	Homo sapiens (human)
adherens junction	Oxytocin receptor	Homo sapiens (human)
apical plasma membrane	Oxytocin receptor	Homo sapiens (human)
plasma membrane	Oxytocin receptor	Homo sapiens (human)
endosome	Vasopressin V1a receptor	Homo sapiens (human)
plasma membrane	Vasopressin V1a receptor	Homo sapiens (human)
endocytic vesicle	Vasopressin V1a receptor	Homo sapiens (human)
plasma membrane	Vasopressin V1a receptor	Homo sapiens (human)
endosome	Vasopressin V1b receptor	Homo sapiens (human)
Golgi apparatus	Vasopressin V1b receptor	Homo sapiens (human)
plasma membrane	Vasopressin V1b receptor	Homo sapiens (human)
plasma membrane	Vasopressin V1b receptor	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cell surface	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
perinuclear region of cytoplasm	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1386980	Agonist activity at human V2 receptor expressed in HEK293FT cells incubated for 30 mins by beta-arrestin recruitment assay relative to AVP	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.
AID1133929	Ratio of oxytocic potency to antidiuretic activity in rat	1977	Journal of medicinal chemistry, Apr, Volume: 20, Issue:4	Combined high oxytocic with negligible antidiuretic and pressor activities in multisubstituted oxytocins.
AID217245	Vasopressor activity at V1a receptor	1995	Journal of medicinal chemistry, May-12, Volume: 38, Issue:10	Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists.
AID1178653	Antagonist activity at human vasopressin V1a expressed in AVP-stimulated HEK293 cells after 5 hrs by firefly luciferase reporter gene assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	New, potent, and selective peptidic oxytocin receptor agonists.
AID1169141	Apparent permeability in RRCK cells	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	EPSA: A Novel Supercritical Fluid Chromatography Technique Enabling the Design of Permeable Cyclic Peptides.
AID230252	Ratio of Oxytocin to Pressor activity	1983	Journal of medicinal chemistry, Dec, Volume: 26, Issue:12	Synthesis and some pharmacological properties of [4-threonine,7-sarcosine]oxytocin, a peptide with high oxytocic potency, and of [4-threonine,7-N-methylalanine]oxytocin.
AID151938	Compound was evaluated for the oxytocic activity with 0.5 mM Mg2+.	1995	Journal of medicinal chemistry, May-12, Volume: 38, Issue:10	Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists.
AID593577	Agonist activity at human oxytocin receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.
AID1199942	Binding affinity to V2R (unknown origin)	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Selective nonpeptidic fluorescent ligands for oxytocin receptor: design, synthesis, and application to time-resolved FRET binding assay.
AID1133493	Ratio of oxytocic potency to antidiuretic activity in rat	1977	Journal of medicinal chemistry, Jan, Volume: 20, Issue:1	Synthesis and some pharmacological properties of [4-threonine, 7-glycine]oxytocin, [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine, 7-glycine]oxytocin (hydroxy[Thr4, Gly7]oxytocin), and [7-Glycine]oxytocin, peptides with high oxytocic-antidiuretic
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1131310	Stability of the compound in 0.2 M potassium phosphate buffer at pH 7.7 assessed as hydrolysis by measuring Leu/Lys level in presence of pronase	1979	Journal of medicinal chemistry, Dec, Volume: 22, Issue:12	[3-(1,4-Cyclohexadienyl)-L-alanine,8-lysine]vasopressin: synthesis and some pharmacological properties.
AID53017	Compound was tested in vitro for avain vasopressor activity	1980	Journal of medicinal chemistry, Feb, Volume: 23, Issue:2	Oxytocin and lysine-vasopressin with N5,N5-dialkylglutamine in the 4 position: effect of introducing sterically hindered groups into the hydrophilic cluster of neurohypophyseal hormones.
AID1450440	Agonist activity at human V1a receptor expressed in CHO cells assessed as calcium mobilization measured after 30 mins by Fluo-4-AM dye based FLIPR assay	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Potent and selective oxytocin receptor agonists without disulfide bridges.
AID13117	Compound was tested for antidiuretic activity in rats	1980	Journal of medicinal chemistry, Jun, Volume: 23, Issue:6	N-Acetyl-[2-(O-methyl)tyrosine]arginine-vasopressin, an interesting antagonist of the vasopressor response to vasopressin.
AID549468	Displacement of [3H]OT from oxytocin receptor expressed in COS1 cells	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Modulating oxytocin activity and plasma stability by disulfide bond engineering.
AID1150128	Antidiuretic activity in iv dosed hydrated rat anesthetized with ethanol	1977	Journal of medicinal chemistry, Sep, Volume: 20, Issue:9	Synthesis and some pharmacological properties of [4-homoserine]oxytocin.
AID1133487	Oxytocic potency in rat by uterus assay	1977	Journal of medicinal chemistry, Jan, Volume: 20, Issue:1	Synthesis and some pharmacological properties of [4-threonine, 7-glycine]oxytocin, [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine, 7-glycine]oxytocin (hydroxy[Thr4, Gly7]oxytocin), and [7-Glycine]oxytocin, peptides with high oxytocic-antidiuretic
AID1450446	Agonist activity at C-terminal GFP-tagged V1a receptor (unknown origin) expressed in HEK293 cells measured after 18 hrs by luciferase reporter gene assay	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Potent and selective oxytocin receptor agonists without disulfide bridges.
AID1131312	Stability of the compound in 0.2 M potassium phosphate buffer at pH 7.7 assessed as hydrolysis by measuring Asn/Gln level in presence of pronase	1979	Journal of medicinal chemistry, Dec, Volume: 22, Issue:12	[3-(1,4-Cyclohexadienyl)-L-alanine,8-lysine]vasopressin: synthesis and some pharmacological properties.
AID171776	Uterotonic activity in vitro in isolated rat uterus in presence of magnesium	1983	Journal of medicinal chemistry, Apr, Volume: 26, Issue:4	Synthesis and some pharmacological properties of oxytocin and vasopressin analogues with sarcosine or N-methyl-L-alanine in position 7.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID197054	In vivo uterotonic activity in rats	1999	Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24	Chemical syntheses and biological studies on dimeric chimeras of oxytocin and the V(2)-antagonist, d(CH(2))(5)[D-Ile(2), Ile(4)]arginine vasopressin.
AID1131311	Stability of the compound in 0.2 M potassium phosphate buffer at pH 7.7 assessed as hydrolysis by measuring Gly level in presence of pronase	1979	Journal of medicinal chemistry, Dec, Volume: 22, Issue:12	[3-(1,4-Cyclohexadienyl)-L-alanine,8-lysine]vasopressin: synthesis and some pharmacological properties.
AID190056	In vivo pressor activity by vasopressin assay in rats	1992	Journal of medicinal chemistry, May-01, Volume: 35, Issue:9	Structure-activity studies of a novel bicyclic oxytocin antagonist.
AID1386968	Agonist activity at human V2 receptor expressed in HEK293FT cells assessed as stimulation of calcium release by Aequorin based assay	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.
AID1306778	Displacement of [3H]8-arginine-vasopressin from human oxytocin receptor expressed in CHO cell membrane incubated for 1 hr by liquid scintillation counting method	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Systematic N-methylation of oxytocin: Impact on pharmacology and intramolecular hydrogen bonding network.
AID734452	Stability of the compound in presence of alpha-chymotrypsin (unknown origin) assessed as degradation measured after 60 mins by HPLC analysis	2013	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4	A comparative protease stability study of synthetic macrocyclic peptides that mimic two endocrine hormones.
AID168372	Tested for antidiuretic activity in rat	1983	Journal of medicinal chemistry, Apr, Volume: 26, Issue:4	Synthesis and some pharmacological properties of oxytocin and vasopressin analogues with sarcosine or N-methyl-L-alanine in position 7.
AID1386978	Agonist activity at human V1b receptor expressed in HEK293FT cells incubated for 30 mins by beta-arrestin recruitment assay	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.
AID1133928	Antidiuretic activity in iv dosed rat	1977	Journal of medicinal chemistry, Apr, Volume: 20, Issue:4	Combined high oxytocic with negligible antidiuretic and pressor activities in multisubstituted oxytocins.
AID496820	Antimicrobial activity against Trypanosoma brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496817	Antimicrobial activity against Trypanosoma cruzi	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1528624	Agonist activity at recombinant human Gi/Go-coupled OTR expressed in CHOK1 cells assessed as induction of beta-arrestin recruitment measured after 90 mins in presence of 10% FBS by pathhunter assay
AID1144698	Agonist activity at oxytocin receptor in chicken by avian vasodepressor assay	1976	Journal of medicinal chemistry, Feb, Volume: 19, Issue:2	Synthesis and some pharmacological properties of five analogs of oxytocin having L-homocysteine in position 6.
AID1151061	Pressor activity in rat after 45 mins	1976	Journal of medicinal chemistry, Jun, Volume: 19, Issue:6	Oxytocin analogues with combined high smooth muscle and negligible antidiuretic activities. Investigation of position 7 in neurohypophyseal hormones.
AID1494505	Displacement of [3H]OT from human mammary gland oxytocin receptor expressed in HEK293 cell membrane after 1 hr by scintillation counting method	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs.
AID151937	In vitro Oxytocin receptor antagonistic activity against rat uterine strips	1992	Journal of medicinal chemistry, May-01, Volume: 35, Issue:9	Structure-activity studies of a novel bicyclic oxytocin antagonist.
AID1131337	Stability of the compound in 0.2 M potassium phosphate buffer at pH 7.7 assessed as hydrolysis by measuring Tyr level in presence of pronase	1979	Journal of medicinal chemistry, Dec, Volume: 22, Issue:12	[3-(1,4-Cyclohexadienyl)-L-alanine,8-lysine]vasopressin: synthesis and some pharmacological properties.
AID496832	Antimicrobial activity against Trypanosoma brucei rhodesiense	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1150129	Vasopressor activity in phenoxybenzamine-treated rat under urethane anesthesia	1977	Journal of medicinal chemistry, Sep, Volume: 20, Issue:9	Synthesis and some pharmacological properties of [4-homoserine]oxytocin.
AID1494502	Displacement of [3H]AVP from human liver vasopressin V1a receptor expressed in HEK293 cell membrane after 1 hr by scintillation counting method	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs.
AID1150194	Induction of vasodepressor activity in conscious chicken	1976	Journal of medicinal chemistry, Jul, Volume: 19, Issue:7	Synthesis and some pharmacological properties of oxytocin analogues having L-thiazolidine-4-carboxylic acid in position 7.
AID186826	Excreted total K+ in 4% water loaded rats after administration of the compound	1999	Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24	Chemical syntheses and biological studies on dimeric chimeras of oxytocin and the V(2)-antagonist, d(CH(2))(5)[D-Ile(2), Ile(4)]arginine vasopressin.
AID1593563	Displacement of [3H]OT from recombinant human OTR expressed in HEK293 cell membranes measured after 1 hr	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.
AID1149617	Vasodepressor activity in fowl	1977	Journal of medicinal chemistry, Apr, Volume: 20, Issue:4	Pharmacological effects of introducing a double bond into a binding site of oxytocin. Analogues with L-3,4-dehydroproline in position 7.
AID549466	Half life in human serum by LC/MS and RP-HPLC method	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Modulating oxytocin activity and plasma stability by disulfide bond engineering.
AID593576	Agonist activity at human vasopressin V1b receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay relative to arginine vasopressin	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.
AID1593569	Cognition enhancing effect in CD38 knock out Slc:ICR mouse sire model of autism spectrum disorder assessed as latency time to retrieve pups by sires at 0.3 mL, ip administered as single dose measured after 30 mins by parental retrieval test (Rvb = 600 sec	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.
AID1636591	Agonist activity at human oxytocin receptor expressed in HEK293 cells coexpressing Rluc8-tagged Galphaq, N-terminal GFP-tagged Ggamma2 and Gbeta1 protein incubated for 2 mins by Gq protein activation based BRET assay	2016	Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15	Design and Characterization of Superpotent Bivalent Ligands Targeting Oxytocin Receptor Dimers via a Channel-Like Structure.
AID1144923	Vasodepressor activity in conscious chicken	1976	Journal of medicinal chemistry, Feb, Volume: 19, Issue:2	Synthetic metabolites of neurohypophyseal hormones. (Des-9-glycinamide)oxytocin and (des-9-glycinamide, des-8-leucine)oxytocin.
AID230138	Tested for the ratio of uterotonic potency to pressor potency(O/P)	1983	Journal of medicinal chemistry, Apr, Volume: 26, Issue:4	Synthesis and some pharmacological properties of oxytocin and vasopressin analogues with sarcosine or N-methyl-L-alanine in position 7.
AID190050	In Vitro evaluation for the uterotonic activity in rat in the absence of Magnesium	2000	Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8	A study of the relationship between biological activity and prolyl amide isomer geometry in oxytocin using 5-tert-butylproline to augment the Cys(6)-Pro(7) amide cis-isomer population.
AID175676	Effective concentration in rat in the presence of 1 mM of Magnesium	2000	Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8	A study of the relationship between biological activity and prolyl amide isomer geometry in oxytocin using 5-tert-butylproline to augment the Cys(6)-Pro(7) amide cis-isomer population.
AID169132	Biological activity was determined by uterotonic in vitro test in magnesium-free solution	1997	Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6	Synthesis and pharmacology of novel analogues of oxytocin and deaminooxytocin: directed methods for the construction of disulfide and trisulfide bridges in peptides.
AID151927	Binding affinity against Oxytocin receptor was determined in rat uterine membrane using radioligand [3H]oxytocin	1997	Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6	Synthesis and pharmacology of novel analogues of oxytocin and deaminooxytocin: directed methods for the construction of disulfide and trisulfide bridges in peptides.
AID1450441	Agonist activity at human V1b receptor expressed in CHO cells assessed as calcium mobilization measured after 30 mins by Fluo-4-AM dye based FLIPR assay	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Potent and selective oxytocin receptor agonists without disulfide bridges.
AID168663	Evaluation of vasopressor activity	1983	Journal of medicinal chemistry, Dec, Volume: 26, Issue:12	Synthesis and some pharmacological properties of [4-threonine,7-sarcosine]oxytocin, a peptide with high oxytocic potency, and of [4-threonine,7-N-methylalanine]oxytocin.
AID217086	Binding affinity for human Vasopressin V1a receptor	2002	Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.
AID217544	Antidiuretic activity at V2 receptor.	1995	Journal of medicinal chemistry, May-12, Volume: 38, Issue:10	Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists.
AID1386976	Agonist activity at human OTR receptor expressed in HEK293FT cells incubated for 30 mins by beta-arrestin recruitment assay relative to OT	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.
AID496827	Antimicrobial activity against Leishmania amazonensis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID734451	Stability of the compound in presence of alpha-chymotrypsin (unknown origin) assessed as degradation measured after 120 mins by HPLC analysis	2013	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4	A comparative protease stability study of synthetic macrocyclic peptides that mimic two endocrine hormones.
AID1494501	Half life in Sherman rat plasma	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs.
AID593575	Agonist activity at human vasopressin V1b receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.
AID1277199	Agonist activity at recombinant human oxytocin receptor expressed in CHO-DUKX-A2 cells assessed as change in intracellular calcium level by FLIPR assay	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors.
AID496821	Antimicrobial activity against Leishmania	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID217359	Binding affinity of compound towards human Vasopressin V1b receptor; Not determined	2002	Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.
AID1199949	Agonist activity at wild type OTR (unknown origin) expressed in HEK293 cells assessed as intracellular calcium flux after 3 mins by fluorescence assay	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Selective nonpeptidic fluorescent ligands for oxytocin receptor: design, synthesis, and application to time-resolved FRET binding assay.
AID190051	In Vitro evaluation for the uterotonic activity in rat in the presence of 1 mM of Magnesium	2000	Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8	A study of the relationship between biological activity and prolyl amide isomer geometry in oxytocin using 5-tert-butylproline to augment the Cys(6)-Pro(7) amide cis-isomer population.
AID314837	Induction of contraction per minute in beta-estradiol stimulated rat myometrium at 1 nM	2008	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6	Synthesis and pharmacological evaluation of a new targeted drug carrier system: beta-cyclodextrin coupled to oxytocin.
AID1131318	Stability of the compound in 0.2 M potassium phosphate buffer at pH 7.7 assessed as hydrolysis by measuring Tyr level in presence of alpha-amylase preparation	1979	Journal of medicinal chemistry, Dec, Volume: 22, Issue:12	[3-(1,4-Cyclohexadienyl)-L-alanine,8-lysine]vasopressin: synthesis and some pharmacological properties.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID169041	In vitro for uterotonic activity in the presence of Mg2+ ion by Munsick method	1983	Journal of medicinal chemistry, Dec, Volume: 26, Issue:12	Synthesis and some pharmacological properties of [4-threonine,7-sarcosine]oxytocin, a peptide with high oxytocic potency, and of [4-threonine,7-N-methylalanine]oxytocin.
AID217709	Binding affinity against Vasopressin receptor in rat liver	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Receptor ligands which bind the oxytocin receptor with selectivity and high affinity. Chemical modification of a Streptomyces silvensis derived cyclic hexapeptide.
AID197217	Volume of excreted urine in 5 hr after administration in 4% water loaded rats	1999	Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24	Chemical syntheses and biological studies on dimeric chimeras of oxytocin and the V(2)-antagonist, d(CH(2))(5)[D-Ile(2), Ile(4)]arginine vasopressin.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1386966	Agonist activity at human V1b receptor expressed in HEK293FT cells assessed as stimulation of calcium release by Aequorin based assay	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.
AID1386967	Agonist activity at human V1b receptor expressed in HEK293FT cells assessed as stimulation of calcium release by Aequorin based assay relative to AVP	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.
AID1370598	Agonist activity at human OTR expressed in CHO cells assessed as increase in calcium flux after 60 to 120 mins by fluo-4 dye based FLIPR assay relative to control	2018	Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3	Hybrid peptide-small molecule oxytocin analogs are potent and selective agonists of the oxytocin receptor.
AID190395	In vivo antidiuretic in conscious rats	1999	Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24	Chemical syntheses and biological studies on dimeric chimeras of oxytocin and the V(2)-antagonist, d(CH(2))(5)[D-Ile(2), Ile(4)]arginine vasopressin.
AID496819	Antimicrobial activity against Plasmodium falciparum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1593577	Antidepressant-like activity in CD38KOCC Slc:ICR mouse model of autism spectrum disorder assessed as decrease in immobility time at 100 ng/ml, ip administered as single dose for 30 mins prior to testing measured for last 4 mins of 6 mins test by tail susp	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.
AID367068	Binding affinity to oxytocin receptor	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3	Discovery and optimization of highly ligand-efficient oxytocin receptor antagonists using structure-based drug design.
AID496828	Antimicrobial activity against Leishmania donovani	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1528628	Ratio of EC50 for agonist activity at recombinant human Gi/Go-coupled OTR expressed in CHOK1 cells in presence of 10% FBS to EC50 for agonist activity at recombinant human Gi/Go-coupled OTR expressed in CHOK1 cells in absence of 10% FBS
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1199952	Competitive binding to SNAP-tagged oxytocin receptor (unknown origin) expressed in HEK293 cells incubated for 1 hr at RT followed by 4 hrs at 4 degC by TR-FRET assay in presence of 2-(5-(3-(1-(5-(3-(2-chloro-4-fluorophenoxy)azetidin-1-yl)-4-(6-methoxypyri	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Selective nonpeptidic fluorescent ligands for oxytocin receptor: design, synthesis, and application to time-resolved FRET binding assay.
AID1199953	Competitive binding to oxytocin receptor (unknown origin) by radioligand binding assay	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Selective nonpeptidic fluorescent ligands for oxytocin receptor: design, synthesis, and application to time-resolved FRET binding assay.
AID1593571	Cognition enhancing effect in CD38 knock out Slc:ICR mouse sire model of autism spectrum disorder assessed as decrease in latency time to retrieve pups by sires at 0.3 mL, ip administered as single dose measured after 6 hrs by parental retrieval test	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.
AID1386961	Agonist activity at human OTR receptor expressed in HEK293FT cells assessed as stimulation of calcium release by Aequorin based assay relative to OT	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.
AID1148688	Antidiuretic activity in iv dosed rat	1978	Journal of medicinal chemistry, Sep, Volume: 21, Issue:9	Design of potent antagonists of the vasopressor response to arginine-vasopressin.
AID1178651	Selectivity ratio of EC50 for human vasopressin V1a expressed in HEK293 cells to EC50 for human oxytocin receptor expressed in CHO-K1 cells	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	New, potent, and selective peptidic oxytocin receptor agonists.
AID1178648	Agonist activity at human vasopressin V1a expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	New, potent, and selective peptidic oxytocin receptor agonists.
AID1593565	Agonist activity at recombinant human V1b receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.
AID1150125	Oxytocic potency in rat uterus	1977	Journal of medicinal chemistry, Sep, Volume: 20, Issue:9	Synthesis and some pharmacological properties of [4-homoserine]oxytocin.
AID230251	Ratio of Oxytocin to Antidiuretic activity	1983	Journal of medicinal chemistry, Dec, Volume: 26, Issue:12	Synthesis and some pharmacological properties of [4-threonine,7-sarcosine]oxytocin, a peptide with high oxytocic potency, and of [4-threonine,7-N-methylalanine]oxytocin.
AID1306777	Intrinsic agonist activity at human oxytocin receptor expressed in CHO cells assessed as increase in intracellular calcium flux measured for 90 sec by fluo-4 dye based FLIPR assay relative to control	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Systematic N-methylation of oxytocin: Impact on pharmacology and intramolecular hydrogen bonding network.
AID1133492	Vasopressor activity in rat	1977	Journal of medicinal chemistry, Jan, Volume: 20, Issue:1	Synthesis and some pharmacological properties of [4-threonine, 7-glycine]oxytocin, [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine, 7-glycine]oxytocin (hydroxy[Thr4, Gly7]oxytocin), and [7-Glycine]oxytocin, peptides with high oxytocic-antidiuretic
AID1133930	Vasopressor activity in rat	1977	Journal of medicinal chemistry, Apr, Volume: 20, Issue:4	Combined high oxytocic with negligible antidiuretic and pressor activities in multisubstituted oxytocins.
AID180441	diuresis half-time in 4% water loaded rats	1999	Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24	Chemical syntheses and biological studies on dimeric chimeras of oxytocin and the V(2)-antagonist, d(CH(2))(5)[D-Ile(2), Ile(4)]arginine vasopressin.
AID1149616	Activity at uterotonic receptor in rat uterus assessed as uterotonic activity	1977	Journal of medicinal chemistry, Apr, Volume: 20, Issue:4	Pharmacological effects of introducing a double bond into a binding site of oxytocin. Analogues with L-3,4-dehydroproline in position 7.
AID1306776	Agonist activity at human oxytocin receptor expressed in CHO cells assessed as increase in intracellular calcium flux measured for 90 sec by fluo-4 dye based FLIPR assay	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Systematic N-methylation of oxytocin: Impact on pharmacology and intramolecular hydrogen bonding network.
AID1591641	Agonist activity at human V1B receptor expressed in HEK293 cells assessed as intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Synthesis of oxytocin derivatives lipidated via a carbonate or carbamate linkage as a long-acting therapeutic agent for social impairment-like behaviors.
AID496829	Antimicrobial activity against Leishmania infantum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1178650	Selectivity ratio of EC50 for human vasopressin V2 expressed in HEK293 cells to EC50 for human oxytocin receptor expressed in CHO-K1 cells	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	New, potent, and selective peptidic oxytocin receptor agonists.
AID169133	Biological activity was determined by uterotonic in vivo test using urethane-anesthetized rats	1997	Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6	Synthesis and pharmacology of novel analogues of oxytocin and deaminooxytocin: directed methods for the construction of disulfide and trisulfide bridges in peptides.
AID1133491	Antidiuretic activity in iv dosed rat	1977	Journal of medicinal chemistry, Jan, Volume: 20, Issue:1	Synthesis and some pharmacological properties of [4-threonine, 7-glycine]oxytocin, [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine, 7-glycine]oxytocin (hydroxy[Thr4, Gly7]oxytocin), and [7-Glycine]oxytocin, peptides with high oxytocic-antidiuretic
AID1593588	Displacement of [3H]OT from recombinant human OTR expressed in HEK293 cell membranes assessed as association rate constant for [3H]OT binding (Rvb = 1.737 10'8/M/min)	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.
AID1150422	Activity at oxytocin receptor in rat uterus relative to oxytocin	1976	Journal of medicinal chemistry, Mar, Volume: 19, Issue:3	Synthesis and some pharmacological properties of [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine]oxytocin (hydroxy [4-thr]oxytocin), a peptide with strikingly high oxytocic potency and of [1-(L-2-hydroxy-3-mercaptopropanoic acid)]oxytocin (hydroxy-
AID1593580	Cognition enhancing effect in CD38KOCC Slc:ICR mouse model of autism spectrum disorder assessed as increase in sucrose consumption over water at 100 ng/ml, ip administered as single dose measured after 24 hrs	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.
AID1450445	Agonist activity at C-terminal GFP-tagged OTR (unknown origin) expressed in HEK293 cells measured after 18 hrs by luciferase reporter gene assay	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Potent and selective oxytocin receptor agonists without disulfide bridges.
AID1386975	Agonist activity at human OTR receptor expressed in HEK293FT cells incubated for 30 mins by beta-arrestin recruitment assay	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1131319	Stability of the compound in 0.2 M potassium phosphate buffer at pH 7.7 assessed as hydrolysis by measuring Leu/Lys level in presence of alpha-amylase preparation	1979	Journal of medicinal chemistry, Dec, Volume: 22, Issue:12	[3-(1,4-Cyclohexadienyl)-L-alanine,8-lysine]vasopressin: synthesis and some pharmacological properties.
AID1178656	Clearance in Sprague-Dawley rat at 0.2 mg/kg, iv administered in cassette mode as bolus dose	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	New, potent, and selective peptidic oxytocin receptor agonists.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1199939	Binding affinity to OTR (unknown origin)	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Selective nonpeptidic fluorescent ligands for oxytocin receptor: design, synthesis, and application to time-resolved FRET binding assay.
AID1494504	Displacement of [3H]AVP from human kidney vasopressin V2 receptor expressed in HEK293 cell membrane after 1 hr by scintillation counting method	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs.
AID1591640	Agonist activity at human V1A receptor expressed in HEK293 cells assessed as intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Synthesis of oxytocin derivatives lipidated via a carbonate or carbamate linkage as a long-acting therapeutic agent for social impairment-like behaviors.
AID1199951	Competitive binding to SNAP-tagged oxytocin receptor (unknown origin) expressed in HEK293 cells incubated for 1 hr at RT followed by 4 hrs at 4 degC by TR-FRET assay in presence of 5-(3-(22-(3-carboxy-4-(3-oxo-3H-xanthen-9-yl)phenyl)-15,22-dioxo-2,5,8,11-	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Selective nonpeptidic fluorescent ligands for oxytocin receptor: design, synthesis, and application to time-resolved FRET binding assay.
AID1150126	Oxytocic potency in rat uterus in presence of 0.5 mM Mg2+	1977	Journal of medicinal chemistry, Sep, Volume: 20, Issue:9	Synthesis and some pharmacological properties of [4-homoserine]oxytocin.
AID151797	Binding affinity for human oxytocin receptor	2002	Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.
AID1150417	Oxytocic activity in rabbit assessed as milk ejection	1976	Journal of medicinal chemistry, Mar, Volume: 19, Issue:3	Synthesis and some pharmacological properties of [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine]oxytocin (hydroxy [4-thr]oxytocin), a peptide with strikingly high oxytocic potency and of [1-(L-2-hydroxy-3-mercaptopropanoic acid)]oxytocin (hydroxy-
AID497005	Antimicrobial activity against Pneumocystis carinii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID409949	Inhibition of human liver MAOA	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1150131	Ratio of oxytocic potency in rat uterus to vasopressor activity in phenoxybenzamine-treated rat under urethane anesthesia	1977	Journal of medicinal chemistry, Sep, Volume: 20, Issue:9	Synthesis and some pharmacological properties of [4-homoserine]oxytocin.
AID1150420	Ratio of activity at oxytocin receptor in rat uterus to vasopressor activity in rat	1976	Journal of medicinal chemistry, Mar, Volume: 19, Issue:3	Synthesis and some pharmacological properties of [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine]oxytocin (hydroxy [4-thr]oxytocin), a peptide with strikingly high oxytocic potency and of [1-(L-2-hydroxy-3-mercaptopropanoic acid)]oxytocin (hydroxy-
AID1593587	Stability in mouse plasma assessed as parent compound remaining at 50 ng/ml measured after 2 hrs by LC-MS/MS analysis	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.
AID1149618	Antidiuretic activity in rat	1977	Journal of medicinal chemistry, Apr, Volume: 20, Issue:4	Pharmacological effects of introducing a double bond into a binding site of oxytocin. Analogues with L-3,4-dehydroproline in position 7.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1494507	Selectivity index, ratio of Ki for human mammary gland oxytocin receptor to Ki for human liver vasopressin V1a receptor	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs.
AID217708	Binding affinity against Vasopressin receptor in rat kidney medulla	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Receptor ligands which bind the oxytocin receptor with selectivity and high affinity. Chemical modification of a Streptomyces silvensis derived cyclic hexapeptide.
AID496818	Antimicrobial activity against Trypanosoma brucei brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496826	Antimicrobial activity against Entamoeba histolytica	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1591643	Improvement in paternal nurturing behavior in CD38 knock out Slc:ICR mouse sire model of autism spectrum disorder assessed as parental scores to retrieve pups by sires at 100 ng/100 g, ip administered as single dose measured after 30 mins by parental retr	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Synthesis of oxytocin derivatives lipidated via a carbonate or carbamate linkage as a long-acting therapeutic agent for social impairment-like behaviors.
AID549467	Activity at oxytocin receptor expressed in COS1 cells assessed as IP-one generation by HTRF assay	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Modulating oxytocin activity and plasma stability by disulfide bond engineering.
AID1151055	Activity at rat oxytocin receptor in rat uterus assessed as uterotonic activity	1976	Journal of medicinal chemistry, Jun, Volume: 19, Issue:6	Oxytocin analogues with combined high smooth muscle and negligible antidiuretic activities. Investigation of position 7 in neurohypophyseal hormones.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1178652	Selectivity ratio of EC50 for human vasopressin V1b expressed in HEK293 cells to EC50 for human oxytocin receptor expressed in CHO-K1 cells	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	New, potent, and selective peptidic oxytocin receptor agonists.
AID1150418	Vasopressor activity in rat	1976	Journal of medicinal chemistry, Mar, Volume: 19, Issue:3	Synthesis and some pharmacological properties of [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine]oxytocin (hydroxy [4-thr]oxytocin), a peptide with strikingly high oxytocic potency and of [1-(L-2-hydroxy-3-mercaptopropanoic acid)]oxytocin (hydroxy-
AID1528649	Half life in C57BL/6J mouse
AID230136	Tested for the ratio of uterotonic potency to antidiuretic potency(O/A)	1983	Journal of medicinal chemistry, Apr, Volume: 26, Issue:4	Synthesis and some pharmacological properties of oxytocin and vasopressin analogues with sarcosine or N-methyl-L-alanine in position 7.
AID1494513	Selectivity index, ratio of EC50 for human mammary gland oxytocin receptor to EC50 for human liver vasopressin V1a receptor	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs.
AID1593575	Antidepressant-like activity in CD38KOCC Slc:ICR mouse model of autism spectrum disorder assessed as immobility time at 100 ng/ml, ip administered as single dose for 30 mins prior to testing measured for last 4 mins of 6 mins test by tail suspension test	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.
AID176218	Effective dose was evaluated for the pressor activity in the dose range 2 x 10e -5-2 x 10e -4 mg/kg of rat	2000	Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8	A study of the relationship between biological activity and prolyl amide isomer geometry in oxytocin using 5-tert-butylproline to augment the Cys(6)-Pro(7) amide cis-isomer population.
AID496825	Antimicrobial activity against Leishmania mexicana	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1132004	Antidiuretic activity in rat	1978	Journal of medicinal chemistry, Jan, Volume: 21, Issue:1	Replacement of the disulfide bond in oxytocin by an amide group. Synthesis and some biological properties of (cyclo-(1-L-aspartic acid,6-L-alpha,beta-diaminopropionic acid))oxytocin.
AID1386965	Agonist activity at human V1a receptor expressed in HEK293FT cells assessed as stimulation of calcium release by Aequorin based assay relative to AVP	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1386963	Agonist activity at mouse OTR receptor expressed in HEK293FT cells assessed as stimulation of calcium release by Aequorin based assay relative to OT	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.
AID1150414	Activity at oxytocin receptor in rat uterus in presence of 0.5 mM Mg2+	1976	Journal of medicinal chemistry, Mar, Volume: 19, Issue:3	Synthesis and some pharmacological properties of [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine]oxytocin (hydroxy [4-thr]oxytocin), a peptide with strikingly high oxytocic potency and of [1-(L-2-hydroxy-3-mercaptopropanoic acid)]oxytocin (hydroxy-
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1494511	Agonist activity at human kidney vasopressin V2 receptor expressed in CHO cells assessed as increase in intracellular calcium flux measured for 5 mins by Fluo-4-AM dye based FLIPR assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs.
AID1386962	Agonist activity at mouse OTR receptor expressed in HEK293FT cells assessed as stimulation of calcium release by Aequorin based assay	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.
AID1178649	Agonist activity at human vasopressin V1b expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	New, potent, and selective peptidic oxytocin receptor agonists.
AID190052	In vivo oxytocin antagonistic activity against rat uterine strips was determined by galactogogic assay	1992	Journal of medicinal chemistry, May-01, Volume: 35, Issue:9	Structure-activity studies of a novel bicyclic oxytocin antagonist.
AID217392	Binding affinity towards human Vasopressin V2 receptor	2002	Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.
AID1494512	Selectivity index, ratio of EC50 for human liver vasopressin V1a receptor to EC50 for human mammary gland oxytocin receptor	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs.
AID1149619	Pressor activity in rat	1977	Journal of medicinal chemistry, Apr, Volume: 20, Issue:4	Pharmacological effects of introducing a double bond into a binding site of oxytocin. Analogues with L-3,4-dehydroproline in position 7.
AID367069	Binding affinity to vasopressin V1a receptor	2009	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3	Discovery and optimization of highly ligand-efficient oxytocin receptor antagonists using structure-based drug design.
AID1133926	Oxytocic potency in rat uterus	1977	Journal of medicinal chemistry, Apr, Volume: 20, Issue:4	Combined high oxytocic with negligible antidiuretic and pressor activities in multisubstituted oxytocins.
AID1148686	Vasopressor activity in iv dosed phenoxybenzamine treated rat	1978	Journal of medicinal chemistry, Sep, Volume: 21, Issue:9	Design of potent antagonists of the vasopressor response to arginine-vasopressin.
AID186071	Compound was tested for percent maximum uterotonic response	1980	Journal of medicinal chemistry, Feb, Volume: 23, Issue:2	Oxytocin and lysine-vasopressin with N5,N5-dialkylglutamine in the 4 position: effect of introducing sterically hindered groups into the hydrophilic cluster of neurohypophyseal hormones.
AID1150130	Ratio of oxytocic potency in rat uterus to antidiuretic activity in iv dosed hydrated rat anesthetized with ethanol	1977	Journal of medicinal chemistry, Sep, Volume: 20, Issue:9	Synthesis and some pharmacological properties of [4-homoserine]oxytocin.
AID186824	Excreted total K+ in 0% water loaded rats after administration of the compound	1999	Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24	Chemical syntheses and biological studies on dimeric chimeras of oxytocin and the V(2)-antagonist, d(CH(2))(5)[D-Ile(2), Ile(4)]arginine vasopressin.
AID1386974	Agonist activity at human V2 receptor expressed in HEK293FT cells incubated for 30 mins by beta-arrestin recruitment assay	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.
AID1131309	Stability of the compound in 0.2 M potassium phosphate buffer at pH 7.7 assessed as hydrolysis by measuring Ile/Phe + DiHPe level in presence of pronase	1979	Journal of medicinal chemistry, Dec, Volume: 22, Issue:12	[3-(1,4-Cyclohexadienyl)-L-alanine,8-lysine]vasopressin: synthesis and some pharmacological properties.
AID195309	In vivo pressor response in rats	1999	Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24	Chemical syntheses and biological studies on dimeric chimeras of oxytocin and the V(2)-antagonist, d(CH(2))(5)[D-Ile(2), Ile(4)]arginine vasopressin.
AID1144924	Pressor activity in atropinized and urethane-anesthetized rat	1976	Journal of medicinal chemistry, Feb, Volume: 19, Issue:2	Synthetic metabolites of neurohypophyseal hormones. (Des-9-glycinamide)oxytocin and (des-9-glycinamide, des-8-leucine)oxytocin.
AID1494510	Agonist activity at human vasopressin V1b receptor expressed in CHO cells assessed as increase in intracellular calcium flux measured for 5 mins by Fluo-4-AM dye based FLIPR assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1199940	Binding affinity to V1aR (unknown origin)	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Selective nonpeptidic fluorescent ligands for oxytocin receptor: design, synthesis, and application to time-resolved FRET binding assay.
AID1593567	Selectivity ratio of EC50 for recombinant human V1b receptor expressed in HEK293 cells to EC50 for recombinant human OTR expressed in HEK293 cells	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.
AID1150415	Activity at oxytocin receptor in rat mammary strip	1976	Journal of medicinal chemistry, Mar, Volume: 19, Issue:3	Synthesis and some pharmacological properties of [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine]oxytocin (hydroxy [4-thr]oxytocin), a peptide with strikingly high oxytocic potency and of [1-(L-2-hydroxy-3-mercaptopropanoic acid)]oxytocin (hydroxy-
AID169008	Compound was tested in vitro for pressor activity on rat	1980	Journal of medicinal chemistry, Feb, Volume: 23, Issue:2	Oxytocin and lysine-vasopressin with N5,N5-dialkylglutamine in the 4 position: effect of introducing sterically hindered groups into the hydrophilic cluster of neurohypophyseal hormones.
AID1593581	Plasma concentration in Slc:ICR mouse at 100 ng/g, iv measured immediately by LC-MS/MS analysis	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.
AID1131317	Stability of the compound in 0.2 M potassium phosphate buffer at pH 7.7 assessed as hydrolysis by measuring Ile/Phe + DiHPe level in presence of alpha-amylase preparation	1979	Journal of medicinal chemistry, Dec, Volume: 22, Issue:12	[3-(1,4-Cyclohexadienyl)-L-alanine,8-lysine]vasopressin: synthesis and some pharmacological properties.
AID1593590	Displacement of [3H]OT from recombinant human OTR expressed in HEK293 cell membranes assessed as dissociation half life for [3H]OT binding (Rvb = 11.85 min)	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.
AID1132003	Effect on vasodepressor activity in conscious chicken	1978	Journal of medicinal chemistry, Jan, Volume: 21, Issue:1	Replacement of the disulfide bond in oxytocin by an amide group. Synthesis and some biological properties of (cyclo-(1-L-aspartic acid,6-L-alpha,beta-diaminopropionic acid))oxytocin.
AID734447	Stability of the compound in presence of pronase (unknown origin) assessed as degradation measured after 360 mins by HPLC analysis	2013	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4	A comparative protease stability study of synthetic macrocyclic peptides that mimic two endocrine hormones.
AID1150193	Induction of oxytocic activity in rat uterus	1976	Journal of medicinal chemistry, Jul, Volume: 19, Issue:7	Synthesis and some pharmacological properties of oxytocin analogues having L-thiazolidine-4-carboxylic acid in position 7.
AID1150413	Activity at oxytocin receptor in rat uterus	1976	Journal of medicinal chemistry, Mar, Volume: 19, Issue:3	Synthesis and some pharmacological properties of [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine]oxytocin (hydroxy [4-thr]oxytocin), a peptide with strikingly high oxytocic potency and of [1-(L-2-hydroxy-3-mercaptopropanoic acid)]oxytocin (hydroxy-
AID1151057	Induction of vasodepressor activity in conscious chicken	1976	Journal of medicinal chemistry, Jun, Volume: 19, Issue:6	Oxytocin analogues with combined high smooth muscle and negligible antidiuretic activities. Investigation of position 7 in neurohypophyseal hormones.
AID1593589	Displacement of [3H]OT from recombinant human OTR expressed in HEK293 cell membranes assessed as dissociation rate constant for [3H]OT binding (Rvb = 0.05433 +/- 0.007 /min)	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.
AID1137269	Agonist activity at oxytocin receptor in rat uterus	1979	Journal of medicinal chemistry, Jan, Volume: 22, Issue:1	[1-Penicillamine,2-leucine]oxytocin. Synthesis and pharmacological and conformational studies of a potent peptide hormone inhibitor.
AID1150195	Effect on pressor activity in rat	1976	Journal of medicinal chemistry, Jul, Volume: 19, Issue:7	Synthesis and some pharmacological properties of oxytocin analogues having L-thiazolidine-4-carboxylic acid in position 7.
AID1144925	Antidiuretic activity in inactin- and ethanol-anesthetized, hydrated Sprague-Dawley rat assessed as maximal depression of rate of urine flow	1976	Journal of medicinal chemistry, Feb, Volume: 19, Issue:2	Synthetic metabolites of neurohypophyseal hormones. (Des-9-glycinamide)oxytocin and (des-9-glycinamide, des-8-leucine)oxytocin.
AID1150419	Antidiuretic activity in rat	1976	Journal of medicinal chemistry, Mar, Volume: 19, Issue:3	Synthesis and some pharmacological properties of [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine]oxytocin (hydroxy [4-thr]oxytocin), a peptide with strikingly high oxytocic potency and of [1-(L-2-hydroxy-3-mercaptopropanoic acid)]oxytocin (hydroxy-
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1591645	Improvement in paternal nurturing behavior in CD38 knock out Slc:ICR mouse sire model of autism spectrum disorder assessed as parental scores to retrieve pups by sires at 100 ng/100 g, ip administered as single dose measured after 6 hrs by parental retrie	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Synthesis of oxytocin derivatives lipidated via a carbonate or carbamate linkage as a long-acting therapeutic agent for social impairment-like behaviors.
AID294439	Agonist activity in phenoxybenzamine-treated rat by Pressor assay	2007	European journal of medicinal chemistry, Jun, Volume: 42, Issue:6	Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.
AID168661	Evaluation of antidiuretic activity against ethanol-anesthetized rats	1983	Journal of medicinal chemistry, Dec, Volume: 26, Issue:12	Synthesis and some pharmacological properties of [4-threonine,7-sarcosine]oxytocin, a peptide with high oxytocic potency, and of [4-threonine,7-N-methylalanine]oxytocin.
AID1370595	Agonist activity at human OTR expressed in CHO cells assessed as increase in calcium flux after 60 to 120 mins by fluo-4 dye based FLIPR assay	2018	Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3	Hybrid peptide-small molecule oxytocin analogs are potent and selective agonists of the oxytocin receptor.
AID197053	In vitro uterotonic activity was determined	1999	Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24	Chemical syntheses and biological studies on dimeric chimeras of oxytocin and the V(2)-antagonist, d(CH(2))(5)[D-Ile(2), Ile(4)]arginine vasopressin.
AID169009	Compound was tested in vitro for uterotonic activity in rat	1980	Journal of medicinal chemistry, Feb, Volume: 23, Issue:2	Oxytocin and lysine-vasopressin with N5,N5-dialkylglutamine in the 4 position: effect of introducing sterically hindered groups into the hydrophilic cluster of neurohypophyseal hormones.
AID175675	Effective concentration in rat in the absence of Magnesium	2000	Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8	A study of the relationship between biological activity and prolyl amide isomer geometry in oxytocin using 5-tert-butylproline to augment the Cys(6)-Pro(7) amide cis-isomer population.
AID1593564	Agonist activity at recombinant human V1a receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.
AID1494506	Selectivity index, ratio of Ki for human liver vasopressin V1a receptor to Ki for human mammary gland oxytocin receptor	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs.
AID168538	Tested for vasopressor activity in rat	1983	Journal of medicinal chemistry, Apr, Volume: 26, Issue:4	Synthesis and some pharmacological properties of oxytocin and vasopressin analogues with sarcosine or N-methyl-L-alanine in position 7.
AID1593582	Half life in Slc:ICR mouse plasma during fast phase at 100 ng/g, iv measured for 15 mins by LC-MS/MS analysis	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1882822	Stability of the compound in simulated intestinal fluid at pH 6.8 assessed as half life measured up to 24 hrs by RP-HPLC-UV analysis	2022	Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8	On the Utility of Chemical Strategies to Improve Peptide Gut Stability.
AID1178646	Agonist activity at human oxytocin receptor expressed in CHO-K1 cells after 5 hrs by firefly luciferase reporter gene assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	New, potent, and selective peptidic oxytocin receptor agonists.
AID1386979	Agonist activity at human V1b receptor expressed in HEK293FT cells incubated for 30 mins by beta-arrestin recruitment assay relative to AVP	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.
AID1150127	Oxytocic activity in iv dosed lactating rat anesthetized with pentobarbital assessed as milk ejection	1977	Journal of medicinal chemistry, Sep, Volume: 20, Issue:9	Synthesis and some pharmacological properties of [4-homoserine]oxytocin.
AID496830	Antimicrobial activity against Leishmania major	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1370597	Agonist activity at vasopressin 1a receptor (unknown origin)	2018	Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3	Hybrid peptide-small molecule oxytocin analogs are potent and selective agonists of the oxytocin receptor.
AID1199950	Agonist activity at SNAP-tagged oxytocin receptor (unknown origin) expressed in HEK293 cells assessed as intracellular calcium flux after 3 mins by fluorescence assay	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Selective nonpeptidic fluorescent ligands for oxytocin receptor: design, synthesis, and application to time-resolved FRET binding assay.
AID496823	Antimicrobial activity against Trichomonas vaginalis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1593562	Agonist activity at recombinant human OTR expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.
AID1591639	Agonist activity at human OTR receptor expressed in HEK293 cells assessed as intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Synthesis of oxytocin derivatives lipidated via a carbonate or carbamate linkage as a long-acting therapeutic agent for social impairment-like behaviors.
AID734448	Stability of the compound in presence of pronase (unknown origin) assessed as degradation measured after 120 mins by HPLC analysis	2013	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4	A comparative protease stability study of synthetic macrocyclic peptides that mimic two endocrine hormones.
AID1593583	Half life in Slc:ICR mouse plasma during slow phase at 100 ng/g, iv measured for 15 to 60 mins by LC-MS/MS analysis	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.
AID1133927	Vasodepressor activity in conscious chicken	1977	Journal of medicinal chemistry, Apr, Volume: 20, Issue:4	Combined high oxytocic with negligible antidiuretic and pressor activities in multisubstituted oxytocins.
AID1133498	Oxytocic potency in rabbit assessed as milk ejection	1977	Journal of medicinal chemistry, Jan, Volume: 20, Issue:1	Synthesis and some pharmacological properties of [4-threonine, 7-glycine]oxytocin, [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine, 7-glycine]oxytocin (hydroxy[Thr4, Gly7]oxytocin), and [7-Glycine]oxytocin, peptides with high oxytocic-antidiuretic
AID1150421	Ratio of activity at oxytocin receptor in rat uterus to antidiuretic activity in rat	1976	Journal of medicinal chemistry, Mar, Volume: 19, Issue:3	Synthesis and some pharmacological properties of [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine]oxytocin (hydroxy [4-thr]oxytocin), a peptide with strikingly high oxytocic potency and of [1-(L-2-hydroxy-3-mercaptopropanoic acid)]oxytocin (hydroxy-
AID734450	Stability of the compound in presence of alpha-chymotrypsin (unknown origin) assessed as degradation measured after 360 mins by HPLC analysis	2013	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4	A comparative protease stability study of synthetic macrocyclic peptides that mimic two endocrine hormones.
AID1636606	Effect on social behavior in OXTR+/- DBA/2J mouse assessed as increase in time spent exploring stranger mouse over time spent exploring empty cage at 0.5 ng/mouse, icv administered as single dose measured for 10 mins by three chamber method	2016	Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15	Design and Characterization of Superpotent Bivalent Ligands Targeting Oxytocin Receptor Dimers via a Channel-Like Structure.
AID1178647	Agonist activity at human vasopressin V2 expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	New, potent, and selective peptidic oxytocin receptor agonists.
AID1386960	Agonist activity at human OTR receptor expressed in HEK293FT cells assessed as stimulation of calcium release by Aequorin based assay	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.
AID496831	Antimicrobial activity against Cryptosporidium parvum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1133489	Oxytocic potency in rat by mammary strip assay	1977	Journal of medicinal chemistry, Jan, Volume: 20, Issue:1	Synthesis and some pharmacological properties of [4-threonine, 7-glycine]oxytocin, [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine, 7-glycine]oxytocin (hydroxy[Thr4, Gly7]oxytocin), and [7-Glycine]oxytocin, peptides with high oxytocic-antidiuretic
AID1144928	Hydroosmotic activity in toad urinary bladder assessed as water transport	1976	Journal of medicinal chemistry, Feb, Volume: 19, Issue:2	Synthetic metabolites of neurohypophyseal hormones. (Des-9-glycinamide)oxytocin and (des-9-glycinamide, des-8-leucine)oxytocin.
AID734449	Stability of the compound in presence of pronase (unknown origin) assessed as degradation measured after 60 mins by HPLC analysis	2013	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4	A comparative protease stability study of synthetic macrocyclic peptides that mimic two endocrine hormones.
AID1151058	Antidiuretic activity in rat	1976	Journal of medicinal chemistry, Jun, Volume: 19, Issue:6	Oxytocin analogues with combined high smooth muscle and negligible antidiuretic activities. Investigation of position 7 in neurohypophyseal hormones.
AID1131321	Stability of the compound in 0.2 M potassium phosphate buffer at pH 7.7 assessed as hydrolysis by measuring Asn/Gln level in presence of alpha-amylase preparation	1979	Journal of medicinal chemistry, Dec, Volume: 22, Issue:12	[3-(1,4-Cyclohexadienyl)-L-alanine,8-lysine]vasopressin: synthesis and some pharmacological properties.
AID190023	Compound was evaluated for the pressor activity in rat	2000	Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8	A study of the relationship between biological activity and prolyl amide isomer geometry in oxytocin using 5-tert-butylproline to augment the Cys(6)-Pro(7) amide cis-isomer population.
AID169040	In vitro for uterotonic activity in the absence of Mg2+ ion by Munsick method	1983	Journal of medicinal chemistry, Dec, Volume: 26, Issue:12	Synthesis and some pharmacological properties of [4-threonine,7-sarcosine]oxytocin, a peptide with high oxytocic potency, and of [4-threonine,7-N-methylalanine]oxytocin.
AID1131320	Stability of the compound in 0.2 M potassium phosphate buffer at pH 7.7 assessed as hydrolysis by measuring Gly level in presence of alpha-amylase preparation	1979	Journal of medicinal chemistry, Dec, Volume: 22, Issue:12	[3-(1,4-Cyclohexadienyl)-L-alanine,8-lysine]vasopressin: synthesis and some pharmacological properties.
AID188260	Excreted total Na+ in 4% water loaded rats after administration of the compound	1999	Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24	Chemical syntheses and biological studies on dimeric chimeras of oxytocin and the V(2)-antagonist, d(CH(2))(5)[D-Ile(2), Ile(4)]arginine vasopressin.
AID1494508	Agonist activity at human mammary gland oxytocin receptor expressed in CHO cells assessed as increase in intracellular calcium flux measured for 5 mins by Fluo-4-AM dye based FLIPR assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs.
AID1151059	Pressor activity in rat	1976	Journal of medicinal chemistry, Jun, Volume: 19, Issue:6	Oxytocin analogues with combined high smooth muscle and negligible antidiuretic activities. Investigation of position 7 in neurohypophyseal hormones.
AID1528626	Agonist activity at recombinant human Gi/Go-coupled OTR expressed in CHOK1 cells assessed as induction of beta-arrestin recruitment measured after 90 mins in absence of 10% FBS by pathhunter assay
AID1133488	Oxytocic potency in rat by uterus assay in presence of 0.5 mM Mg2+	1977	Journal of medicinal chemistry, Jan, Volume: 20, Issue:1	Synthesis and some pharmacological properties of [4-threonine, 7-glycine]oxytocin, [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine, 7-glycine]oxytocin (hydroxy[Thr4, Gly7]oxytocin), and [7-Glycine]oxytocin, peptides with high oxytocic-antidiuretic
AID1370596	Stability in human liver microsomes by LC/MS/MS analysis	2018	Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3	Hybrid peptide-small molecule oxytocin analogs are potent and selective agonists of the oxytocin receptor.
AID1199941	Binding affinity to V1bR (unknown origin)	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Selective nonpeptidic fluorescent ligands for oxytocin receptor: design, synthesis, and application to time-resolved FRET binding assay.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID197216	Volume of excreted urine in 5 hr after administration in 0% water loaded rats	1999	Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24	Chemical syntheses and biological studies on dimeric chimeras of oxytocin and the V(2)-antagonist, d(CH(2))(5)[D-Ile(2), Ile(4)]arginine vasopressin.
AID151940	Compound was evaluated for the oxytocic activity with out Mg2+.	1995	Journal of medicinal chemistry, May-12, Volume: 38, Issue:10	Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists.
AID188258	Excreted total Na+ in 0% water loaded rats after administration of the compound	1999	Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24	Chemical syntheses and biological studies on dimeric chimeras of oxytocin and the V(2)-antagonist, d(CH(2))(5)[D-Ile(2), Ile(4)]arginine vasopressin.
AID1169139	Oral bioavailability in rat	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	EPSA: A Novel Supercritical Fluid Chromatography Technique Enabling the Design of Permeable Cyclic Peptides.
AID1450439	Agonist activity at human OTR expressed in CHO cells assessed as calcium mobilization measured after 30 mins by Fluo-4-AM dye based FLIPR assay	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Potent and selective oxytocin receptor agonists without disulfide bridges.
AID1151056	Induction of oxytocic activity in rabbit assessed as milk ejection	1976	Journal of medicinal chemistry, Jun, Volume: 19, Issue:6	Oxytocin analogues with combined high smooth muscle and negligible antidiuretic activities. Investigation of position 7 in neurohypophyseal hormones.
AID1591644	Improvement in paternal nurturing behavior in CD38 knock out Slc:ICR mouse sire model of autism spectrum disorder assessed as parental scores to retrieve pups by sires at 100 ng/100 g, ip administered as single dose measured after 24 hrs by parental retri	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Synthesis of oxytocin derivatives lipidated via a carbonate or carbamate linkage as a long-acting therapeutic agent for social impairment-like behaviors.
AID169007	Compound was tested in vitro for antidiuretic activity in rat	1980	Journal of medicinal chemistry, Feb, Volume: 23, Issue:2	Oxytocin and lysine-vasopressin with N5,N5-dialkylglutamine in the 4 position: effect of introducing sterically hindered groups into the hydrophilic cluster of neurohypophyseal hormones.
AID151793	Compound was evaluated for its dissociation constant (Kd) to guinea pig myometrial Oxytocin receptor	1999	Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5	Synthesis of oxytocin antagonists containing conformationally constrained amino acids in position 2.
AID1277198	Displacement of [Tyrosyl-2,6-3H]-Oxytocin from recombinant human oxytocin receptor expressed in CHO-DUKX-A2 cells after 180 mins by liquid scintillation counting analysis	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors.
AID171775	Uterotonic activity in vitro in isolated rat uterus in absence of magnesium	1983	Journal of medicinal chemistry, Apr, Volume: 26, Issue:4	Synthesis and some pharmacological properties of oxytocin and vasopressin analogues with sarcosine or N-methyl-L-alanine in position 7.
AID1450442	Selectivity ratio of EC50 for human V1a receptor to EC50 for human OTR	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Potent and selective oxytocin receptor agonists without disulfide bridges.
AID169130	Biological activity was determined by pressor test using pithed rat preparations	1997	Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6	Synthesis and pharmacology of novel analogues of oxytocin and deaminooxytocin: directed methods for the construction of disulfide and trisulfide bridges in peptides.
AID1386977	Agonist activity at human V1a receptor expressed in HEK293FT cells incubated for 30 mins by beta-arrestin recruitment assay	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.
AID314836	Induction of contraction in beta-estradiol stimulated rat myometrium	2008	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6	Synthesis and pharmacological evaluation of a new targeted drug carrier system: beta-cyclodextrin coupled to oxytocin.
AID1593578	Cognition enhancing effect in CD38KOCC Slc:ICR mouse model of autism spectrum disorder assessed as sucrose consumption over water at 100 ng/ml, ip administered as single dose measured after 60 mins relative to control (Rvb = 0.46 +/- 0.04 No_unit)	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.
AID294434	Agonist activity in rat uterus by uterotonic assay	2007	European journal of medicinal chemistry, Jun, Volume: 42, Issue:6	Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.
AID190392	In vivo antidiuretic in anesth rats	1999	Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24	Chemical syntheses and biological studies on dimeric chimeras of oxytocin and the V(2)-antagonist, d(CH(2))(5)[D-Ile(2), Ile(4)]arginine vasopressin.
AID1593585	Drug level in Slc:ICR mouse cerebrospinal fluid at 100 ng/g, iv measured after 30 mins by LC-MS/MS analysis	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.
AID1450443	Selectivity ratio of EC50 for human V1b receptor to EC50 for human OTR	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Potent and selective oxytocin receptor agonists without disulfide bridges.
AID496824	Antimicrobial activity against Toxoplasma gondii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID171590	The compound was tested for milk ejection activity in rat	1983	Journal of medicinal chemistry, Apr, Volume: 26, Issue:4	Synthesis and some pharmacological properties of oxytocin and vasopressin analogues with sarcosine or N-methyl-L-alanine in position 7.
AID294438	Displacement of [3H]OT from human OT receptor expressed in HEK cells	2007	European journal of medicinal chemistry, Jun, Volume: 42, Issue:6	Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1386964	Agonist activity at human V1a receptor expressed in HEK293FT cells assessed as stimulation of calcium release by Aequorin based assay	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.
AID1144922	Oxytocic activity in uterine horns of rat by vaginal smear assay	1976	Journal of medicinal chemistry, Feb, Volume: 19, Issue:2	Synthetic metabolites of neurohypophyseal hormones. (Des-9-glycinamide)oxytocin and (des-9-glycinamide, des-8-leucine)oxytocin.
AID1144700	Agonist activity at oxytocin receptor in rat assessed as pressor response	1976	Journal of medicinal chemistry, Feb, Volume: 19, Issue:2	Synthesis and some pharmacological properties of five analogs of oxytocin having L-homocysteine in position 6.
AID1494503	Displacement of [3H]AVP from human vasopressin V1b receptor expressed in HEK293 cell membrane after 1 hr by scintillation counting method	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs.
AID1144696	Agonist activity at oxytocin receptor in rat uterus	1976	Journal of medicinal chemistry, Feb, Volume: 19, Issue:2	Synthesis and some pharmacological properties of five analogs of oxytocin having L-homocysteine in position 6.
AID1593586	Drug level in Slc:ICR mouse cerebrospinal fluid at 100 ng/g, iv measured after 12 hrs by LC-MS/MS analysis	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.
AID1593566	Selectivity ratio of EC50 for recombinant human V1a receptor expressed in HEK293 cells to EC50 for recombinant human OTR expressed in HEK293 cells	2019	Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7	Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.
AID151936	Binding affinity against oxytocin receptor in rat uterus	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Receptor ligands which bind the oxytocin receptor with selectivity and high affinity. Chemical modification of a Streptomyces silvensis derived cyclic hexapeptide.
AID151627	Inhibition of radioligand [3H]OT binding to oxytocin receptor (OT) in guinea pig myometrium membrane	1994	Journal of medicinal chemistry, Jan-21, Volume: 37, Issue:2	Enhanced selectivity of oxytocin antagonists containing sarcosine in position 7.
AID1386969	Agonist activity at human V2 receptor expressed in HEK293FT cells assessed as stimulation of calcium release by Aequorin based assay relative to AVP	2018	Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19	LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.
AID168662	Evaluation of milk ejecting activity	1983	Journal of medicinal chemistry, Dec, Volume: 26, Issue:12	Synthesis and some pharmacological properties of [4-threonine,7-sarcosine]oxytocin, a peptide with high oxytocic potency, and of [4-threonine,7-N-methylalanine]oxytocin.
AID1132002	Uterotonic activity in rat	1978	Journal of medicinal chemistry, Jan, Volume: 21, Issue:1	Replacement of the disulfide bond in oxytocin by an amide group. Synthesis and some biological properties of (cyclo-(1-L-aspartic acid,6-L-alpha,beta-diaminopropionic acid))oxytocin.
AID1494509	Agonist activity at human liver vasopressin V1a receptor expressed in CHO cells assessed as increase in intracellular calcium flux measured for 5 mins by Fluo-4-AM dye based FLIPR assay	2018	Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11	Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs.
AID1882821	Stability of the compound in simulated gastric fluid at pH 1.2 assessed as half life measured up to 24 hrs by RP-HPLC-UV analysis	2022	Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8	On the Utility of Chemical Strategies to Improve Peptide Gut Stability.
AID1346460	Human V1B receptor (Vasopressin and oxytocin receptors)	1998	Naunyn-Schmiedeberg's archives of pharmacology, Jan, Volume: 357, Issue:1	Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist.
AID1346453	Human V2 receptor (Vasopressin and oxytocin receptors)	1998	British journal of pharmacology, Dec, Volume: 125, Issue:7	Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.
AID1346469	Human OT receptor (Vasopressin and oxytocin receptors)	2003	The Journal of pharmacology and experimental therapeutics, Jul, Volume: 306, Issue:1	Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor.
AID1346432	Human V1A receptor (Vasopressin and oxytocin receptors)	1997	Biochemical pharmacology, Jun-01, Volume: 53, Issue:11	1-desamino-8-D-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor.
AID1346432	Human V1A receptor (Vasopressin and oxytocin receptors)	1999	British journal of obstetrics and gynaecology, Oct, Volume: 106, Issue:10	Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women.
AID1346455	Rat V1A receptor (Vasopressin and oxytocin receptors)	1995	The EMBO journal, May-15, Volume: 14, Issue:10	Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor.
AID1346460	Human V1B receptor (Vasopressin and oxytocin receptors)	1997	Biochemical pharmacology, Jun-01, Volume: 53, Issue:11	1-desamino-8-D-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor.
AID1346432	Human V1A receptor (Vasopressin and oxytocin receptors)	2003	The Journal of pharmacology and experimental therapeutics, Jul, Volume: 306, Issue:1	Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor.
AID1346453	Human V2 receptor (Vasopressin and oxytocin receptors)	1995	The EMBO journal, May-15, Volume: 14, Issue:10	Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor.
AID1346460	Human V1B receptor (Vasopressin and oxytocin receptors)	1998	British journal of pharmacology, Dec, Volume: 125, Issue:7	Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.
AID1346432	Human V1A receptor (Vasopressin and oxytocin receptors)	1997	The Journal of biological chemistry, Oct-17, Volume: 272, Issue:42	Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist.
AID1346432	Human V1A receptor (Vasopressin and oxytocin receptors)	1998	Naunyn-Schmiedeberg's archives of pharmacology, Jan, Volume: 357, Issue:1	Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist.
AID1346469	Human OT receptor (Vasopressin and oxytocin receptors)	2005	British journal of pharmacology, Nov, Volume: 146, Issue:5	Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist.
AID1346432	Human V1A receptor (Vasopressin and oxytocin receptors)	1994	The Journal of biological chemistry, Feb-04, Volume: 269, Issue:5	Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor.
AID1346453	Human V2 receptor (Vasopressin and oxytocin receptors)	1998	Naunyn-Schmiedeberg's archives of pharmacology, Jan, Volume: 357, Issue:1	Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist.
AID1346469	Human OT receptor (Vasopressin and oxytocin receptors)	1995	The EMBO journal, May-15, Volume: 14, Issue:10	Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor.
AID1346469	Human OT receptor (Vasopressin and oxytocin receptors)	1995	Life sciences, , Volume: 57, Issue:24	Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells.
AID1346453	Human V2 receptor (Vasopressin and oxytocin receptors)	1997	Endocrinology, Oct, Volume: 138, Issue:10	The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways.
AID1346453	Human V2 receptor (Vasopressin and oxytocin receptors)	2003	The Journal of pharmacology and experimental therapeutics, Jul, Volume: 306, Issue:1	Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor.
AID1346453	Human V2 receptor (Vasopressin and oxytocin receptors)	1997	Biochemical pharmacology, Jun-01, Volume: 53, Issue:11	1-desamino-8-D-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor.
AID1346432	Human V1A receptor (Vasopressin and oxytocin receptors)	1997	Endocrinology, Oct, Volume: 138, Issue:10	The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways.
AID1346469	Human OT receptor (Vasopressin and oxytocin receptors)	1996	FEBS letters, Nov-18, Volume: 397, Issue:2-3	Two aromatic residues regulate the response of the human oxytocin receptor to the partial agonist arginine vasopressin.
AID1346469	Human OT receptor (Vasopressin and oxytocin receptors)	1999	British journal of obstetrics and gynaecology, Oct, Volume: 106, Issue:10	Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women.
AID1346460	Human V1B receptor (Vasopressin and oxytocin receptors)	1997	Endocrinology, Oct, Volume: 138, Issue:10	The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways.
AID1346460	Human V1B receptor (Vasopressin and oxytocin receptors)	2005	British journal of pharmacology, Nov, Volume: 146, Issue:5	Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist.
AID1346436	Rat OT receptor (Vasopressin and oxytocin receptors)	2003	The Journal of pharmacology and experimental therapeutics, Jul, Volume: 306, Issue:1	Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor.
AID1346432	Human V1A receptor (Vasopressin and oxytocin receptors)	1998	British journal of pharmacology, Dec, Volume: 125, Issue:7	Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.
AID1346469	Human OT receptor (Vasopressin and oxytocin receptors)	1994	European journal of endocrinology, Oct, Volume: 131, Issue:4	Molecular characterization of a cloned human oxytocin receptor.
AID1346469	Human OT receptor (Vasopressin and oxytocin receptors)	1982	Science (New York, N.Y.), Mar-12, Volume: 215, Issue:4538	Oxytocin receptors and human parturition: a dual role for oxytocin in the initiation of labor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	8399 (40.70)	18.7374
1990's	3383 (16.40)	18.2507
2000's	2712 (13.14)	29.6817
2010's	4262 (20.66)	24.3611
2020's	1878 (9.10)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1,831 (8.47%)	5.53%
Reviews	2,274 (10.52%)	6.00%
Case Studies	353 (1.63%)	4.05%
Observational	74 (0.34%)	0.25%
Other	17,079 (79.03%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (604)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Randomized Controlled Trial: Cervical Ripening Balloon With and Without Oxytocin for Cervical Ripening in Multiparas[NCT03138252]	Phase 3	180 participants (Actual)	Interventional	2014-11-30	Completed
Integrated Oxytocin and Nonverbal, Emotion Recognition, and Theory of Mind Training for Children With Autism Spectrum Disorder[NCT02918864]	Phase 2	83 participants (Actual)	Interventional	2016-06-15	Completed
Low-Dose Versus High-Dose Oxytocin Dosing for Induction and Augmentation of Labor: A Randomized Control Trial[NCT05782816]	Phase 4	170 participants (Anticipated)	Interventional	2023-04-17	Recruiting
Translating Neuroprediction Into Precision Medicine Via Brain Priming[NCT03370510]	Phase 2	5 participants (Actual)	Interventional	2018-12-07	Terminated(stopped due to Covid-19 Pandemic)
Renal Effects of Carbetocin and Oxytocin in Cesarean Section for Preventing Post-partum Haemorrhage: a Prospective Randomized Study[NCT03939806]		100 participants (Anticipated)	Observational	2019-05-31	Not yet recruiting
Comparing Oxytocin and Oxytocin-ergometrine Combinations for Increasing Uterine Tone in Cesarean Delivery: a Pharmacokinetic-pharmacodynamic Study.[NCT01236482]	Phase 4	80 participants (Anticipated)	Interventional	2010-11-30	Not yet recruiting
Oxytocin-based Pharmacotherapy for Autism Spectrum Disorders: Investigating the Neural and Behavioral Effects of a Promising Intervention Approach[NCT02940574]	Phase 4	40 participants (Actual)	Interventional	2015-04-30	Completed
[NCT01263158]		2,072 participants (Actual)	Interventional	1998-10-31	Completed
Effects of Intranasal Oxytocin and Vasopressin on Social Behavior and Decision Making[NCT02526914]		432 participants (Anticipated)	Interventional	2015-10-31	Not yet recruiting
Role of Topical Oxytocin Gel On Vaginal Atrophy, Psycho-sexual and Psychological Function and Metabolic and Inflammatory Parameters in Post-Menopausal Egyptian Women[NCT05275270]		50 participants (Actual)	Interventional	2020-12-01	Completed
[NCT01094028]	Phase 3	412 participants (Actual)	Interventional	2009-12-31	Completed
Augmenting Prolonged Exposure Therapy for PTSD With Intranasal Oxytocin[NCT03238924]	Phase 2	17 participants (Actual)	Interventional	2015-01-01	Completed
A Clinical Trial Evaluating the Interaction of Rapid Hydration and the Rate of Oxytocin Labor Augmentation on Fetal Heart Rate Changes and Maternal Fetal Outcomes[NCT02121184]		177 participants (Actual)	Interventional	2014-04-30	Completed
Carbetocin Versus Oxytocin Infusion Plus Tranexamic Acid for Prevention of Postpartum Hemorrhage at Cesarean Section: A Double-Blind Randomized Clinical Trial[NCT03777878]		400 participants (Anticipated)	Interventional	2019-01-01	Recruiting
Assessing the Effectiveness, Safety and Feasibility of Expanding Use of Oxytocin in Uniject™ by Auxiliary Nurse Midwives to Prevent Postpartum Hemorrhage: A Community-based Cluster Randomized Trial in Bagalkot, India[NCT01108302]		0 participants (Actual)	Interventional	2011-09-30	Withdrawn(stopped due to PATH withdrew IRB approval)
Timing of Umbilical Cord Occlusion in Premature Babies( <33 w). Delayed vs Early.[NCT02187874]		150 participants (Anticipated)	Interventional	2014-07-31	Recruiting
Validate a Pharmacodynamic Model of Oxytocin for Peripheral Analgesic Effects[NCT04435704]	Phase 2	26 participants (Anticipated)	Interventional	2024-06-30	Not yet recruiting
Apply the Pharmacodynamic Model of Peripheral Oxytocin Action to a Multimodal Stimulus That Increases (Heat) or Decreases (Vibration) Pain Perception[NCT04433741]	Phase 2	30 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
Generate a Pharmacodynamic Model of Oxytocin for Peripheral Analgesic Effects[NCT04431206]	Phase 2	38 participants (Anticipated)	Interventional	2020-11-04	Recruiting
Generate and Test the Reliability of a Pharmacodynamic Model of Oxytocin on Pupillary Hippus as a Measure of Central Nervous System Activity[NCT04427709]	Phase 2	38 participants (Anticipated)	Interventional	2020-11-30	Recruiting
Testing the Efficacy of Intranasal Oxytocin for the Prevention of Postpartum Depression and PTSD[NCT02505984]	Phase 2	56 participants (Actual)	Interventional	2015-10-31	Completed
Phase IB Study of Efficacy and Safety of Oxytocin and Tibolone Adjuncts in Treatment Resistant Depression[NCT01239888]	Phase 1	15 participants (Anticipated)	Interventional	2012-01-31	Recruiting
The Clinical Carbetocin Myocardium Trial[NCT02528136]	Phase 4	40 participants (Actual)	Interventional	2015-09-30	Completed
Misoprostol With Mechanical Dilation Versus Oxytocin With Mechanical Dilation for High-risk Pregnancy Inductions: A Randomized Control Trial[NCT04492072]		150 participants (Actual)	Interventional	2020-08-17	Completed
Effects of Oxytocin on Social Cognition Training: Relationship to Target Engagement[NCT03245437]	Phase 4	120 participants (Anticipated)	Interventional	2018-01-04	Active, not recruiting
Safety and Efficacy of Intravenous Oxytocin Versus Tranexamic Acid in Reducing Blood Loss During Abdominal Myomectomy; A Randomized Controlled Trial[NCT03892668]	Phase 4	150 participants (Actual)	Interventional	2019-04-30	Completed
Carbetocin at Elective Cesarean Delivery: A Dose Finding Study[NCT01262742]		80 participants (Actual)	Interventional	2010-11-30	Completed
Single Dose Intranasal Oxytocin (IN-OT) Versus Placebo in Autism: Examining Cognitive Effects[NCT02493426]	Phase 2	27 participants (Actual)	Interventional	2014-05-31	Completed
A Pilot, Proof of Concept, Placebo-controlled, Parallel Study of the Effects of High Dose Intranasal Oxytocin for the Treatment of Tinnitus[NCT04210310]	Phase 3	33 participants (Actual)	Interventional	2020-01-15	Terminated(stopped due to PI departure from the institution.)
Effects of Intramuscular Oxytocin on Pupil Diameter and Heart Rate Variability[NCT04105998]	Phase 4	22 participants (Actual)	Interventional	2019-10-24	Completed
Oxytocin to Enhance Alcohol Behavioral Couple Therapy (ABCT)[NCT03846505]	Phase 2	194 participants (Actual)	Interventional	2019-05-16	Active, not recruiting
Target Engagement for Intranasal Oxytocin in Autism Spectrum Disorders, an fMRI Dose Response Study[NCT03033784]	Phase 2	51 participants (Actual)	Interventional	2017-05-10	Completed
Effect of Oxytocin Infusion on Reducing the Blood Loss During Abdominal Myomectomy: A Randomized Controlled Trial[NCT03702946]	Phase 3	60 participants (Actual)	Interventional	2017-07-15	Completed
Efficacy of Intrathecal Oxytocin to Speed Recovery After Hip Surgery[NCT03011307]	Phase 2	126 participants (Actual)	Interventional	2017-01-12	Terminated(stopped due to Cessation of funding period prior to completion, due to slow recruitment during the pandemic.)
Use of Oxytocin in MRI-HIFU Treatment[NCT03937401]	Phase 4	100 participants (Anticipated)	Interventional	2019-02-01	Enrolling by invitation
[NCT01216605]	Phase 4	56 participants (Actual)	Interventional	2009-11-30	Completed
Brain Blood Flow Changes Elicited by Oxytocin in Healthy and Schizophrenic Volunteers, an Assessment Using Positron Emission Tomography and 15-Oxygen Labeled Water[NCT01123317]		0 participants (Actual)	Interventional	2010-07-31	Withdrawn(stopped due to Never started)
To Mirror or Not to Mirror Upon Perceived Eye Contact? The Effect of Oxytocin on Socially Adaptive Mirror System Functioning in Autism[NCT03640156]	Phase 3	25 participants (Actual)	Interventional	2018-07-26	Completed
Investigating the Effect of Oxytocin and the Neurochemistry of Antisocial Personality Disorder and Psychopathy Using Neuroimaging[NCT05383300]		72 participants (Actual)	Interventional	2017-05-01	Completed
Comparison of Umbilical Cord Blood vs Personalized Treatment for Improving Autistic Spectrum Disorder[NCT04007224]	Phase 1	35 participants (Actual)	Interventional	2019-01-17	Completed
Phase IV, Multicenter, Open Label, Randomized Trial to Compare the Effectiveness and Safety of the Dinoprostone Vaginal Pessary vs. Oxytocin for Women Requiring Cervical Ripening Prior to Induction of Labor[NCT01190163]	Phase 4	170 participants (Actual)	Interventional	2010-06-30	Terminated(stopped due to Study was early terminated due to problems enrolling adequate number of patients)
Combined Colloids And Crystalloids Versus Crystalloids in Women With Preeclampsia Undergoing Cesarean Delivery Under Spinal Anesthesia: A Randomized Controlled Trial[NCT03252496]		140 participants (Actual)	Interventional	2017-08-19	Completed
Influence of Oxytocin on Resting State Neurophysiological Measures[NCT03255148]	Phase 1	56 participants (Actual)	Interventional	2017-07-24	Completed
The Association Between Fluid Administration, Oxytocin Administration, and Fetal Heart Rate Changes[NCT00787176]		251 participants (Actual)	Interventional	2007-09-30	Terminated(stopped due to Study concluded prematurely prior to meeting intended goal recruitment.)
The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity[NCT03119610]	Phase 1/Phase 2	23 participants (Actual)	Interventional	2017-09-22	Completed
Effects of Oxytocin on Alcohol Craving and Intimate Partner Aggression[NCT03046836]	Phase 2	200 participants (Actual)	Interventional	2017-07-01	Completed
Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia[NCT01012167]	Phase 2	86 participants (Actual)	Interventional	2010-02-28	Completed
Faces: Choices Study[NCT02409862]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2019-01-01	Withdrawn(stopped due to Technical issues preventing recruitment.)
A Randomized Trial of Intracervical Balloon Placement Versus Intravenous Oxytocin in Women With Premature Rupture of Membranes and Unripe Cervices[NCT03172858]		200 participants (Anticipated)	Interventional	2017-07-31	Not yet recruiting
Neural Substrates of Emotion: Impact of Cocaine Dependence[NCT02682784]	Phase 2	138 participants (Actual)	Interventional	2015-07-31	Completed
6-week Trial of Oxytocin for Co-occurring Cocaine and Opioid Use Disorders[NCT03016598]	Phase 2	42 participants (Actual)	Interventional	2018-01-26	Completed
Estimate Serum Oxytocin Pharmacodynamic Range in the Periphery[NCT04431193]	Phase 2	0 participants (Actual)	Interventional	2023-12-31	Withdrawn(stopped due to Study will be replaced by a revised study protocol)
To Evaluate the Efficacy and Safety of Balloon Catheter Combined With Oxytocin Induction in Nulliparous Women With Estimated Fetal Weight ≥3500g at 39-40 Weeks of Gestation: a Randomized, Controlled, Observational Study[NCT05197101]		150 participants (Anticipated)	Interventional	2022-01-17	Not yet recruiting
Oxytocin and Cognitive Behavioral Therapy in Drug Dependence[NCT00975416]	Phase 4	63 participants (Actual)	Interventional	2008-11-30	Terminated
Mode of Induction in Fetal Growth Restriction and Its Affects on Fetal and Maternal Outcomes[NCT03625518]	Early Phase 1	280 participants (Anticipated)	Interventional	2018-09-30	Not yet recruiting
A Randomized, Open-label Study to Characterize the Pharmacokinetics of Inhaled Oxytocin (GR121619) Compared With IM Oxytocin in Women in the Third Stage of Labour, and With IV Oxytocin in Non-pregnant, Non-lactating Women of Childbearing Potential[NCT02999100]	Phase 1	31 participants (Actual)	Interventional	2016-11-23	Terminated(stopped due to Inability to reliably measure plasma oxytocin levels during third stage labour, regardless of administration method (intramuscular or inhaled).)
The Use of Oxytocin, Carbetocin and Buccal Misoprostol in Patients Undergoing Elective Cesarean Section[NCT02053922]	Phase 3	270 participants (Actual)	Interventional	2012-12-31	Completed
A One Year Double Blind Randomized Controlled Trial of Sublingual Misoprostol (400 µg) Versus Intramuscular Oxytocin (10 IU) in the Prevention of Postpartum Bloodloss at KLE Hospital, Belgaum[NCT01373359]	Phase 3	652 participants (Actual)	Interventional	2007-03-31	Completed
Up-down Determination of the ED90 of Oxytocin Infusions for the Prevention of Postpartum Uterine Atony in Parturients Undergoing Cesarean Delivery[NCT00785395]	Phase 4	40 participants (Actual)	Interventional	2008-06-30	Completed
A Dose Ranging Study for a Pharmacodynamic Model of Oxytocin for Peripheral Analgesia Effects[NCT05179421]	Phase 2	24 participants (Actual)	Interventional	2022-05-09	Completed
The Effect of Oxytocin Versus, Sublingual Misoprostol in the Secondary Prevention of Postpartum Hemorrhage After Vaginal Delivery: a Randomized Controlled Trial[NCT05077540]		150 participants (Anticipated)	Interventional	2021-11-01	Not yet recruiting
Oxytocin in Opiate Dependence: A Double-blind, Within-subjects, Placebo-controlled Pilot Study of the Effects of Intranasal Oxytocin on Emotional Processes and Stress Responses in Patients With Opiate Dependence[NCT02052258]	Phase 1	0 participants	Interventional	2013-01-31	Recruiting
Mild Induced Labour Prior to Planned Caesarean Delivery to Improve Neonatal and Maternal Outcome - a Randomized Trial[NCT03693885]		1,450 participants (Anticipated)	Interventional	2019-01-01	Recruiting
[NCT02183948]	Early Phase 1	86 participants (Actual)	Interventional	2014-06-30	Completed
Does Intramyometrial Oxytocin Improve Outcome in Elective Cesarean Delivery?[NCT01252342]	Phase 4	0 participants (Actual)	Interventional	2011-08-31	Withdrawn(stopped due to Proposed doses were too large, bolus oxytocin may cause cases of arrythmias, and some even advocate slowing down the infusion rates that are currently used.)
The Pharmacokinetics of Oxytocin in Pregnant Women Undergoing Cesarean Delivery - a Feasibility Pilot Study[NCT03898882]		30 participants (Actual)	Observational	2019-05-24	Completed
[NCT02465164]		26 participants (Actual)	Interventional	2015-07-01	Completed
Effect of a Single Dose of Intranasal Oxytocin on Food Intake in Obese Adolescents[NCT03497988]	Phase 2	0 participants (Actual)	Interventional	2018-09-30	Withdrawn(stopped due to Grant proposal not funded, study has been withdrawn with IRB)
A Comparison Between Continuous Versus Intermittent Oxytocin Infusion for Induction of Labor[NCT04017247]		153 participants (Actual)	Interventional	2019-11-01	Completed
The Management of Spontaneous Labour in Primigravida (SLiP): Labor Scale Versus WHO Partograph[NCT02486822]		120 participants (Anticipated)	Interventional	2015-07-31	Active, not recruiting
A Prospective, Randomized and Placebo Controlled Trial Comparing the Role of ARTificial Uterine CONtractions and no Intervention in Perinatal Respiratory Morbidity of Term Infants Delivered by Elective Caesarean Section - ARTCON Study[NCT03899597]		200 participants (Anticipated)	Interventional	2024-01-30	Not yet recruiting
The Influence of Oxytocin on the Mirror Neuron System: Developing Brain Imaging Paradigms for Future Therapeutic Interventions[NCT02228031]	Early Phase 1	44 participants (Actual)	Interventional	2014-10-31	Completed
Oxytocin in Individuals With Spectrum Autism Disorders[NCT03183674]	Phase 1	80 participants (Actual)	Interventional	2016-07-15	Completed
The Influence of Intranasal Oxytocin on Communication[NCT02415920]		50 participants (Actual)	Interventional	2017-11-06	Completed
Laboratory Studies on Oxytocin for Treatment of Alcohol Use Disorder[NCT02407340]	Phase 1	27 participants (Actual)	Interventional	2015-03-31	Completed
Carbetocin vs. Oxytocin at Elective Cesarean Section: a Double-blind, Randomized Controlled Non-inferiority Trial of High and Low Dose Regimens[NCT03168698]		278 participants (Actual)	Interventional	2017-05-25	Completed
Effects of Oxytocin on Familial Interactions[NCT02302209]	Phase 1	104 participants (Actual)	Interventional	2011-04-30	Completed
Oxytocin's Effects on Behavior and Neural Activity During Social Cognition Tasks[NCT02393456]	Early Phase 1	161 participants (Actual)	Interventional	2015-01-31	Completed
Ergometrine Versus Oxytocin in the Management of Atonic Post-partum Haemorrhage (PPH) in Women Delivered Vaginally: A Randomised Controlled Trial[NCT02306733]	Phase 3	200 participants (Anticipated)	Interventional	2014-11-30	Recruiting
Analysis of Contemporary Labor Patterns Measured Via Transperineal Ultrasonography[NCT02393144]		1,000 participants (Anticipated)	Interventional	2015-02-28	Recruiting
Concurrent Versus Sequential Administration of Amniotomy and Oxytocin for Augmentation of Labour: a Randomized Controlled Trial[NCT02318121]	Phase 2	150 participants (Actual)	Interventional	2014-04-01	Completed
Impact of Oxytocin on Obstructive Sleep Apnea Induced Changes in Sleep[NCT03148899]	Phase 2	32 participants (Actual)	Interventional	2016-07-27	Completed
The Effect of Preoperative and Post Operative Misoprostol Administration on Intraoperative Blood Loss and Postpartum Hemorrhage in CS[NCT03680339]	Phase 4	200 participants (Actual)	Interventional	2018-09-02	Completed
Effects of Oxytocin on Negative Symptoms and Social Cognition in Schizophrenia and Its Behavioral Mechanisms[NCT03662425]		43 participants (Actual)	Interventional	2018-07-21	Completed
The Effect of Oxytocin on the Acquisition and Consolidation of Trauma-Associated Memories: A Model to Understand the Development of Posttraumatic Stress Disorder[NCT03875391]		217 participants (Actual)	Interventional	2019-03-06	Completed
Target Engagement for Oxytocin: Response to 8 Doses[NCT02498236]		51 participants (Actual)	Interventional	2015-09-30	Completed
Effects of Oxytocin on Emotion Recognition and Response Inhibition[NCT02350946]	Phase 2	40 participants (Anticipated)	Interventional	2015-01-31	Recruiting
Comparative Study Between Oxytocin Versus Tranexamic Acid and Ethamsylate to Reduce Blood Loss Intraoperative and Post Operative During Elective Cesarean Section[NCT04656067]	Phase 1/Phase 2	230 participants (Actual)	Interventional	2020-04-01	Completed
Intrauterine Misoprostol Versus Intravenous Oxytocin Infusion During Cesarean Delivery to Reduce Intraoperative and Postoperative Blood Loss: A Randomized Clinical Trial.[NCT03148574]	Phase 3	240 participants (Actual)	Interventional	2017-07-02	Completed
The Use of Thromboelastometry (ROTEM) to Evaluate the Changes in Coagulation With Two Different Doses of Oxytocin Following Cesarean Delivery[NCT02063568]		0 participants (Actual)	Interventional	2015-01-31	Withdrawn
Intramuscular Versus Intravenous Prophylactic Oxytocin for the Third Stage of Labour Following Vaginal Delivery: A Randomised Controlled Trial[NCT02080104]		2 participants (Anticipated)	Interventional	2014-02-28	Recruiting
Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section[NCT02079558]	Phase 2	220 participants (Actual)	Interventional	2012-09-30	Completed
Effects of Intranasal Oxytocin in Patients With Central Diabetes Insipidus - A Pilot Study[NCT04789148]	Phase 1	30 participants (Anticipated)	Interventional	2023-06-30	Not yet recruiting
Effect of Intranasal Oxytocin on Dysphagia Related to Oropharyngo-oesophageal Dysmotility in Children and Adolescents With Prader-Willi Syndrome: a Phase 2B Study[NCT05298085]	Phase 2/Phase 3	25 participants (Actual)	Interventional	2022-04-05	Completed
Oxytocin Treatment in Neonates and Infants Aged From 0 to 3 Months With Prader-Willi Syndrome : a Study of Safety and Efficacy on Oral and Social Skills and Feeding Behavior of Intranasal Administration of Oxytocin vs Placebo[NCT04283578]	Phase 3	52 participants (Actual)	Interventional	2020-03-10	Completed
Psychobiological Assessment and Enhancement of Team Cohesion and Psychological Resilience Using a Virtual Team Cohesion Test.[NCT02302430]	Phase 1	486 participants (Actual)	Interventional	2015-10-31	Completed
Carbetocin Versus Syntocinon for Prevention of Postpartum Hemorrhage in Cardiac Patients With Stenotic Valvular Heart Disease Undergoing Caesarean Section[NCT05110482]	Phase 4	38 participants (Anticipated)	Interventional	2021-11-30	Enrolling by invitation
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Repeat Doses of Intranasal Oxytocin in Obese Adults[NCT03043053]	Phase 2	61 participants (Actual)	Interventional	2017-07-01	Completed
Carbetocin in the Prevention of Primary Postpartum Haemorrhage in Obese Versus Non-obese Women Undergoing Elective Cesarean Section[NCT06159959]		244 participants (Actual)	Observational	2023-01-01	Completed
Oxytocin as a Neuroendocrine Therapy for Obesity in Youth[NCT04551482]	Phase 2	75 participants (Anticipated)	Interventional	2021-07-28	Recruiting
Effects of Oxytocin on Cognitive Control in Adults With Attention Deficit/Hyperactivity Disorder[NCT03136263]	Early Phase 1	24 participants (Actual)	Interventional	2017-12-14	Completed
Relationship Between Oxytocin Level, Trust, and Attachment in Individuals With Borderline Personality Disorder[NCT06045650]		92 participants (Anticipated)	Observational	2024-02-09	Not yet recruiting
Postpartum Hemorrhage Prevention in Patients With Preeclampsia (PHP3 Study)[NCT02221830]	Early Phase 1	66 participants (Actual)	Interventional	2015-02-28	Completed
Buccal Misoprostol Versus IV Oxytocin in Prevention of Postpartum Hemorrhage :a Randomized Controlled Study[NCT03676621]	Phase 4	154 participants (Actual)	Interventional	2018-11-01	Completed
Effects of Intranasal Oxytocin on Emotion Regulation[NCT03055546]	Early Phase 1	80 participants (Anticipated)	Interventional	2016-02-29	Recruiting
Sequential Use of Foley Catheter With Amniotomy for Second-trimester Pregnancy Termination[NCT04906278]		60 participants (Actual)	Interventional	2021-11-01	Completed
Effect of Peripheral Oxytocin on Touch Pleasantness and Pain[NCT05326776]	Phase 2	20 participants (Actual)	Interventional	2023-04-05	Completed
The HILIO Trial: High vs. Low Oxytocin Dosing for Induction of Labor in Pregnant Patients With Obesity- PILOT STUDY[NCT05289869]	Phase 4	20 participants (Actual)	Interventional	2022-04-06	Completed
PROMMO Trial: Prelabor Rupture of Membranes Managed With Oral Misoprostol Versus Intravenous Oxytocin[NCT04478942]	Early Phase 1	100 participants (Anticipated)	Interventional	2020-10-26	Recruiting
Optimisation of the Management of Placental Delivery in Second Trimester Pregnancy Interruption[NCT00120042]		251 participants (Actual)	Interventional	2005-02-28	Completed
Promoting Social Perceptual Learning With Oxytocin in Autism[NCT02090829]	Phase 2	0 participants (Actual)	Interventional	2014-03-31	Withdrawn(stopped due to Low recruitment)
The Interaction Between Oxytocin and Serotonin on the Social-emotional Brain Networks[NCT03426176]		100 participants (Anticipated)	Interventional	2018-02-01	Recruiting
Effects of Intranasal Oxytocin on Male's Functional Brain Network in Resting-state and Tasks[NCT03428906]		34 participants (Actual)	Interventional	2016-05-24	Completed
Prenatal Cocaine, Nasal Oxytocin, and Maternal Psychophysiology[NCT02872467]	Phase 1	31 participants (Actual)	Interventional	2016-05-31	Completed
Effects of an Oxytocin-augmented Cognitive-behavioral Group-based Short-term Intervention on Neural and Behavioral Correlates of Loneliness[NCT04137432]	Phase 1	60 participants (Anticipated)	Interventional	2019-09-26	Enrolling by invitation
[NCT02156661]	Phase 1	97 participants (Actual)	Interventional	2013-05-31	Completed
The Efficacy of Four Different Treatment Regimes of Uterotonic Agents for Prevention of Postpartum Hemorrhage at Vaginal Delivery: A Multicentric Randomized Controlled Trial[NCT05467462]		300 participants (Actual)	Interventional	2022-08-01	Completed
Carbetocin Versus Oxytocin in the Prevention of Post Partum Haemorrhage (PPH) in Women Undergoing Caesarean Sections for Placenta Previa: A Randomised Controlled Trial[NCT02303418]	Phase 3	500 participants (Anticipated)	Interventional	2014-11-30	Recruiting
Carbetocin Versus Oxytocin in the Prevention of Post Partum Haemorrhage (PPH) in Women Delivered Vaginally With at Least 2 Risk Factors for Atonic PPH: A Randomised Controlled Trial[NCT02304042]	Phase 3	200 participants (Actual)	Interventional	2014-11-30	Completed
Oxytocin Dosing at Planned Cesarean Section and Postpartum Anemia: A Comparison of Two Protocols[NCT03361124]	Phase 4	0 participants (Actual)	Interventional	2019-03-01	Withdrawn(stopped due to Investigator no longer interested in proceeding with study)
Investigation of the Effect of Intranasal Oxytocin on Relapse Risk in Cocaine-dependent Patients[NCT02255357]	Phase 2/Phase 3	43 participants (Actual)	Interventional	2015-03-31	Completed
Oxytocin at Elective Cesarean Deliveries: A Dose-finding Study in Women With BMI ≥ 40kg/m2[NCT03957083]		30 participants (Actual)	Interventional	2019-06-26	Completed
A Possible Effect of Oxytocin During Interaction Between Humans and Animals[NCT01226017]		18 participants (Actual)	Interventional	2010-10-31	Completed
Changes in Rate of Hemorrhage With Prophylactic Oxytocin for Second Trimester Dilation and Evacuation in the Clinic Setting[NCT06141447]	Phase 2	150 participants (Anticipated)	Interventional	2023-11-20	Not yet recruiting
Piloting Treatment With Intranasal Oxytocin in Phelan-McDermid Syndrome[NCT02710084]	Phase 2	18 participants (Actual)	Interventional	2016-04-29	Completed
High Dose Versus Low Dose Oxytocin for Augmentation of Delayed Labour in Obese Women: A Randomized Clinical Trial[NCT03604874]	Phase 4	202 participants (Actual)	Interventional	2018-09-01	Completed
The Oxytocin Initiative: Determining the Effect of Prophylactic Administration of Oxytocin in Uniject™ by a Community Health Officer on Postpartum Hemorrhage at Home Births in Four Districts in Ghana[NCT01108289]		1,586 participants (Actual)	Interventional	2011-04-30	Completed
Dose-dependent Effects of Oxytocin on the Amygdala and Reward System Vary Between Women and Men[NCT03846739]	Phase 1	92 participants (Actual)	Interventional	2017-04-03	Completed
The Effects of Intranasal Oxytocin on Reward Sensitivity and Performance Monitoring During Reinforcement Learning: an ERP Study[NCT03846271]		40 participants (Anticipated)	Interventional	2018-12-04	Recruiting
The Effect of IV Tranexamic Acid Plus Buccal Misoprostol on Blood Loss During and After Cesarean Delivery: a Randomized Controlled Trial[NCT03710304]		400 participants (Actual)	Interventional	2018-11-01	Completed
Ultrasonography for Fluid Assessment in Parturients With Preeclampsia Undergoing Elective Cesarean Section Under Spinal Anesthesia[NCT04370847]		100 participants (Actual)	Observational	2020-06-01	Completed
An Eye-tracking Study to Investigate Oxytocin's Effect on Attentional Bias Training[NCT03128242]		60 participants (Anticipated)	Interventional	2016-11-25	Recruiting
Carbetocin Versus Oxytocin for Prevention of Postpartum Hemorrhage in Patients With Severe Preeclampsia: a Double Blind Randomized Controlled Trial[NCT01382732]	Phase 3	636 participants (Anticipated)	Interventional	2012-01-31	Recruiting
Randomized Controlled Comparison of Blood Loss in Patients Who Received Oxytocin Infusion, Oxytocin Infusion, and Intrauterine Misoprostol and Carbetocin During Cesarean Delivery[NCT05083910]		156 participants (Actual)	Interventional	2021-07-01	Completed
Pre-operative Intranasal Oxytocin for Enhancing Bariatric-induced Diabetes remissionPre-operative Intranasal Oxytocin for Enhancing Bariatric-induced Diabetes Remission[NCT05207774]		3 participants (Actual)	Interventional	2020-01-09	Active, not recruiting
The Effect of Oxytocin on Satiety in Patients With Dyspepsia[NCT01152047]		14 participants (Actual)	Interventional	2010-05-31	Completed
Oxytocin and Dopamine's Effect on Vicarious Optimism[NCT03891095]		156 participants (Actual)	Interventional	2018-12-01	Completed
Carbetocin Versus Oxytocin Plus Sublingual Misoprostol in the Management of Atonic Post-partum Hemorrhage (PPH) After Vaginal Delivery: a Randomized Controlled Trial[NCT03870503]		135 participants (Actual)	Interventional	2019-04-01	Completed
Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) With Long Term Follow-Up (CARE-PWS)[NCT03649477]	Phase 3	130 participants (Actual)	Interventional	2018-11-20	Completed
Effects of Intranasal Oxytocin and Vasopressin on Social Behavior in Healthy Controls[NCT01296269]		150 participants (Anticipated)	Interventional	2011-04-30	Recruiting
Oxytocin Administration During Cesarean Section Before Versus After Fetal Delivery Randomized Clinical Trial[NCT03344302]	Phase 4	200 participants (Actual)	Interventional	2016-10-31	Completed
Short-term Effects of Oxytocin Nasal Spray on Chronic Tinnitus[NCT02508220]		15 participants (Actual)	Interventional	2015-07-31	Completed
The Effect of the Timing of Uterotonic Administration in the Third Stage of Labour on Postpartum Hemorrhage[NCT02495272]		330 participants (Anticipated)	Interventional	2014-06-30	Recruiting
The Moderating Role of Baseline Oxytocin on Its Psychotherapy-facilitating Effects Among Patients With Eating Disorders[NCT05865288]	Phase 1	90 participants (Anticipated)	Interventional	2023-06-30	Not yet recruiting
Interest of Oxytocin as an Adjuvant Treatment of Psycho-educational Measures in Challenging Behaviors in Children With Autism Spectrum Disorders and Moderate to Severe Intellectual Disability: Feasibility and Safety Study.[NCT05864508]	Phase 2	30 participants (Anticipated)	Interventional	2023-07-31	Not yet recruiting
Medical Management of Late Intrauterine Death Using a Therapeutic Combination of Isosorbide Dinitrate and Oxytocin.[NCT02488642]	Phase 4	60 participants (Actual)	Interventional	2008-05-31	Completed
Labor Scale Versus WHO Partograph for Management of Spontaneous Labor in Primigravidae (ScaLP): A Randomized Controlled Trial[NCT05341076]		206 participants (Anticipated)	Interventional	2022-08-01	Not yet recruiting
Heat Stable Carbetocin Versus Oxytocin for the Prevention of Primary Postpartum Hemorrhage in Emergency Caesarean Delivery[NCT03755531]	Phase 4	300 participants (Actual)	Interventional	2018-01-04	Completed
Efficacy of Intrathecal Oxytocin in Patients With Neuropathic Pain[NCT02100956]	Phase 2	8 participants (Actual)	Interventional	2014-06-19	Terminated(stopped due to Cessation of funding period prior to completion, due to slow recruitment during the pandemic)
The Effect of Intravenous Oxytocin Infusion Using Different Diluents on Neonatal Bilirubin & Sodium Levels .A Prospective Randomized Controlled Trial.[NCT02602301]	Phase 4	327 participants (Anticipated)	Interventional	2015-11-30	Active, not recruiting
A Pilot Study of Oxytocin in Children and Adolescents With Autistic Disorder[NCT01308749]	Phase 2	25 participants (Actual)	Interventional	2011-03-31	Completed
Randomized, Double-Blind, Placebo Controlled Study of Intranasal Oxytocin During Detoxification of Crack Cocaine[NCT04306354]	Phase 1/Phase 2	96 participants (Anticipated)	Interventional	2018-09-15	Recruiting
Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome[NCT01254045]	Phase 2	10 participants (Actual)	Interventional	2007-02-28	Completed
Comparison of Intrauterine Misoprostol Plus Intravenous Oxytocin Versus Intravenous Oxytocin Alone for Prevention of Primary Postpartum Haemorrhage in Population of Bhara Kahu.[NCT04724187]	Phase 2	180 participants (Anticipated)	Interventional	2021-02-03	Recruiting
Deciphering the Role of Oxytocin in Motivation: an fMRI Study. Part II[NCT02652195]	Phase 2	88 participants (Anticipated)	Interventional	2016-11-30	Active, not recruiting
Evaluating the Efficacy of Intranasal Oxytocin Among Individuals With Persistent Pain[NCT02888574]	Phase 2/Phase 3	24 participants (Actual)	Interventional	2016-11-30	Completed
Disentangling Effects of Oxytocin on Cognitive and Reactive Fear and the Moderating Role of the Receptor for Advanced Glycation End-products[NCT04292444]	Phase 1	60 participants (Anticipated)	Interventional	2019-12-13	Recruiting
Effects of Oxytocin on Neural Activation Patterns During Social Cognitive Tasks in Patients With Schizophrenia[NCT02568709]	Early Phase 1	40 participants (Actual)	Interventional	2012-02-29	Completed
The Efficacy and Safety of Intrauterine Misoprostol Versus Intravenous Tranexamic Acid in Reducing Blood Loss During and After Cesarean Delivery in Patients With Placenta Previa: A Randomized Controlled Trial[NCT05340205]	Phase 4	81 participants (Actual)	Interventional	2022-05-04	Completed
A Randomized Controlled Trial Evaluating the Effect of the Oxytocin Infusion Rate on Fetal Heart Rate Changes and Maternal-Fetal Outcomes During the Initiation of Combined Spinal-Epidural Labor Analgesia[NCT03232918]	Phase 4	730 participants (Anticipated)	Interventional	2019-02-20	Recruiting
A Comparison of Titrated Oral Misoprostol Solution to Intravenous Oxytocin for Labor Augmentation: A Randomized Controlled Trial[NCT00695331]	Phase 4	143 participants (Anticipated)	Interventional	2008-02-29	Recruiting
Is Placental Transfusion Influenced by the Early Administration of Oxytocin?[NCT02618499]	Phase 3	180 participants (Actual)	Interventional	2016-05-31	Terminated(stopped due to Futility suggested by DSMC)
Does Oral Propranolol Accelerate Labor Induction/Augmentation With Oxytocin in Nulliparous Women in Abakaliki?[NCT05251610]		110 participants (Actual)	Interventional	2020-11-02	Completed
Double-blind Randomised Non-inferiority Trial to Assess Efficacy and Safety of Carbetocin After Caesarean Section Applied as Iv-bolus as Compared to a Short-infusion[NCT02221531]	Phase 4	140 participants (Actual)	Interventional	2014-08-31	Completed
Female Sexual Dysfunction in the Menopause: Effect of Intranasal Oxytocin Administration on Sexual Function and Activity[NCT02229721]	Phase 2	30 participants (Actual)	Interventional	2012-06-30	Completed
Mindfulness Training Plus Oxytocin to Reduce Smoking and Craving Among Smokers in Withdrawal[NCT03819231]	Phase 2/Phase 3	180 participants (Anticipated)	Interventional	2018-10-10	Suspended(stopped due to Study recruitment temporarily suspended due to COVID-19 pandemic.)
Intranasal Oxytocin to Promote Weight Loss in Children, Adolescents, and Adults With Brain Tumors and Hypothalamic Obesity Syndrome[NCT02849743]	Phase 2	18 participants (Actual)	Interventional	2016-10-31	Completed
Oxytocinergic Modulation of Perceived Social Exclusion[NCT03122067]		60 participants (Anticipated)	Interventional	2017-01-10	Recruiting
Vaginal Misoprostol Versus Combined Intracervical Foley's Catheter and Oxytocin Infusion for Second Trimester Pregnancy Termination in Women With Previous Caesarean Sections[NCT04501809]		158 participants (Anticipated)	Interventional	2020-07-15	Recruiting
Carbetocin Versus Oxytocin and Ergometrine for Prevention of Postpartum Hemorrhage Following a Cesarean Section in Women With Multiple Gestation[NCT03578263]		220 participants (Actual)	Interventional	2018-04-01	Completed
The Effects of Probiotics and Oxytocin Nasal Spray on Social Behaviors of ASD Children- A Pilot Study[NCT03337035]	Phase 1	35 participants (Actual)	Interventional	2018-12-01	Completed
A Pilot Feasibility Study of Intramuscular Oxytocin on Fear of Pain and Trust in Physical Therapist During Outpatient Rehabilitation After Total Knee Arthroplasty[NCT04493229]	Phase 2	0 participants (Actual)	Interventional	2024-01-31	Withdrawn(stopped due to study team decided not to proceed with project)
Long-term Consequences of Childhood Adversity: Exploring Stress Responsive Molecular Pathways and Psychobiological Intervention Models[NCT03335085]		80 participants (Actual)	Interventional	2011-07-01	Completed
Effect of Oxytocin Infusion on Blood Loss During Abdominal Myomectomy[NCT03308643]	Phase 4	100 participants (Actual)	Interventional	2017-10-01	Completed
Effects of Oxytocin on Physical and Cognitive Functioning in the Elders[NCT02069431]	Phase 1	153 participants (Actual)	Interventional	2016-02-29	Terminated(stopped due to This study was halted prematurely due to the COVID-19 pandemic, resulting in the inability to enroll participants. Funding for this project has also ended.)
Evaluating the Efficacy of Intranasal Oxytocin on Pain and Function Among Individuals Who Experience Chronic Pain: A Multisite, Placebo-controlled, Blinded, Sequential, Within-subjects Crossover Trial[NCT04903002]	Phase 2/Phase 3	336 participants (Anticipated)	Interventional	2022-04-01	Recruiting
The Behavioral and Neural Effects of Oxytocin on Face Perception in Congenital Prosopagnosia[NCT02091817]	Early Phase 1	100 participants (Anticipated)	Interventional	2013-11-30	Suspended(stopped due to We are currently engaged in other behavioral study.)
A Comparison Between Carbetocin, Oxytocin and Ergometrine in Prevention of Postpartum Haemorrhage Following Caesarean Section[NCT02101567]	Phase 4	200 participants (Actual)	Interventional	2014-05-31	Completed
Oxytocin Modulates Eye Gaze Behavior During Social Processing and Associations With Trait Autism[NCT03293511]		40 participants (Anticipated)	Interventional	2017-06-09	Recruiting
Double-blind, Placebo-controlled, Randomized Study: Oxytocin Modulation of Stress-Associated Chemosignals Processing[NCT03265899]	Phase 1	60 participants (Actual)	Interventional	2015-07-01	Completed
The Interaction Between Oxytocin and Serotonin on the Social-reward Brain Networks and Decision Making[NCT03577457]		100 participants (Anticipated)	Interventional	2018-02-01	Recruiting
A Randomized, Placebo-controlled, Double-blind, 2-period Cross-over Study in Youth With Autism Spectrum Disorders Evaluating Social and Repetitive Behaviors After Four Weeks of Twice Daily-doses of 24IU of Intranasally Administered Oxytocin[NCT05934812]	Phase 2	128 participants (Anticipated)	Interventional	2023-09-18	Not yet recruiting
In Vitro Evaluation of Spontaneous and Oxytocin-induced Contractility of Pregnant Human Myometrium During Exposure to Dexmedetomidine[NCT05511415]		28 participants (Anticipated)	Interventional	2022-11-02	Recruiting
Intranasal Oxytocin as Enhancer of Psychotherapy Outcomes in Severe Mental Illness: A Randomized Controlled Study[NCT03566069]	Phase 2	120 participants (Anticipated)	Interventional	2018-06-01	Recruiting
4 Versus 6 cm Cervical os Dilatation to Demarcate Active Phase of Labour: Comparative Cross Ectional Study[NCT05339399]		155 participants (Actual)	Observational	2021-05-01	Completed
Recovery of Oxytocin Responsiveness in Pregnant Human Myometrial Explants After Oxytocin-Induced Desensitization[NCT02051231]		22 participants (Actual)	Interventional	2013-12-31	Completed
Nefopam vs Tramadol in the Prevention of Post Anaesthetic Shivering Following Subarachnoid Block[NCT02441673]	Phase 2	130 participants (Anticipated)	Interventional	2018-10-12	Not yet recruiting
A Randomized Trial of Foley Bulb Induction With and Without Simultaneous Use of Oxytocin[NCT02098421]	Phase 1	312 participants (Actual)	Interventional	2014-11-30	Completed
Oxytocin Pharmacokinetics After Intramuscular Injection[NCT04427540]	Phase 2	0 participants (Actual)	Interventional	2021-12-31	Withdrawn(stopped due to Study was not initiated; no subjects were consented or enrolled)
Intranasal Oxytocin Treatment for Alcohol Use Disorders: A Randomized, Placebo-Controlled Trial[NCT03636555]	Phase 2	0 participants (Actual)	Interventional	2019-10-31	Withdrawn(stopped due to PI no longer employed at Institution)
A Phase 2 Clinical Trial of Intranasal Oxytocin for Frontotemporal Dementia[NCT03260920]	Phase 2	112 participants (Anticipated)	Interventional	2018-01-31	Active, not recruiting
Combined Use of Intranasal Oxytocin and Interpersonal Psychotherapy for the Treatment of Major Depressive Disorder (MDD): A Randomized Controlled Trial[NCT02405715]	Phase 2	24 participants (Actual)	Interventional	2015-02-28	Completed
The Effect of Oxytocin on Brain Attachment and Empathy Networks, and the Association Between the Brain Response and Treatment Outcome of Brief Dyadic Psychotherapy - in Women Suffering From Postpartum Depression[NCT02191423]		50 participants (Anticipated)	Interventional	2015-01-31	Not yet recruiting
A Randomized, Double-blind, Placebo-controlled Study of Intranasal Oxytocin for Bone Health in Children With Autism Spectrum Disorder[NCT05754073]	Phase 2	96 participants (Anticipated)	Interventional	2023-08-01	Recruiting
The Effects of Oxytocin on Social Cognition in Patients With Schizophrenia[NCT02577575]	Early Phase 1	120 participants (Actual)	Interventional	2010-08-31	Completed
OXYMIND: Oxytocin-augmented Group Psychotherapy for Patients With Schizophrenia[NCT06136390]		120 participants (Anticipated)	Interventional	2023-11-15	Not yet recruiting
Maintenance Infusion of Oxytocin Following Elective Cesarean Deliveries: an Up-down Sequential Allocation Dose-response Study[NCT04946006]		40 participants (Actual)	Interventional	2021-07-26	Completed
Investigation of the Effects of Intranasal Oxytocin on Cognition and Emotion Processing in Frontotemporal Dementia[NCT01002300]		24 participants (Actual)	Interventional	2009-09-30	Completed
Role of Oxytocin in Telling and Detecting Lies[NCT02361177]	Early Phase 1	0 participants (Actual)	Interventional	2016-01-31	Withdrawn(stopped due to Drug not available)
A Single Centre, Single Blind Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses of Oxytocin (GR121619) Administered Via an Inhaled Route in Healthy Female Volunteers[NCT02542813]	Phase 1	16 participants (Actual)	Interventional	2015-09-14	Completed
A Pharmacokinetic Study of Intravenous and Intranasal Oxytocin in Healthy Subjects[NCT05672667]	Phase 1	24 participants (Actual)	Interventional	2023-02-27	Completed
Can Oxytocin Enhance the Placebo Effect?[NCT02745522]	Phase 1	224 participants (Actual)	Interventional	2015-12-31	Completed
The Effects of Oxytocin Administration to Patients and Therapists on Physiological Synchronization: a Randomized Controlled Pilot Study[NCT05432089]	Phase 2	120 participants (Anticipated)	Interventional	2023-03-30	Recruiting
The Effect of Oxytocin on the Training of Attachment-related Interpretation Bias in Middle Childhood[NCT02737254]	Phase 4	100 participants (Actual)	Interventional	2016-03-31	Completed
Outcomes After Implementation of a New Oxytocin Protocol for the Prevention of Postpartum Hemorrhage in Non-emergent Cesarean Sections[NCT02722356]		64 participants (Actual)	Interventional	2016-04-30	Completed
Understanding the Neurobiological Effects of Oxytocin on Social Trust Deficits in Schizophrenia: A Multimodal Imaging - Genetics Study[NCT04177719]		44 participants (Anticipated)	Interventional	2019-11-08	Recruiting
Tearing of Membranes Before Birth - a Comparison Between Two Ways of Induction of Labor Pitocin Opposite Prostaglandin[NCT02720978]	Phase 3	1,200 participants (Anticipated)	Interventional	2016-05-31	Active, not recruiting
Intranasal Oxytocin: A Neuropharmacological Intervention for Maternal Neglect?[NCT02737436]		150 participants (Actual)	Interventional	2010-05-31	Completed
A Randomized, Controlled Trial of Oral Misoprostol for Labor Augmentation[NCT00906347]	Phase 4	350 participants (Actual)	Interventional	2008-12-31	Completed
A Cross Over Randomized Controlled Trial of the Effect of Nasal Ocytocine on Cerebral Activations in Relation With Attachement in the General Population[NCT02847143]	Phase 2	100 participants (Actual)	Interventional	2015-04-09	Completed
Intranasal Oxytocin and Resting State fMRI in Healthy Volunteers[NCT02689596]		0 participants	Interventional	2014-10-31	Completed
Prophylactic Use of Intraumbilical Vein Oxytocin Injection in The Management of Third Stage of Labor A Randomized Controlled Study[NCT02680938]	Phase 1	1 participants (Anticipated)	Interventional	2015-01-31	Recruiting
Amniotomy and Early Oxytocin Infusion Versus Amniotomy and Delayed Oxytocin Infusion in Nulliparous Women: a Randomised Controlled Trial[NCT04200599]		250 participants (Actual)	Interventional	2014-08-01	Completed
A Randomized Controlled Study Comparing Cervical Foley Catheter, Vaginal Dinoprostone and a Combination of the Two Methods for Induction of Labor[NCT02815865]		360 participants (Anticipated)	Interventional	2016-08-31	Not yet recruiting
Randomized Double-Blinded Clinical Trial of Oxytocin Bolus Versus Infusion in Elective Cesarean Section[NCT05236985]	Phase 4	120 participants (Anticipated)	Interventional	2022-03-15	Recruiting
The REDUCED-I Pilot Trial: REDucing the Utilization of CEsarean Sections With Induction[NCT05037617]		200 participants (Anticipated)	Interventional	2021-10-25	Recruiting
Longitudinal Clinical, Controlled, Randomized, Open-label, Phase III Study to Assess the Equivalence of Tranexamic Acid (TXA) vs Oxytocin (OXY) in Reducing Post Partum Haemorrhage (PPH) in Patients at the End of Pregnancy (37-42 w), at Low Risk of PPH[NCT02775773]	Phase 3	256 participants (Anticipated)	Interventional	2017-01-01	Active, not recruiting
Effect of Magnesium Sulphate Pre-exposure on Oxytocin-induced Contractility in Desensitized Human Myometrium - an in Vitro Study[NCT02647268]		26 participants (Actual)	Interventional	2016-01-31	Completed
[NCT02745431]		86 participants (Actual)	Interventional	2015-06-30	Completed
Transcervical Foley Catheter With or Without IV Oxytocin Infusion for Induction of Labor: a Randomized Controlled Trial[NCT00684606]		120 participants (Anticipated)	Interventional	2008-05-31	Recruiting
[NCT02741063]	Early Phase 1	120 participants (Anticipated)	Interventional	2016-05-31	Recruiting
Oxytocin Buffers Cortisol Responses to Stress in Individuals With Impaired Coping Abilities[NCT01065610]		0 participants	Interventional	2008-01-31	Completed
Breast Pump Nipple Stimulation Versus Pitocin for Induction of Labor: Efficacy, Safety and Satisfaction[NCT00984347]		150 participants (Anticipated)	Interventional	2009-11-30	Not yet recruiting
Impact of Uterotonic Agents on Isolated Human Myometrium[NCT00989027]		56 participants (Actual)	Interventional	2007-06-30	Completed
Mechanisms and Effects of Oxytocin on Social Cognition in Schizophrenia - Behavioral[NCT02567032]	Early Phase 1	324 participants (Actual)	Interventional	2010-10-31	Completed
Oxytocin Effects on the Prosocial Learning[NCT04105140]		90 participants (Actual)	Interventional	2018-01-01	Completed
[NCT02618096]		154 participants (Actual)	Interventional	2015-10-31	Completed
Compariıson Of The Effects Of Carbetocin And Oxytocin, Which Are Uterotonic Agents, In C-Section Operations[NCT05742854]	Phase 4	200 participants (Anticipated)	Interventional	2023-03-09	Not yet recruiting
Neurobiological Effects of Oxytocin on Metacognitive Deficits in Schizophrenia: A Pharmacological - Imaging Genetics Study[NCT04158167]		90 participants (Actual)	Interventional	2013-09-01	Completed
A Randomized Trial to Determine the Best Strategy for the Control of Blood Loss at Elective Caesarean Section[NCT01412073]	Phase 3	600 participants (Actual)	Interventional	2011-09-30	Completed
Carbetocin Versus Oxytocin Plus Misoprostol in Decreasing Intraoperative Blood Loss in Women Undergoing Planned Cesarean Section[NCT05664659]	Phase 4	90 participants (Actual)	Interventional	2022-12-20	Completed
Evaluation of Tolerance, Suckling and Food Intake After Repeated Nasals Administrations of Oxytocin in PWS Infants[NCT02205034]	Phase 1/Phase 2	18 participants (Actual)	Interventional	2013-05-31	Completed
"The Effects of Oxytocin on Patients With Borderline Personality Disorder"[NCT01243658]		138 participants (Actual)	Interventional	2011-01-31	Completed
Does Induction Dosage in Latent Phase Affect Active Phase of Labor?A Randomized Study[NCT03742531]	Phase 2	300 participants (Actual)	Interventional	2018-12-15	Completed
Phase 4 Study of Oxytocin Used During Cesarean Section[NCT00777166]	Phase 4	103 participants (Actual)	Interventional	2005-12-31	Completed
Effects of Oxytocin on Hemodynamics in Patients Undergoing Laparoscopic Myomectomy[NCT04109339]		80 participants (Anticipated)	Interventional	2019-05-01	Recruiting
Prophylactic Ergonovine-Oxytocin Versus Oxytocin During Cesarean Delivery Following Failure to Progress in Labour[NCT00481533]		47 participants (Actual)	Interventional	2005-06-30	Completed
Carbetocin Versus Oxytocin for Prevention of Postcesarean Hemorrhage in Pregnant Women With High Risk Postpartum Hemorrhage: a Randomized Controlled Trial[NCT04089176]	Early Phase 1	120 participants (Actual)	Interventional	2019-02-01	Completed
Continued Versus Discontinued Oxytocin Stimulation of Labour in a Double-blind Randomised Controlled Trial[NCT02553226]	Phase 4	1,200 participants (Actual)	Interventional	2016-04-30	Completed
The Effect of Intranasal Administration of Oxytocin on Empathic Abilities of Healthy People and People Who Suffer From Schizophrenia.[NCT00813436]	Phase 2	100 participants (Anticipated)	Interventional	2008-05-31	Recruiting
Randomised Controlled Trial Comparing Continuous Intravenous Oxytocin Infusion With Pulsatile Administration of Intravenous Oxytocin for Augmentation of the First Stage of Labor[NCT02723461]	Phase 4	120 participants (Anticipated)	Interventional	2016-03-31	Recruiting
Changes in Cardiac Output During Cesarean Delivery Under Spinal Anesthesia. A Prospective Observational Study Using Transthoracic Echocardiography[NCT05269537]		60 participants (Actual)	Observational	2022-03-12	Completed
Stepwise Labor Induction Following Failure of Prostaglandin Vaginal Insert for Labor Induction[NCT02684305]	Phase 3	320 participants (Anticipated)	Interventional	2016-04-30	Not yet recruiting
Comparison Between Misopristol and Pitocin After Mifepristone Preparation for Second Trimeter Abortion[NCT00784797]	Phase 4	145 participants (Actual)	Interventional	2009-01-31	Completed
Oxytocin to Enhance Integrated Exposure-Based Treatment of Co-occurring Alcohol Use Disorder and PTSD[NCT04523922]	Phase 2	180 participants (Anticipated)	Interventional	2021-03-29	Recruiting
Comparison Between Adjunctive Sublingual Misoprostol Versus Adjunctive Placebo in the Reduction of Intraoperative Blood Loss During Caesarean Section[NCT05532215]		152 participants (Anticipated)	Interventional	2023-03-14	Recruiting
A Randomized Trial of Active Versus Expectant Management of the Third Stage of Labor[NCT00473707]		218 participants (Actual)	Interventional	2002-08-31	Completed
Impact of Oxytocin on Obstructive Sleep Apnea Induced Changes in Sleep[NCT02564068]	Early Phase 1	8 participants (Actual)	Interventional	2015-05-22	Completed
Mechanisms and Effects of Oxytocin on Social Cognition in Schizophrenia - fMRI[NCT02566356]	Early Phase 1	59 participants (Actual)	Interventional	2012-09-30	Completed
High Dose vs. Low Dose Oxytocin for Labor Induction in Obese Women: a Randomized Controlled Trial - the OPS (Obese Pitocin Study) Trial[NCT03140488]	Phase 4	140 participants (Actual)	Interventional	2017-06-05	Completed
Comparison Between Two Protocols for Management of Prelabor Rupture of the Membranes at Term[NCT04307069]		524 participants (Anticipated)	Interventional	2020-05-01	Not yet recruiting
Comparative Study of Sublingual Misoprostol Versus Oxytocin in Reducing Bleeding at Cesarean Section[NCT02562300]	Phase 2	120 participants (Actual)	Interventional	2014-01-31	Completed
A Phase 2b, Double-blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the 12-week Efficacy of Vagitocin in Postmenopausal Women With Symptoms of Vulvovaginal Atrophy[NCT04629885]	Phase 2	202 participants (Actual)	Interventional	2016-05-03	Completed
A Phase I Dose Finding Study of Intranasal Oxytocin in Frontotemporal Dementia, Protocol # FTDOXY10EF[NCT01386333]	Phase 1	23 participants (Actual)	Interventional	2011-06-30	Completed
Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia[NCT01394471]	Phase 1	68 participants (Actual)	Interventional	2011-07-31	Completed
Accelerate Versus Gradual Titration of Oxytocin Dose for Labour Dystocia: A Pilot Study[NCT01397630]	Phase 3	79 participants (Actual)	Interventional	2012-04-30	Terminated(stopped due to Due to budgetary concerns, the TSC decided it best to adjust sample size as there was sufficient data to assess feasibility. Recruitment was terminated early.)
BMI-Associated Labor Induction: A Prospective Trial[NCT04035382]		82 participants (Anticipated)	Interventional	2019-10-31	Recruiting
The Comparison of the Effect of Different Oxytocin Administrations on the Blood Loss During Cesarean Delivery: a Randomised Controlled Trial[NCT03967171]		101 participants (Actual)	Interventional	2019-05-01	Completed
Oxytocin and Social Behavior Over the Lifespan: Interventional Study[NCT00914953]	Early Phase 1	41 participants (Actual)	Interventional	2010-02-28	Completed
Effects of Intranasal Administration of Oxytocin in Adults With Prader-Willi Syndrome[NCT02804373]	Phase 2/Phase 3	50 participants (Actual)	Interventional	2014-06-30	Completed
Minimum Oxytocin Dose for Cesarean During Labor: Adaptative Clinical Trial[NCT02794779]	Phase 3	64 participants (Anticipated)	Interventional	2016-07-31	Recruiting
Undesired Effects of Carbetocin Compared To Oxytocin Administered As Single Intravenous Dose or Infusion During Cesarean Delivery: A Prospective Randomised Controlled Study[NCT05758012]		260 participants (Anticipated)	Observational	2023-05-01	Not yet recruiting
Nasal Oxcytocin Fails to Increase Pregnancy Rate of IUI[NCT00805662]		86 participants (Actual)	Interventional	2003-05-31	Completed
[NCT02733237]		160 participants (Actual)	Interventional	2015-04-30	Completed
Oxytocin and Brain Reward and Stress Responses to Infant Cues in Addicted Mothers[NCT02979093]	Phase 2	73 participants (Actual)	Interventional	2017-05-05	Terminated(stopped due to Unable to recruit proposed study sample size due to COVID restrictions.)
Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia[NCT01937013]	Phase 2	52 participants (Actual)	Interventional	2013-09-12	Completed
Oxytocin in Adolescents With Autism Spectrum Disorders[NCT02007447]	Phase 2/Phase 3	30 participants (Actual)	Interventional	2015-06-30	Terminated(stopped due to Most of our patients had no willingness to participate in the survey)
[NCT00844350]	Phase 2	177 participants (Actual)	Interventional	2006-10-31	Completed
Carbetocin Versus Syntometrine for Prevention of Postpartum Hemorrhage After Cesarean Section[NCT02044549]	Phase 4	300 participants (Actual)	Interventional	2014-06-30	Completed
A Randomized Trial Comparing Oxytocin and Oxytocin + Ergometrine for Prevention of Postpartum Haemorrhage at Caesarean Section[NCT02046499]		540 participants (Actual)	Interventional	2014-01-01	Completed
Antipsychotic Effects of Oxytocin[NCT01621737]		42 participants (Actual)	Interventional	2011-06-30	Terminated(stopped due to Break in funding)
Comparaison of 3 Protocols of Ocytocin Administration in Cesarean Section[NCT04046510]		180 participants (Actual)	Interventional	2018-09-01	Completed
Oxytocin Treatment of Opioid Dependence[NCT02548728]	Phase 1/Phase 2	12 participants (Actual)	Interventional	2016-02-29	Completed
The Effects of Intranasal Oxytocin on Social Cognition and Social Approach Behaviors in Opioid-dependent Patients[NCT01728909]	Early Phase 1	64 participants (Actual)	Interventional	2012-05-31	Completed
[NCT03011970]	Phase 1	116 participants (Actual)	Interventional	2014-09-30	Completed
Assessment of Pharmacokinetics and Bioavailability of Carbon-14 ([14C])-Labelled Oxytocin[NCT02911480]	Phase 1	0 participants (Actual)	Interventional	2016-04-30	Withdrawn(stopped due to Study/financial issues)
Intravenous Oxytocin Use to Decrease Blood Loss During Cesarean Section. What is the Optimal Dose: A Randomized Blinded Trial[NCT00891150]		200 participants (Anticipated)	Interventional	2012-07-31	Completed
Is Oxytocin Given During Surgical Procedure for Abortion Before 12 Weeks of Pregnancy Useful ?[NCT00540748]		400 participants (Anticipated)	Interventional	2007-10-31	Completed
An Open Label Pilot Study of Intranasal Oxytocin for Methamphetamine Withdrawal in Women[NCT05760807]		10 participants (Anticipated)	Interventional	2023-03-29	Recruiting
Evaluation of the Effect of the Oxytocin Administered in Nasal Pulverizing on the Social Skills, the Stress, the Anxiety and the Eating Habits at Grown-up Patients Presenting a Syndrome of Prader-Willi: Pilot Study[NCT01038570]	Phase 2	24 participants (Actual)	Interventional	2009-06-30	Completed
A Randomized, Double-blind, Placebo-controlled Single-center Study on the Influence of Oxytocin on the Startle Reflex and on Its Modulation in Healthy Male Subjects[NCT01066299]		50 participants (Anticipated)	Interventional	2010-05-31	Recruiting
The Efficacy of the Proximate Administration of Oxytocin After a Traumatic Event in Preventing the Development of Post Traumatic Stress Disorder[NCT01039766]		24 participants (Anticipated)	Interventional	2010-02-28	Recruiting
Elective Induction of Nulliparous Labor: A Randomized Clinical Trial[NCT01076062]		200 participants (Anticipated)	Interventional	2010-02-28	Recruiting
Adjuvant Use of Misoprostol and Oxytocin vs. Carbetocin for the Prevention of Post-partum Hemorrhage in Elective Cesarian Section[NCT02786992]	Phase 2/Phase 3	600 participants (Actual)	Interventional	2016-05-31	Completed
The Effect of Intranasal Oxytocin on Emphatic Abilities in Patients With PTSD[NCT01325168]	Phase 4	62 participants (Actual)	Interventional	2011-08-31	Completed
The Effect of Oxytocin on Placebo Analgesia: an Experimental Study in Healthy Volunteers Using a Double-blind Design[NCT01886014]		80 participants (Actual)	Interventional	2012-01-31	Completed
Phase 1 Study of Intranasal Oxytocin on Parents' Behavioral and Physiological Responses to Children With Autism[NCT01912378]	Phase 1	0 participants (Actual)	Interventional	2013-08-31	Withdrawn(stopped due to unable to launch the study due to lack of participation with Autism Clinic)
Administration of Oxytocin Via Intramuscular Injection and Intravenous Bolus or Intravenous Infusion in the Third Stage of Labor for Prevention of Postpartum Hemorrhage[NCT01914419]		4,983 participants (Actual)	Interventional	2014-04-30	Completed
A Randomized, Controlled Trial of Intranasal Oxytocin as an Adjunct to Behavioral Therapy for Autism Spectrum Disorder[NCT01914939]	Phase 2	92 participants (Actual)	Interventional	2014-04-30	Completed
The Effects of Social Support and Oxytocin Administration on Physiological Stress Reactivity in Essential Hypertension[NCT01938911]		16 participants (Actual)	Interventional	2014-11-30	Terminated(stopped due to PI moved away from Bern; lack of personnel in Bern to conduct the study within a reasonable time frame.)
Intranasal Oxytocin for Treatment of Infants and Children With Prader-Willi Syndrome in Nutritional Phase 1a - Phase 2 Study[NCT03245762]	Phase 1/Phase 2	15 participants (Actual)	Interventional	2017-08-01	Completed
[NCT01939639]	Phase 1	40 participants (Actual)	Interventional	2013-03-31	Completed
Physiologic Correlates of Perceived [Therapist] Empathy and Social-Emotional Process During Psychotherapy: Testing Oxytocin in a Cross-Over Design Pilot Study[NCT01081249]	Phase 4	18 participants (Actual)	Interventional	2008-12-31	Completed
Effects of Different Oxytocin Infusions on Blood Loss and Postpartum Hemoglobin Values in Patients Undergoing Elective Cesarean Delivery[NCT01932060]	Phase 3	51 participants (Actual)	Interventional	2013-08-31	Completed
Brain Imaging and Eye-tracking in Response to Intranasal Oxytocin Treatment in Children and Adolescents With Autism[NCT01945957]	Phase 1	33 participants (Actual)	Interventional	2014-09-30	Completed
When and How to Administer Oxytocin for Active Management of Third Stage of Labour[NCT01954186]		600 participants (Actual)	Interventional	2010-01-31	Completed
A Pharmacokinetic Study of Vaginally and Intravenously Administered Oxytocin in Postmenopausal Women With Vaginal Atrophy[NCT01975129]	Phase 2	12 participants (Actual)	Interventional	2013-09-30	Completed
Intranasal (Optinose Bidirectional Nose-to-brain Device) Versus Intravenous Slow Infusion of Oxytocin - a Randomized, Placebo- Controlled Double-blind, Double-dummy 4-period Cross-over Study in Healthy Adult Volunteers Evaluating Brain Functional Magnetic[NCT01983514]	Phase 1	19 participants (Actual)	Interventional	2013-10-31	Completed
A Double-blind, Placebo Controlled Single Centre Trial to Evaluate the Dose-relationship of the Effects of Vaginally Administered Oxytocin on the Vaginal Mucosal Membrane in Postmenopausal Women With Vaginal Atrophy[NCT01987804]	Phase 2	64 participants (Actual)	Interventional	2012-01-31	Completed
The Effect of Intranasal Oxytocin on Pain Sensitivity and Threshold: A Randomized, Double Blinded, Crossover Volunteer Study[NCT01988649]		0 participants (Actual)	Interventional	2015-04-30	Withdrawn(stopped due to Duplicate Study)
Comparing Preoperative Vaginal Misoprostol, Intraoperative Oxytocin Infusion, Intravenous Carbetocin and Pericervical Hemostatic Tourniquet in Reducing Blood Loss During Abdominal Myomectomy, a Randomized Controlled Trial[NCT04595812]	Phase 4	120 participants (Anticipated)	Interventional	2020-11-01	Not yet recruiting
Social Safety Learning in the Brain Oxytocin System[NCT05968651]	Phase 2	120 participants (Anticipated)	Interventional	2023-06-26	Recruiting
The Effects of Oxytocin on Complex Social Cognition in Autism Spectrum Disorders[NCT01183221]	Phase 2	30 participants (Actual)	Interventional	2010-06-18	Completed
Oxytocin Trial in Prader-Willi Syndrome[NCT02013258]	Phase 1	24 participants (Actual)	Interventional	2015-03-31	Completed
Pilot Test of Intranasal Oxytocin as an Enhancer of Brief Couples Therapy for PTSD[NCT05207436]	Phase 2	20 participants (Actual)	Interventional	2022-01-17	Completed
Chronic Intranasal Oxytocin as an Adjunct to Methadone Maintenance Treatment in Patients With Co-occuring Opioid Use Disorder and Cocaine Use: A 2-week Pilot Study[NCT02028533]	Phase 1	30 participants (Actual)	Interventional	2014-07-31	Completed
Effects of Prosocial Neuropeptides on Human Brain Function in Healthy Volunteers and Individuals With Autism Spectrum Disorders[NCT01093768]	Phase 1	38 participants (Actual)	Interventional	2010-02-19	Completed
Outpatient Labor Induction With the Transcervical Foley Balloon: A Randomized Trial Comparing Outpatient Immediate Removal Foley Versus Standard Inpatient Foley Induction[NCT02210598]		64 participants (Anticipated)	Interventional	2014-03-31	Recruiting
Oxytocin vs. Prostaglandin for Induction of Labor in Primiparas With Prelabor Rupture of Membrane and Low Bishop Score: Randomized Control Study[NCT02801227]	Phase 4	68 participants (Anticipated)	Interventional	2016-09-30	Not yet recruiting
Effects of Oxytocin and Vasopressin on Moral Decision Making[NCT04890470]		180 participants (Actual)	Interventional	2021-03-02	Completed
Neuropeptides and Social Behavior[NCT01680718]	Early Phase 1	160 participants (Actual)	Interventional	2012-10-31	Completed
Double-blind, Placebo-controlled, Randomized Study: Oxytocin Modulation of Startle Reactivity to Social Stimuli and Moral Decision Making[NCT01607970]	Phase 1	80 participants (Actual)	Interventional	2011-08-31	Completed
In Vitro Myometrial Contractions in Laboring and Non-laboring Women: Oxytocin is Superior to Other Uterotonic Agents[NCT01689311]		53 participants (Actual)	Interventional	2009-03-31	Completed
A Randomized Double Blind Comparison of Atosiban in Patients With Repeated Implantation Failure Undergoing IVF Treatment[NCT02893722]	Phase 1	200 participants (Anticipated)	Interventional	2017-01-31	Not yet recruiting
The Impact of Spinal Anesthesia and Use of Oxytocin on Fluid Absorption in Patients Undergoing Operative Hysteroscopy; Results From a Prospective Controlled Study[NCT04328870]		88 participants (Actual)	Interventional	2018-05-20	Completed
The Effects of Intranasal Oxytocin on Mixed HIV Sero-status, Methamphetamine-using Men Who Have Sex With Men[NCT02881177]	Phase 1	48 participants (Actual)	Interventional	2017-01-31	Completed
Oxytocin Vs Carbetocin at Cesarean Delivery in Women With Morbid Obesity: Double-blind, Randomised Control, Non-inferiority Trial[NCT04902729]		48 participants (Actual)	Interventional	2021-07-20	Completed
The Effect of Oxytocin on Gastric Emptying in Patients With Gastro Paresis[NCT00776360]	Early Phase 1	12 participants (Actual)	Interventional	2008-12-31	Completed
Oxytocin in Alcohol Use Disorder: A Novel and Translational Approach[NCT02711189]	Phase 1	0 participants (Actual)	Interventional	2016-03-08	Withdrawn
The Neural Mechanisms Associated With Alcohol and Cigarette Craving in Alcohol Use Disorder Smokers During Oxytocin Treatment[NCT04071119]	Phase 1	55 participants (Anticipated)	Interventional	2020-11-09	Recruiting
Oxytocin Versus Oral Misoprostol for Induction of Labor in Pregnant Women With Term Prelabor Rupture of Membranes[NCT05215873]	Phase 4	200 participants (Actual)	Interventional	2021-02-01	Completed
Oxytocin Treatment of Alcohol Withdrawal[NCT01212185]	Phase 1	14 participants (Actual)	Interventional	2010-07-31	Completed
The Biology of Resilience: Oxytocin, Social Relationships and Health[NCT01011465]		270 participants (Actual)	Interventional	2009-02-28	Completed
The Effect of Coadministration of Oral Propranolol to Oxytocin on Induction of Labor[NCT02702674]	Phase 3	242 participants (Anticipated)	Interventional	2015-12-31	Recruiting
The Efficacy and Safety of Preoperative Intravenous Tranexamic Acid Versus Sublingual Misoprostol in Reducing Blood Loss During and After Elective Cesarean Section Among High Risk Pregnant Cases.[NCT04117243]	Phase 2	345 participants (Anticipated)	Interventional	2020-01-20	Recruiting
Intranasal Oxytocin for the Treatment of Children and Adolescents With Autism Spectrum Disorders (ASD)[NCT01256060]	Phase 2	15 participants (Actual)	Interventional	2010-11-30	Completed
To Study the Effectiveness and Safety of Oxytocin Induction in Full Term Pregnant Women With Cesarean Section of Prelabor Rupture of Membranes: a Multi-center, Prospective, Observational Study[NCT05333731]		528 participants (Anticipated)	Observational	2022-03-30	Recruiting
Early Usage of Bakri Postpartum Ballon is More Effective for the Management of Postpartum Hemorrhage[NCT02861482]		472 participants (Actual)	Interventional	2015-01-31	Completed
Influence of Oxytocin on Approach-avoidance Tendencies to Social and Non-social Stimuli[NCT04443647]		64 participants (Actual)	Interventional	2018-12-15	Completed
Carbetocin at Elective Cesarean Delivery: A Dose Finding Study (Part 2)[NCT01428817]		120 participants (Actual)	Interventional	2011-06-30	Completed
A Double-blind, Placebo Controlled Multi-centre Study to Evaluate the Effects of Topical Oxytocin on Vaginal Atrophy in Postmenopausal Women[NCT01432470]	Phase 2	74 participants (Anticipated)	Interventional	2010-08-31	Completed
Acute and Long-term Effects of Intranasal Oxytocin in Alcohol Withdrawal and Dependence: A Prospective Randomized Parallel Group Placebo-controlled Trial[NCT02903251]	Phase 3	40 participants (Actual)	Interventional	2016-10-31	Completed
Intracervical Catheters for Induction of Labour in Women With Prelabour Rupture of Membranes at Term: A Pilot Study.[NCT00890630]	Phase 2	5 participants (Actual)	Interventional	2010-04-30	Terminated(stopped due to Inadequate Patient Recruitment.)
[NCT02740101]	Early Phase 1	62 participants (Actual)	Interventional	2014-11-30	Completed
The Differential Effects of Intranasal Vasopressin and Oxytocin on Attention Control[NCT04715737]		160 participants (Actual)	Interventional	2017-12-19	Completed
A RCT in Sweden of Acupuncture and Care Interventions for the Relief of Inflammatory Symptoms of the Breast During Lactation[NCT00405158]		210 participants	Interventional	2002-01-31	Completed
Safety and Efficacy of Misoprostol Versus Oxytocin for Prevention of Post Partum Hemorrhage[NCT01863706]	Phase 1	400 participants (Anticipated)	Interventional	2013-05-31	Completed
In-vitro Myometrial Contractility After Oxytocin Pre-exposure in Women With Advanced Maternal Age and Morbid Obesity[NCT01865669]		44 participants (Actual)	Interventional	2013-05-31	Completed
Comparison of Intravenous Ergonovine With Intramuscular Carboprost, Both in Combination With Oxytocin Infusion, During Cesarean Section for Failure to Progress in Labor: A Double-blinded Placebo-controlled Randomized Controlled Trial[NCT01869556]		105 participants (Actual)	Interventional	2013-06-04	Completed
The Effects of Oxytocin on Social Touch: an fNIRS-based Study[NCT05265806]		180 participants (Actual)	Interventional	2021-09-01	Completed
Labour Outcomes With Partograph Action Line Placement at 2 Hour Versus 4 Hours: A Randomised Controlled Trail[NCT02911272]		640 participants (Actual)	Interventional	2008-04-30	Completed
Early Versus Late Amniotomy Following EAB Cervical Ripening - Does Parity Matter?[NCT04216628]		146 participants (Actual)	Interventional	2020-02-10	Terminated(stopped due to Study was terminated due to difficulties in recruitment)
A Study of Oxytocin Pharmacokinetics After Intravenous Administration in Healthy Subjects and Advanced Knee Arthritis Subjects[NCT04429880]	Phase 2	0 participants (Actual)	Interventional	2023-01-31	Withdrawn(stopped due to Study was not initiated; no subjects enrolled. A replacement study will be submitted)
Comparison of Direct and Indirect Effects of Intranasal Oxytocin Using Co-administration With a Vasoconstrictor[NCT04134663]		96 participants (Actual)	Interventional	2019-03-02	Completed
Hemodynamic Effects of Carbetocin 100 µg, Oxytocin 5 U or Placebo After Cesarean Delivery Under Spinal Anesthesia in Healthy Pregnant Women.[NCT00977769]	Phase 4	76 participants (Actual)	Interventional	2009-11-30	Completed
Carbetocin Versus Combined Oxytocin and Misoprostol for Prevention of Postpartum Hemorrhage in Women With Severe Preeclampsia[NCT04756661]		124 participants (Actual)	Interventional	2020-01-01	Completed
The Effects of Oxytocin on Couples Conflict Resolution Interactions[NCT02941692]	Phase 2	66 participants (Actual)	Interventional	2014-06-30	Completed
Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress[NCT02742532]	Phase 2	63 participants (Actual)	Interventional	2017-04-20	Completed
[NCT03085628]		252 participants (Anticipated)	Interventional	2016-07-31	Recruiting
Influence of Oxytocin on Neurophysiological Responses to Direct and Averted Gaze[NCT03272321]	Phase 1/Phase 2	56 participants (Actual)	Interventional	2017-07-24	Completed
Carbetocin Versus Syntometrine for the Third Stage of Labour Following Vaginal Delivery - A Double-blind Randomised Trial[NCT00499005]	Phase 4	720 participants (Anticipated)	Interventional	2006-11-30	Completed
Oxytocin Treatment of Social Deficits and Paranoia in Schizophrenia[NCT01028677]		17 participants (Actual)	Interventional	2009-11-30	Completed
Evaluating Potential Benefits of Intranasal Oxytocin on Undersea Operator Training and Performance: Hyperoxic Swim-Induced Oxidative Stress and Inflammation[NCT04732247]	Phase 2	40 participants (Anticipated)	Interventional	2021-07-01	Not yet recruiting
Reducing Neonatal Morbidity by Discontinuing Oxytocin During the Active Phase of 1st Stage of Labor: a Multicenter Randomized Controlled Trial[NCT03991091]	Phase 4	2,459 participants (Actual)	Interventional	2020-01-17	Completed
Double-blind, Placebo-controlled, Randomized Study: Oxytocin and OXTR-genotypes Influence Behavioral and Neural Social Reactions[NCT01606462]	Phase 1	153 participants (Actual)	Interventional	2011-06-30	Completed
Oral Oxytocin Modulation of Brain and Behavioral Responses to Emotional Stimuli in Healthy Men[NCT04320706]		80 participants (Anticipated)	Interventional	2020-02-20	Recruiting
A Comparative Study Between Preoperative and Postoperative Rectal Misoprostol in the Reduction of Blood Loss During and After Elective Cesarean Section : A Double Blinded Randomized Controlled Trial[NCT06049160]		128 participants (Anticipated)	Interventional	2023-08-31	Recruiting
Role of Local Skin Incision Infiltration by Oxytocin On Wound Healing of Caesarean Section Scar in Primiparous Women A Double Blind Randomized Controlled Study[NCT05745935]		120 participants (Anticipated)	Interventional	2023-03-01	Recruiting
Computational Modeling of Oxytocin in the Regulation of Trust[NCT01834261]	Phase 1	51 participants (Actual)	Interventional	2013-04-30	Completed
Monitoring the Influence of Oxytocin on Socio-communicative Sensitivity Using Fast Periodic Visual Stimulation[NCT03096249]	Phase 1/Phase 2	31 participants (Actual)	Interventional	2016-11-21	Completed
Effects of Intranasal Oxytocin and Induced Stress on People's Belief Updating[NCT03597893]		131 participants (Actual)	Interventional	2016-12-27	Completed
Oxytocin Effects on Cytokines and Endocrine Parameters After LPS Induced Systemic Inflammatory Effects in Healthy Volunteers[NCT00360048]		10 participants	Observational	2006-08-31	Completed
The Relaxant Effect of Nitroglycerin on Oxytocin Desensitized Human Myometrium and the Return of Contractility on Re-exposure to Oxytocin- an in Vitro Study[NCT03408054]		17 participants (Actual)	Interventional	2018-01-03	Completed
A Randomized Double-blind Comparison of a 5 Unit Intravenous Oxytocin Bolus Versus Placebo as a Strategy to Prevent Uterine Atony at Cesarean Section in Women Who Are at Increased Risk of Post-Partum Hemorrhage[NCT00257803]		150 participants (Actual)	Interventional	2005-11-30	Completed
The Use of Oxytocin as Adjunctive Therapy for the Treatment of Schizophrenia: a Randomized, Double Blind Trial[NCT01699997]	Phase 2	32 participants (Actual)	Interventional	2014-01-31	Completed
An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders[NCT01931033]		8 participants (Actual)	Interventional	2013-10-31	Completed
Pharmacokinetics and Pharmacodynamics of Oxytocin in Cesarean Delivery[NCT05488457]	Phase 2	100 participants (Anticipated)	Interventional	2024-01-01	Not yet recruiting
Oxytocin Maintenance Infusion in Labouring Women Undergoing Cesarean Delivery: an Up-down Sequential Allocation Study[NCT05290129]		30 participants (Anticipated)	Interventional	2022-08-17	Recruiting
Effect of Oxytocin on Stress Response in Marijuana-dependent Individuals[NCT01335789]		16 participants (Actual)	Interventional	2011-03-31	Completed
Randomized Study to Compare the Cook Cervical Ripening Balloon (CRB) Plus Pitocin to Pitocin Alone in Premature Rupture of Membranes (PROM) Patients[NCT01736852]		129 participants (Actual)	Interventional	2012-11-30	Completed
The Developmental Origins of Endometriosis[NCT05951452]		40 participants (Anticipated)	Observational	2023-10-01	Recruiting
The Effects of Intranasal Oxytocin on Social Touch: an fMRI-based Study[NCT03278860]		50 participants (Anticipated)	Interventional	2017-08-28	Recruiting
Oxytocin Treatment for Chronic Pain in Hypermobile Ehlers-Danlos Syndrome[NCT05405257]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2022-05-13	Recruiting
Investigating the Effect of Extracellular Calcium on Oxytocin-induced Human Myometrial Contractility In-vitro[NCT02274454]		41 participants (Actual)	Interventional	2014-11-30	Completed
Effects of Vaginal Oxytocin Gel on Vaginal Cytologic Parameters in Postmenopausal Woman: A Randomized Placebo-controlled Trial[NCT05627791]	Phase 2/Phase 3	6 participants (Actual)	Interventional	2022-11-30	Terminated(stopped due to Unable to recuit participant number in time.)
Oxytocin Effects on Food Motivation Pathways[NCT02276677]	Early Phase 1	10 participants (Actual)	Interventional	2014-10-31	Completed
Intravenous Versus Intramuscular Administration of Oxytocin and Its Relationship With Postpartum Bleeding and Other Clinical Signs: a Randomized Placebo-controlled Study[NCT02954068]	Phase 4	543 participants (Actual)	Interventional	2016-12-01	Completed
A Prospective, Randomized Trial of Transcervical Foley Catheter With or Without Oxytocin for Preinduction Cervical Ripening[NCT00468520]		200 participants (Actual)	Interventional	2003-11-30	Completed
Association Between Time of Oxytocin Initiation at 2nd Stage of Labor and Adverse Outcomes[NCT06181396]		120 participants (Anticipated)	Interventional	2023-10-01	Recruiting
Comparison of the Effectiveness of 3 Different Dose Regimens of Oxytocin in Preventing Uterine Atony and Postpartum Hemorrhage During Vaginal Delivery[NCT00790062]	Phase 4	1,798 participants (Actual)	Interventional	2008-11-30	Completed
Trait Anxiety Modulates Resting State Functional Connectivity of Defensive Networks[NCT02682888]		131 participants (Actual)	Interventional	2015-12-08	Completed
Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia?[NCT01312272]		24 participants (Actual)	Interventional	2011-04-30	Completed
Promoting Social Perceptual Learning With Oxytocin in Autism[NCT01417026]	Phase 2	36 participants (Actual)	Interventional	2011-09-30	Completed
Can Cooling the Uterus During Cesarean Delivery Reduce Blood Loss, Reduce Drug Use, and Decrease the Risk for Hysterectomy in Women With Dysfunctional Labor?[NCT02910115]		100 participants (Anticipated)	Interventional	2016-09-30	Enrolling by invitation
A Pilot Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder[NCT02985749]	Phase 3	7 participants (Actual)	Interventional	2017-10-09	Completed
Compare Efficacy of Oxytocin Administrations on Postpartum Uterine Contractility[NCT02908126]	Phase 1	4 participants (Actual)	Interventional	2018-04-03	Terminated(stopped due to No approval CA (MPA) of protocol amendment)
[NCT02859571]	Phase 2	200 participants (Anticipated)	Interventional	2016-08-31	Recruiting
Effects of Oxytocin Nasal Inhalation and Social Familiarity on Empathy Analgesia: a Factorial Randomized Controlled Trial[NCT05823441]	Phase 4	120 participants (Anticipated)	Interventional	2023-07-15	Not yet recruiting
Clinical Outcomes of Bilateral Uterine Artery Ligation During the Cesarean Delivery of Twins: A Randomized Controlled Trial[NCT04518176]		400 participants (Anticipated)	Interventional	2020-09-01	Recruiting
Effects of MDMA on Social and Emotional Processing[NCT01849419]		65 participants (Actual)	Interventional	2010-07-31	Completed
Effect of Intranasal Oxytocin on Appetite and Caloric Intake in Humans[NCT01513499]	Early Phase 1	25 participants (Actual)	Interventional	2012-01-31	Completed
Pharmacological Approach to Improve the Outcome of Social Cognition Training[NCT01517360]	Phase 1	27 participants (Actual)	Interventional	2012-01-31	Completed
Balloon + Oxytocin Versus Oral Misoprostol to Induce Labor in Case of Premature Rupture of Membranes (PROM) at Term in Nulliparous: a Randomized Controlled Trial (RUBAPRO2).[NCT05568745]	Phase 4	520 participants (Anticipated)	Interventional	2023-01-18	Recruiting
Randomised Study on Cardiac Effects of Oxytocin During Caesarean Section in Preeclamptic Women[NCT01530230]		25 participants (Actual)	Interventional	2005-11-30	Completed
A Randomized Double-blinded Controlled Trial Comparing Dilation and Evacuation Outcomes With and Without Oxytocin Use[NCT02083809]		166 participants (Actual)	Interventional	2014-10-31	Completed
Open-label Study of the Long-Term Efficacy of Intranasal Oxytocin in Patients With Schizophrenia[NCT02144155]		14 participants (Actual)	Interventional	2012-03-31	Terminated(stopped due to Break in funding)
Tolerance of Intranasal Administration of OT in Prader-Willi Newborn Babies and Effect on Suck and Food Intake.[NCT01548521]	Phase 1/Phase 2	5 participants (Actual)	Interventional	2011-07-31	Completed
Misoprostol for the Treatment of Primary Postpartum Hemorrhage[NCT00116350]		1,786 participants (Actual)	Interventional	2005-07-31	Completed
Foley With Oxytocin Versus Foley no Oxytocin for Induction of Labor (NOFOX): a Randomized Control Trial[NCT02273115]	Phase 4	323 participants (Actual)	Interventional	2014-10-31	Completed
Foley Catheter Versus Oxytocin for Labor Induction in Women With Term and Near Term Premature Rupture of Membranes: A Randomized Clinical Trial (FOLCROM Trial)[NCT01973036]		201 participants (Actual)	Interventional	2014-03-31	Completed
Premature Rupture of Membranes at Term With an Unfavorable Cervix (Bishop Score<6): Comparison of Oxytocin, Dinoprostone Induction and Expectant Management[NCT02825641]		458 participants (Actual)	Interventional	2016-08-01	Completed
The Effect of Oxytocin on Fear Memory Consolidation: A Novel Intervention to Prevent PTSD[NCT01466127]		60 participants (Actual)	Interventional	2011-10-31	Completed
Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations[NCT02149823]	Phase 1	92 participants (Actual)	Interventional	2013-09-30	Terminated(stopped due to All study proceedings stopped prematurely due to Covid-19 restrictions for intranasal formulations)
A Randomized, Control Trial for Preinduction Cervical Ripening[NCT00393731]	Phase 2	540 participants (Anticipated)	Interventional	2004-01-31	Completed
Uterine Electromyography for Estimation of Uterotonic Efficiency for Postpartum Hemorrhage Prevention[NCT04201665]		60 participants (Actual)	Interventional	2020-09-13	Completed
The Effect of Oxytocin Administration on Interpersonal Cooperation in Borderline Personality Disorder Patients and Healthy Adults: A Pilot Behavioral Study[NCT02225600]		40 participants (Anticipated)	Interventional	2014-08-26	Recruiting
Effect of Intra-venous Oxytocin Injection After Fetal Expulsion in Management of Third-stage of Labor After Second Trimester Medical Pregnancy Termination[NCT02969447]	Phase 4	27 participants (Anticipated)	Interventional	2016-10-20	Completed
[NCT02963194]		44 participants (Actual)	Interventional	2015-11-30	Completed
Effect of Oxytocin on Pro-Social Behavior in Social Anxiety Disorder[NCT01856530]	Phase 1/Phase 2	60 participants (Actual)	Interventional	2012-07-31	Completed
The Effects of Orally Administered Oxytocin on Behavioral and Neural Responses to Self Versus Other Touch Distinction[NCT05899517]		40 participants (Anticipated)	Interventional	2022-06-22	Recruiting
A Phase 2, Double-blind, Randomized, Multicenter, Placebo-controlled, Three Arm Parallel Study to Evaluate the Efficacy and Safety of TNX-1900 (Intranasal Oxytocin) in Patients With Chronic Migraine (PREVENTION Study)[NCT05679908]	Phase 2	88 participants (Actual)	Interventional	2022-12-06	Active, not recruiting
A Phase 2b, Double-blind, Randomized, Parallel, Placebo-Controlled, Multiple-Dose Study to Evaluate the 12-week Efficacy of Vagitocin in Postmenopausal Women With Symptoms of Vaginal Atrophy[NCT02497547]	Phase 2	227 participants (Actual)	Interventional	2014-10-31	Completed
Investigating the Impact of Oxytocin on Irritability/Emotional Dysregulation in Children and Adolescents With Disruptive Behavior and Mood Disorders, and the Possible Mediating Role of Amygdala Activity[NCT02824627]	Phase 2	58 participants (Actual)	Interventional	2017-01-27	Completed
Neurobiological Effects of Oxytocin on Social Decision Making in Schizophrenia: A Pharmacological MRI Study[NCT04176835]		55 participants (Actual)	Interventional	2016-04-30	Completed
The Role of Antibiotic Prophylaxis in Immediate Versus Delayed Induction in Term-PROM - a Randomized Controlled Trial[NCT02985086]		568 participants (Anticipated)	Interventional	2013-07-31	Recruiting
The Association of Affective Resonance With Empathy Modulated by Negative Symptomatology and Oxytocin[NCT05247151]		41 participants (Actual)	Interventional	2021-08-02	Completed
In-vitro Study to Assess the Coagulation Effects of Exogenous Oxytocin Using Thromboelastography.[NCT00788255]		25 participants (Actual)	Observational	2008-10-31	Completed
A Randomized Double Blind Clinical Trial Comparing Oxytocin Low-dose and High-dose Regimens for Labor Augmentation[NCT02487797]	Phase 4	1,003 participants (Actual)	Interventional	2015-09-28	Completed
Role of Oxytocin in the Second Stage of Labor: a Randomized Controlled Trial (The ROSSoL Trial)[NCT04303702]		400 participants (Anticipated)	Interventional	2022-07-01	Recruiting
Oxytocin and Social Cognition in Schizophrenia[NCT00884897]	Phase 2	28 participants (Actual)	Interventional	2010-01-31	Completed
Psychophysiology of Delayed Extinction and Reconsolidation in Humans[NCT01631682]	Phase 4	186 participants (Actual)	Interventional	2010-11-30	Completed
Intramuscular Versus Intravascular Oxytocin for the Third Stage of Labour[NCT00200252]	Phase 4	300 participants (Actual)	Interventional	2005-09-30	Completed
Tranexamic Acid Plus Oxytocin Versus Oxtocin Only in Reducing Blood Loss After Cesarean Section[NCT04549012]	Early Phase 1	130 participants (Anticipated)	Interventional	2020-09-30	Not yet recruiting
Study IVF116828:A Multi-Cohort Phase I Study to Investigate the Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban (GSK557296) in Healthy Female Volunteers During Control and Challenge States With and Without Oxytocin[NCT02213029]	Phase 1	33 participants (Actual)	Interventional	2014-08-28	Terminated
Intramuscular Oxytocics: A Randomised Control Trial of Intramuscular Carbetocin, Syntocinon and Syntometrine for the Third Stage of Labour Following Vaginal Birth[NCT02216383]	Phase 3	5,798 participants (Actual)	Interventional	2015-02-28	Completed
Effects of Oxytocin on the Functional Architecture of the Brain Before and After Prolonged Naturalistic Fear Induction[NCT05896553]		60 participants (Anticipated)	Interventional	2023-05-29	Recruiting
Mechanisms Underlying Oxytocin's Analgesia in Older Adults[NCT03878589]	Phase 2/Phase 3	370 participants (Anticipated)	Interventional	2019-08-06	Recruiting
An fMRI Study of the Effect of Intravenous Oxytocin vs. Placebo on Response Inhibition and Face Processing in Autism[NCT00263796]	Phase 1	16 participants (Actual)	Interventional	2006-03-31	Completed
Carbetocin vs. Oxytocin: In-vitro Myometrial Contractions With and Without Oxytocin Pre-treatment[NCT01689298]		20 participants (Actual)	Interventional	2010-01-31	Completed
Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial[NCT01600612]		300 participants (Anticipated)	Interventional	2012-09-30	Recruiting
POM PROM: Pitocin or Oral Misoprostol for PROM IOL in Nulliparous Women With Unfavorable Cervical Exams[NCT04028765]	Phase 4	108 participants (Actual)	Interventional	2019-08-12	Completed
An Alongside Qualitative Study Exploring Patients' and Health Care Professionals' Expectations and Experiences of Labour Induction With Misoprostol and Oxytocin for Hypertension in Pregnancy in India[NCT04037683]		136 participants (Actual)	Observational	2019-10-18	Completed
Different Protocols for Prevention of Atonic Postpartum Hemorrhage During Cesarean Delivery in High Risk Group[NCT05099575]		448 participants (Anticipated)	Observational	2021-10-30	Not yet recruiting
Placebo-Controlled Study of the Effects of Oxytocin on Attentional Bias and Startle in PTSD[NCT03211013]	Early Phase 1	17 participants (Actual)	Interventional	2017-07-10	Completed
Carbetocin Versus Oxytocin for Prophylaxis Against Atonic Primary Post-partum Hemorrhage in High-risk Patients in Sohag University Hospital: A Randomized Controlled Clinical Trial[NCT05479357]		80 participants (Anticipated)	Interventional	2022-07-28	Not yet recruiting
Comparison of Two Doses of Carbetocin for Prevention of Uterine Atony During Elective Cesarean Section: a Randomized Controlled Trial[NCT01630187]	Phase 4	72 participants (Actual)	Interventional	2012-04-30	Completed
Neural Correlates of the Empathogenic and Affiliative Actions of Oxytocin[NCT01701180]	Early Phase 1	23 participants (Actual)	Interventional	2012-08-31	Completed
Preventing Postpartum Hemorrhage: Examining Two Strategies for PPH Prevention in Communities: Misoprostol and Oxytocin in Uniject®[NCT01710566]	Phase 3	0 participants (Actual)	Interventional	2013-07-31	Withdrawn
[NCT01711060]		204 participants (Actual)	Interventional	2010-12-31	Completed
Modulation of Reinforcement Learning and Neuronal Activation in Ventral Stratum by Oxytocin - a Pilot Study at Autism Spectrum Disorder[NCT01712464]		60 participants (Actual)	Interventional	2013-10-18	Completed
The Use of Daily, Intranasal Oxytocin for the Treatment of Childhood-Onset Schizophrenia (COS), a Randomized Double-Blind Trial[NCT01712646]	Phase 1/Phase 2	18 participants (Actual)	Interventional	2012-10-05	Terminated
Comparison of Haemodynamic and Cardiovascular Effects of Carbetocin and Oxytocin in Women Undergoing Elective Caesarean Section: A Double-blinded Randomised Clinical Trial[NCT01719952]		50 participants (Actual)	Interventional	2012-01-31	Completed
[NCT01767025]	Phase 3	60 participants (Actual)	Interventional	2012-11-30	Completed
INtranasal OXyTocin for the Treatment of Autism Spectrum Disorders (ASD)[NCT01788072]	Phase 2	70 participants (Actual)	Interventional	2014-06-30	Completed
[NCT01827124]	Phase 4	140 participants (Anticipated)	Interventional	2013-04-30	Recruiting
Concurrent Oxytocin With Membrane Sweeping Versus Dinoprostone Pessary in Labor Induction of Nulliparas at Term[NCT02416583]		140 participants (Actual)	Interventional	2015-04-30	Completed
Optimal Timing of Postpartum Oxytocin Administration in the Era of Delayed Cord Clamping - PROCEEDING (PostpaRtum OxytoCin Era dElayed corD clampING) Study[NCT04632264]		104 participants (Actual)	Interventional	2020-12-10	Completed
A Pull to be Close: the Differentiating Effects of Oxytocin and Grief Stimulus Type on Approach Behavior in Complicated Grief[NCT04505904]		44 participants (Actual)	Interventional	2015-03-20	Completed
Randomized, Double Blind, Placebo-Controlled Trial of the Efficacy of Intranasal Oxytocin for the Treatment of Alcohol Use Disorder[NCT03878316]	Phase 2	100 participants (Anticipated)	Interventional	2022-05-05	Recruiting
Multiple Dose Effect of Oxytocin on Males With High or Low Trait Anxiety[NCT03085654]	Early Phase 1	147 participants (Actual)	Interventional	2017-03-03	Completed
Oxytocin-based Pharmacotherapy: Investigating the Effect on Interpersonal Motor Resonance Upon Direct Eye Gaze[NCT03010670]	Phase 4	27 participants (Actual)	Interventional	2016-01-31	Completed
Efficacy of Intrathecal Oxytocin in Human Volunteers[NCT01996605]	Phase 2	20 participants (Actual)	Interventional	2014-01-02	Terminated(stopped due to Cessation of funding period prior to completion, due to slow recruitment during the pandemic)
Oxytocin Infusion vs. Spontaneous Follow-up for Third-stage Management After Second-trimester Abortion: A Randomized Clinical Trial[NCT02485444]	Phase 4	160 participants (Actual)	Interventional	2015-06-08	Completed
Pilot Study of Intranasal Oxytocin and Cardiac Electrophysiology in Humans[NCT01780337]	Early Phase 1	12 participants (Actual)	Interventional	2013-01-31	Completed
Oxytocin Effects on Neural Processing of Affective Touch and Associations With Trait Autism[NCT03282162]		50 participants (Actual)	Interventional	2017-08-28	Completed
Oxytocin as Adjunctive Treatment of Schizophrenia[NCT01568528]	Phase 2	39 participants (Actual)	Interventional	2013-03-31	Completed
The Gender-Sex Hormone Interface With Craving & Stress-Related Changes in Smoking[NCT01576874]		144 participants (Actual)	Interventional	2012-06-30	Completed
Prophylactic Oxytocin Before Versus After Placental Delivery to Reduce Blood Loss in Vaginal Delivery[NCT03006380]	Phase 2	400 participants (Anticipated)	Interventional	2016-08-31	Recruiting
Foley OR MisO for the Management of Induction (FOR MOMI) Trial[NCT01916681]		491 participants (Actual)	Interventional	2013-05-31	Completed
The Modulatory Effect of Oxytocin on Interoception[NCT03074409]		83 participants (Actual)	Interventional	2017-03-02	Completed
Effect of Oxytocin on Stress Response in Cocaine-dependent Individuals[NCT01963091]	Phase 2	33 participants (Actual)	Interventional	2011-07-31	Completed
Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress[NCT02058251]	Phase 1	73 participants (Actual)	Interventional	2014-02-28	Completed
Pharmacokinetics of Intravenous Oxytocin and Effects on Sensory Function in Healthy Volunteers[NCT03929367]	Phase 4	11 participants (Actual)	Interventional	2019-05-10	Completed
Double-Blind, Randomized, Placebo-Controlled, Cross-Over Pilot Study of Intranasal Oxytocin in Patients With Anxiety Disorder[NCT00989937]		17 participants (Actual)	Interventional	2009-02-28	Terminated(stopped due to Break in funding)
Comparing the Effectiveness of Misoprostol, Oxytocin, Carbetocin, Vasopressin, Bupivacaine and Epinephrine, Combined IV TXA Acid and Ethamsylate and Peri Cervical Tourniquet for the Reduction of Blood Loss During of Abdominal Myomectomy.[NCT05806307]	Phase 4	105 participants (Anticipated)	Interventional	2023-03-15	Recruiting
The Modulatory Effect of Oxytocin on Attentional Processing of Emotional Faces[NCT04413786]		60 participants (Actual)	Interventional	2019-10-14	Completed
Effect of a Labor Induction Protocol on Vaginal Delivery Rate[NCT04004845]		66 participants (Actual)	Observational	2021-03-30	Terminated(stopped due to Study was temporarily paused due to COVID19 and ultimately terminated at the discretion of the PI)
Dissecting the Role of Estradiol in Mediating Gender-specific Anxiolytic and Prosocial Effects of Oxytocin[NCT04330677]	Phase 1	487 participants (Actual)	Interventional	2016-09-18	Completed
Cervical Ripening in Premature Rupture of Membranes[NCT02314728]		230 participants (Actual)	Interventional	2014-10-01	Completed
Enhancing Prolonged Exposure Therapy for PTSD With Oxytocin[NCT04228289]	Phase 2	188 participants (Anticipated)	Interventional	2020-11-16	Recruiting
Use of Tranexamic Acid for the Prevention of Postpartum Haemorrhage After Cesarean Section in High-risk Patients ( a Randomized Control Trial ).[NCT04707950]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2020-01-01	Recruiting
Induction of Labor With Oxytocin: When Should Oxytocin be Held?[NCT00957593]		252 participants (Actual)	Interventional	2009-02-28	Completed
Effects of Intranasal Oxytocin on Emotion Regulation to Stressful Interaction in Insecure Adolescents: a Study Protocol for a Double Blind Randomized Controlled Trial[NCT02301715]	Phase 1	29 participants (Actual)	Interventional	2014-04-29	Completed
Carbetocin Versus Oxytocin in the Management of Atonic Post Partum Haemorrhage (PPH) in Women Delivered Vaginally: A Randomised Controlled Trial[NCT02304055]	Phase 3	100 participants (Actual)	Interventional	2013-05-31	Completed
Investigating the Effect of Pulsatile Administration of Oxytocin on the Desensitization of Human Myometrium In-vitro[NCT02338089]		18 participants (Actual)	Interventional	2015-01-31	Completed
Breast Stimulation vs. Low Dose Oxytocin Augmentation for Women With a History of One Prior Cesarean Section Scar and in Grand Multiparas[NCT05510310]	Phase 1/Phase 2	200 participants (Anticipated)	Interventional	2022-10-31	Not yet recruiting
Non-Invasive, Highly Specific Detection of Oxytocin in Biological Fluids[NCT03140709]		28 participants (Actual)	Observational	2016-05-31	Completed
Management of the Third Stage of Labor[NCT02319707]	Phase 3	500 participants (Anticipated)	Interventional	2015-09-30	Not yet recruiting
Spontaneous and Oxytocin-induced Contractility After Exposure to Intravenous Anesthetic Agents: an In-vitro Study in Human Myometrium[NCT03852797]		33 participants (Actual)	Interventional	2019-03-28	Completed
Effect of Intranasal Neuropeptide on Emotion Perception in Trait Anxiety[NCT01551303]		47 participants (Actual)	Interventional	2009-02-28	Completed
Recovery of Oxytocin Responsiveness in Pregnant Human Myometrial Explants After Oxytocin-Induced Desensitization: an In-vitro Analysis of Oxytocin Receptor Expression and Signaling[NCT02762669]		16 participants (Anticipated)	Interventional	2016-08-03	Recruiting
Labor Induction With Misoprostol Versus Oxytocin in Women With Premature Rupture of Membranes[NCT04143685]		200 participants (Anticipated)	Interventional	2019-12-01	Recruiting
The Neural Basis of Oxytocin's Effects on Empathy[NCT03084029]	Early Phase 1	72 participants (Actual)	Interventional	2016-01-31	Completed
Amr Maneuver for Prevention of Postpartum Hemorrhage After Vaginal Delivery in Term Women[NCT04401839]		306 participants (Anticipated)	Interventional	2020-05-31	Recruiting
Effect of Misoprostol in Reducing Post Partum Hemorrhage After Labor Induction by Oxytocin: a Prospective Randomized Controlled Trial[NCT02983591]		300 participants (Actual)	Interventional	2016-11-30	Completed
Affective and Genomic Mediators of Sustained Behavior Change: A Randomized, Dual-blind, Placebo-controlled Experimental Design That Will Examine Wellness Behavior as a Function of Oxytocin vs. Placebo.[NCT01929161]	Phase 1	239 participants (Actual)	Interventional	2013-09-30	Completed
Oxytocin and Naltrexone: Investigation of Combined Effects on Stress- and Alcohol Cue-induced Craving in Alcohol Use Disorder - a Randomized Double-blind Placebo-controlled Parallel-group Trial[NCT05093296]	Phase 2/Phase 3	62 participants (Anticipated)	Interventional	2021-12-02	Recruiting
[NCT01891201]		98 participants (Actual)	Observational [Patient Registry]	2011-03-31	Completed
The Stimulation To Induce Mothers (STIM) Study: A Parallel Group Randomized Controlled Trial[NCT05079841]	Phase 4	988 participants (Anticipated)	Interventional	2021-11-15	Recruiting
Intramyometrial and Intravenous Oxytocin Compared to Intravenous Carbetocin for Prevention of Postpartum Hemorrhage in Elective Cesarean Sections - a Monocentric Randomized Controlled Study[NCT03651882]	Phase 4	550 participants (Actual)	Interventional	2018-08-07	Completed
The Effect of Intranasal Oxytocin on Headache Intensity and Headache-associated Symptoms in Patients Suffering From Chronic Daily Headache[NCT00963040]		60 participants (Actual)	Interventional	2009-11-30	Completed
The Impact of Oxytocin Administration on Short and Long Term Prognosis in Patients Undergoing ST Elevation Myocardial Infarction[NCT03001635]	Phase 2/Phase 3	52 participants (Anticipated)	Interventional	2017-01-31	Not yet recruiting
Exploring the Effects of Oxytocin on Appetite Regulation in Healthy Adult Men[NCT03225456]	Phase 2	60 participants (Anticipated)	Interventional	2017-09-30	Not yet recruiting
Biological Bases of Individual Variation in Paternal Nurturance[NCT02223429]		35 participants (Actual)	Interventional	2014-08-31	Completed
Effects of Oxytocin Administration on Social Influence Effects on Pain[NCT03060031]	Phase 1	51 participants (Actual)	Interventional	2017-06-21	Completed
Oxytocin to Reduce Stress-induced Craving in Individuals With Opioid Use Disorder[NCT04051619]	Phase 1	50 participants (Anticipated)	Interventional	2020-01-06	Recruiting
Does Oxytocin Alter Tolerance to Alcohol or Motivation for Alcohol in Heavy Drinking Human Subjects: Testing a Novel Anti-Addiction Mechanism[NCT05312008]	Phase 2	12 participants (Anticipated)	Interventional	2022-01-16	Recruiting
A Phase 2, Enriched-enrollment, Randomized-withdrawal, Double-blinded, Placebo-Controlled Study to Assess the Efficacy, Tolerability, and Safety of Intranasal Oxytocin in Subjects With Chronic Migraine[NCT01839149]	Phase 2	240 participants (Actual)	Interventional	2013-05-31	Completed
The Effect of Oxytocin on the Acquisition and Consolidation of Trauma-Associated Memories: A Model to Understand the Development of Posttraumatic Stress Disorder[NCT03031405]		220 participants (Actual)	Interventional	2017-01-15	Completed
In Vitro Optimization of Oxytocin-induced Myometrial Contractility by Propranolol - Potential Applications in Induction of Labour and Treatment of Postpartum Hemorrhage[NCT03434444]		57 participants (Actual)	Interventional	2017-09-08	Completed
A Pharmaco-imaging Approach to Predicting Social Functioning and Clinical Responses to Oxytocin Administration in Schizophrenia[NCT03900754]	Phase 2	26 participants (Actual)	Interventional	2020-01-13	Active, not recruiting
[NCT01571323]	Phase 1/Phase 2	150 participants (Actual)	Interventional	2012-02-29	Completed
High Dose Versus Low Dose Oxytocin for Augmentation of Delayed Labour[NCT01587625]		1,376 participants (Actual)	Interventional	2013-08-31	Completed
[NCT01594775]	Phase 1	160 participants (Actual)	Interventional	2011-10-31	Completed
A Randomized Trial Administering Oxytocin vs Placebo as add-on to Antipsychotics in Patients With Schizophrenia and Schizo-affective Disorder[NCT01598623]	Phase 2	48 participants (Anticipated)	Interventional	2012-05-31	Not yet recruiting
Intravenous and Intramuscular Administration of Oxytocin in the Third Stage of Labor for Prevention of Postpartum Hemorrhage[NCT01608958]		653 participants (Actual)	Interventional	2012-05-31	Completed
Comparison Between the Use of Standard Oxytocin Induction Protocol and the Double-balloon Catheter Device With Concurrent Oxytocin[NCT01615107]		300 participants (Anticipated)	Interventional	2012-07-31	Not yet recruiting
The Effects of Intranasal Oxytocin on Social Cognition, Implicit Preferences and Craving in Moderate to Heavy Social Alcohol Drinkers[NCT01829516]	Phase 4	32 participants (Actual)	Interventional	2013-05-31	Completed
Intraumbilical Oxytocin Compared to Placental Cord Drainage in the Management of Third Stage of Labor: A Randomized Controlled Study[NCT03395730]	Phase 2	150 participants (Anticipated)	Interventional	2017-09-30	Recruiting
Oxytocin Treatment of Alcohol Dependence: A Randomized, Placebo-Controlled Trial[NCT02275611]	Phase 2	13 participants (Actual)	Interventional	2013-01-31	Completed
Double-blind, Randomized, Placebo Controlled Trial of Intranasal Oxytocin Treatment for Social Deficits in Children With Autism.[NCT01624194]	Phase 2	54 participants (Actual)	Interventional	2012-06-30	Completed
Effects of Intramuscular Oxytocin on Sensory Function in Healthy Volunteers With Ultraviolet Burn Injury to the Skin[NCT03935399]	Phase 4	10 participants (Actual)	Interventional	2019-08-08	Completed
Oxytocin and Aging: Neuro-Behavioral Effects on Social Cognition and Prosocial Behavior[NCT01823146]		106 participants (Actual)	Interventional	2013-07-31	Completed
The Potential of Oxytocin to Reduce Opioid Abuse Liability and Pain Among Older Adults[NCT05761860]	Early Phase 1	45 participants (Anticipated)	Interventional	2023-09-12	Recruiting
Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome[NCT02629991]	Phase 2	23 participants (Actual)	Interventional	2015-10-31	Completed
Breast Stimulation for Labor Induction: a Parallel-group Randomized Controlled External Pilot Study of Acceptability and Feasibility[NCT04756089]		24 participants (Actual)	Interventional	2021-03-13	Completed
Common and Differentiated Representations Between Social Exclusion and Social Separation[NCT05920707]		120 participants (Anticipated)	Interventional	2023-04-20	Recruiting
Posttraumatic Stress Disorder and Affective Functioning: A Test of the Potentially Normalizing Effects of Oxytocin[NCT02546570]	Phase 2	11 participants (Actual)	Interventional	2015-08-31	Completed
Emotional Processing and Oxytocin Mechanisms in Premenstrual Dysphoric Disorder: A Pilot Study[NCT02508103]	Phase 2/Phase 3	10 participants (Actual)	Interventional	2015-07-31	Completed
Evaluating Potential Benefits of Intranasal Oxytocin on Undersea Operator Training and Performance: Cold Water Task Performance and Recovery[NCT04738838]	Phase 2	24 participants (Anticipated)	Interventional	2021-07-01	Not yet recruiting
Efficacy of Administering Oxytocin Orally Using a Medicated Lollipop Approach on Peripheral Concentrations and Attention: Comparisons With Intranasal and Lingual Spray Administration[NCT05444738]		72 participants (Anticipated)	Interventional	2022-04-01	Recruiting
The Role of Oxytocin in the Perception of Infant Faces[NCT02443727]	Early Phase 1	71 participants (Actual)	Interventional	2015-04-30	Completed
The Effects of Intranasal Oxytocin on Approach Bias and Craving in Moderate to Heavy Alcohol Drinkers[NCT03865615]	Phase 2	0 participants (Actual)	Interventional	2023-11-01	Withdrawn(stopped due to COVID made study visits impossible during the funding period.)
Double-Blind, Randomized, Placebo-Controlled, Cross-Over Study of Intranasal Oxytocin Augmentation of Antidepressant Medication in Depressed Patients.[NCT01211756]		1 participants (Actual)	Interventional	2010-10-31	Terminated(stopped due to Break in funding)
Impact of Oxytocin on Neurobiologic Substrates of Social Stress in Individuals With Alcohol Use Disorder[NCT03610633]	Phase 2	11 participants (Actual)	Interventional	2016-03-31	Completed
Effect of Intranasal Oxytocin on Social Cognition[NCT02671266]	Phase 2	41 participants (Actual)	Interventional	2014-12-31	Completed
Comparison Between Carbetocin and Oxytocin in Elective Caesarean Section With High Risk of Postpartum Hemorrhage: A Randomized Controlled Trial[NCT02391636]	Phase 4	264 participants (Actual)	Interventional	2015-02-28	Completed
The Effect of 21-Days Intranasal Oxytocin on Clinical Symptoms and Social Function in Patients With Post Traumatic Stress Disorder (PTSD), a Randomized Controled Trail[NCT02336568]	Phase 4	40 participants (Anticipated)	Interventional	2015-03-31	Not yet recruiting
Evaluation of the Impact of Carbetocin Administration (Bolus Versus Infusion) on Heart Rate and Other Hemodynamic Parameters.[NCT03404544]	Phase 4	70 participants (Actual)	Interventional	2018-06-11	Completed
Exploring the Effects of Oxytocin on Non-verbal Communication[NCT03228901]	Phase 2	104 participants (Actual)	Interventional	2007-01-31	Completed
Effects of Intranasal Oxytocin on Cigarette Smoking[NCT02595749]	Phase 4	83 participants (Actual)	Interventional	2016-07-31	Completed
Clinical Study,Longitudinal,Controlled, Randomized, Open-label, Phase III,to Assess the Equivalence of Tranexamic Acid vs Oxytocin in Reducing the Post Partum Hemorrhage (PHH) in Patients at the End of Pregnancy (37-42 w) at Low Risk of PPH[NCT02503319]	Phase 3	486 participants (Anticipated)	Interventional	2015-10-31	Suspended(stopped due to Authorization denied)
The Influence of Oxytocin on Pair-bonding and Emotion Regulation[NCT02501837]	Early Phase 1	40 participants (Actual)	Interventional	2014-07-31	Completed
Differential Modulation of Neural and Behavioral Responses to Emotional Scenes by Intranasal and Oral Oxytocin Administration in Healthy Men[NCT05532501]		160 participants (Anticipated)	Interventional	2022-09-20	Recruiting
An Evidence Based Protocol for Oxytocin Administration in Vaginal Delivery[NCT02410655]	Phase 4	0 participants (Actual)	Interventional	2015-11-30	Withdrawn(stopped due to Submission discarded. Study never enrolled subjects.)
Effects of Intranasal Administrations of Oxytocin on Behavioural Troubles, Hyperphagia and Social Skills in Children With Prader-Willi Syndrome Aged From 3 to 12 Years.[NCT03114371]		40 participants (Actual)	Interventional	2016-11-28	Completed
A Randomized, Placebo Controlled, Double-blind, 3-period Cross-over Study in Adult Patients With Autism Spectrum Disorders Evaluating Cognitive Response After Single- Dose Oxytocin 8 or 24 IU Intranasal Administration Using the OptiNose Bi-directional Nos[NCT02414503]	Phase 1/Phase 2	17 participants (Actual)	Interventional	2015-04-30	Completed
Double-Blind, Randomized, Placebo-Controlled, Cross-Over Study of Intranasal Oxytocin Augmentation of Antipsychotic Medication in Schizophrenia Patients[NCT00506909]		21 participants (Actual)	Interventional	2008-03-31	Terminated(stopped due to Break in funding)
The Effects of Oxytocin on Learning With Social Versus Nonsocial Motivation[NCT02393443]	Early Phase 1	161 participants (Actual)	Interventional	2015-01-31	Completed
Effects of Intranasal Oxytocin on Fear Processing in Naturalistic Contexts[NCT05892939]		60 participants (Anticipated)	Interventional	2023-05-23	Recruiting
Benefits of Oxytocin in OSA Patients Using CPAP[NCT03860233]	Phase 1	40 participants (Anticipated)	Interventional	2019-03-04	Recruiting
Hexakaprone Treatment for Post-Partum Hemorrhage Prophylactic[NCT02362945]	Phase 3	1,000 participants (Anticipated)	Interventional	2015-10-31	Not yet recruiting
Phase II Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors[NCT01944046]	Phase 2	290 participants (Actual)	Interventional	2014-08-01	Completed
Oxytocine Versus Prostaglandines Pour le déclenchement du Travail Des Femmes Dont le Col Est défavorable après 24 Heures de Maturation Cervicale : Essai Multicentrique randomisé de Non infériorité[NCT04949633]	Phase 3	1,494 participants (Anticipated)	Interventional	2021-09-28	Recruiting
Intravenous Oxytocin for Post Operative Pain After Minimally Invasive Hysterectomy: A Randomized Placebo-Controlled Trial[NCT05608070]	Phase 4	0 participants (Actual)	Interventional	2023-06-01	Withdrawn(stopped due to Sponsor declined to fund)
Does Oxytocin Modulate Rewarding Effect of Metaphorical Compliments Fluctuating With Women's Fertility and Luteal Phase in a Romantic Context[NCT03144115]	Early Phase 1	80 participants (Actual)	Interventional	2016-10-31	Completed
Effects of Oxytocin Nasal Spray on Social Affiliation[NCT00663039]	Phase 2	27 participants (Actual)	Interventional	2009-10-31	Completed
Phase II, Multicenter, Open-label, Rct With an Adaptive Design, to Assess Efficacy of Intravenous Administration of Oxytocin in Hospitalized Patients Affected by COVID-19[NCT04386447]	Phase 2	0 participants (Actual)	Interventional	2020-09-01	Withdrawn(stopped due to The study was not approved by the Italian Medicines Agency (AIFA).)
Cervical Ripening for Induction of Labor: Misoprostol Versus Oxytocin in Conjunction With Foley Balloon[NCT01139801]		50 participants (Actual)	Interventional	2009-09-30	Completed
Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders[NCT01337687]		19 participants (Actual)	Interventional	2009-10-31	Completed
A Randomized Controlled Trial of Standardized Versus Conventional Oxytocin and Uterotonic Agent Use for Cesarean Delivery[NCT01549223]	Phase 4	60 participants (Actual)	Interventional	2011-04-30	Completed
The Biological Basis of Individual Variation in Social Cooperation[NCT01566539]		707 participants (Actual)	Interventional	2008-04-30	Completed
Uterotonic Efficacy of Oxytocin 2.5 Versus 10 Units During Caesarean Section at Mulago Hospital; Adouble Blinded Clinical Trial.[NCT01726478]		386 participants (Actual)	Interventional	2011-02-28	Completed
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Effect of Continuous Infusion of Tafoxiparin as an Adjunct Treatment to Oxytocin for up to 36 Hours in Term Pregnant, Nulliparous Women to Treat Primary Slow [NCT03001193]	Phase 2	361 participants (Actual)	Interventional	2016-12-31	Completed
Intranasal Oxytocin for the Treatment of Pain Associated With Interstitial Cystitis[NCT00919802]	Phase 4	25 participants (Actual)	Interventional	2010-06-30	Completed
Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia[NCT01614093]	Phase 4	24 participants (Actual)	Interventional	2012-06-30	Completed
Effect of Oxytocin on Craving and Therapy Response in Marijuana-dependent Individuals[NCT01827332]		16 participants (Actual)	Interventional	2013-03-31	Completed
A Randomized Trial Comparing Oral Misoprostol Alone With Oral Misoprostol Followed by Oxytocin in Women Induced for Hypertension of Pregnancy[NCT03749902]	Phase 4	520 participants (Actual)	Interventional	2020-01-06	Completed
ELECTIVE INDUCTION OF LABOUR VS SPONTANEOUS LABOUR IN WOMEN WITH HEART DISEASE - A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL[NCT01677364]		50 participants (Actual)	Interventional	2009-07-31	Completed
Long Term Evaluation of Infants Aged From 3 to 4 Years Old Included in the Ancient Study (Repeated Administrations of Oxytocin in Infants With Prader Willi Syndrome Aged From 0 to 6 Months) and Comparison With Not Treated and Age-matched Prader Willi Synd[NCT03081832]		34 participants (Actual)	Interventional	2017-01-31	Completed
Phase 2 Study: Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Children and Adolescents With Prader-Willi Syndrome[NCT03197662]	Phase 2	50 participants (Anticipated)	Interventional	2018-04-11	Recruiting
Common and Distinct Effects of Oxytocin on Reinforcement Learning Under Stable and Volatile Associations[NCT05245708]		80 participants (Actual)	Interventional	2021-04-15	Completed
Defining a Pharmacokinetic and Pharmacodynamic Model for Peripheral Analgesia After Intravenous Oxytocin[NCT05929339]	Phase 2	24 participants (Anticipated)	Interventional	2023-08-17	Recruiting
Effect of Increased Oxytocin Doses on the Mode of Delivery in Obese Primiparous Women With Spontaneous or Induced Labour. A Double-blind, Randomised, Controlled Trial[NCT04760496]	Phase 4	882 participants (Anticipated)	Interventional	2021-10-02	Recruiting
Intranasal Oxytocin for the Treatment of Children and Adolescents With Autism[NCT01908205]	Phase 2	60 participants (Actual)	Interventional	2013-09-30	Completed
Intrauterine Misoprostol With Active Management of Labour Versus Active Management of Labour for Prevebtion of Postpartum Hemorage in Cesarean Section ,Randomized Controlled Trial[NCT03390010]	Phase 1	300 participants (Actual)	Interventional	2017-12-28	Completed
Efficacy of Tranexamic Acid in Preventing Postpartum Haemorrhage After Elective Caesarean Section[NCT03463993]	Phase 3	506 participants (Actual)	Interventional	2018-04-08	Completed
The Efficacy and Safety of Tranexamic Acid Versus Uterotonic Agents in Reducing Blood Loss During and After Cesarean Section Among High-risk Patients: a Comparative Study[NCT06060327]		444 participants (Anticipated)	Interventional	2023-10-15	Not yet recruiting
Investigating the Impact of Oxytocin on the Neurobiological Underpinnings of Socioemotional Deficits in Anorexia Nervosa[NCT03414112]	Early Phase 1	16 participants (Actual)	Interventional	2018-09-25	Completed
Combined Oxytocin and CBSST for Social Function in People With Schizophrenia[NCT01752712]		83 participants (Actual)	Interventional	2014-01-31	Completed
Identifying the miR Fingerprint in NAF, Serum, and Tissue in Patients With Ductal Carcinoma in Situ (DCIS) or Invasive Breast Cancer[NCT02127073]	Phase 2	8 participants (Actual)	Interventional	2015-01-30	Terminated(stopped due to Could not identify collaborator and secure additional funding after transferring the record to Montefiore Medical Center)
The Differential Effects of Oral and Intranasal Oxytocin on Attention Control[NCT04815395]		151 participants (Actual)	Interventional	2017-12-19	Completed
Fundamental Biobehavioral Mechanisms Underlying the Integrated Development of Emotion, Attachment, and Nutritive Intake in the Mother-Infant Dyad[NCT06039878]		240 participants (Anticipated)	Observational	2023-12-31	Recruiting
Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination[NCT04218409]	Early Phase 1	45 participants (Anticipated)	Interventional	2021-09-02	Recruiting
Intranasal Oxytocin in the Treatment of Autism[NCT00490802]	Phase 2	19 participants (Actual)	Interventional	2006-06-30	Completed
[NCT01573273]		112 participants (Actual)	Interventional	2012-10-31	Completed
Long-term Effects of Intranasal Oxytocin in Alcohol Withdrawal and Dependence: Follow-up of a Randomized Controlled Trial[NCT03339024]	Phase 3	38 participants (Actual)	Interventional	2017-11-01	Completed
Common and Dissociable Effects of Oxytocin and Lorazepam on the Neurocircuitry of Fear - an Ultra-high Field Imaging Study[NCT03829839]	Phase 1	120 participants (Actual)	Interventional	2016-03-03	Completed
Deciphering the Role of Oxytocin in Motivation: an fMRI Study[NCT01722071]	Phase 2	20 participants (Actual)	Interventional	2012-10-31	Completed
Sex/Gender Differences in Risk and Resilience to PTSD; Implication of Oxytocin[NCT01963078]	Phase 2	38 participants (Actual)	Interventional	2013-04-30	Completed
Saving Lives at Birth in Uganda: Building and Sustaining Capacity of Frontline Health Workers - A Program Evaluation[NCT03254628]		3,440 participants (Actual)	Interventional	2014-11-14	Completed
Dose-Response Relationship and Pharmacokinetics of Intranasal Oxytocin on Neural Impact in Youth With High Levels of Irritability[NCT03863288]	Phase 1/Phase 2	80 participants (Anticipated)	Interventional	2022-02-18	Recruiting
A Comparative Study Between Cervical Traction and Active Management of 3rd Stage of Labor in Prevention of Postpartum Hemorrhage After Vaginal Delivery[NCT04747015]		306 participants (Anticipated)	Interventional	2020-07-13	Recruiting
Oxytocin at Elective Cesarean Deliveries: A Dose-finding Study in Women With Twin Pregnancy[NCT04025658]		30 participants (Actual)	Interventional	2019-08-06	Completed
Effect of Oxytocin Massage and Music on Breastfeeding: Randomized Controlled Trial[NCT05059028]		120 participants (Actual)	Interventional	2021-11-01	Completed
An Eye-tracking Study to Investigate Oxytocin Effect on Attention Inhibition[NCT03486925]		71 participants (Actual)	Interventional	2017-12-19	Completed
Randomized Comparison of Vaginal Misoprostol and Intravenous Oxytocin for Labor Induction in Multiparous Women[NCT01634854]		130 participants (Actual)	Interventional	2012-07-31	Completed
Effect of Oral Oxytocin of Brain and Behavioral Responses to Emotional Stimuli in Healthy Women[NCT05073939]		80 participants (Anticipated)	Interventional	2021-04-01	Recruiting
The Clinical Carbetocin Myocardium Trial Part 2[NCT03899961]	Phase 4	240 participants (Actual)	Interventional	2019-04-02	Completed
Oxytocin Treatment of Alcohol Dependence: A Randomized, Placebo-Controlled Trial[NCT02251912]	Phase 2	22 participants (Actual)	Interventional	2015-07-31	Completed
Effects of Intranasal Oxytocin on Striatal Functional Connectivity in Healthy Males[NCT03128203]		135 participants (Actual)	Interventional	2016-09-30	Completed
Effects of a Prolonged Oxytocin Treatment on Intrusions and Amygdala Reactivity in an Analogue Trauma Model[NCT03425929]	Phase 1	70 participants (Actual)	Interventional	2016-06-01	Completed
Hemostatic Effect of Intrauterine Instillation of Oxytocin in Hysteroscopic Myomectomy: A Randomized Double Blinded Control Trial[NCT04996498]		60 participants (Actual)	Interventional	2021-04-15	Completed
Role of Bilateral Uterine Artery Ligation in Reducing Incidence of Postpartum Hemorrhage in Cesarean Section in Patients At Risk of Uterine Atony A Randomized Controlled Trial[NCT03591679]		1,070 participants (Actual)	Interventional	2017-12-01	Completed
The Effect of Intramyometrial Tranexamic Acid Versus Intramyometrial Oxytocin in Reducing Blood Loss During and After Elective Cesarean Section in Term Primigravida: A Double-blinded, Randomized, Comparative-placebo Trial[NCT06010368]	Phase 3	100 participants (Anticipated)	Interventional	2023-09-01	Recruiting
Understanding Oxytocin's Neural and Behavioral Effects in Adolescents Diagnosed With Autism[NCT05096676]		58 participants (Actual)	Interventional	2016-08-01	Completed
A Randomized Comparison of Foley Bulb With Low Dose Pitocin Versus Foley Bulb With a Standard Incremental Infusion Protocol for the Induction of Labor[NCT02150954]	Phase 4	121 participants (Actual)	Interventional	2007-12-31	Completed
The Psychobiology of Resilience in Mother-child Pairs: Inhaled Oxytocin and HPA Axis Reactivity[NCT03593473]	Phase 2	150 participants (Anticipated)	Interventional	2019-02-07	Enrolling by invitation
Oral Oxytocin's Effects on Attention Control: An Eye-tracking Study[NCT04493515]		80 participants (Anticipated)	Interventional	2020-07-28	Recruiting
A Randomized Controlled Trial of Double Simultaneous Uterotonic Agents (Misoprostol Plus Intravenous Oxytocin) Versus Single Agent Regimen (Intravenous Oxytocin Only) to Prevent Early Postpartum Hemorrhage[NCT05245227]	Phase 3	1,358 participants (Anticipated)	Interventional	2022-03-01	Recruiting
The Effects of Oxytocin on Social Ability, Alcohol Approach Bias, and Startle Hyperreactivity in Veterans With Alcohol Use Disorder and Post Traumatic Stress Disorder[NCT02469259]	Early Phase 1	88 participants (Actual)	Interventional	2016-02-29	Completed
Ideal Time of Oxytocin Infusion During Cesarean Section[NCT03246919]	Phase 4	68 participants (Actual)	Interventional	2017-09-13	Terminated(stopped due to PI left Loyola and Sub-I graduated.)
Comparison Study Between Oxytocin Versus Tranexamic Acid and Ethamsylate Versus Placebo to Reduce Blood Loss Intraoperative and Post Operative During Elective Cesarean Section[NCT05273632]		300 participants (Actual)	Interventional	2022-03-20	Completed
Oxytocin Pilot: Oxytocin and Face Perception[NCT02238379]	Early Phase 1	26 participants (Actual)	Interventional	2014-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Time From Cervical Ripening to Delivery

Time from placement of cervical ripening balloon to delivery (NCT03138252)
Timeframe: Time to delivery

Intervention	hours (Median)
Cervical Ripening Balloon Alone	16.88
Cervical Ripening Balloon + Oxytocin	13.13

Intervention	score on a scale (Mean)
Pivotal Response Treatment (PRT)/Oxytocin (OXT) Nasal Spray	39
Pivotal Response Treatment (PRT)/Placebo Nasal Spray	-16

Intervention	Change-from-base z-transformed r-value (Mean)
Syntocinon (Oxytocin, Product Code RVG 03716)	-0.04
Placebo (Physiological Water(Sodium Chloride (NaCl) Solution))	0.11

Intervention	Change-from-base z-transformed r-value (Mean)
Syntocinon (Oxytocin, Product Code RVG 03716)	-0.06
Placebo (Physiological Water(Sodium Chloride (NaCl) Solution))	0.11

Intervention	Change-from-base z-transformed r-value (Mean)
Syntocinon (Oxytocin, Product Code RVG 03716)	-0.07
Placebo (Physiological Water(Sodium Chloride (NaCl) Solution))	0.13

Intervention	Change in performance (acc/rt ratio) (Mean)
Syntocinon (Oxytocin, Product Code RVG 03716)	0.000044
Placebo (Physiological Water(Sodium Chloride (NaCl) Solution))	0.000073

Intervention	Change in performance (acc/rt ratio) (Mean)
Syntocinon (Oxytocin, Product Code RVG 03716)	0.000071
Placebo (Physiological Water(Sodium Chloride (NaCl) Solution))	0.000084

Intervention	Change in performance (acc/rt ratio) (Mean)
Syntocinon (Oxytocin, Product Code RVG 03716)	0.000070
Placebo (Physiological Water(Sodium Chloride (NaCl) Solution))	0.000088

Intervention	Change in performance (acc/rt ratio) (Mean)
Syntocinon (Oxytocin, Product Code RVG 03716)	0.000029
Placebo (Physiological Water(Sodium Chloride (NaCl) Solution))	0.000065

Intervention	Change-from-baseline (BOLD response) (Mean)
	Brain activity - Superior temporal sulcus	Brain activity - Amygdala
Placebo (Physiological Water(Sodium Chloride (NaCl) Solution))	-0.29	0.06
Syntocinon (Oxytocin, Product Code RVG 03716)	-0.10	-0.09

Intervention	Change from base (units on a scale) (Mean)
	SRS-A self-report	SRS-A informant-based	RBS-R	SAAM avoidance	SAAM security	SAAM anxiety	IPPA Peers	IPPA Mother	IPPA Father	WHO-QOL	POMS - Tension	POMS - Anger	POMS - Depression	POMS - Vigor	POMS - Fatigue
Placebo (Physiological Water(Sodium Chloride (NaCl) Solution))	-1.06	-0.87	-1.76	0.06	0.05	0.28	0.56	0.44	-0.61	-1.35	-2.39	-0.61	-0.33	-2.94	-1.11
Syntocinon (Oxytocin, Product Code RVG 03716)	-5.55	0.0	-4.77	-0.40	0.27	-0.14	1.45	-0.52	0.43	1.77	-2.00	0.00	-1.14	-1.00	-2.09

Intervention	total raw score (Mean)
	Intervention Period 1	Intervention Period 2
Intranasal Oxytocin Then Placebo	8.45	8.92
Placebo Then Oxytocin	8.5	8.36

Intervention	naming time (seconds) (Mean)
	Symbolic: Intervention Period 1	Symbolic: Intervention Period 2	Non-symbolic: Intervention Period 1	Non-symbolic: Intervention Period 2
Intranasal Oxytocin Then Placebo	16.13	15.28	24.13	23.31
Placebo Then Oxytocin	18.08	17.98	27.93	28.70

Intervention	milliseconds (Mean)
Placebo in ASD Participants	91786.05
8IU of Oxytocin Spray	82503.23
24IU of Oxytocin Spray	134913.00
48IU of Oxytocin Spray	130600.90

Intervention	Smiles per minute (Mean)
Placebo in ASD Participants	0.954
8IU of Oxytocin Spray	0.954
24IU of Oxytocin Spray	1.013
48IU of Oxytocin Spray	1.015

Intervention	z-scores rsFC salience-visual (Mean)
Placebo in ASD Participants	0.338
8IU of Oxytocin Spray	0.400
24IU of Oxytocin Spray	0.428
48IU of Oxytocin Spray	0.522
Healthy Controls Receiving Placebo	0.591

Intervention	z-scores (Mean)
	Face versus Fixation, Insular Cortex	Face versus Fixation, Cingulate Gyrus, Anterior Division	Face versus Fixation, Frontal Orbital Cortex	Face versus Fixation, Occipital Fusiform Gyrus	Face versus Fixation, Left Laterobasal Amygdala	Face versus Fixation, Right Laterobasal Amygdala	Face versus Fixation, Left Accumbens	Face versus Fixation, Right Caudate	Face versus Fixation, Right Hippocampus	Face versus Fixation, Right Amygdala	Face versus Fixation, Right Accumbens	Face versus Fixation, Left Caudate	Face versus Fixation, Left Hippocampus	Face versus Fixation, Left Amygdala	Happy versus Neutral, Frontal Orbital Cortex	Happy versus Neutral, Occipital Fusiform Gyrus	Happy versus Neutral, Left Accumbens	Happy versus Neutral, Right Caudate	Happy versus Neutral, Right Amygdala	Happy versus Neutral, Right Accumbens	Happy versus Neutral, Left Caudate	Happy versus Neutral, Left Amygdala	Emotion versus Neutral, Insular Cortex	Emotion versus Neutral, Cingulate Gyrus, Anterior Division	Emotion versus Neutral, Frontal Orbital Cortex	Emotion versus Neutral, Occipital Fusiform Gyrus	Emotion versus Neutral, Left Laterobasal Amygdala	Emotion versus Neutral, Right Laterobasal Amygdala	Emotion versus Neutral, Left Accumbens	Emotion versus Neutral, Right Caudate	Emotion versus Neutral, Right Hippocampus	Emotion versus Neutral, Right Amygdala	Emotion versus Neutral, Right Accumbens	Emotion versus Neutral, Left Caudate	Emotion versus Neutral, Left Hippocampus	Emotion versus Neutral, Left Amygdala	Negative Emotions versus Neutral, Insular Cortex	Negative Emotions versus Neutral, Cingulate Gyrus, Anterior Division	Negative Emotions versus Neutral, Occipital Fusiform Gyrus	Negative Emotions versus Neutral, Left Laterobasal Amygdala	Negative Emotions versus Neutral, Right Laterobasal Amygdala	Negative Emotions versus Neutral, Right Amygdala	Negative Emotions versus Neutral, Left Amygdala
24IU of Oxytocin Spray	-0.602304	-0.922999	0.133334	3.403614	0.347864	0.57701	-0.76235	0.536007	0.194145	0.175908	-0.418176	-0.041339	-0.033878	0.078968	0.243287	0.206772	0.984787	0.025731	0.928212	0.565472	0.58712	0.561367	1.049595	0.89113	0.434074	0.830858	0.31737	0.482033	1.752678	1.197835	0.716515	1.009125	1.396064	1.498338	0.471703	0.435674	1.280621	1.064596	1.007465	0.276778	0.6247	1.018509	0.368682
48IU of Oxytocin Spray	0.33747	0.03105	0.51544	3.39230	1.06647	0.989042	-0.364131	-0.602492	0.485382	1.302074	-0.556553	-0.280602	0.295781	1.120718	-0.625216	0.32432	-0.777588	-0.292749	-0.922439	-0.776844	0.00862	-0.62126	0.145474	0.239665	-0.042926	0.981023	-0.039061	-0.291652	-0.373102	0.246921	-0.011004	0.031841	-0.421539	0.470775	0.150852	0.659752	0.791272	0.906276	1.263083	0.561114	0.230971	0.554755	1.091867
8IU of Oxytocin Spray	-0.758427	-0.59443	-0.339727	3.556448	-0.46194	-0.80763	-0.358148	-0.820473	-0.391579	-0.638315	-0.567634	-0.698518	-0.72534	-0.631298	-0.195753	-0.459616	-1.177278	0.132704	0.040877	-0.129955	0.185452	-0.477983	0.462527	0.663003	0.084622	0.377043	-0.085989	-0.247527	-1.05875	0.916936	-0.093067	0.567225	-0.307024	0.971035	-0.154759	0.328634	0.814225	1.001123	0.664895	0.11396	0.143468	0.735094	0.512198
Healthy Controls Receiving Placebo	-0.540874	-0.573381	0.504016	3.322934	1.341538	1.03517	-0.859178	0.232223	0.613169	1.701371	-1.532579	0.017432	0.632196	1.65022	1.04841	0.795348	1.059391	1.470176	1.078819	0.683166	1.613145	1.542177	0.779819	1.267345	1.116102	0.967798	1.879398	1.808126	1.120372	1.354862	1.203561	1.60342	0.996732	1.577967	1.211722	2.130943	0.869933	1.07742	0.926976	1.910744	1.905216	1.683817	2.214728
Placebo in ASD Participants	0.347824	0.313911	0.517829	3.427291	-0.003581	0.817701	0.324295	0.086391	0.86138	1.047957	-0.316604	0.241254	0.699955	0.221233	0.39487	0.684501	1.430518	0.050791	0.505732	0.821772	0.377711	0.13828	0.3329	-0.13682	0.444076	0.547858	-0.477913	-0.203773	2.022323	-0.500704	-0.015598	0.147144	0.893013	-0.188575	-0.057242	-0.148364	0.078993	-0.189082	0.336816	-0.50816	-0.516251	-0.119579	-0.192095

Intervention	picogram/milliliter (Mean)
	Prior to spray	After spray
24IU of Oxytocin Spray	9.06	17.52
48IU of Oxytocin Spray	9.72	20.86
8IU of Oxytocin Spray	11.17	14.36
Placebo in ASD Participants	8.09	7.75

Intervention	percent change in contrast (Mean)
	Human Minus Computer, Negative Feedback, Left Amygdala	Human Minus Computer, Negative Feedback, Right Amygdala	Human Minus Computer, Negative Feedback, Right Laterobasal Amygdala	Human Minus Computer, Negative Feedback, Left Laterobasal Amygdala	Human Minus Computer, Negative Feedback, Ventral Anterior Insula (Sphere)	Human Minus Computer, Negative Feedback, Anterior Cingulate (Sphere)	Human Minus Computer, Positive Feedback, Anterior Cingulate (Sphere)	Human Minus Computer, Positive Feedback, Frontal Orbital Cortex	Human Minus Computer, Positive Feedback, Ventral Tegmental Area	Human Minus Computer, Positive Feedback, Right Caudate	Human Minus Computer, Positive Feedback, Right Nucleus Accumbens	Human Minus Computer, Positive - Negative Feedback, Anterior Cingulate (Sphere)	Human Minus Computer, Positive - Negative Feedback, Frontal Orbital Cortex	Human Minus Computer, Positive - Negative Feedback, Ventral Tegmental Area	Human Minus Computer, Positive - Negative Feedback, Right Caudate	Human Minus Computer, Positive - Negative Feedback, Right Nucleus Accumbens
24IU of Oxytocin Spray	0.1631	0.1979	0.0984	0.1094	-0.0575	0.0419	0.1526	0.1826	0.1889	0.2605	0.1779	0.1156	0.0826	0.0302	0.1188	0.1174
48IU of Oxytocin Spray	0.3304	0.3576	0.2569	0.2014	0.1866	0.3214	0.2343	0.1859	0.1770	0.2824	0.1341	-0.0996	-0.0957	-0.0940	-0.0452	-0.0615
8IU of Oxytocin Spray	0.1379	0.1118	0.0921	0.0739	0.0311	0.0953	0.0996	0.1338	0.1010	0.1114	0.1017	0.0084	0.081	-0.0175	0.0205	0.0528
Healthy Controls Receiving Placebo	0.3502	0.3823	0.2258	0.2717	0.0815	0.1406	0.1218	0.2301	0.0848	0.3004	0.2092	-0.0320	0.0286	-0.0457	-0.0057	-0.0737
Placebo in ASD Participants	0.2568	0.3141	0.1724	0.1512	0.1830	0.2604	0.2774	0.2263	0.2412	0.2540	0.1139	0.0175	0.0142	0.1417	0.0072	-0.0277

Intervention	milliseconds (Mean)
	Congruent Blocks	Incongruent Blocks	Training Blocks
24IU of Oxytocin Spray	905.99	920.23	765.53
48IU of Oxytocin Spray	896.63	921.90	761.89
8IU of Oxytocin Spray	972.08	960.41	800.25
Healthy Controls Receiving Placebo	762.72	791.65	655.27
Placebo in ASD Participants	939.43	969.17	790.49

Intervention	units on a scale (Mean)
	Preoperative	2 Months postoperatively
Oxytocin	6.3	8.4
Placebo	6.8	7.7

oxytocin

Description

Cross-References

Synonyms (120)

Research Excerpts

Overview

Effects

Actions

Treatment

Roles (2)

Drug Classes (2)

Pathways (2)

Protein Targets (14)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (91)

Molecular Functions (18)

Ceullar Components (14)

Bioassays (305)

Research

Studies (20,634)

Study Types

Clinical Trials (604)

Trial Overview

Trial Outcomes

Time From Cervical Ripening to Delivery

Social Responsiveness Scale, 2nd Edition (SRS-2)

Change From Baseline in Brain Connectivity During Rest (Resting-state fMRI) After 4 Weeks of Nasal Spray

Change From Baseline in Brain Connectivity During Rest (Resting-state fMRI) After 52 Weeks, Including 48 Weeks Without Nasal Spray

Change From Baseline in Brain Connectivity During Rest (Resting-state fMRI) After 8 Weeks, Including 4 Weeks Without Nasal Spray

Change From Baseline in Brain Connectivity During Rest (Resting-state fMRI) After a Single Dose of Nasal Spray

Change From Baseline in Performance on the Emotion Recognition Task (Accuracy/ Reaction Time) After 4 Weeks of Nasal Spray

Change From Baseline in Performance on the Emotion Recognition Task (Accuracy/ Reaction Time) After 52 Weeks (Including 48 Weeks Without Nasal Spray)

Change From Baseline in Performance on the Emotion Recognition Task (Accuracy/ Reaction Time) After 8 Weeks (Including 4 Weeks Without Nasal Spray)

Change From Baseline in Performance on the Emotion Recognition Task (Accuracy/Reaction Time) After a Single Dose of Nasal Spray

Change From Baseline in Brain Activity During Task (Task-based fMRI) After 4 Weeks of Nasal Spray

Change From Baseline in Brain Activity During Task (Task-based fMRI) After 52 Weeks, Including 48 Weeks Without Nasal Spray

Change From Baseline in Brain Activity During Task (Task-based fMRI) After 8 Weeks, Including 4 Weeks Without Nasal Spray

Change From Baseline in Brain Activity During Task (Task-based fMRI) After a Single Dose of Nasal Spray

Change From Baseline in Informant-based/ Self-report Scores on Questionnaires Assessing Attachment, Social Functioning, Quality of Life and Mood After 4 Weeks of Nasal Spray

Change From Baseline in Informant-based/ Self-report Scores on Questionnaires Assessing Attachment, Social Functioning, Quality of Life and Mood After 52 Weeks, Including 48 Weeks Without Nasal Spray

Change From Baseline in Informant-based/ Self-report Scores on Questionnaires Assessing Attachment, Social Functioning, Quality of Life and Mood After 8 Weeks, Including 4 Weeks Without Nasal Spray

Change From Baseline in Scores on Questionnaire Assessing Mood After a Single Dose of Nasal Spray

Depression Symptom Severity

PTSD Symptom Severity

PTSD Symptom Severity

Dynamic Affect Recognition Evaluation (DARE)

Rapid Automatized Naming (RAN)

Reading the Mind in the Eyes Task (RMET)

Fluctuation in Pupil Diameter (Hippus) -Post Drug Administration

Fluctuation in Pupil Diameter (Hippus) -Post Drug Administration

Fluctuation in Pupil Diameter (Hippus) -Pre Drug Administration

Heart Rate Variability in the High Frequency Range

Heart Rate Variability in the High Frequency Range

Heart Rate Variability in the High Frequency Range

Milliseconds of Visual Fixation

Rate of Smiling During Global Clinical Interview

Resting State Functional Connectivity (rsFC) Salience Network (Anterior Cingulate Cortex (ACC) and Insula Versus Visual Cortex)

Blood Oxygen Level Dependent (BOLD) Activity in Response to Social Cues

Oxytocin Plasma Concentration

Percent Change in Blood Oxygen Level Dependent (BOLD) Activity During Ball-Game Task

Social Learning Test (SLT) Reaction Time

Comparison of Adjusted Trajectory Model for Daily Steps Between Oxytocin and Placebo--Intercept

Comparison of Adjusted Trajectory Model for Daily Steps Between Oxytocin and Placebo--Slope

Comparison of Adjusted Trajectory Model for Pain Between Oxytocin and Placebo--Intercept

Comparison of Adjusted Trajectory Model for Pain Between Oxytocin and Placebo--Slope

Comparison of Adjusted Trajectory Model for Probability of Taking Opioids Daily Between Oxytocin and Placebo--Intercept

Comparison of Adjusted Trajectory Model for Probability of Taking Opioids Daily Between Oxytocin and Placebo--Slope

Comparison of Adjusted Trajectory Model for World Health Organization Disability Assessment Score 2.0 Value Between Oxytocin and Placebo--Intercept

Comparison of Adjusted Trajectory Model for World Health Organization Disability Assessment Score 2.0 Value Between Oxytocin and Placebo--Slope

Iowa Gambling Task

Tampa Scale of Kinesiophobia

Wisconsin Card Sort Task

Delivery Type

Number of Participants With Non-reassuring Fetal Heart Rate Tracings During the First 30 Minutes After the Placement of Epidural Analgesia

Change in Body Mass Index

Change in Body Weight

Change in Center for Epidemiologic Studies Scale (CES-D)

Change in Fat Mass

Intervention	participants (Number)
	Normal spontanous vaginal delivery	Forceps assisted vaginal delivery	Cesarean delivery
Group A	50	6	13
Group B	43	8	11
Group C	44	2	14
Group D	44	6	10
Group Sum	181	22	48

Intervention	participants (Number)
	Favorable fetal heart rate tracings	Non reassuring fetal heart rate tracings
Group A	47	15
Group B	54	5
Group C	44	10
Group D	47	8

Intervention	mg/dL (Mean)
	Fasting glucose	2-hour glucose
Oxytocin Nasal Spray	3.36	-3.15
Placebo Nasal Spray	2.85	-3.375

Intervention	percentage of participants (Number)
	No worsening (0)	Worsening of 1	Worsening of 2	Worsening of 3	Worsening of 5
1: Oxytocin/Placebo-galantamine	86.67	6.67	6.67	0	0
2: Galantamine/Placebo-oxytocin	77.78	16.67	0	0	5.56
3: Placebo-galantamine /Placebo-oxytocin	76.47	17.65	0	5.88	0

Intervention	units on a scale (Mean)
	Treatment Week 0	Treatment Week 6	Change
1: Oxytocin/Placebo-galantamine	10.5	13.5	3.0
2: Galantamine/Placebo-oxytocin	21.2	19.2	-2.0
3: Placebo-galantamine /Placebo-oxytocin	29.0	30.0	0.0

Intervention	units on a scale (Mean)
	Treatment Week 0	Treatment Week 2	Treatment Week 4	Treatment Week 6
1: Oxytocin	9.34	9.40	9.87	9.67
2: Galantamine	7.30	7.21	7.00	6.78
3: Placebo	8.18	7.90	8.06	7.59

Intervention	QTc (Mean)
	Evaluation Week 0	Treatment Week 6	Change
1: Oxytocin/Placebo-galantamine	416.5	415.7	-2.9
2: Galantamine/Placebo-oxytocin	419.0	408.1	-10.2
3: Placebo-galantamine /Placebo-oxytocin	422.6	423.8	0.9

Intervention	g/dL (Mean)
	Evaluation	Treatment Week 6	Change
1: Oxytocin	1.65	1.71	0.04
2: Galantamine	1.58	1.62	0.05
3: Placebo	1.57	1.60	0.07

Intervention	units on a scale (Mean)
	Treatment Week 0	Treatment Week 6	Change from Week 0 at Week 6
1: Oxytocin	20.5	18.8	-1.7
2: Galantamine	18.2	18.0	-0.2
3: Placebo	20.2	18.9	-1.3

Intervention	mm-Hg (Mean)
	Treatment Week 0	Treatment Week 1	Treatment Week 2	Treatment Week 3	Treatment Week 4	Treatment Week 5	Treatment Week 6
1: Oxytocin/Placebo-galantamine	78.8	78.4	76.7	75.0	73.9	76.2	74.4
2: Galantamine/Placebo-oxytocin	76.6	76.2	77.5	79.1	75.1	79.2	80.7
3: Placebo-galantamine /Placebo-oxytocin	78.3	75.5	79.7	78.9	73.7	77.2	76.0